10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-15-189219.txt : 20150515 0001193125-15-189219.hdr.sgml : 20150515 20150515095656 ACCESSION NUMBER: 0001193125-15-189219 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150515 DATE AS OF CHANGE: 20150515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 15866090 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d897649d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of Common Shares, without par value, outstanding as of May 13, 2015 was 9,443,408.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	March 31, 2015 (unaudited)			June 30, 2014
ASSETS
Current Assets:
Cash and cash equivalents	$	4,885		$	3,587
Receivables - net		10,018			9,850
Inventory		3,936			3,757
Deferred income tax asset		1,861			2,978
Due from third party payors		1,525			2,786
Current assets held for sale		0			270
Prepaid expense and other assets		2,705			2,547

Total current assets		24,930			25,775

Property, plant and equipment, at cost		54,567			53,466
Less accumulated depreciation		32,030			30,389

Property, plant and equipment - net		22,537			23,077

Noncurrent Assets:
Intangible assets - net		2,873			2,979
Goodwill		461			461
Deferred income tax asset		5,100			4,432
Noncurrent assets held for sale		0			6,111
Other noncurrent assets		1,522			1,012

Total noncurrent assets		9,956			14,995

TOTAL ASSETS	$	57,423		$	63,847


LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	4,429		$	4,530
Current maturities of long-term debt		840			561
Accrued payroll and related taxes		3,415			4,186
Income tax payable		32			73
Current liabilities held for sale		0			4,842
Other accrued expenses		1,981			2,314

Total current liabilities		10,697			16,506

Long-Term Liabilities
Long-term debt		11,474			11,948
Noncurrent liability for professional liability risks		992			1,268
Other noncurrent liabilities		755			807

Total long-term liabilities		13,221			14,023

Commitment and Contingencies

Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 9,444 shares at March 31, 2015 and at June 30, 2014		4,722			4,722
Additional paid-in capital		13,478			13,444
Retained earnings		15,639			15,486
Accumulated other comprehensive loss		(334	)		(334	)

Total Shareholders’ Equity		33,505			33,318

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	57,423		$	63,847

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(Unaudited)


	Three Months Ended March 31,						Nine Months Ended March 31,
	2015			2014			2015			2014

Operating revenues (net of contractual allowances)	$	25,196		$	26,303		$	74,913		$	76,500
Less provision for bad debts of Healthcare Facilities Segment		1,845			1,837			6,060			6,125

Net revenues		23,351			24,466			68,853			70,375

Costs and Expenses
Cost of goods sold		6,181			7,078			16,253			17,838
Salaries, wages and benefits		10,729			10,591			32,135			32,105
Provision for bad debts of Specialty Pharmacy Segment		65			75			188			170
Supplies		1,877			1,808			6,017			5,790
Purchased services		1,208			1,289			3,410			3,884
Other operating expenses		2,695			2,994			7,035			8,967
Rent and lease expense		343			366			1,020			1,079
Insurance settlement		0			0			(1,000	)		0
EHR incentive payments		(64	)		(43	)		(64	)		(1,258	)
Depreciation and amortization		602			773			1,817			2,310


Operating Profit (Loss)		(285	)		(465	)		2,042			(510	)

Other Income, (Expense):
Gain on sale of assets		13			18			13			18
Interest expense - net		(213	)		(234	)		(677	)		(714	)


Earnings (Loss) from Continuing Operations before income taxes		(485	)		(681	)		1,378			(1,206	)
Income Tax Expense (Benefit)		(169	)		(105	)		816			(200	)

Earnings (Loss) from Continuing Operations		(316	)		(576	)		562			(1,006	)

Loss from Discontinued Operations, net of tax		(95	)		(388	)		(409	)		(889	)


Net Earnings (Loss)		(411	)		(964	)		153			(1,895	)

Other comprehensive income		0			0			0			0


Comprehensive Earnings (Loss)	$	(411	)	$	(964	)	$	153		$	(1,895	)


Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	(0.03	)	$	(0.06	)	$	0.06		$	(0.11	)

Diluted	$	(0.03	)	$	(0.06	)	$	0.06		$	(0.11	)


Discontinued Operations:
Basic	$	(0.01	)	$	(0.04	)	$	(0.04	)	$	(0.09	)

Diluted	$	(0.01	)	$	(0.04	)	$	(0.04	)	$	(0.09	)


Net Earnings (Loss):
Basic	$	(0.04	)	$	(0.10	)	$	0.02		$	(0.20	)

Diluted	$	(0.04	)	$	(0.10	)	$	0.02		$	(0.20	)


Weighted-Average Common Shares Outstanding:
Basic		9,443			9,443			9,443			9,443

Diluted		9,443			9,443			9,481			9,443

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended March 31,
	2015			2014

Net Cash Provided by Operating Activities	$	1,292		$	3,319

Cash Flows from Investing Activities:

Proceeds from sale of hospital		6,090			—
Net change in cash in escrow		—			(160	)
Expenditures for property, plant and equipment - continuing operations		(995	)		(1,130	)
Expenditures for property, plant and equipment - discontinued operations		(11	)		(83	)


Net Cash Provided by (Used in) Investing Activities		5,084			(1,373	)

Cash Flows from Financing Activities:
Proceeds from long-term debt		175			0
Payments on long-term debt - continuing operation		(411	)		(529	)
Payments on long-term debt - discontinued operations		(4,842	)		(91	)


Net Cash Used in Financing Activities		(5,078	)		(620	)


Net increase in Cash and Cash Equivalents		1,298			1,326

Cash and Cash Equivalents Beginning of Period		3,587			2,497


Cash and Cash Equivalents End of Period	$	4,885		$	3,823


Supplement Disclosure of Cash Flow Information:

Cash Paid (Received) for:
Interest	$	614		$	854

Income taxes	$	203		$	(1,625	)


Assets acquired under capital least obligation - continuing operations	$	41		$	0

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED MARCH 31, 2015

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. – Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2015 and for the three and nine month periods ended March 31, 2015 and 2014 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segment is composed of three operational areas:

•

Three community hospital subsidiaries in two states with a total of 183 licensed beds;

•

Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to a corresponding SunLink community hospital; and

•

A healthcare facility which is currently vacant except for two medical offices which are rented.

•

The Specialty Pharmacy Segment is composed of four operational areas:

•

Retail pharmacy products and services, all of which are conducted in rural markets;

•

Institutional pharmacy services;

•

Specialty pharmacy services; and

•

Durable medical equipment.

SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2015			2014			2015			2014
Net Revenues:
Fulton Hospital	$	(9	)	$	3,255		$	6,721		$	9,985
Dexter Hospital		186			47			764			560
Memorial of Adel		10			(62	)		63			(66	)

	$	187		$	3,240		$	7,548		$	10,479

Earnings (loss) before income taxes:
Fulton Hospital	$	(299	)	$	(601	)	$	(1,196	)	$	(1,748	)
Dexter Hospital		184			34			754			516
Memorial of Adel		2			(82	)		34			(94	)
Life sciences and engineering		(31	)		(40	)		(95	)		(119	)
Lon sale of Fulton Hospital		(6	)		—			(197	)		—

Earnings (Loss) before income taxes		(150	)		(689	)		(700	)		(1,445	)


Income tax expense (benefit)		(55	)		(301	)		(291	)		(556	)


Loss from discontinued operations	$	(95	)	$	(388	)	$	(409	)	$	(889	)

Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri, LLC (“HOM”) sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of March 31, 2015 and June 30, 2014 and for the three and nine month periods ended March 31, 2015 and 2014. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $197 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the Fulton RDA Loan described below.

Fulton RDA Loan - SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2015 and 2014. The components of pension expense for the three and nine months ended March 31, 2015 and 2014, respectively, were as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2015			2014			2015			2014
Interest Cost	$	16		$	15		$	49		$	45
Expected return on assets		(7	)		(7	)		(22	)		(21	)
Amortization of prior service cost		22			32			70			95

Net pension expense	$	31		$	40		$	97		$	119

SunLink contributed $84 to the plan in the three and nine months ended March 31, 2015.

Note 4. – Shareholders’ Equity

Stock-Based Compensation

For the three months ended March 31, 2015 and 2014, the Company recognized $12 and $9, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2015 and 2014, the Company recognized $33 and $40, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the nine months ended March 31, 2015 and 2014, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2015 and 2014, respectively.

Note 5. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues before provision for doubtful accounts by payor were as follows for the three and nine months ended March 31, 2015 and 2014:


	Three Months Ended March 31,						Nine Months Ended March 31,
	2015			2014			2015			2014
Healthcare Facilities Segment:
Medicare	$	6,573		$	6,784		$	20,536		$	20,407
Medicaid		3,591			3,287			10,562			10,131
Self-pay		1,565			1,978			5,555			6,683
Managed Care & Other Insurance		3,911			3,855			12,425			12,427
Other		55			50			151			148

Revenues before provision for doubtful accounts		15,695			15,954			49,229			49,796
Provision for doubtful accounts		(1,845	)		(1,837	)		(6,060	)		(6,125	)

Healthcare Facilities Segment Net Revenues		13,850			14,117			43,169			43,671
Specialty Pharmacy Segment Net Revenues		9,307			10,217			25,191			26,385
Other Revenues		194			132			493			319

Total Net Revenues	$	23,351		$	24,466		$	68,853		$	70,375

The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:


	March 31, 2015			June 30, 2014
Accounts receivable (net of contractual allowances)	$	15,650		$	16,753
Less allowance for doubtful accounts		(5,632	)		(6,903	)

Patient accounts receivable - net	$	10,018		$	9,850

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and nine months ended March 31, 2015:


Three Months Ended March 31, 2015:	Healthcare Facilities			Specialty Pharmacy			Total
Balance at January 1, 2015	$	7,055		$	224		$	7,279
Additions recognized as a reduction to earnings		1,554			65			1,619
Accounts written off, net of recoveries		(3,165	)		(101	)		(3,266	)

Balance at March 31, 2015	$	5,444		$	188		$	5,632


Nine Months Ended March 31, 2015:	Healthcare Facilities			Specialty Pharmacy			Total
Balance at July 1, 2014	$	6,649		$	254		$	6,903
Additions recognized as a reduction to earnings		7,805			145			7,950
Accounts written off, net of recoveries		(9,010	)		(211	)		(9,221	)

Balance at March 31, 2015	$	5,444		$	188		$	5,632


Three Months Ended March 31, 2014:	Healthcare Facilities			Specialty Pharmacy			Total
Balance at January 1, 2014	$	6,760		$	479		$	7,239
Additions recognized as a reduction to revenues		2,521			75			2,596
Accounts written off, net of recoveries		(2,552	)		(39	)		(2,591	)

Balance at March 31, 2014	$	6,729		$	515		$	7,244


Nine Months Ended March 31, 2014:	Healthcare Facilities			Specialty Pharmacy			Total
Balance at July 1, 2013	$	7,286		$	475		$	7,761
Additions recognized as a reduction to revenues		8,138			170			8,308
Accounts written off, net of recoveries		(8,695	)		(130	)		(8,825	)

Balance at March 31, 2014	$	6,729		$	515		$	7,244

Net revenues included increases of $10 and $105 for the three months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($287) and $611 for the nine months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives

Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services.

For the three and nine months ended March 31, 2015, the Company reported $64 Medicaid incentive payments. For the three and nine months ended March 31, 2014, the Company reported net gains of $43 and $1,258, respectively, for Medicare and Medicaid EHR incentive payments.

Note 7. – Goodwill and Intangible Assets

SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition. SunLink’s Healthcare Facilities Segment has intangible assets related to its Healthmont acquisition.

Goodwill consists of the following:


	March 31, 2015		June 30, 2014

Specialty Pharmacy Segment	$	461	$	461

Intangibles consist of the following, net of amortization:


	March 31, 2015			June 30, 2014

Specialty Pharmacy Segment
Trade Name		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(985	)		(879	)


Total	$	2,873		$	2,979

The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset.

Amortization expense was $35 and $36 for the three months ended March 31, 2015 and 2014, respectively, and $106 and $108 for the nine months ended March 31, 2015 and 2014, respectively.

Note 8. – Long-Term Debt

Long-term debt consisted of the following:


	March 31, 2015			June 30, 2014
Trace RDA Loan	$	8,290		$	8,624
SHPP RDA Loan		2,002			2,033
Carmichael Notes		1,852			1,852
Other		170			—

Total		12,314			12,509
Less current maturities		(840	)		(561	)

	$	11,474		$	11,948

Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (now known as Crown Healthcare Investments, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2015). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds was used to repay a portion of the Company’s then currently outstanding debt. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.

The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ended March 31, 2015, $750 and (b) for the quarter ending June 30, 2015, $625. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At March 31, 2015, there were no outstanding borrowings under the Trace Working Capital Loan.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at March 31, 2015 and June 30, 2014).

SHPP RDA Loan - On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at March 31, 2015). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare.

Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company.

Note 9. – Insurance settlement

In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the nine months ended March 31, 2015.

Note 10. – Income Taxes

Income tax benefit of $169 ($272 federal tax benefit and $103 state tax expense) and income tax benefit of $105 ($112 federal tax benefit and $7 state tax expense) was recorded for the three months ended March 31, 2015 and 2014, respectively. Income tax expense of $816 ($591 federal tax expense and $225 state tax expense) and income tax benefit of $200 ($190 federal tax benefit and $10 state tax benefit) was recorded for the nine months ended March 31, 2015 and 2014, respectively.

At March 31, 2015, the Company had $5,084 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At March 31, 2015, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,961. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

Note 11. – Commitments and Contingencies

Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of the sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not either pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation in November 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the settlement in the quarter ended March 31, 2015. The promissory note is included in long-term assets in the March 31, 2015 balance sheet.

SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred.

Sale of Hospital Facilities — The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and various and contingent liabilities. – See Note 3 Discontinued Operations.

Office of Inspector General Investigation— In March 2014, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD has cooperated with the government with respect to document production, as well as conducting a joint medical necessity review of a sampling of medical records. Based upon our investigation and evaluation of the facts to date, we do not believe these matters and any results from these matters are likely to have any material adverse impact on our business, financial position, operating results or cash flows.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2015 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	840	$	795	$	709
2 years		798		351		697
3 years		1,971		221		642
4 years		610		95		498
5+ years		8,095		75		2,649

	$	12,314	$	1,537	$	5,195

At March 31, 2015, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of March 31, 2015. SunLink expensed $15 and $16 on physician guarantees and recruiting for the three months ended March 31, 2015 and 2014, respectively. SunLink expensed $46 and $83 on physician guarantees and recruiting for the nine months ended March 31, 2015 and 2014, respectively.

Note 12. – Related Party Transactions

A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $42 and $258 for legal services to these law firms in the three months ended March 31, 2015 and 2014, respectively. The Company has expensed an aggregate of $232 and $577 for legal services to these law firms in the nine months ended March 31, 2015 and 2014, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2015 and June 30, 2014 is $43 and $116, respectively, of amounts payable to these law firms.

Note 13. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of March 31, 2015 and 2014 and for the three and nine months then ended is as follows:


	Healthcare Facilities		Specialty Pharmacy		Corporate and Other			Total
Three months ended March 31, 2015
Net revenues from external customers	$	13,850	$	9,307	$	194		$	23,351
Operating profit (loss)		285		146		(716	)		(285	)
Depreciation and amortization		258		201		143			602
Assets		29,597		12,510		15,316			57,423
Expenditures for property, plant and equipment		63		194		1			258

Nine months ended March 31, 2015
Net revenues from external customers	$	43,169	$	25,191	$	493		$	68,853
Operating profit (loss)		3,659		365		(1,982	)		2,042
Depreciation and amortization		978		546		293			1,817
Assets		29,597		12,510		15,316			57,423
Expenditures for property, plant and equipment		195		768		32			995

Three months ended March 31, 2014
Net revenues from external customers	$	14,117	$	10,217	$	132		$	24,466
Operating profit (loss)		226		524		(1,215	)		(465	)
Depreciation and amortization		378		185		210			773
Assets		37,385		12,023		17,217			66,625
Expenditures for property, plant and equipment		162		150		24			336

Nine months ended March 31, 2014
Net revenues from external customers	$	43,671	$	26,385	$	319		$	70,375
Operating profit (loss)		2,342		659		(3,511	)		(510	)
Depreciation and amortization		1,147		522		641			2,310
Assets		37,385		12,023		17,217			66,625
Expenditures for property, plant and equipment		456		433		215			1,104

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, homecare and specialty pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions and capital improvements at existing healthcare and specialty pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and,

•

fluctuations in the market value of equity securities including SunLink common shares;

Operational Factors

•

ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

the ability or inability to obtain external financing for working capital included under lending agreements;

•

changes in interest rates under debt agreements

•

the ability or inability to refinance former or existing indebtedness and potential defaults under existing indebtedness;

•

restrictions imposed by existing or future debt agreements;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, government payors and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Facilities and Specialty Pharmacy Segments;

•

changes in wages as a result of inflation or competition for management, physician, nursing, pharmacy and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality or costs with respect to our information systems for our Healthcare Facilities and Specialty Pharmacy Segments and our corporate office, including both software and hardware; and

•

the availability of and competition from alternative drugs or treatments provided by our Specialty Pharmacy Segment;

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees and other obligations relating to discontinued operations, including sold facilities, retained or acquired subsidiaries and former subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general and other claims which may be asserted against us; and,

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate hospitals (Georgia, Mississippi, Missouri) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

anticipated adverse changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Facilities and Specialty Pharmacy Segments; and,

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding, and other reforms).

Dispositions, Acquisitions, and Renovation Related Matters

•

the ability to dispose of underperforming facilities;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement facilities; and

•

competition in the market for acquisitions of hospitals and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to an mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

SunLink’s business strategy is to focus its efforts on improving internal operations of its existing healthcare facilities and its pharmacy business. We also consider from time to time potential healthcare facility upgrades, acquisitions, development and dispositions, including but not limited to hospitals, physician clinics, ambulatory surgery centers, nursing, long-term care and assisted living homes, medical office buildings and pharmacy businesses. We consider dispositions of facilities or operations based on a variety of factors including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, corporate strategy and other corporate objectives.

Since fiscal 2012, our efforts have been more focused on the disposition of hospital facilities than on acquisitions due to our financial position and need to reduce our leverage and interest expense, the changing nature of certain of our subsidiary hospital markets resulting in, among other things, substantial additional competition, and pressure from Federal and state programs (e.g., Medicare and Medicaid) and private payors to reduce reimbursement for medical services. In July 2012, we sold our Adel, Georgia hospital and its related nursing home; in December 2012, we sold our Dexter, Missouri hospital and its related home health agency; and in December 2014, we our sold our Fulton, Missouri hospital. As a result of the sale of these three hospitals and the efforts to improve operations of our remaining three hospitals and our Specialty Pharmacy Segment, the Company has reduced its debt from $29,021 at June 30, 2012 to $12,314 at March 31, 2015, and added approximately $16,000 to its working capital over the two and a half year period.

Even though the Company’s financial position has improved, we believe our ability to compete for acquisitions is still limited. However, during the last fiscal year, we have evaluated certain rural and exurban healthcare facilities, pharmacy operations and businesses which were for sale, monitored other selected acquisition targets which we believed might become available for sale, and considered the feasibility of developing healthcare facilities on property we own as well as on property that may be for sale. Although we have no current plans to do so, from time to time we may consider the acquisition of other complementary based healthcare businesses, outside of our existing business segments, which are or may become available for acquisition.

At its Board of Directors meeting on February 9, 2015, the Board discussed the Company’s future strategic alternatives. No action was taken on future strategic alternatives other than the Board determined that the Company should discontinue pursuing its previously announced going-private strategy at that time. The Board has not, however, ruled out any future strategic alternative and discussion of various alternatives is continuing.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2014 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; Accounting for income taxes; and

•

Electronic Health Record incentives

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Facilities and Specialty Pharmacy.


	Three Months Ended									Nine Months Ended
	March 31,									March 31,
	2015			2014			% Change			2015			2014			% Change

Net Revenues - Healthcare Facilities	$	13,850		$	14,117			-1.9	%	$	43,169		$	43,671			-1.1	%
Net Revenues - Specialty Pharmacy		9,307			10,217			-8.9	%		25,191			26,385			-4.5	%
Other Revenues		194			132			47.0	%		493			319			54.5	%

Total Net Revenues		23,351			24,466			-4.6	%		68,853			70,375			-2.2	%
Costs and expenses		(23,636	)		(24,931	)		-5.2	%		(66,811	)		(70,885	)		-5.7	%

Operating profit (loss)		(285	)		(465	)		38.7	%		2,042			(510	)		NA
Interest expense - net		(213	)		(234	)		-9.0	%		(677	)		(714	)		-5.2	%
Gain on sale of assets		13			18			-27.8	%		13			18			-27.8	%

Earning (Loss) from continuing operations before income taxes	$	(485	)	$	(681	)		28.8	%	$	1,378		$	(1,206	)		NA


Healthcare Facilities Segment:
Admissions		621			636			-2	%		1,913			1,869			2	%
Equivalent admissions		1,673			1,968			-15	%		5,409			5,981			-10	%
Surgeries		381			481			-21	%		1,209			1,340			-10	%
Revenue per equivalent admission	$	8,279		$	7,173			15	%	$	7,981		$	7,271			10	%

Equivalent admissions – Equivalent admissions is used by management (and certain investors) as a general measure of combined inpatient and outpatient volume for our hospital operations. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and dividing the result by gross inpatient revenues. The equivalent admissions computation is intended to relate outpatient revenues to the volume measure (admissions) used to measure inpatient volume to result in a general approximation of combined inpatient and outpatient volume (equivalent admissions).

Results of Operations

Healthcare Facilities Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Facilities Segment for the periods indicated:


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2015			2014			2015			2014
Source:
Medicare		41.9	%		42.7	%		41.9	%		41.0	%
Medicaid		22.9	%		20.7	%		21.5	%		20.5	%
Managed Care Insurance & Other		24.9	%		24.2	%		25.3	%		25.0	%
Self-pay		10.3	%		12.4	%		11.3	%		13.5	%

		100.0	%		100.0	%		100.0	%		100.0	%

Healthcare Facilities net revenues decreased $267 and $502 for the three and nine months ended March 31, 2015, respectively, compared to the prior year periods. Self-pay net revenues decreased $413 and $1,128 for the three and nine months ended March 31, 2015, respectively, compared to the prior year periods primarily due to the closing of the emergency room in one of our hospitals in September 2014. For the three months ended March 31, 2015, Medicare net revenues decreased 3.1% from the prior year while Medicaid and Managed Care Insurance increased from the prior year.

Healthcare Facilities net revenues included increases of $10 and $105 for the three months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($287) and $611 for the nine months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

Specialty Pharmacy Segment Net Revenues

Specialty Pharmacy net revenues for the three months ended March 31, 2015 were $9,307, a decrease of $910, or 8.9%, from $10,217 for the three months ended March 31, 2014. Specialty Pharmacy net revenues for the nine months ended March 31, 2015 were $25,191, a decrease of $1,194, or 4.5%, from $26,385 for the nine months ended March 31, 2015. The decrease was a result of decreased Louisiana Medicaid revenues including sales of one specialty product which is primarily sold to patients with Louisiana Medicaid coverage. Medicaid has restricted both the number of eligible customers and the number of approved doses of this drug. Sales of oral medications and durable medical equipment and related products increased during the quarter ended March 31, 2015 compared to the prior year.

Healthcare Facilities Segment Cost and Expenses

Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $13,565 and $13,891 for the three months ended March 31, 2015 and 2014, respectively. Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $39,510 and $41,329 for the nine months ended March 31, 2015 and 2014, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2015			2014			2015			2014
Salaries, wages and benefits		60.0	%		59.7	%		58.0	%		58.8	%
Supplies		12.1	%		12.6	%		12.6	%		12.9	%
Purchased services		8.8	%		9.4	%		8.6	%		9.3	%
EHR incentive payments		-0.5	%		-0.3	%		-0.1	%		-2.9	%
Other operating expenses		15.5	%		14.8	%		13.5	%		14.9	%
Rent and lease expense		1.6	%		2.3	%		2.1	%		2.4	%
Depreciation and amortization expense		1.9	%		2.7	%		2.0	%		2.3	%

Salaries, wages and benefits increased slightly as a percentage of net revenue for the three months ended March 31, 2015 compared to the prior year period due to the decreased net revenue in the current year. Salaries, wages and benefits expense for the Segment decreased slightly for the three months ended March 31, 2015 compared to the prior year period.

Supplies expense decreased as a percentage of net revenue in the three and nine months ended March 31, 2015 due to fewer surgeries performed incurred as compared to the three and nine months ended March 31, 2014.

For the three and nine months ended March 31, 2015, the Company reported $64 EHR incentive payments. For the three and nine months ended March 31, 2015, the Company reported a net $43 and $1,258 gain for Medicare and Medicaid EHR incentive payments which were for successful Medicaid attestation by the three hospitals and also adjustments calculated at the time of filing Medicare cost reports for the preceding fiscal year.

Other operating expenses increased as a percentage of net revenues for the three months ended March 31, 2015 compared to the comparable prior year period due to increased insurance expense as a result of higher professional and general liability claims accrued for in the three months ended March 31, 2015 than in the same period during the prior year.

Specialty Pharmacy Segment Cost and Expenses

Cost and expenses for our Specialty Pharmacy Segment, including depreciation and amortization, were $9,161 and $9,693 for the three months ended March 31, 2015 and 2014, respectively. Cost and expenses for our Specialty Pharmacy Segment, including depreciation and amortization, were $24,826 and $25,726 for the nine months ended March 31, 2015 and 2014, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2015			2014			2015			2014
Cost of goods sold		66.4	%		69.3	%		64.5	%		67.6	%
Salaries, wages and benefits		21.1	%		16.4	%		22.5	%		19.3	%
Provision for bad debts		0.7	%		0.7	%		0.6	%		0.6	%
Supplies		0.3	%		0.3	%		0.4	%		0.5	%
Purchased services		3.6	%		3.2	%		3.8	%		3.6	%
Other operating expenses		3.2	%		2.7	%		3.6	%		3.1	%
Rent and lease expense		1.0	%		0.7	%		0.9	%		0.8	%
Depreciation and amortization expense		2.2	%		1.8	%		2.2	%		2.0	%

Cost of goods sold as a percent of net revenues decreased in the three and nine month periods ended March 31, 2015 as compared to the comparable periods of the prior year due to the sales product mix for the current periods. Sales of one high sales volume product with a higher than average cost of goods sold decreased approximately 60%, based on units sold for the three and nine months compared to the comparable periods last year.

Salaries, wages and benefits as a percent of net revenues increased in the three and nine month period ended March 31, 2015 as compared to the comparable period of the prior year due to the increased staffing requirements related to the net growth in the institutional pharmacy business as seven new institutional supply contracts have been added this fiscal year, and due to the Specialty Pharmacy Segment’s inability to reduce costs, especially staffing costs, commensurate with the decline in sales of one high-cost specialty product.

Insurance settlement

Operating Profit and Loss

SunLink had operating losses of $285 and $465 for the three months ended March 31, 2015 and 2014, respectively. SunLink had an operating profit of $2,042 for the nine months ended March 31, 2015 and an operating loss of $510 for the nine months ended March 31, 2015. The decreased operating loss for the three months ended March 31, 2015 compared to the prior year resulted from decreased depreciation and amortization expense this year.

Interest Expense

Interest expense was $213 and $234 for the three months ended March 31, 2015 and 2014, respectively and $677 and $714 for the nine months ended March 31, 2015 and 2014, respectively.

Income Taxes

Income tax benefit of $169 ($272 federal tax benefit and $103 state tax expense) and $105 ($112 federal tax benefit and $7 state tax expense), respectively was recorded for the three months ended March 31, 2015 and 2014, respectively. Income tax expense of $816 ($591 federal tax expense and $225 state tax expense) and income tax benefit of $200 ($190 federal tax benefit and $10 state tax benefit) was recorded for the nine months ended March 31, 2015 and 2014, respectively.

Earnings (Loss) After Taxes

Loss from continuing operations was $316 (a loss of $0.03 per fully diluted share) for the three months ended March 31, 2015 compared to loss from continuing operations of $576 (a loss of $0.06 per fully diluted share) for the three months ended March 31, 2014. Earnings from continuing operations were $562 ($0.06 per fully diluted share) for the nine months ended March 31, 2015 compared to a loss from continuing operations of $1,066 (a loss of $0.11 per fully diluted share) for the nine months ended March 31, 2014. The increased earnings for the three and nine months ended March 31, 2015 resulted from the increased operating profit as compared to the comparable prior year period.

Loss from discontinued operations of $95 for the three months ended March 31, 2015 resulted from loss from operations of business sold. Tax benefit for discontinued operations for the three months ended March 31, 2015 was $55. The loss from discontinued operations for the nine months ended March 31, 2015 of $409 resulted from pre-tax expenses of businesses sold of $503, offset by the loss on sale of Fulton of $197. Tax benefit for discontinued operations for the nine months ended March 31, 2015 was $291.

Net loss for the three months ended March 31, 2015 was $411 (a loss of $0.04 earnings per fully diluted share) compared to a net loss of $964 (a loss of $0.10 earnings per fully diluted share) for the three months ended March 31, 2014. Net earnings for the nine months ended March 31, 2015 were $153 ($0.02 per fully diluted share) compared to a net loss of $1,895 ($0.20 loss per fully diluted share) for the nine months ended March 31, 2015.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service existing debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges we refer to such measurement as “Adjusted EBITDA”, which we report on a company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Facilities Segment Adjusted EBITDA and Specialty Pharmacy Segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three and nine months ended March 31, 2015 and 2014, respectively, is shown below.


	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2015			2014			2015			2014
Healthcare Facilities Adjusted EBITDA	$	543		$	604		$	4,637		$	3,489
Specialty Pharmacy Adjusted EBITDA		347			709			911			1,181
Corporate overhead costs		(573	)		(1,005	)		(1,689	)		(2,870	)
Taxes and interest expense		(44	)		(234	)		308			(914	)
Other non-cash expenses and net change in operating assets and liabilities		1,071			(300	)		(2,875	)		2,433

Net cash provided by (used in) operations	$	1,344		$	(226	)	$	1,292		$	3,319

Liquidity and Capital Resources

Overview

Our primary sources of liquidity are cash on hand and one facility-based revolving loan facility of $625, which has limited availability. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We are nevertheless seeking options to obtain financing for the Company’s liquidity needs.

Although two of the Company’s subsidiaries have been able to borrow money through facility based mortgages, each of which is guaranteed by the Company, utilizing USDA Rural Development Authority guaranties, (individually, an “RDA Loan” and collectively, the “RDA Loans”), and, in the case of our Trace hospital subsidiary, obtain a working revolving capital loan facility of $625, the Company and its subsidiaries currently are funding its working capital needs primarily from cash from operations and from the sale of additional assets. See “Subsidiary Loans” below.

Although continuing operations of the Company’s Healthcare Facilities and Specialty Pharmacy segments have improved in fiscal 2015 compared to the prior year, the Company believes its hospital facilities and its specialty pharmacy business continue to underperform. The Company has incurred losses from continuing operations in eleven of the last fourteen fiscal quarters through the quarter ending March 31, 2015.

In light of the current underperformance of certain of the Company’s hospital facilities , the Company is currently considering the possible sale of one or more hospital facilities. There can be no assurance that the sale will occur or that, if a sale occurs, it will be at a price that results in a gain or net proceeds after transaction costs, taxes and outstanding debt. The Company expects to use a portion of the net proceeds, if any, from future asset sales to fund its working capital needs if its remaining hospitals and its specialty pharmacy segment are not, at that time, providing sufficient cash flow to fund working capital.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, Crown Healthcare Investments, LLC, a wholly owned subsidiary or the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

The Trace RDA Loan had an original term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2015). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural

Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds were used to repay a portion of the Company’s senior debt under the Term Loan under the then outstanding Credit Facility. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.

The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ending March 31, 2015, $875; (b) for the quarter ended March 31, 2015, $750; (c) for the quarter ending June 30, 2015, $625; and (d) thereafter, $500. The Trace Working Capital Loan expires July 2, 2015 and is subject to annual renewal at the discretion of the lender. At March 31, 2015, there were no outstanding borrowings under the Trace Working Capital Loan.

The SHPP RDA Loan had an original term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at March 31, 2015). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and Crown Healthcare Investments, LLC.

Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued the Carmichael Purchase Note. On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue PIK Notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note. The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note, the Carmichael Note for the remaining balance payable of $1,852. The Carmichael Note is payable in five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company.

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	840	$	795	$	709
2 years		798		351		697
3 years		1,971		221		642
4 years		610		95		498
5+ years		8,096		75		2,649

	$	12,315	$	1,537	$	5,195

At March 31, 2015, we had outstanding long-term debt of $12,314 of which $8,290 was incurred under the Trace RDA Loan, $2,002 was incurred under the SHPP RDA Loan, $1,852 was incurred under the Carmichael Notes, and $170 was related to other debt.

Off-balance Sheet Arrangements

At March 31, 2015, SunLink had no material off-balance sheets arrangements.

Discontinued Operations

Fulton Hospital – On December 31, 2014, the Company’s subsidiary, HealthMont of Missouri sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of March 31, 2015 and June 30, 2014 and for the three and nine month periods ended March 31, 2015 and 2014. Fulton retained accounts receivable and certain other assets, including the right to EHR Funds for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. Loss of $197 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the RDA loan described below.

Dexter Hospital - On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). The assets of Dexter consisted of a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, Missouri. Subsequent to the sale, Dexter managed the hospital and related businesses for Southeast Health Center of Stoddard County, LLC through a transition period ended June 30, 2014. Dexter retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology and substantially all liabilities of the hospital as of December 31, 2012. Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially of all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014.

Related Party Transactions

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of March 31, 2015.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2015.

Remediation of Material Weakness

During the quarter end March 31, 2015, our management in response to correspondence from the SEC with respect to our annual report for the year ended June 30, 2014 re-examined the effectiveness of our disclosure controls and procedures. As noted in Amendment No. 1 to our Annual Report on Form 10-K/A, our chief executive officer and chief financial officer concluded that, for the reasons set forth therein under “Management’s Report on Internal Control Over Financial Reporting,” that our disclosure controls and procedures were not effective as of June 30, 2014.

Also as noted therein, in addition, our chief executive officer and chief financial officer also re-evaluated the conclusions regarding our disclosure controls and procedures for other prior periods and concluded that our disclosure controls and procedures were not effective as of the annual periods ended June 30, 2012 and June 30, 2013 for the same reason. Likewise under “Management’s Report on Internal Control Over Financial Reporting” in the Company’s Amendment No. 1 to our Annual Report on Form 10-K/A, we identified a material weakness in the preparation of the Form 10-K for the fiscal years ended June 30, 2014, 2013 and 2012 as management’s assessment of the effective of our internal controls over financial reporting as of June 30, 2014, 2013 and 2012 did not meet the requirement under item 308(a) of Regulation S-K. Finally, as stated in Amendment No. 1 to our Annual Report on Form 10-K/A, the Company believes that it has implemented procedures in the preparation and filing of Form 10-K and its other periodic reports which will remediate for future periods such material weakness in internal controls.

Changes in Internal Control Over Financial Reporting

Except as described above, there were no changes during the quarter ended March 31, 2015, or in the other periods referred to herein, in our internal control over financial reporting or in other factors that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1.

LEGAL PROCEEDINGS

Office of Inspector General Investigation

In March 2014, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD has cooperated with the government with respect to document production, as well as by conducting a joint medical necessity review of a sampling of medical records. Based upon our investigation and evaluation of the facts to date, we do not believe these matters and any results from these matters are likely to have any materially adverse impact on our business, financial position, operating results or cash flows.

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2014. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS

Exhibits:


31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended March 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2015 (unaudited) and June 30, 2014, (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows, for the three months ended March 31, 2015 and 2014 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: May 15, 2015

EX-31.1 2 d897649dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2015 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of March 31, 2015 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


May 15, 2015		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		SunLink Health Systems, Inc.
		Chief Executive Officer

EX-31.2 3 d897649dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2015 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


May 15, 2015		/s/ Mark J. Stockslager
		Mark J. Stockslager
		SunLink Health Systems, Inc.
		Chief Financial Officer

EX-32.1 4 d897649dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2015, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

May 15, 2015

EX-32.2 5 d897649dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2015, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

May 15, 2015

EX-101.INS 6 ssy-20150331.xml XBRL INSTANCE DOCUMENT

2100000

9443408

0.08

3000000

5000000

7239000

6760000

479000

7244000

3823000

66625000

37385000

12023000

17217000

6729000

515000

7279000

7055000

224000

9444000

2000000

24.74

2000000

33505000

1981000

170000

32030000

10697000

32000

13221000

4722000

-334000

4429000

15639000

840000

13478000

755000

11474000

57423000

3415000

12314000

5632000

4885000

461000

22537000

10018000

2705000

5100000

15650000

54567000

9956000

57423000

6961000

1861000

3936000

5084000

1525000

2873000

1522000

24930000

992000

798000

1971000

12314000

610000

840000

8095000

351000

221000

1537000

95000

795000

75000

697000

642000

5195000

498000

709000

2649000

29597000

12510000

15316000

1255000

5444000

985000

188000

461000

3858000

2873000

1089000

2000000

769000

43000

0.060

8290000

750000

0.80

0.0525

2002000

0.08

1852000

600000

9975000

1000000

7761000

2497000

7286000

475000

9444000

2000000

33318000

2314000

30389000

4842000

16506000

73000

14023000

4722000

-334000

4530000

15486000

561000

13444000

807000

11948000

63847000

4186000

12509000

6903000

3587000

461000

23077000

9850000

2547000

4432000

16753000

53466000

14995000

63847000

2978000

6111000

3757000

2786000

270000

2979000

1012000

25775000

1268000

6649000

879000

254000

461000

3858000

2979000

1089000

2000000

769000

116000

8624000

2033000

1852000

625000

Claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006.

1000000

252000

247000

8350000

-197000

6090000

4745000

237000

2012-03-16

-0.20

3319000

8308000

-0.11

-0.09

9443000

-0.20

-0.11

-0.09

9443000

160000

-1625000

18000

529000

-889000

611000

70375000

-1206000

-510000

21000

-1895000

-1445000

1104000

-1895000

854000

-1006000

40000

2310000

714000

32105000

170000

8825000

108000

1326000

3884000

-200000

-1373000

1079000

-190000

17838000

-10000

95000

-620000

119000

5790000

6125000

45000

-556000

8967000

1130000 10479000 83000 83000 91000 1258000 76500000

43671000

2342000

456000

1147000

26385000

659000

433000

522000

319000

-3511000

215000

641000

6683000 148000 12427000 20407000 10131000 319000

8138000

43671000

8695000

6125000

49796000

170000

130000

26385000

516000

560000

-119000

-94000

-66000

-1748000

9985000

577000

21000

<div> Note 11. – Commitments and Contingencies Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of the sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not either pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation in November 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the settlement in the quarter ended March 31, 2015. The promissory note is included in long-term assets in the March 31, 2015 balance sheet. SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred. Sale of Hospital Facilities — The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and various and contingent liabilities. – See Note 3 Discontinued Operations. Office of Inspector General Investigation— In March 2014, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD has cooperated with the government with respect to document production, as well as conducting a joint medical necessity review of a sampling of medical records. Based upon our investigation and evaluation of the facts to date, we do not believe these matters and any results from these matters are likely to have any material adverse impact on our business, financial position, operating results or cash flows. Contractual Obligations, Commitments and Contingencies Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2015 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">840</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">709</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">697</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,971</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">221</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">642</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">610</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">498</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,095</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,649</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,195</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   At March 31, 2015, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of March 31, 2015. SunLink expensed $15 and $16 on physician guarantees and recruiting for the three months ended March 31, 2015 and 2014, respectively. SunLink expensed $46 and $83 on physician guarantees and recruiting for the nine months ended March 31, 2015 and 2014, respectively. </div>

0.02

<div> Revenues before provision for doubtful accounts by payor were as follows for the three and nine months ended March 31, 2015 and 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,573</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,784</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,536</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,407</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,591</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,287</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,562</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,131</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,565</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,555</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,683</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,855</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,425</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,229</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,796</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,845</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,837</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,060</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,125</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,169</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,671</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Specialty Pharmacy Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,307</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,385</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">493</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,351</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,466</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,375</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

10-Q SUNLINK HEALTH SYSTEMS INC SSY

<div> Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2015 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">840</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">709</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">351</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">697</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,971</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">221</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">642</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">610</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">498</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,095</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,649</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,195</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 7. – Goodwill and Intangible Assets SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition. SunLink’s Healthcare Facilities Segment has intangible assets related to its Healthmont acquisition. Goodwill consists of the following:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(985</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(879</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,873</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset. Amortization expense was $35 and $36 for the three months ended March 31, 2015 and 2014, respectively, and $106 and $108 for the nine months ended March 31, 2015 and 2014, respectively. </div>

<div> Goodwill consists of the following:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 13. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.   We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of March 31, 2015 and 2014 and for the three and nine months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,307</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,351</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(716</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(285</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">143</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">602</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,597</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,510</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,316</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,423</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Nine months ended March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,169</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">493</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,659</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,982</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,042</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,817</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,597</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,510</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,316</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,423</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">195</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">768</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">995</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,466</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">226</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,215</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">210</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">773</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,023</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66,625</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Nine months ended March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,375</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,342</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">659</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,511</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(510</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,147</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">522</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,310</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,023</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66,625</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">433</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">215</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

Smaller Reporting Company

<div> Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Healthcare Facilities Segment is composed of three operational areas:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Three community hospital subsidiaries in two states with a total of 183 licensed beds;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to a corresponding SunLink community hospital; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A healthcare facility which is currently vacant except for two medical offices which are rented.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Specialty Pharmacy Segment is composed of four operational areas:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Retail pharmacy products and services, all of which are conducted in rural markets;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Institutional pharmacy services;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Specialty pharmacy services; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="13%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Durable medical equipment.</td> </tr> </table> SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC. </div>

1292000

<div> Note 12. – Related Party Transactions A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $42 and $258 for legal services to these law firms in the three months ended March 31, 2015 and 2014, respectively. The Company has expensed an aggregate of $232 and $577 for legal services to these law firms in the nine months ended March 31, 2015 and 2014, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2015 and June 30, 2014 is $43 and $116, respectively, of amounts payable to these law firms. </div>

7950000

0.06

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Results for all of the businesses included in discontinued operations are presented in the following table: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Fulton Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,255</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,721</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,985</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Dexter Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">560</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Memorial of Adel </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(62</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(66</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,240</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,548</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,479</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(299</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(601</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,196</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,748</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dexter Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">516</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Memorial of Adel </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(94</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(40</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(95</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(119</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Lon sale of Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(150</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(689</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(700</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,445</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(55</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(301</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(291</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(556</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss from discontinued operations </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(95</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(388</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(409</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(889</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of March 31, 2015 and 2014 and for the three and nine months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Corporate and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,307</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,351</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">285</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">146</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(716</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(285</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">201</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">143</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">602</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,597</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,510</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,316</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,423</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Nine months ended March 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,169</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">493</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,853</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,659</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,982</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,042</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">293</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,817</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,597</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,510</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,316</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">57,423</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">195</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">768</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">995</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,466</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">226</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,215</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">378</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">210</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">773</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,023</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66,625</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">336</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Nine months ended March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43,671</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,375</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,342</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">659</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,511</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(510</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,147</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">522</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">641</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,310</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,023</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66,625</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">456</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">433</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">215</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

2015-03-31

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 3. – Discontinued Operations <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Results for all of the businesses included in discontinued operations are presented in the following table: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Fulton Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,255</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,721</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,985</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Dexter Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">560</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Memorial of Adel </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(62</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(66</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,240</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,548</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,479</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(299</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(601</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,196</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,748</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dexter Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">184</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">516</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Memorial of Adel </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(82</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">34</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(94</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(31</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(40</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(95</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(119</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Lon sale of Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(150</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(689</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(700</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,445</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(55</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(301</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(291</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(556</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss from discontinued operations </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(95</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(388</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(409</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(889</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri, LLC (“HOM”) sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of March 31, 2015 and June 30, 2014 and for the three and nine month periods ended March 31, 2015 and 2014. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $197 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the Fulton RDA Loan described below. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Fulton RDA Loan - SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Dexter Hospital - On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2015 and 2014. The components of pension expense for the three and nine months ended March 31, 2015 and 2014, respectively, were as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net pension expense </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">119</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 17%; -webkit-text-stroke-width: 0px"> SunLink contributed $84 to the plan in the three and nine months ended March 31, 2015. </div>

-0.04

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,650</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,753</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,632</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,903</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,850</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

false --06-30 2015

9481000

0.02

0.06

<div> Note 10. – Income Taxes Income tax benefit of $169 ($272 federal tax benefit and $103 state tax expense) and income tax benefit of $105 ($112 federal tax benefit and $7 state tax expense) was recorded for the three months ended March 31, 2015 and 2014, respectively. Income tax expense of $816 ($591 federal tax expense and $225 state tax expense) and income tax benefit of $200 ($190 federal tax benefit and $10 state tax benefit) was recorded for the nine months ended March 31, 2015 and 2014, respectively.   At March 31, 2015, the Company had $5,084 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At March 31, 2015, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,961. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized. </div>

<div> Note 8. – Long-Term Debt Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,290</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,624</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,002</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less current maturities </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(840</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(561</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,474</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,948</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (now known as Crown Healthcare Investments, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi. The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2015). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds was used to repay a portion of the Company’s then currently outstanding debt. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.   The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ended March 31, 2015, $750 and (b) for the quarter ending June 30, 2015, $625. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At March 31, 2015, there were no outstanding borrowings under the Trace Working Capital Loan. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at March 31, 2015 and June 30, 2014). SHPP RDA Loan - On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia. The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at March 31, 2015). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare. Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company. </div>

<div> Note 1. – Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2015 and for the three and nine month periods ended March 31, 2015 and 2014 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

0000096793

-0.04

9443000

1000000

203000

13000

411000

-409000

-287000

68853000

1378000

84000

2042000

22000

153000

-700000

995000

153000

614000

562000

33000

1817000

677000

32135000

188000

9221000

106000

1298000

3410000

816000

5084000

1020000

6090000

591000

16253000

225000

70000

-5078000

97000

6017000

6060000

41000

49000

-291000

7035000

175000

995000 7548000 <div> Note 5. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received. Revenues before provision for doubtful accounts by payor were as follows for the three and nine months ended March 31, 2015 and 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,573</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,784</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,536</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,407</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,591</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,287</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,562</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,131</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,565</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,555</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,683</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,855</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,425</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,427</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">151</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,695</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,954</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,229</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,796</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,845</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,837</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,060</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,125</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,850</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,169</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,671</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Specialty Pharmacy Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,307</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,217</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,385</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">194</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">493</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,351</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,466</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,853</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">70,375</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.   Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,650</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,753</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,632</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,903</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,850</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and nine months ended March 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended March 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,619</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,165</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(101</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,266</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2015 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">188</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,632</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Nine Months Ended March 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,903</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,805</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,010</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(211</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,221</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2015 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">188</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,632</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended March 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,596</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,552</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(39</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,591</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">515</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,244</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Nine Months Ended March 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,286</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">475</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,138</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,308</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,695</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,825</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">515</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,244</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Net revenues included increases of $10 and $105 for the three months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($287) and $611 for the nine months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. </div> <div> Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,290</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,624</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,002</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less current maturities </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(840</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(561</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,474</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,948</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records  Incentives Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services. For the three and nine months ended March 31, 2015, the Company reported $64 Medicaid incentive payments. For the three and nine months ended March 31, 2014, the Company reported net gains of $43 and $1,258, respectively, for Medicare and Medicaid EHR incentive payments. </div> 1 46000 11000 3 <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and nine months ended March 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended March 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,619</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,165</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(101</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,266</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2015 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">188</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,632</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Nine Months Ended March 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,903</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to earnings </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,805</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">145</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,010</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(211</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9,221</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2015 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">188</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,632</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended March 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,596</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,552</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(39</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,591</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">515</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,244</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Nine Months Ended March 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Specialty Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,286</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">475</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,138</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,308</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,695</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,825</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at March 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">515</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,244</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(985</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(879</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,873</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The components of pension expense for the three and nine months ended March 31, 2015 and 2014, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net pension expense </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">97</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">119</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> P3Y <div> Note 9. – Insurance settlement In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the nine months ended March 31, 2015. </div> 4842000 64000 74913000

43169000

3659000

195000

978000

25191000

365000

768000

546000

493000

-1982000

32000

293000

5555000 151000 12425000 20536000 10562000 493000

7805000

43169000

9010000

6060000

166 2 3 2 183 3 49229000

145000

211000

4 25191000

754000

764000

-95000

34000

63000

-197000

-1196000

6721000

4745000

237000

2012-07-05

232000

2012-07-05

0.015

Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%

2015-07-02

0.06

P15Y

8500000

850000

0.020

The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%

0.05

P25Y

1800000

2012-10-31

2008-04-22

2017-10-22

185000

90000

500000

P5Y

-0.10

2596000

-0.06

-0.04

9443000

-0.10

-0.06

-0.04

9443000

18000

-388000

105000

24466000

-681000

-465000

7000

-964000

-689000

336000

-964000

-576000

9000

773000

234000

10591000

75000

2591000

36000

1289000

-105000

366000

-112000

7078000

7000

32000

40000

1808000

1837000

15000

-301000

2994000

3240000 16000 43000 26303000

14117000

226000

162000

378000

10217000

524000

150000

185000

132000

-1215000

24000

210000

1978000 50000 3855000 6784000 3287000 132000

2521000

14117000

2552000

1837000

15954000

75000

39000

10217000

34000

47000

-40000

-82000

-62000

-601000

3255000

258000

-0.04

1619000

-0.03

-0.01

9443000

-0.04

-0.03

-0.01

9443000

13000

-95000

10000

23351000

-485000

84000

-285000

7000

-411000

-150000

258000

-411000

-316000

12000

602000

213000

10729000

65000

3266000

35000

1208000

-169000

343000

-272000

6181000

103000

22000

31000

1877000

1845000

16000

-55000

2695000

187000 15000 64000 25196000

13850000

285000

63000

258000

9307000

146000

194000

201000

194000

-716000

1000

143000

1565000 55000 3911000 6573000 3591000 194000

1554000

13850000

3165000

1845000

15695000

65000

101000

9307000

184000

186000

-31000

2000

10000

-6000

-299000

-9000

42000

0000096793 us-gaap:ManagementMember 2015-01-01 2015-03-31 0000096793 ssy:FultonHospitalMember 2015-01-01 2015-03-31 0000096793 ssy:MemorialHospitalOfAdelMember 2015-01-01 2015-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2015-01-01 2015-03-31 0000096793 ssy:DexterHospitalMember 2015-01-01 2015-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2015-01-01 2015-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 ssy:OtherMemberMember 2015-01-01 2015-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2015-01-01 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2015-01-01 2015-03-31 0000096793 2015-01-01 2015-03-31 0000096793 us-gaap:ManagementMember 2014-01-01 2014-03-31 0000096793 ssy:FultonHospitalMember 2014-01-01 2014-03-31 0000096793 ssy:MemorialHospitalOfAdelMember 2014-01-01 2014-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2014-01-01 2014-03-31 0000096793 ssy:DexterHospitalMember 2014-01-01 2014-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-01-01 2014-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 ssy:OtherMemberMember 2014-01-01 2014-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-01-01 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-01-01 2014-03-31 0000096793 2014-01-01 2014-03-31 0000096793 ssy:CastlemarkPropertiesLlcMember 2014-07-01 2015-03-31 0000096793 ssy:TwoThousandFiveEquityIncentivePlanMember 2014-07-01 2015-03-31 0000096793 ssy:StockIncentivePlanTwoThousandElevenMember 2014-07-01 2015-03-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-07-01 2015-03-31 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-07-01 2015-03-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-07-01 2015-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2014-07-01 2015-03-31 0000096793 us-gaap:ManagementMember 2014-07-01 2015-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2014-07-01 2015-03-31 0000096793 ssy:FultonRdaLoanMemberssy:FultonHospitalMember 2014-07-01 2015-03-31 0000096793 ssy:FultonHospitalMember 2014-07-01 2015-03-31 0000096793 ssy:MemorialHospitalOfAdelMember 2014-07-01 2015-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2014-07-01 2015-03-31 0000096793 ssy:DexterHospitalMember 2014-07-01 2015-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-07-01 2015-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 ssy:OtherMemberMember 2014-07-01 2015-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-07-01 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-07-01 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2015-03-31 0000096793 2014-07-01 2015-03-31 0000096793 ssy:TwoThousandFiveEquityIncentivePlanMember 2013-07-01 2014-03-31 0000096793 ssy:StockIncentivePlanTwoThousandElevenMember 2013-07-01 2014-03-31 0000096793 us-gaap:ManagementMember 2013-07-01 2014-03-31 0000096793 ssy:FultonHospitalMember 2013-07-01 2014-03-31 0000096793 ssy:MemorialHospitalOfAdelMember 2013-07-01 2014-03-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2013-07-01 2014-03-31 0000096793 ssy:DexterHospitalMember 2013-07-01 2014-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-07-01 2014-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 ssy:OtherMemberMember 2013-07-01 2014-03-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2013-07-01 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2013-07-01 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2014-03-31 0000096793 2013-07-01 2014-03-31 0000096793 ssy:FultonRdaLoanMember 2014-07-01 2014-12-31 0000096793 ssy:FultonRdaLoanMemberssy:FultonHospitalMember 2014-07-01 2014-12-31 0000096793 ssy:FultonHospitalMember 2014-07-01 2014-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2012-07-02 2012-07-02 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:PaymentInKindPIKNoteMember 2012-04-22 2012-04-22 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:PaymentInKindPIKNoteMember 2012-10-22 2012-10-22 0000096793 2015-01-31 2015-01-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:ScenarioForecastMember 2015-06-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-06-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2014-06-30 0000096793 us-gaap:ManagementMember 2014-06-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-06-30 0000096793 2014-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-06-30 0000096793 2013-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2012-07-11 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2012-07-11 0000096793 ssy:CastlemarkPropertiesLlcMember 2015-03-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2015-03-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2015-03-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2015-03-31 0000096793 us-gaap:ManagementMember 2015-03-31 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2015-03-31 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2015-03-31 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2015-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2015-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-03-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:ScenarioForecastMember 2015-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2015-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2015-03-31 0000096793 ssy:InterestOnOutstandingDebtMember 2015-03-31 0000096793 ssy:OperatingLeasesMember 2015-03-31 0000096793 us-gaap:LongTermDebtMember 2015-03-31 0000096793 2015-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-12-31 0000096793 2014-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-03-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-03-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-03-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-03-31 0000096793 2014-03-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-12-31 0000096793 2013-12-31 0000096793 ssy:FultonRdaLoanMember 2012-03-16 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2008-04-22 0000096793 2015-05-13 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2012-10-31 iso4217:USD shares pure utr:acre iso4217:USD shares ssy:Segment ssy:Physician ssy:Hospital ssy:Beds ssy:State ssy:Areas ssy:Law_Firm ssy:Installment

EX-101.SCH 7 ssy-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Insurance Settlement link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Revenue Recognition and Accounts Receivables - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Insurance settlement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20150331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accounts Receivable, Net, Current Due from third party payors Accrued Income Taxes, Current Income tax payable Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to earnings/revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts Table [Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Area of Real Estate Property Real property Assets Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Assets, Noncurrent [Abstract] Noncurrent Assets: Disposal Group, Including Discontinued Operation, Assets, Current Current assets held for sale Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Carmichael. Carmichael's Cashway Pharmacy, Note [Member] Carmichael Notes [Member] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase in Cash and Cash Equivalents Castlemark Properties Llc [Member] Castlemark Properties Llc [Member] Castlemark Properties, LLC [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 9,444 shares at March 31, 2015 and at June 30, 2014 Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings (Loss) Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Line Items] Debt Disclosure [Line Items] Debt Disclosure [Line Items] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Floating rate of interest, spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument, Interest Rate, Effective Percentage Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum Floating rate of interest, lesser Debt Instrument, Interest Rate, Stated Percentage Interest rate percentage Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Note due date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt instrument number of installment payment. Debt Instrument Number Of Installment Payment Number of semi-annual installment of interest payment Debt Instrument, Periodic Payment Principal and interest payment Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Net of Valuation Allowance Net deferred tax asset Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income tax asset Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income tax asset Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan, Expected Return on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Depreciation, Depletion and Amortization Depreciation and amortization Dexter hospital. Dexter Hospital [Member] Dexter Hospital [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Loss sale of Fulton Hospital Loss on sale of assets Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Earnings (Loss) before income taxes Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (loss) before income taxes: Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operation, Tax Effect of Discontinued Operation Income tax expense (benefit) Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets held for sale Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Early repayment penalty on debt. Early Repayment Penalty On Debt Early repayment penalty Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings (Loss): Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Electronic health records incentive reimbursement receivable. Electronic Health Records Incentive Reimbursement Receivable [Text Block] Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Expenses on physician guarantees and recruitment. Expenses On Physician Guarantees And Recruitment Expenditure on physician guarantees and recruitment Extinguishment of Debt, Amount Loan proceeds applied as payment against the company's senior debt Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Revenue from Financial and Health Care Services Financial And HealthCare Services Revenue Net revenues Operating revenues (net of contractual allowances) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fulton Hospital [Member] Fulton Hospital [Member] Fulton Hospital [Member] Fulton Rda Loan [Member] Fulton Rda Loan [Member] Fulton RDA Loan [Member] Gain (Loss) Related to Litigation Settlement Estimated fair value of the real property Gain (Loss) on Disposition of Assets for Financial Service Operations Gain on sale of assets Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. Health Care Organization, Medicare and Medicaid Electronic Health Records Incentives, Gain (Loss) Gain (loss) realized on incentive payments EHR incentive payments Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities Segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Significant Changes in Estimates Net revenues for settlements and filings of prior year Medicare and Medicaid cost reports Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings (Loss) from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings (Loss) from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Loss from Discontinued Operations, net of tax Loss from discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit) Increase (Decrease) in Restricted Cash Net change in cash in escrow Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Insurance Receivable for Malpractice [Abstract] Insurance Receivable for Malpractice [Abstract] Insurance Recoveries Insurance settlement Insurance settlement Insurance settlements. Insurance Settlements [Text Block] Insurance Settlement Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Total Interest Expense Interest expense - net Interest on outstanding debt. Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory Labor and Related Expense Salaries, wages and benefits Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities held for sale Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Long-term Line of Credit Line of credit, outstanding borrowings Line of credit facility borrowing base percentage of eligible billed accounts receivable. Line Of Credit Facility Borrowing Base Percentage Of Eligible Billed Accounts Receivable Line of credit, borrowing base Line of Credit Facility, Borrowing Capacity, Description Line of credit, loan description Line of Credit Facility, Expiration Date Working capital expiration date Line of Credit Facility, Initiation Date Date of loan agreement Line of Credit Facility, Maximum Borrowing Capacity Line of credit, ceiling amount Loan proceeds to be used to finance improvements. Loan Proceeds To Be Used To Finance Improvements Loan proceeds to be used to finance improvements Loan proceeds used for acquisition. Loan Proceeds Used For Acquisition Loan proceeds used for acquisition Loans Payable RDA Loan Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt Total Long-term debt, excluding current maturities, total Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Malpractice Insurance, Description Insurance claim, malpractice description Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medicare license. Medicare License [Member] Medicare License [Member] Medicare. Medicare [Member] Medicare [Member] EX-101.PRE 11 ssy-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) (Trace RDA Loan [Member], USD $)	9 Months Ended
	Mar. 31, 2015	Jun. 30, 2014	Jul. 11, 2012	Jun. 30, 2015
Debt Disclosure [Line Items]
Date of loan agreement	Jul. 05, 2012
Line of credit, ceiling amount	$ 750,000		$ 1,000,000
Debt instrument maturity period	15 years
Floating rate of interest, spread	1.50%
Floating rate of interest, lesser	6.00%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	6.00%
Loan proceeds applied as payment against the company's senior debt	8,500,000us-gaap_ExtinguishmentOfDebtAmount
Loan proceeds to be used to finance improvements	850,000
Debt instrument description	Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%
Line of credit, borrowing base	80.00%
Line of credit, outstanding borrowings	0us-gaap_LineOfCredit	0us-gaap_LineOfCredit
Working capital expiration date	Jul. 02, 2015
Line of credit, loan description	The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ended March 31, 2015, $750 and (b) for the quarter ending June 30, 2015, $625.
Scenario, Forecast [Member]
Debt Disclosure [Line Items]
Line of credit, ceiling amount				625,000
Mortgages [Member]
Debt Disclosure [Line Items]
Date of loan agreement	Jul. 05, 2012
Loan agreement amount			$ 9,975,000

XML 13 R48.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 23,351us-gaap_SalesRevenueNet	$ 24,466us-gaap_SalesRevenueNet	$ 68,853us-gaap_SalesRevenueNet	$ 70,375us-gaap_SalesRevenueNet
Operating profit (loss)	(285)us-gaap_OperatingIncomeLoss	(465)us-gaap_OperatingIncomeLoss	2,042us-gaap_OperatingIncomeLoss	(510)us-gaap_OperatingIncomeLoss
Depreciation and amortization	602	773	1,817	2,310
Assets	57,423us-gaap_Assets	66,625us-gaap_Assets	57,423us-gaap_Assets	66,625us-gaap_Assets	63,847us-gaap_Assets
Expenditures for property, plant and equipment	258	336	995	1,104
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	13,850	14,117	43,169	43,671
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	13,850	14,117	43,169	43,671
Operating profit (loss)	285	226	3,659	2,342
Depreciation and amortization	258	378	978	1,147
Assets	29,597	37,385	29,597	37,385
Expenditures for property, plant and equipment	63	162	195	456
Operating Segments [Member] \| Specialty Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	9,307	10,217	25,191	26,385
Operating profit (loss)	146	524	365	659
Depreciation and amortization	201	185	546	522
Assets	12,510	12,023	12,510	12,023
Expenditures for property, plant and equipment	194	150	768	433
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	194	132	493	319
Operating profit (loss)	(716)	(1,215)	(1,982)	(3,511)
Depreciation and amortization	143	210	293	641
Assets	15,316	17,217	15,316	17,217
Expenditures for property, plant and equipment	$ 1	$ 24	$ 32	$ 215

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#A_+]<%@(``"\>```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4]OTS`8QN](?(?(5]2X M_L,8J.T.`XXPB?$!3/*VB9K8ENV-]MOCI%LU3:55126>2Z,F]OO\XL/OD&=V ML^F[XI%";)V=,U%.64&V/MF=K_U M%(N\V\8Y:U+RGSB/54.]B:7S9/.3I0N]2?EO6'%OJK59$9?3Z16OG$UDTR0- M,]AB]IF6YJ%+Q9=-OKTC"=1%5MSN%@Y9.: MV+0^OLL8C!],&)[\/>!IW_=\-*&MJ;@S(7TS?<;@FX[_=F']R[EU>7S(`4JW M7+85U:YZZ/,)E-$',G5LB%+?E>.U[$UKG[F/Y(^+(Q\OXL(@P_N-@\_DD"`< M"H1#@W"\!^&X`N'X`,)Q#<+Q$81#3%%`4(PJ4)0J4)PJ4*0J4*PJ4+0J4+PJ M4,0J4,PJ4P3')7I MJMLF-V@7/H3]W&/YN=:["\['7'`&.A_@N<$<=D]\'D0AM;3O,`]U@?O$7(Z> M'_BJC*2A?JVI/I#-Q[IW\0<``/__`P!02P,$%``&``@````A`+55,"/U```` M3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ? M>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSB MIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`S4_#WD4"``!T'0`` M&@`(`7AL+U]R96QS+W=O=^5WP/ M0]SV765D-C=%Z.J^V7:;RGQ]^71S9XJ8?-?X7=^%RAQ#-(^K]^\>/H>=3_E+ ML=T>8I%7Z6)EVI0.'\HRUFW8^SCK#Z'+3];]L/?#UJ]^$4N?S93E< MKF%6;]8LGIO*#,^-6%.\'`]YZ_\OWJ_7VSI\[.MO^]"EO^Q1_NB'U]B&D/*B M?MB$5)EQ*I:G)V)G6;,I_R$GGP=7SAV2HTNR'%TB.?:>+,?>(SDJ9#DJ2(YU M9#G6(3E.R7*<0CFW;#FW2,XBDW"Z0H_IN,OD'*'S>XSV9Y\&/`RV4Z!1A,T\ M@X5]M$(M(M.:I+FT;:!MA$U`@ M`85-0($$5#9R%"+'TJT#O6/916YAE3OV7`54P-; M#13#-L[HF_+-?Z6K7P```/__`P!02P,$%``&``@````A`#'4Y9)`!```"@\` M``\```!X;"]W;W)K8F]O:RYX;6R4E]N.XC@0AN]7VG>(2#*&,(6JNP`3_*?_U555R]^FMY-Y/JC23 M8N8''\:^1T4F<_/OJ>-D3DA$M!9_Z>:O_3_>^_W>VD^O$JY0\/ M!(2>^84QU>UHI+."ED1_D!45<&4C54D,+-5VI"M%2:X+2DW)1^%XG(Q*PH3? M*=RJ]VC(S89E]$EF=4F%Z404Y<1`^+I@E?;O[S:,TV_=B3Q255])"7&_<=_C M1)OGG!F:S_P)+.6.6C^HNGJH&8>K-]$X\D?W_2&7RLOIAM3S:2]]9;@JX/AZ/^]^^4+8M MS.%'D!\A_=9!N$_[Z8GV>`='4LA4^BP,,_MT(3KWF804-JXOX&2![ZE;!E_4 M(@^:P+'*HQ0Y%9KF*7S3DK.<@%GI`^%$9!2IQ#=()KQ.!B+HHXF03&OX.Z)9 M&0BJM*)!*O$[@_FE@H,!]WMK)J@D$\ANO[LE`A_E MH=9,4*W3?RJJ.ECQ7IR4Z>F=GYC.)&14U)"*\_M#=.^/I_M7!5&TD#R'DDB? M_ZL!#7QOG(*;T[TO]">%^Z8O-)-;P9HJ:PF;9YFLH7+[1$YB%$(P/M7YF^8L M@S#:S=V"`:><9D9)2P%`H;!V0Z_L&0@<$A?05TN:KLD; M]%!D':ZEP`'O498E,\V=='MJJ$Q@80M-FEDR"08P<`A\:9HD`+0D"EK#&DZA M2=9V311*@D$,'!(_,P&'9X2CUB+2USVXL;4*,L%`!@Z1%X@&9R"7V)H$PQE< M22*,*U#HNK(H)J.@KA8H\CL@R&W,=.5S;[6=5ER51^^:AI;V`O)Y:7CM8:%B<.V3JK+\OE46:>(YT8TPB+09U'HDJ6%83R]*LTUL"8 MXM3'#M7'^0V/"[_F][%@<3PX8;$#-9[DQ_V'L8AUL,^QP_1PP\=,3_'$19`6$6VSL(#TLA(LLMH1:ID=M)-WP'AU>8^__!P``__\#`%!+`P04``8`"````"$`[;,L MN-0'```2)```&````'AL+W=OGKF[[=,F>`JYT)>9KI] MC@L?5[FJH/WTZ?MA/_E6U$U9'9^G8NY,)\5Q76W*X]OS])^_O\RBZ:1I\^,F MWU?'XGGZHVBFGUY^_NGIHZJ_-KNB:"=@X=@\3W=M>UHM%LUZ5QSR9EZ=BB,@ MVZH^Y"W\6K\MFE-=Y)MNTF&_GDL%[]]G:LZOQU M#[J_"S]?][:[7RSSAW)=5TVU;>=@;H$+M37'BW@!EEZ>-B4H4-L^J8OM\_2S M6&6^,UV\/'4;]&]9?#3&SY-F5WW\4I>;W\MC`;L-?E(>>*VJKXKZVT8-P>2% M-?M+YX$_Z\FFV.;O^_:OZN/7HGS;M>#N)2A2PE:;'[)HUK"C8&;N+I6E=;6' M!<"_DT.I0@-V)/_>_?]1;MK=\]0+YLO0\030)Z]%TWXIEM-7A/R0) M;0J-N-H(S-!&A#O6R`(7U.F3>9N_/-75QP2"!A[9G'(5@F(%AGMAN(RSU&M* M0:(R\EE9Z6R!B`;<\^TE=)\6WV!'UYJ2(`4.Q$#Q*27M*6K_E%G9#PQS!)V2 M]0SE/%!TE@5[Q65YX/7+_NI5J$E,A4>?E]@4IC.U&>&2&I$VA1G);(9AA`CU MJ-#;`A7Y>>J;/@CHVA*D8`PK'Z1\0/*!S!@@2X/G/.X#-0E.A[G$D"T1*7$7 M9NY2Q$Q"2O#`=#;?!7V"E+"3 M)R*?!4]*88]MCC3AP`F&M7?&,P)#\CD_FT@+J+3;0:7(3%)\-HN2D(*27,]; MLE.<$MSW`^91:>)!%"VYQTP1MXPGXB*'Q&E MR$P4RXH)4O3)<$*7A5E*\67,-D6:N.<*;XA^/!P,=P:)YBR[LQ\,C^^6EQ+4B/$.E005T>`2U$;A<`AE*DW5T]%Q*+#ZFLDZ M8C4]T9P^G84L7Z4,=]BZ)<$#1[#Y&<&787Q-F*JHXX5A_27"F#<2@1PMS.4+ M3QD>L6"5!/=\,2Q<.\RT[T7&QE*/J>H[7IABLR!DR381R$%A;A`SX2G%XYAY M7!(%]9K(8B\AX%.4Q5:5W@*E!G'),^$8G8Z.PL[L MR&)%-1'(T=YR(W;<4XK[O*I)C>N%.S[;EXS.7UX5IHKW>&%8ZN'(GM]&8_;@ M1"#':.^L$6F-9.8(V7F7=0VW6[R.31-US$(BT1S<>?X6DU)TB/(N&"5%F>6, MHL-<*NBA7L&U>P5>.1+-Z4/)EH0V>MQCF4'2^0'O-3**AV*83X6Q7F%@XK-\ERO'=P MD:/U>7R!*<67(1,@";X,6*[)-(R.595XF$\%LNYAI$"[BXB'0ZT=:);Z&8_< M5'VF/#<9,VA'SP[0_B.X[S#_9W1^9'3#5-]#S81K-Q,Q>W"B.?V1$ZQ\I12/ M>;\@"2ZL-V$-]XZ+C(VCPE1Y-B+S3O;'8FY&),0$W?+$-1L&!J:W0'D+S*Z` M5,U#781K=Q'"87Y(-`F_ZLU\VT]H1.,7_&3B%_QDPC-QW4\/M1&NW48(WM@E MFF3T$=:(M$8RALY6'MIMF*M92))AD;S#)`:C.8 M&^5=1F8SAGI`%;).X8X/[`[A0I`AZ99"BV$IO,?(/(MQ3:&JR.-]B/4;C)]? MB`0_PHG7%_G^#W2I-2*MD9+K48ECQ\CC9Q21XAW)"G*JH17^-: M40_K,(TSWFQKDIG-<-HP(BU.9HY01SQ4TSVLZ7>R&9*P[8M]_A$JU4:NX?(. MGEW'B3*X\D!\<#N+=6S>"_`0TZ1K*T_OX)+A_!56W=)0+Q(7[*,RO(*!5Q0. M1?U6I,5^WTS6U;NZ7N%"AW(>Q:L?B5C!Q0'(2&Q5E7; M_Z(N'IQO\[S\#P``__\#`%!+`P04``8`"````"$`BN#F5:<"``"M!@``&0`` M`'AL+W=OFF:E\`GY][?,_=^5C?OH@*/3.E MN:P3''H!1JRF,N-UD>`?W^^O5AAI0^J,5+)F"7YE&M]N/GY8GZ1ZTB5C!@%# MK1-<&M/$OJ]IR031GFQ8#3NY5((86*K"UXUB)&N=1.5'07#M"\)K[!AB]1X. MF>>[8!'T/G2#JZ=A<42D:H#CPBIO7EA0C0>.' MHI:*'"K0_1+.">VXV\4%O>!422USXP&=[P*]U'SCW_C`M%EG'!38M"/%\@3? MA?%^COW-NLW/3\Y.>O"-="E/GQ3/'GG-(-E0)EN`@Y1/%OJ061,X^Q?>]VT! MOBJ4L9P<*_--GCXS7I0&JKT`0597G+VF3%-(*-!XT<(R45E!`/!$@MO.@(20 ME_9]XIDI$SR[]A;+8!8"'!V8-O?<4F)$C]I(\3-? M7*_]9T@I/6.V#@,7HLM#/\\0G'+OL.8:L'DGI=D*RIKAF4 M_>V"=3*LTUA&-#EO^P9D'-'N$K%KAI:&PO=V]R:W-H965T'6E'6JUV9YY-8L#J)(YBTW3__99=:;`-TW1> M@-C'IXY/V95B\>6UKH(7UDDNFF5(1G$8L*80)6_VR_"_?Y\>IF$@%6U*6HF& M+<,W)L,OJ]]_6YQ$]RP/C*D`&!JY#`]*M?,HDL6!U52.1,L:F-F)KJ8*'KM] M)-N.T=(LJJLHB>-Q5%/>A,@P[S[#(78[7K!'41QKUB@DZ5A%%>B7!][*=[:Z M^`Q=3;OG8_M0B+H%BBVON'HSI&%0%_-O^T9T=%O!OE])1HMW;O-P15_SHA-2 M[-0(Z"(4>KWG632+@&FU*#GL0-L>=&RW#+^2^89,PFBU,`;]X.PDK=^!/(C3 M'QTO_^(-`[-?1;J8=@<72U^LEDX.\N*-F.'BOUCSC]R?C^H"#= M.>Q(;VQ>OCTR68"C0#-*"2$^%)$E/`M\]"4D&DZ0]"7R?2>XIB'`WQIQ'JNAJ MT8E3`"<.],J6ZO-+YD"H74G!V]NN@!UZS5>]R"P%M(14OJRR?+J(7L#^HL>L M$0.WYXQ)7,3F!N("B4#?6238-5RD7N2*3(BK8(V0J4F1WMC&&G`$@#.V@(_= MT>!EF%D[S_*9%QDQ>,Y,9&O`B0PTGX^LP9`_*W*2I%YDQ,Q,UL@D=FA@9[,C+_>"!F@C*2E&2>$'<^CR\&.KK&0W1I\#U=B/FU+G?^E[HF M0W1IL*LKC2\WP5RY-6)RX]?#-//SYDSGX\M!=]S2[[+!EUTO%-ZD.T++C,C;O1!19=@Q82-GQN!Z]=A#[*C MX[(;T0>55N@H_;VGL5\E>E#_3ISF5UE!DAOSZ`OVG-A6U:S;LPVK*AD4XJC[ MR01J]GD4>]TUF4/O`3VF-[Z!'MB,1^<):$%;NF??:;?GC0PJM@/*>#2!Y'38 MQ.*#$JUI=K9"0?-I?A[@SP:#KB8>`7@GA'I_T&WR^>_+ZG\```#__P,`4$L# M!!0`!@`(````(0`E8#51$@4``.H3```9````>&PO=V]R:W-H965T?*7$25,`1 MT*]_OS,8B#UN$]J')CD<#\?C\1SP^MM;GCDOHJQ266Q<-AJ[CB@2N4^+X\;] M^>_#W<)UJCHN]G$F"[%QWT7E?MO^_MOZ599/U4F(VH$(1;5Q3W5]7GE>E9Q$ M'E18%7#G(,H]K^%D>O>IIX6K(JS*(3'DX9`F(I+) M>JBY8G0\+ENMUTW"?J5BM=*^^Y4)_GZ1YGN?Z2%@&S#.N$*/$KYA-3O>X1@L&>- M?FA6X._2V8M#_)S5_\C7/T5Z/-6PW#.8$4YLM7^/1)5`1B',R)]AI$1F(`#^ M.WF*I0$9B=\VK@\W3O?U:>-.YJ-9,)XPH#N/HJH?4@SI.LES5X'53%K.3G'@?\]A)B/L&+AT&#:B`-<`#R;0SP+FK\_BXXKHQ"(9Q7:WV2E` M5^8391\P""6R*=/YW`S#/^($/<>8$=37\!DA&=9-2^UTMNSC-KG<*8[:%YC< MD`(1!;@&&-K@1L.U(1EVFJZ-38DVQ9FKPF'C)2F=4%V_:(\HP#7`D`JE/%PJ MDHG4^8)(59QE(S68C>'/)(2*H&G51S`<0(=P;8@A?OX5\4BFXFD-*`[0)!,M1,I.\5IM8]'8](*0G5=DTH!K@&&U*4I%3OV'+STNF0< M1"5/S,K=*<[GDM5U33(%N`88DAGHT].+FBCJ&C:.EI2T-3(HMF0M*); MBB;<0KB.F-+1 M,URWR$*XCIGKT'TW]C;)6;F6*IEV;:9;6;CR*1!:' MZXBI$&UGN$)E4E",ER<*Z\F3:4[6*J1(9'&XCI@*T66&*U2>9.30>JACFG&U M"BD261S>(JI_SWWTGKY_&XI]8G_75[UA$]M;4-MK29<]%%I(9"%<1TR%Q.5N M*%0F='W5?>I4H85$%L)UQ%1(W.R&P@].EG!)DBY[00J(642\HRV7SBM)795/;>$:#]])ZJSIR4><"N2B/ M(A195CF)?,;C%`;/5CW:'_7<^\UA37\!3EK.\5'\%9?'M*B<3!Q@Z'@40&LO MU5F-^E'+`AW0@,``$4*```9````>&PO=V]R:W-H965TOO(!B4*JAJ[;I$V:IGT\.V""5<#( M=IKVW^_:)@F8+DWSD`0X]]QS[SW87MT^UY7S1+B@K$E0X/K((4W&:+E!.9?N:--*0<%)A M"?I%25MQ9*NS:^AJS!_W[4W&ZA8HMK2B\D63(J?.EE]W#>-X6T'=S\$49T=N M?3&BKVG&F6"%=('.,T+'-2^\A0=,ZU5.H0+5=H>3(D%WP3(-)LA;KW2#_E!R M$+W_CBC9X3.G^3?:$.@VS$E-8,O8HX)^S=4M"/9&T0]Z`C^XDY,"[ROYDQV^ M$+HK)8Q[!A6IPI;YRST1&704:-QPII@R5H$`^'9JJJP!'<'/"0HA,#/2-$UW6/)5ZO M.#LX8!9()5JLK!QK.5]P2=RSK,9HP) MAHCTB%`-!S4G25",+6D"DWJ]QT=)*F@H*;3R;5Z!6(K&B&D\/V$&(J%7?9&7 MQ2DP]!4YYW[-%B=>W=.-P1C3J":GO1N#S$!S?68%!I/U,\_MS`8#0S^KBZ.A MNO2(L6<%4=>+46!+3&0/R6"B4+O*=_W0$F*>ZS8-NC)_CQ`%MH58B38&6,H.)],B"V/>'CU/S>*QC,=1QW=*C@BP]T?D5-:^2P8!3>H:V M3)\>,;:A`YC5]=W1:$O.PJI_TX%T`[3`M']GX.+`6HXOST:CWUI7.E`_NUEX MQP-1V\@[:C>KY6!M"6S3:LH$];.;L(5V2QCTW#+LA%K^KG8I[/DC6P33H0\W M'6AN-JP@M,6JDX-BZ37&'`3,AMGB'?F.^8XVPJE(`=[RW0A,QLTQP%Q(UNI= M:,LD;-_Z;PG'-0(+NN\"N&!,'B^4]4X'P/4_````__\#`%!+`P04``8`"``` M`"$`3FXUJL8#``"$#0``&0```'AL+W=OU)J MFU+@A9#Q\4U[AK:/^V[NU(T';A8\YJK5^,T#)IR]F/;BIZN:SCW"TEI^>;;W)RX M;WC9"RDV:@3N(B1Z>N8\RB/PM)Q7'$Z@TQ[T;+,(OY%90:9AM)R;!/W'V4%: M_P.Y$X<_>U[]Y"V#;$.==`760CQIZ(]*FV!S=++[T53@KSZHV(;N:_6W.'QG M?+M34.X,3J0/-JM>'Y@L(:/@9I1DVE,I:B``OT'#=6M`1NB+N1YXI7:+<'P_ MRB;QF``\6#.I'KEV&0;E7BK1_(\@,KA")\G@!*Z#$Y+<[&0\.('KT MQB3G@2JZG/?B$$#'`5_94=V_9`8.=5;2LUF!=.@]W_0FLQ70$DKYO$S3Z3QZ MAO27`V:%&'AZCIC$110?(-XA$?`[DH1T^23'T``?E^Z-I-[DDDR(RV"%$--T MYF"%97`(0&9L`I\'UF#(HG7R-,V]R(C!/M,I+2R#$QG<7!]9@Z$OK9&W:%&"L?EL&)?']+9`V^5`G$ M6)$M@Q-YXD;63\KE)M2;W+.G6>R='3$34Y'Q-/,>I.+LLL-.OZ:LY_CS#M5@ MEU62^ZP0DQE6=_G4*UCA+$_/]4E^"RL-]EB=="]B,%4`62UDVUQ*D8\Z?V\9`9]J9<'D!T=1=98W.B>IEZ(CL)H*TN: MO8NU$<\50=!0G#CV.JHXO^XRTU)HM?*5U4$!=1EZXK8B"++S8UE<%C<)+T'9 MA-_CV^Y4\P>0'1VW?5"=FP16CS'>DY-FJ:@9-E<5EX8GRA>U%"+U0'079U+(L;_2:QA:'VBNH@"%_+ MD_N3XIQ;1EXX].)RJ!F&W`9CR;0FK;50,/V:OSOXVF$PW,0C M`&^$4&\W>DX_?C\M?P,``/__`P!02P,$%``&``@````A`)#C5I2I`@``<0<` M`!D```!X;"]W;W)K&ULE%5=;]L@%'V?M/^`>*^) MG:_&BE.UJ;I56J5IVL'<\\]%ZZ75\^R M1D]<&Z&:#,?1""/>,)6+ILSPKY]W%Y<8&4N;G-:JX1E^X09?K3Y_6NZ4?C05 MYQ8!0V,R7%G;IH085G%)3:1:WL";0FE)+2QU24RK.`C5*/#GJ?NQ!L)J]V MW_D&?-'Q+)K.1^,8X&C#C;T3CA(CMC56R3\!%.^I`DFR)X'GGB1. MSB89[TG@>23Y2`$)U7AS;JFEJZ56.P0'#O2:EKKC&Z=`Z%P9@[=ONP)VN#W7 M;I/?"F@#G7Q:32:S)7D"^]D>9 MQ'T%-P%RZ5OD"EMW`CT!X$Q7P/_=<>`,3SJ53R;S0>:`">?,9^X$>IF!YO3, M#@S]ZV0>#Q,'R"(T;38P9/W>VYXD..ZG2W+@@:3%=&!&P'3,Z`1ZF6?G9';@ MC]H0,)W,G4`O\_R.Z#`SP\*J MUM^MC;(PZ_S?"CYM'"[1*`)PH90]+-Q4/GXL5W\!``#__P,`4$L#!!0`!@`( M````(0`(>Z.BH@(``+4&```9````>&PO=V]R:W-H965T8T[YQD3:+9[)I(*AKL&1+]%@Y5%(+Q3+&#Y(WU))K7U$+\IA*MZ=DD>PN= MI/KQT%XQ)5N@V(M:V)>.%"/)DD]EHS3=UZ#[.8PIZ[F[Q06]%$PKHPH;`!WQ M@5YJOB6W!)C6JUR``I=VI'F1XOLPV<68K%==?GX*?C1GW\A4ZOA!B_RS:#@D M&\KD"K!7ZM%!/^7.!,[DPONA*\!7C7)>T$-MOZGC1R[*RD*U%R#(Z4KREXP; M!@D%FB!:.":F:@@`GD@*UQF0$/KV[L@W"4&+&# ML4K^\J#P1.5)HA,)>)Q(PNBM),0'U.G+J*7KE59'!#T#1YJ6N@X,$R#NA?DP M!JE_4PH2'38FP\QG>S*\9V:LBFAMV9810C'/3OQ7!. M<$]&,4X2N?&8VZ[CKB<"MN>;TV[,SC>GGC!)W-&>%F[HS5`P=3J[&38@*G1TI)_H;H4C4$U+X!R M%BSA;FH_=_S"JK;KU+VR,"^ZSPI^#QP*-0L`7"AE^X6[&\,/9_T;``#__P,` M4$L#!!0`!@`(````(0"$5[?FJP(``*\&```9````>&PO=V]R:W-H965T M%%()8F"I2E^WBI&\2Q*U'P7!K2\(;[!C2-1'.&11<,HR20^"-<:1*%83`_7K MBK>Z9Q/T(W2"J/VAO:%2M$"QXS4W+QTI1H(FCV4C%=G5H/LYC`GMN;O%%;W@ M5$DM"^,!G>\*O=8\]^<^,"T7.0<%MNU(L2+%#V&RB;&_7'3]^T,^*%0S@IRJ,U/>?S*>%D9<'L* M@JRN)'_)F*;04*#QHJEEHK*&`N`7"6XG`QI"GKO_(\]-E>+)K3>=!9,0X&C' MM-ER2XD1/6@CQ5\'"D]4CB0ZD4#&B22,/DKBNX(Z?1DQ9+E0\HA@9F!+W1([ M@6$"Q+TP5\99ZGM*0:(E>;`L'1>(T.#.TS*.PX7_!"VE)\S*8>!`G#&S>`A9 M]Q#;0,N;]8'7G!'KID=8]T#261OARW/O+MS?1W6R8#)>( MW=TQWX:O[CM=[H)P!T@P5;(UJVN-J#S8PQ]!/>>HNY=680)3#<,YBF=P7W5Q M__P"[HN6E.P[425O-*I9`92!-X.&*7?CN(61;3>C.VG@IN@>*_@P,+`J\`!< M2&GZA3T5YT_-\A\```#__P,`4$L#!!0`!@`(````(0#RE-`_\@0``*42```9 M````>&PO=V]R:W-H965T M-ARB#7F2&=@(\22AW[9R"92=B?;CD($_6VO+=_ESU?\E3K_S%= M_UA*D[95/'>]J/]3('(VI8S0LQ'0.!LA]%XCCG)HX,?R/E\M6G&R8-/`3W;' M7&Y!,@?#%V+*C2O5CY@"16GDJ[0RV`(2':3G9>5[T<)Y@9`69\Q:8:`BKIC( MQY#T`I$!E';996'4(5@ENR!D]H#2E1<$R^3E0=K?3]B%AE3"-*CQ>^MW(-BC M=(J(`@QA4PC%B&R*T(P@HM[/$)5*2]O7U,UT<1>&X`Q`G M*!:=DRR>.<47< M0LSM\WQ),.9$@S%F0QVO%49Q>O!H:'B=(CFP,O09DB?4K,H,R>.8C@6'>$4_ MPDN",2_?-\*Y5AC%*P@]HXI371Q1WVAW3!=/M3-=C+01)WG$,!KX[7THE3`W M+Q[W@LJ9PFCU;RXP; M?D#C"/J3+G4&J>T1N<&X*X<(IT@>1J&QNQB6A[[1"C(DCV@\5A5F)F?D#V\1 MHB8K[L.&!^LSZ-RL@L#8X2F2T\"L6X;D4>P:$C,,B,-D_`G,3H[5^]E)M+$S)WV+ M*-"Y&Y,%$/T-RI(^9R5%[/S,UF/6\>5K,5-0[JE2&U?8!)/I*]A3.0,U3V_4@)J8>BS? MZ5\*%`Q'$4HGQ:V+??,0QH@NIF9KR)#8_^AT2^00U%C=&7\U.C$[8P^O!]-+ M6[&;EKF)K).;'K0@LN]K"AUXB?F625% MXH`8^6!(/-&6+P>C<5U;I4N]"JA;<\W;/4]Y5756(9[EC9]"=5Q7U6O$FLSA M*@LW4F.=R5>*X9WA*H!'@F.^YW_D[;YL.JOB.S#ISB+H!*UZ9E!?>G$<+J8; MTGAUP$FL!(]O9[/Y]QS8A8+9[ M>8G#^,QASLQX\.+VJ2JM1\PXH?72]B:N;>$ZIP6I#TO[]Z_L9F9;7*"Z0"6M M\=)^QMR^77W^M#A3]L"/&`L+&&J^M(]"-(GC\/R(*\0GM,$U[.PIJY"`1W9P M>,,P*I1353J^ZT9.A4AM:X:$O8>#[OA^\J8HOW"KAQ%]17)&.=V+ M"=`Y.M"QYKDS=X!IM2@(*)!IMQC>+^T[+]E&MK-:J/S\(?C,>_\M?J3G+2/% M-U)C2#:4219@1^F#A'XMI`F*W)+"V))[_89*@)8'U2N+/0B^,/A#*M&6!M6-YMPY0 MK)(!:^?\81U12P+KE>3#.N*6!=:.Y2T=CJZM:I44";1:,'JVX/A!]7B#Y&'V M$B"4/3+];X]`H1GS%G.O,3!*.HP_1*S'B&`^ M&V+2,<8W:#9C2!P.6;(Q9!H8F.U+F*CC<2!=7M.0FH:-:G`(8I#(RT;TR$S#=N>8:`1CF%?X^L5DF!3FW&8[C4F5MINPB@P3M)Z ML!_[\7RH/1WL1W/7E#K8C_VI,1(R8S\P^+?#_3BZGH]!7F!ZOC\O$FSD97KE MU>=.8]J:NZYGY&VM]WLU[SO,9V:/;$Q\9AK@JR^C4HQ:FOZ(Z\E<87;`:UR6 MW,KI27Z@(RA99]5WAWLO@7D!'VW#OO82&!MC>^HE,#W&]HV7P!`9VS,O@5DR MMF_ASJ+L3O=BN#,TZ("_(W8@-;=*O(>0W4D,Y63ZUJ$?!&W4`-Q1`;<%]?<( MET,,D\Z=`'A/J;@\P(N=[KJY^@<``/__`P!02P,$%``&``@````A`*8R66"W M!```R1$``!D```!X;"]W;W)K&ULE%A=CZ)(%'W? M9/\#X7WX$E2(.AF!VIUD-MEL=F:?$4LE#90!;+O__=[B`M9'3P_](GHX=3CW MUJVZE)O/+U5I/-.F+5B]-5W+,0U:Y^Q8U.>M^?U?\FEM&FV7U<>L9#7=FJ^T M-3_O?O]M+Z63YJ]S\T^:K(&]:R M4V>!G(U&]9A#.[1!:;^M\-UH+^S^ M1U,\36A;0X9!1G+"[A2SDHP`)]&5?#2@(QD+_WU7AR[R]9<+*U@Y2Q< MH!L'VG:DX)*FD=_:CE7_(5[P6K]$97%H`+7404$9UKP MA\%PG09;KN\L/Q`&!-SG`JZ3QFP#RV$P7*?!,PW8."?]%"=9E^TV#;L;L&X@ MZ^TUXZO0C4!WG%N='[H;^QFJ*A\X>YVC M,&)DP+;Q4'$"6249.;S,^*/3478$B`#8$.04*4RT&ND"UL+;53P&Q@?)@7F* MZ_T;%-ESC`PIKG`A[Y93H8=433K*L6Q1XY@5@42%4A5@"`0]HMSX3C.E`_).FP! M\ZUSLF(]7$ZZ_?+<(V?E]<]U+&^;];+YG['Y@ M8>JR^N)UD32L7B_0*D5HH?U6E`PC'E&F&D)$1(Z`-[GY$6!+%",(A+Z(_8L? M=&!J'GYB#4DT)-40(B*R9][.YGO&Y@=IF[+N:^\VKMHR8PU)-"35$"(BLF?> MM^9[QBXGYMG7&A0<8-4\(X)O+%Z@;/S),&"X[2L-+]7T^!%Y>@)&@R=>/`Y5 MM#G3F)9E:^3LQD^S?&^;4#QIQVX$!Q#8U53?76< M>!&\`0-N3P^`@_0U.]._LN9/G M[KGS'=O;Q[I"#U1(QIL(>PL7(]JD/&--$>$?WY.K&XRD(DU&*M[0"#]1B6]W M[]]M+US8/<54IE!0H%GX M71HIKR`!>**:Z9L!!2&/$?8A,,M4&>'E]2)8NTL/X.A$I4J8IL0H/4O%ZU\& MY.FD!I+E,\GU0.+Y;R5Q3$*=OI@HLML*?D%P9R"D;(F^@5X(Q+TPD\8@]6]* M(3M-J#TVE^E:\_1P2N/Y4QF&.L1#Q M'+&VRG6<0RR29(X8D4R*`;?K_XNA#T5X->I7X"ZG2O<&8Z9"-^Q@&V+;<+0- MR<@P21HBCY-^O7,:#(,W2O;FQLK50#;=#?9"%,.L0TK(?8=-W=F=PP*9M24&_ M$%&P1J**YD#I+M:0A#"[VGPHWG:3>^(*=FSW6L(OE<*E=!<`SCE7_8?>%<-/ M>O<;``#__P,`4$L#!!0`!@`(````(0#D_9;W.P,``+H)```9````>&PO=V]R M:W-H965T@$E)0I2D:H!NDS9I MFO;CV0$3K`)&MM.T__W..%#CM%'[DF#?YX_[[LYWK&^?ZLIY)%Q0UFQ<-/5= MAS09RVESV+A_?M]/EJXC)&YR7+&&;-QG(MS;[>=/ZQ/C#Z(D1#K`T(B-6TK9 MKCQ/9"6IL9BREC1@*1BOL80E/WBBY03GW:&Z\@+?GWLUIHVK&5;\/1RL*&A& M$I8=:])(3<))A27X+TK:BIZMSMY#5V/^<&PG&:M;H-C3BLKGCM1UZFSU[=`P MCO<5Z'Y"-SCKN;O%!7U-,\X$*^04Z#SMZ*7FR(L\8-JNX=6 MZ=+UMNLN/G\I.0GCV1$E.WWA-/].&P+!AC2I!.P9>U#0;[G:@L/>Q>G[+@$_ MN9.3`A\K^8N=OA)Z*"5D.P1!2MA M/U][CQ#2[(S9:0Q2!IT0;!L73-( M^^L)ZV6H0V,9@?6^W2N0L4?Q)6(1CB'))208(])+A$$R$CH;"[TN4($W[HV1 M@QFR\Z0QNHI5$F)[([$W4F-CY!N\R$S"==\4&.Z%X5MDNZ8A45=@$S2/QD&+ MQV;?CKII7MJR4],Z@>XZ<(\4P15YOR(%'BL*_<7`VU7X3F-"+2E86'40C\P( M6>;$-(>15:NI:9V@Z`U)\X](4F!;TM*2I#%:$O)G8VML6JU@)*8M"*S\I:9U M@MY0L_B(&@6VU5A%M=.8Q;FI+>V6I"T8>O7Q4%MOPV MXJ$+2V/T79E'O7DC6 M=NUZSR0,S>ZQA&\D`EW+GP*X8$SV"S4@AJ^N[7\```#__P,`4$L#!!0`!@`( M````(0!0=C8R'PP``)]P```-````>&POV_BV!7_OU*_ M@^5IJUVI"6!,@&S(:B!Q.](T7>VD:J5N53E@$F_\H,;,)+OJ=^\YUZ]S`=O7 MX=IWI#;J#ACN.;_S/O>!??7]B^]IGYUHZX;!3!^<]W7-"9;AR@T>9_K?[JVS MB:YM8SM8V5X8.#/]U=GJWU__]C=7V_C5MMET^. M;V_/PXT3P"?K,/+M&-Y&C[WM)G+LU18'^5[/Z/K[M!GI"X=)?BA#Q[>AY MMSE;AO[&CMT'UW/C5T9+U_SEY8?'((SL!P^@O@Q,>YG19F\.R/ON,@JWX3H^ M!W*]<+UVE\XARFEOV@-*UU?!SK?\>*LMPUT0SW0COZ0EGWQ8S?0+74M$7H0K M`/&'_^S"^+O?)?^\^^.[=_U_?_O=/W]T5O_ZZ9O#SW[Z5N]E;`A-L$$US?-^ M)5GX.*'<2R6XOEJ'02'($$`S!5T^!^&7P,+/P!E`//S:]=7V%^VS[<&5`<); MAEX8:3%8&>1C5P+;=Y)O+&S/?8A<_-K:]EWO-;ELX`7F&.GW?!?,A!=["8=N M^3P@FDRF"<+@9!KB%2J3#R+9>+%:)OOG(S)QO$;UO$[1'\>+25$MES1>AWYQ MH,-3>.6V(GRBQX>9;EF00P;]/JJ5&JPE9M-%'_AUQNQBU)ED0VMHC:5*QOGB MH=V0X="2JN?CZ?3Z61P,9E,IN9P M8)I,R0^I1[O!RGEQ<&%,FIH.$8P`P70XF5X8`*1O3ABK3A$,`FJK4H0*+(J0:#(JFRVTI.0^=-(@>5=Q;%*$"BR*D&@R*IC MR1EXK-RJ!($BJQ($BJS*)@H28Q7V>A3'*D&@R*H$@2*K2FL^TPP\56Y5@D"1 M50F"KJV:3:L6M[<66TP^[,S*^V,VDX.YXT,8K6"C/-O]'>#L,;EV?>4YZQAF MB9'[^(3_QN$&_OL0QC%L*U]?K5S[,0QL#U[VLA'9OQ4C8>,=]MAG>OSD+I^! M6;(:EG>_"35DT1:'/!.9V.&;8[,_-D?&13*)2J0[F;7OK-R=?RA=SONHKX`: MQ00G.@QR)JD[%'L+/;1":C[!$(ZC13'N27@]B8&_C'.M8CDM:,.)2S9L`1*6M&B,K(^\U1B;F$>@3)GKZY MK[\-!H!*!F9X]I)@FI^*W15A]STN;BUY(C50:%:N,AGVU'0H@PPF323)@-6. MJ3)B6J^A_"\=S_N$!?D?Z[P'@*6NZZN7-3FJ!>?G\"P3G@3#E[">G+Y,ZGWR M!G1<-L@H':39FXWW>K?S'YS(8H?J&`MV%=>MBW=SUJ@4[]][[F/@.VRQ3D_( M_!"%L;.,V:$_MAM5AF=8@F>0$A+!ZI`@%,I3($X*`%`H!3 MX16GQ,&`9#/P@8(E\&^+)>283$J.98M2EJ5?X%\AI<6EWY/43/(M.'JA9GA3 M`>`DEF4I5E6*(6:'2"M4`&\J5&!!U953\@9E.5^90DC2!0R%1B`-5&E$GE>2 MG`L\"P#5&IE+[$.(4V`J4@T!X"B!0`PQ4%1_!Q2#H@I,O4%1":80N!K<84Q0 M2W`54A$&P*,D*HH^8 M739-%E')^NEX^*;U4^UE7;N0.BB;-('=L^')["F9.8(MV%R*3*7Q![!VMG:J M/861^PM,,O&'L$M83'4B'7\X';M+>N5+9&_NG1>8BB;[3B_KO;5>-KM,5XC% M,?++K!G6;I&#XNJ7MO=T6ZK-0G.P+:!KM6HCS,6U)JB?$[`@K'0I$%YRJ9UW MLE)%U$I.'4:8W7%_>3L(7):JW=;8L[UL#&VZ@*3@QIRC6DU0WI5CH*:"4B\6 M(H+16ALPE#DJ0R@^6V`N'*RE87E"8L*)<#/)*S8EFQ-K4$OQ>`&MI,WK06-1 M:]"=H/;3;=[(O57&%JXQ-/.P&K4WDERVS9LPAQ]WJ)/<(#M$8(&*EJ.%E(8+ M*LIL3OQMN+^JPC=;%MOYR+KD-M*K="Q-_(\PK_:`4LEIN\,.:PETX!VT@&^! MA"IJL"%[/MO$XTJ9PQVA]KI^/NO,TRW`VEBL17/<_6KL?'P* M(I@>3K1^N[E*W!@7#!("J0\G74;&^"\O8/E#@)!^KR=&BA;D:GU(Q%` MN,,LQ4+M(81P^"H0EGIYC0I+2U,3`_[_]D)&Q:&=*K^0H_:*`S+M,R>+U^!C M'?>_*J<=N&.AK/FF2P`U19?O`-Y0;&M7!#2\J4!2,FN+#K%8&[B;I"NJ0RFN M2\N+N-+8K1D/*S5IL,2!EC187#]3FG,H?-%9",9`VNY3E&V8EL)K2[LUN$74 M^X8`4Z'LBJD--:3TN'B#K+@GJBS1EC+O;JI5$F/232,>5"5[J25`:X+JY/HD MTZ7P%&=5S]3*9%!I)S&$>:[4Z*)Y^BW3P%)`7\TTL!SAUS(-+$4((5KEWJ6] M09.^JC1E=L'<4+D'0RMG&UGOA)TP"DUZY4@R<%WOCQJ1FFD:.67C-%?1(<&= M"A5*0J;[;3@9S=\GMP3L=VJ'^P'5'GB\S6Z4F]@Y-SC91GXGS/]*.#\'I^'- MF.'A$?W?:V?:^R56+'"5)$D.\%SDSO7@#D!XP`WK]'*WA3M\S).+Z:FR*EIY M/X&+8Y06N%!36GEU,6#1A=*"27536L`^D1%+!:$%/Z%N3`L<,J6%IXH+?9FP M1](4%PQ):?&Z'PGJWCQF1W;^OL"%(HO@HK0*.X+FB(Q#$+DIK<*.8#A*"T1N M2JNP(R`DM$Q@TI1684>P`J4%[M:45FY'$V.]T/U(4/<71^W(^RHV&B*X**W" MCKROXC-7FM(J[,C[*HKHO@H[\KH?">I^ M/Z/R'H_=FHAT"97"=O"*Z`BKH#B5PFJ\EP\%O3S!4MB+]V]3T+\3*H6E@!Z1 MR(0/Q"7*;33DM6L*:G=NK[*LRSL,UAD1&'"W_N7.@\<_A?CP*'88')='B$!X M4D6(TI.S?-86<&^/G!`?#UA&10C=OFP\.[#C,'K5\`!X3HXW^DB0W)_",-<1 M3P%WW$0`_1D>M05/\=)`+XF&>!_&W=@F9/)8X-6#OP9M0@9&)VAX_\/90A,R M,#HAPR=5[)]$R'P(-KO<0GPNQ=(M0N*C&SP[*]YS>`WC'IT(I3MG%T=V[G]\ M2!F"BKG#.\+D-/@4D3QN(+M]3=I_WL$-8#(EXA%S$CO80XL`_^LN)FK$480( M'I(3(7+OQG#CKBR(.1((2XA$"#_*R$GL911!&G^WHP"CA0O=/1\MD:CXB0MT M_ZN7XNY`3.\Q/HR.W3_P\``/__`P!02P,$%``&``@````A M`#%+C1_U.@``K,8``!0```!X;"]S:&%R9613=')I;F=S+GAM;-R=V6X8=P@(=#N%(57<1=I5:K!(JD1;"RVRX#&,ODAF!LET)3.SN#\8W7SSY/O+EQL'3[+9O#OJ=X?C4?[-D_M\]N1?7_SW M__;U;#;/>'3^^Z<_XYO?EJ-IGF MW?[L-L_G=\.OMC>#&:?_-D^_D6ZRQ&@W]?Y,?NI[W=PR?]].F;[O19MK.UGFUO;NVE#^-*1XTK97\\NIK-I]W>_-]:W[R\G^3I MPZW-C=^EOQUQHKZ=ZN6P>Y,^C1LYSZ>#L4[=STZZ\]K,<=S+P:S7'69_R+O3 M["7PFK7.Z$?ZB1O'_FXG??MRVA5.9!?W=U?C8?KTXN(/Z4_^FM[G-P-!C,M[ MV[VK;?_B^[>OS][^-GMU>O3Z\E5V\8>+R],W%]G9V^.6^8Y!@RGG/.-J?\Q^ MF]^GXXX7TZE0I0R/-N#Y/;X<#/-I=@QT;\;3VH07=]VAGK_/)^/I7#`X'M]- MNJ/:0#\;3^_&H^QB/N[]L)Y=W':G^2Q[MY@;%?%Z;<-CCC*:Y7WF'X/K09T(?K,8002;1@2[Z:0!A$>S&4O_JO:X.[LU2NSIC_S?%X,/ MW2$@KV'<^[R7\^R*364;V2B?IS.=C3[P7@/,3_+KG&OL9P-XT5V>S;L_9EWM M)IWA9)%GU]/Q73:_'4S[V:0[A35,NO?C:6TWX50VSRR[S8?]#!:2S=A\.NWY M-)]T!_TL_Q%>!AS%=PRJ;A>UN2_')F`-Q$/ M6,^Z&EOT)TW,+[SZ9(EFJ_@[7@4MMURW6Z+OQN/]Q,*RQAM("#X'\.^%N-BIVU0Q,!_#5P]Y='KW.CBXN M3B\OTOL(^#`<=*\&P\%\D-=1_:AG`FHFE!(>M\V!H%M,;8IL?)TA*6\VYOGT M+NOG5[4;9<[I`M1FRNEX.#3K2Y"D87NO`ESKPZP*8C8-:H5)"D[#0O9'G9#J^A@;`=BBL>#0=S'ZH M;;B&/&$\=YMNQQVNN*HE0\71!_.H@,"F)090DQJF_?SI\Z=T*9,!M^-A'S7K ME]DI-#^O"0\XCF=Y3F+`$!;SV_%T\&=01>P'Y6@V`V]@V>N;FYO9S`1+NE00 M/O9P/?LX8([%7'PQ@TDO\E]E9S:+XVB%4%K/#M=W=W?]K&)&J$F]VZ@GV7A^ M16[DK7+CJ-^'!NRBQ#TW!J.LUYT,8(WI-M_G<]0_3H:V,@*6M=N!2"+'9$=O3[*+5T?O3U^] M>WUR^OZ":_K=]V>7?T@WSMT_1%B?(_310//Y`)WL:9OPOIC#T0VM8!HO!R/D M_0`D/Q_/#(Q+E,T"6QP:E+$EW7)];$"E=*1'GC!E#7E6C'?XN6(0V/A(12A" M"<7F.GN'##79AU2$*MAR"2M./39EG=?@A^`^ZB[`R;S?>@=5!2K_L9=/YAFJ ML5/<,G2Q[F/TJIT'FQZ[*:`\FX_'77+]'@BHHM,<#6J!?M5!O1)\>C`GV2<+ M$`F]=?Q12N2LIC>:6@%K_3`09S5&>]7MF[PR,+_*N\/Y;0\TSEYV>UX\9A?Y MC=`UW?E;E@X;29\=H].XJSIUNE2-;#5".[]!@9AE*,#]=(X+5.$IO!9^UKWA MK+KXJWR47P_J.B-?MW;<=Z&(QF0P;F/OY`I[8E:H^ MRZ,=HYASGQA6#K;V6BVP'3""D#UG0^-5Z1C M3E^]EY;,?.*+*`BZH=J^3DI:H^/E=S)F_MRH1A;H!30!LB>G=&5W5H>VZUG' MW^_3FKWP':P^`\FD:.NBFS4ZU,P<2VD>8-&L9:84;KJ_$\@+P;O$'JYRM/N\ M9$'4;\N3W"76A=]]UOG6(5:-8AZ^<@HG\2)GI)Q@HYOR(/VOV.JZ;"-!!O4O M?5FTE2R=#G'W4)6/8`1V4SIR*;>L#Y::DT"U=KG?=F>#7OKJR6"X@.G6?VX\ M?FW.AC/7QOP^']SK7=7:0SVD!C6'WPX>H^H`1X?-2#G,V@2(%8FMV07S;TS'A-\4[M MR"S2RW/8J[T2"/%V/&O4SK0W^!PJ+M2#"@.Y9N%AF=20LL0EZZ0Z73O!80'G8!/6T3I^/\5%(20>#: MW07!E*[KA4>CR>Y<*?AM.+/<6`NLAFDPAC+)?/C]U7!P8_*WY5YK5"%>:\P) ME7Z&E&\4WMYE(9"=XTR4C;I$DWP[GN?9UK/L;W_Y#SR.#YC^\A8W$%X1\X!J MD45@CG)?-ME&A6$3N20JG)W#;,S/GX(SWA03\1`L)_Y_FCO'&]>?9_#V^6V& M7@4&S`A1B&,VO8Y3?S>[[:(*7>7Y"&Z$(\\Y$FW;T[ZI4S)MLO<+]!$\\YM; MPA(GQW_[R M7T]U`$PQM-A%[W8]ZX]Q9!E)#!=]SH*S9U!$+5"9/7;`^072A;D5V#(T-)C( M:8J/`>$V'-IS#!-C4[:O[T>R:G`R8T$:*(DF3#$V;3??'1V=:SO/\`WG8AG^ M6OBK\"_+D@?TW@6<77EWL\5H1,7:LK@BRX%T`VEG@[OL&E.`2T<)=O`%K5$[ M<:0Z'RR'=/86`X,Y.PM6+K<^9S;^"ZN*^UGPQYC=IS#RH"^#2K`//C*&\U(9 M>#JOR1ZAY3!G[J;5#1HPIL>@Z0SO"6[BJYSU,(\D#<>C/RU&2&=NWK!(6!(. M70%PTQX2P()?B]'KP>B'S-E;1%=F>`0P=&`NSQQFN0%#$M M_3D+?R_T5^9IB!=`U`FQ"GY\FAV-1C(+72!#XN4E(3I1P&\->CK)M8LBW>C@_F:Z4+8>7>53S]_VMYW485G',)P=3P9C`0N[O6N.T)7 MDX6R;H\><1<8?[<#/%(R22//60\`->+J]O^TF)F?#@CJ+H@\F>@804&L/E)$ M`:&-1CUH4Y(UM$DLR]YZ4M8'U`1'85##-BT7U-FH2>IL*P1X5WW7H@M M"[4G7A(8+\=&9E4P`70"AWP$)+`"=[1G7R?!UV\7,_@U%D]AWZ1#WDKH;'NA MLWKX,AH1&DW'BYM;6.[5;-`?>$?!^.,(#N7GAET4N(-^^F$`V[(;NRW<',&B M!VQ9CSB-C-:[[O0'!=_X4QA08;K/`NW^[2]_+9;*X)7B0F.IE![J[(7E;@<3 M^^'C..X+J][\*?6XP]_^\G]2H%VR@:5>F?K2$J`1)T%\2*=;7^O2!"V;OL,O MB',D6`45B!H(V+HQ<\`I^=F%4!3VXIA;!SOXYG%"Z-A7&!J_KFV?ET<+T@PD M/3!-&^;8WZ_.L8YW&()G>G=[@'8X-B(2X7;E\A"I=@$XL<+9!#FGV0.ZU$_T M:\GG=&-'1$JBK^O:^;KNBQ7%*E@(`4(X5) M:AR7!HI/\34-`\[7+A!?%'D7B^#?#RN%R6OCBS/&7<6Q3?=PPNJ*,0:`QM!H M#8+A@LL4[U2^XC@BU_J]2A<.3"$#%7&LD8NR95#2&Q8N-P]AW',R_`CM;*B7 M#APC+TYY'B#BG:0A&BQ&#*^!6XK]1W9UC`<2<=;-A\8_9,1\A"&'64H:0'GD M?SWE$@O"-*D6P''1FPXF\]G[']>SUZ^/:U!K\3VEZ-DRS$#$,Q@;./(=+'>R MTJS8<1R^9<9TX2.'F[J&`'-NJX\^LB#P[S51$W)2[7',F":`>H\?D\A^*M0A!OU-)&WJ(7KYJ\@Q0N[PFD.NL\Q^L3U$!'*U7+1 M7G$P0Z)V!^^]V`^S>P%1.F]9\6X]#X3KERG@?Q1_&\N,JI9L<;E/W]R MB5&?/V$:U_USA3V57LY;F6#NW>:D*IG^[WTLHK;V2W0=]+]7+>ZFM72USF'Z MR]-Z4/4D_Q&3I'72-SD.;D73@/%1/Z]%(#O[V^DBG?W]]*?"\ZJ`XU,0CZNK M^I1KI^UL'];VW]G?W$KG[FRM;QW65N37Y[L'M;$']=T>[J:C7@^NX6%8_`KY M&,7F)&Z,MI19Z>^H]W-=,K.X5[MIZVMVOE(`(CN_16WW:D=^6]_^=]- M4?/.UN'S=.WB/ER`K^$^TE;Y9'[=%4+P&`&RSD),DY5GY M09VKEJA!9Z_V>F>G`1>V#^NWL;=7`U412FAA#K73[QS4D6EWLW[Z@Q0B4R5> M-MXE3_2?<_YK]F>E%9`WNOGDJQ=?]\9#F.7TYNJ;)R]?DJ/`_^GGZ4NXLAMW MW!T.KJ8#_7K=O9.18J]OZP=+'\W=#W<#;#7]^)4M,W_Q^9,\5.]&V0E6FK,S M=W!;R=L3+$EOY_Y5WA=O"I!KY51FL2YQ@C?X;-"H!B8BS;Y^]>Z-V<:*.]J+ M)#O-X1ML3?Q?XPG)13^L00[Q#3N4,2H2T63#.7%.*N M)G@!3/JQD:E"0Y+,;TPYAV'K)MP_\/=*[^..2]%2NS@%4E_BJ)4#Q3S!J*)= MN9ZO%\-L`9&#`+D$_73,37KM4ML;DW@XSWNW(]#_!I0SG1L4K&)2*;](,PFQ MHJ7EP*V?T*Y05!`V.HO<9,^R(X(Q[H=UCP\L:MF)>J&43Q%]>!Y3WY\<9:_' M77.\K.TB5O:8S#)GM($UV"L3R0^!%A']=[8!OS^'?1[_@__%:RBS;&U[Y[GR M=T!7[5=C1.7_H8AVWZ./A0&.3:]@Q!MB`09G%$67=;&W/DJP,?$@Q#=+A5J MO5Y(%Z[R.N=3$Q%[B[1PP84K0-2[KTN*UG6=(/BF\9BV6C)M"'/QLPN#OP=^=7E*F94/,J*5' M$0IDI:Y#2?\1=/Y_!J*B:?QF,;S'F]V$GT(VH52)S[#O[W)*70:DBZ$@/BNA MVY>@,],)F]$Q)N:]1P%HAY6V$Y\>CT>*LL[,/>;1M8-F)LF%S(-;PZ3":.-. M"$JM%:_@R"6>PL79Q>7@FD0%C^+^A(:C>F"OFS%;U5X.UG?VT%Z*5=C^_SDFNG5DFDNL+1U>(CG M[/3ZVF%C]C*_FBZ(N4!H!^L93Y\[2>!VQ/M=-HBK0MK<-6+XSTIQ(W&-`*F< ML=[L7ACE'\L#Y\](X6`J!"B-1AN(IT06"22'R94`"T,X83> MP\,V.(D6",HX("CAM6.4)8@LXYRK@MA.49`DI.Z.C#Z!6\9F>?<_9?YU'4*A M'V,*:'=VZ!V2[9C,?E;(:#6#FOO-^9_AP?4MR7"5@33<3:`G=:XY^JLRV;.U@ M5P@6D^&5FMPMK6M@U:.TPQ#!C-5!2' MG:(-";7#ALP$'D\47,!$=A4*@+?@-:)3IU91V>4X3Y2.&(]^_UAK/E/DR[>_ ML^.VOTMF1)5"?K[]7P)[19KE_*"@S7/:F>X8_N*@7[>--D=.948^!?AFRE7UM.@S;*FIJR_&Q^MHG-L=='Y M3UE-6%56(*,]HC!8I%C^\B4$GH>Y8();M]A3IN*UTGXYH-^W<+MM-X(C:T&^ M8D'$UUV9F&2U/PV0&9P`KC",I#I`F%@1*D&))OA M[*%H5"Q$\5%!/1:1#3&JN3*_1>R/[:`0KP`I#H5%S2]UW8CJ[8[**-<1+." M38_0,D".(?>A+=F[CH*FREFPDS)Y)$5=>I,'%!^1"W?Z0VF,68C:4H4DYDX$:NQ>(N+;=E6>#2F?!&=B]KA4ZU^0*)IHP]^);3 MWR_RX344>Y_^_L;RX%#*@/[G3__2O9O\.G-E'+'D)WW%'J<_/A+JZ>OGRR\I M'4YL\J`>#M.O.W5]G0C&?CV@MK^^M5V+B"V]@ZP<6DYWM"3]8MEK#M0!>.FD MKHYTV?N2K**12*]>8UNR'9'9!+D#[X?.]#+OF$41BO6*Y$4G`*L45*G.$R-: MLA8,K%@*P:(,*6]&:E5OL<(QO(D;$]R.(]_@+RQWWXKB8@YKEM0RS?N=I;*8 MIBXV)LVPN%G=H!4I(E.Y@%D@K-V?O[+AJA!:=76+T*;VS)F7D M2THB5\B&=-G.WOK^3MTPW5\_W-Q)QYX[A:"1KS=VQQ"6%6D=`@RJ@H.DQS=0 M1U5"@JP)IQ6[C[QU.<'I5E=@F&D[CV/2-5Y:Y\TAIA+J`6JO%/M.@5OP[O1) MI)/T04BU2G\W\D]_#-U8$)"_Z9)%+8]52PNAH,"4=&R+&75A%TJVDP,'84KD M#(.IL?+=JZ@UPM?Z5SN+ZY59<9VULU/P\CM^O>GY48 M55<0RENKWFMM=P^\UR`34@SJ;*_O[=59Q4X]%8.!]6R0TD:K]U/;YZK[60X$ M"WJX^ZEQL,[!^GY3/M!._,U343\-&X6^NCL66Q*AAD%4\!/7.A@2=#N&)'>LT;^R3 MYD-(H',B)5B3#=3/W5]/)6X[:]L'SY_:E&O[^"O"EK[47?(S'"K%U68XG!;) M#XX19^_-;I@5/J$944IO65K5]T9AU#[D[70?EX0\<6S)9[BDDI9J@L^?]I^Y MP,??;>OROL3)VC?_^5-TB-7J]=K?DCE^^NJ]Q<]\Z@1XB8H(#J%GR:$PS0=W M5R3,>\7+&9CR^$6OG+^$4B.\[#*FH1B:G:)@CDDS-N0[M@PD'`_^/SS=("MZJFO<%N0%']/B?J@BV=9NPA)-S-6*JI+E:'Q M^=-UCL<3")6KH!"!)']>;CZWH:4OVJM6AE"JA=C8=V2MP[VH3_*#6 ME4@FR:D*M69;<:.V;3)CG!,+DU]NEN*IH'=\],KCDH^-6=V3UPHC%NOX[A]D M00%-YWX2VL5%Q9PJF%=@)*:]^>W!`%P>VH3R5.ZY"SBS6OS9FO6<*:X%EYOR MMERFFNZF2)?B%K`UP)$9H6G%_A3#*P[GR@5='67+JBH92/.TJFL89>']_!/1 M+O,H59*5Y`WEU'W*=#XJGZ-4%*;!;OL1AI%:KV)E\F#4>I][-5M(R"V32?54 MT<,CJ&O+!?7'9;A##2O7K7I;1RX?+#,Z5GFL*1&PH-(0RF!I#-@=]D)QL6>154A4 M2'"_\ M8-5R6>Q,$^+G&;&MU?@8@J++.]P9XX)NR)B##3$K@5SN/6Q-F!'V.@ M!#-SQ)L]!MRH^(EE)KZB<.ZZ#<$>%G.$)]>*3-$N75J-ZW?1#)\+WQ^H1O\O M(75-X71:8=U*/3`E-^\"7MO?+;AYG7,44=&'+U7-I?8Z+\>6=BO*=BKZ[HY) MI+6M]>T]DC;J"GJ MYJF)7I=8T995,J,*EUYQQ:JTJ(X;^PR?+P@\0"= M%!5T:!)2U;@U7(IH^]I5LJ9@0.[&GH1'I8VDXSJ'!S6G2>?@>7W:,.#1AP_G:E&8^7=!R>P)1:L[>PYVM[9CU+.L8\O MLK[%WK#D]SV_V#R(DZYD>O:*2S0I,YC:4:@\NG&M1T\:>JWJMTDHGKNKL&G(5+>LG>3A0@*%'$D+N>HLW%J_/SUHNM:>5&+AU5J0[ M0M)W=)#?2FJ"+@<2VF])U7L_IC]$6AMDPWT9D!K._VHV`8K?/)DHF#+]D#]Y M0?N<=R%==\NYKLC:];R9,IN\KS";R^7VF=XCRD=_X+_0-I'HF*[.>1?DR>-\HB.;6DR%+<[[(EK?F`Y(L2=K@[6O**!-P62I9K?BU?'9M#I=T1$CPD=-E MI&$=/M_+WL`W;]0F;4E%@_/-[KF$9SMR%0?,PM1Q%A-I8LSMLG2:$")K+IIH M6Z)I"ENN4CDAJ`C@3GEU82Q0Q^\2>\Q:S[[R9::R>.R1380.&<&L!'S]9S(9 M>'Y237,48ZX>W<0I_0Y$]5S8UI[Y"WT/`V.-H$)0:30"IZ*:^*#["V`P9+(K M\2(NL+V&TJOH.^4T^F2=*\("'$\I*,Z>5E:$)HQ34!?/K,XPS:A,X;G5(W0& M%,D*\Y2#@_M([W7`[LDB)%H``IWL]T2),!Q)IB6606$8!LI3,F87,_I`[?UB M7;9P9Z#)]G^1=?:?;?Y"60%5G_.>;RV4;!XM6HD7VI%2'9R^[*\`#4D)$)99 MP] MU3L`E=P69(=BR.`6\TY"CQ7!DG-P15V[JS2IH+Y^,.R+A1MU:]QTF MZ0?03\VS_*&C2?O1\W[?UMD6\,5IYB:OQWXO(RR;:%SL%]V'E/A!NY3II6O!ITZC0:&^&,'G3Q5*4.Y1B1"ZV;L<;/X"7&?ZT^!K\/Z5F;N-Y4K9787B$`P)M=;HL M&OP(;(T>!J'A4D)JZ]G:,XYRM?'C'XK-DGP7 M,ACC/V'>%NO"KQQ:2!7/\.#(/O7BVJ,"+!`_#I?@//&^V1E0FQKN6W6&US<@ M!]P>$][PLM+T"J,7QW:@,5G.HIN@()9J4>E2)QU9JA16CQU![535Y^M'-D6' MDBE:@T6=[6<=^%K7Y)I%:];3;\\N3XZ`C:Q;^>9=G8DGDRHC!;DHG9,VO9U$WIC'?(*PCU/_VIRYB(=PL M^$G*Q(S7=>``#MAKFV8*Z5T4J!HFVY57J&WW:8*2IC\WJ//_5/WXK:2$Q2I\ MQ6I4DX8(H?XN(^I0I.^A95X#8+=7*8#)9X[/R% M-E]E@&9],04V/$W0U)#_YF!`;BNKG3U+<%E$[`*VU810L;=<:XY6BU(U0`3=+=M35O3,//<>V9;Q+HTE\-3N< M_ED23%XY?#S6?8U242O*WB3V$$KS?.^SS#<_@RSUJ1RP>VW'"HF@#K7KY4MC MZI+I50LLG,C(@IE]$N`&F"C/,9RMKB*LQ)$P']1O6Y"EU)RT6-NNT]$R`Q' MAPE=(4HOAX](("OFZN8*>RJ.MA7KS=F=649FR'IT;9O%%865);!3I)U"$X"D MD("VZVO#F-/`)#.O#!S3%#5N&03`TQ"E!`C.(317?\C\;K#AS84'^$-4$E3H M_*W'"U`\/_NM0G;):-&S0X>M3-NQB;SO914P[<91` M@DHP)7_"/FJ3.@"W7HI@JJ,'D&&LR#.!,7)EL5)H"]:*Z6X4%ZZP-)W'?VMS M0_T<6Q\&VM[:C2=RLD3\_\JWJ`:H9C>`>))U>W22O60?RX:5Z240ECP+SD/3->*!J$,R7V'I3-B`[$FKSP9\+U'W\S$??L@W MS$/)#R.`,)TI%=]O1HCMJL4<)]-5M4*S(DQL&2]+&I746,A"X*_MVS7"@.S0 M!5V*\46NYM=);^$SW/PN2]=[.736(-!BAEQT3!<3.5\X'5)H87ZG**%C.I8) M$+^Q,U&[?%4N`B3P#8,6N/'A`191S)Z?(;0FIKCCPM<^9R?NN;"^,L#-O8]7Y1)KBY:5G M!F>8=.MPLS)I@(H'9&E._^2I21MA5>70*Y'*.,X#0K9'-9]*-NBEIY>#D+A/LT3YP16\0T809\6;)]EGQJYFFDW0,]KBV;5 MF"9;\=\%=:[EXW)J92J[E@Y^#&/U7VM9.E]U'ON0HMW<%"<+!P2.Y8R'FW(DSU05ZW7?F4%0Y2I$`A"0+\TEN")[L M2)SGDKZN^T_0?\*GYB806(SP;>\^>[Z+M::0!]1L+AZ>FX^SY(7+OAN@%D[! MM(4U=@O>O&#:61I@VH6[A)IB\C1RG`]FUR3/E\(C'G6-Y$P7X6`EPO:'0N]P MVJIED[*_LG$6)'Q)2[4N!3K/VKYS^P3K%Z#05ER?#>0S!HIZZJ`DA5A.@TO[ M+9Z;>U7:NF=SY;V6&T)@H/?->08^$NHP/=9>2]&7:FS M?H!BS?<;F#A837XK;K'(?=UU:7%YGP`$;B-I7R[IY1[HNZ%FN1=?F!%TC8'$ M&Z^]:@(L?I(F1Y4'"]B,O>9V(7&A,(?\-99D@RI-[K@"U5XXN.U58&^,RSZ' M%2ZC$0#P*SJZAAY6$9JFQW=_`,D'O![<$^$4[CY*U"+&361.2.,NYD]CC!>D M_&`24I`1>H'XI$?34N@H)3&[VTBY)>0V=FQZP62:;XB7>D$K!"1^[IAT(;2A MT*2M304M8E=1YYJX4ZD51[LR`R^V6-#Z)4;BM=RE85,'%Z:J4H^2(F/=&30? M/M3M8V1^YB0$&RU/^SA2H[43?"RZ+$F[,LEDLPW)#WSM!8;+0!Q MYPQ:BCZNPJE-?_`,!D+%GF/5;A\U`ITOM^YSP50N7,5`R`+#?#LH=H&Q$(.3 M/28SO/[)N1)&Z:UF7]GA%7<^6.+/:Q_!-1R'4X(.W*.BLVD?#9/4%UYXQ42F MM+CY9Q?=+7EV"'3G:?&GE$/1A0"LS49,.T'LA2\&TYX*K*Z$2UU[,"@-[.!S M17;'T6VB7K84-S$QF05=\R,%G[XG4>%5B.I[''/U+/.(O\@X9WQ>Y.0#2U3M MF()EZIG\PN]@TH:4(5\%B,8FPW8'[^QS+KIC_!**&,#EOW-?8^,7^TKD/UR9 MDEIAG,F8=N'\1FI83Q9X3'],BC+L0?QG,B89H6B_7/EX49)&Y=,2!>-L&1P4'GUW]IUI#@W7R32NWB_H<0`S,B%+6^(64-OPR1B_1)564!CV MY,*F8IILR/TCI,O%P*S+N>\H6YQ5`7Z^%E3BP9.'),DC2/*=28CD@&GO%_:\22(1/ MJ6:J>\5\BC\"R[^*K(>.\O0]K$CV#URR.6,''X"^52N\A^ZUDC&0WM@Q:\X8 MURD:<+G?X.PA'!BN0N?S;1JX+3FU75H+%V0_X^OK9DZG"@+GOVZ[Y.GTYYWFGW>;?][['\V_']7@6@A* M.18I427;TG*+,;Y#8W]C$+)^8[&XPG#Q'XY9D'Y_U_(^VK9QY*(7GLUMY&I- M^5!E,GT>"F(PHS+H^UJ81]U8?4D[/=5E3W!-25%$@!M_%IM2?:_R5OD";M;A M^RC8#>:8XQ`.%I9?>B6:-GP%HWV&,AS,9IE4$Y4+2`05PEM-H6+>.':T"MQ6 M8!#E]X*M+IQD02,9I2,F*7PF?-2[V/3FYDLH@`>@>K5$".VLR#N"-*Y MECGN&'9X>.A7[LR)"1CX8#$75PV`)NB)\`7L!'\DQ?A=M"U$J'5_X$AQ?&.9 M5_:=87U(&FD!KT_(.A;M!7^_PA=[I@<0Z1!3C87#?(6BVF=(6=%1[#6<6'D&+]U#Q3VF;B]S155EV=U9EJ5A@F)^5.7CKI=2 MINX92AQ&(E6_:^D5,Y3@H*I!2/ZVJF:E[*)X?>C7W1LX&':(>>W6=IUEM495 MKN&+LSW+DSH-(6X$(?)3D>JR@(4I7>V[V][QV]M[_OQQV_MB9,-@*GP]Z:TA MEG&DR$?&7UBQOM==2#(P5T^CF)9V5C%H=^5L68M5T?HBC-,BL+8EU&[*G=XP=/:4DCK?P;-C`7:[C]T:E80D<1`:]6P"6_5I&&`U?^93 MG+-HJLYX<.;73)4_PO7"8U.V,[B#POED/B1^\5HTEPR=X/[4QXH4C`=K,9#R MC996`]!_D,^-;]/^&F#G\2$;_392]D@.-!PP^FG6T+ZW*4B=4KBU<6C M(],&604B8"B*5[5PW0?XC3GBK M/W#?H,6<`T.=$['$C,HOSG(^R#WEI"$*Z#8D?H7&@)*0Z+N5JRL52A:.*5OS M0DJ*??[IW'\,M8;4O\?]YMR("/,"(#J9;(L&;*$.0B?G\[0^PFJGBU@%\[S& MW=E1.)A,NH"!9608^[DKWS?MO&J=-4"99X#M@@I93H+R11F5F`V?"*A MH-A0UIFG\D0SOF.::?K@TAQGRVJKTS?>$M[UD&`CZ#8(!,A%(6@^E&I5[C71 M&75]V;8%M-*I.\^W:A\<[&S7:]F/K)XD??M4GT*DLH9XD`O$LQ:WI.J!"8WB MYP;HF$B=OOU6SNC'P(&NLX?UCV*NA&>M6Q[S;-=[''9VZ[T45VVQ/O7.^EY# MZ\*]>HM#M:EH<$YFG4L1XNQI"BVZ_--*4B;I=9MC,WU%"DO!9<_E,X*F[-)F M-7R]%'^LO,#=_H._/%*054BM>(_SA$9#YC`61374Z='HO`UD1>=4/]\L^]:U MJCX/&1VFEIR$?N!A^A22H9MM62J+@83Q".#0?K[M5:X-DZ/4A'SEHK$%APZ. M,1[:ASA:;#VUN(464S#1]X*OOYWN,OH1\!)3&O8`B%;?2.<#]=K3)-JG+^'X M\=_%0;1*SVG?BO_`4>G&TS/&2F//:V7H;I1ZV0-U$_Z&O)T3Q3:&=;(N?SNJ MP/\X]Y'$2*FM?_;'UV*;9S1GGOU;NJ.W"U5[Z?:#]$Y'-`OR($'_R->[F&#) MO%Y86]$]ED^W)G>*+-PV]/GMZU&(G MH\74/IF"+Z?NY2J&U=8([ZEHN"['ZYI/U$3:X-C&\_FB90GSVT8%%,HZWU^< M9&LU5-JGX\-H?CMK_EKW2=Y[%E2AFMAZ2<06T1"CCVT'>*T$/,7KA&/)2RG\ MD^\M9FUSAB_&%:N+>^E[@&UO+/\:6]M;;6!=2;)M\-Y<"F^JP)]EF[ZT(X4- M_J)G6?B,:/H0"U8)OQ>*,BG`L4Y$'FVJQT^W:N!@R7'`\.(-8UD@;!):Q%`2E:X)@>J>N/MVN,6I](DO*!7914!ND`:9C#7\8 M%E#(Q7?341ZQ8F5WVXU:7Y/"H>OL[72R$^\JL8K?.#@=U;9D]K]2-&_%2FQP MWV,2_"6X!4MS31^T:?,W=--A;3>V8<5XZN'WOYA.B???]],#VUH:S_]`A MA$LND^2H"/C)FB^/._=@/[)6GLN0N?P6-!9G)^CG,NKPOOIOFJ4;(Z^Z[7-8 M;>C9OEKR?:_Z6LL_<=6VX*.49GU%.7Y8X)'J\4K\"CV/Y!PM:R\T;(F*LO&Q ML&4A.N:\&9++;O!A^@M4&_,)VH#UR)EP]?_DF2[T91BP]:?/]*;T+9GL7YH^ M)?/3US#G1>LT[JG3%UL'A=M]@!6'YASPL:PVMQA9*Q&PK.WLI/2%)Q=5"-\E MSJ#:PR_;LU26Y=;=RBU_&YL+>W]TNNT'?HR`F@8\63>SKZ;.>5;3JD^=6&I9 MY1'G?X"YTZ8[55U:6-)%JJ=SHWYIL_X4:)$/2&MR_X"4V[NTHRVA MAXTL#EBE8,2!RYAY'*13UAT<&_;=!5'64E?&2L(RCP8I??.IRY-;MB7\!0-< M^FY#%K#@GQNOP8>&':Y+QY[5Z(N(9M_U)(V,$8'T!>8BWK MEC-4+!/Q$F>.^R29+8#WP74>->UZN+`PE$_`5NJ6[_Q)'OZ8^N9T_^`CMN-* M:RH,2%^O-IUI4X*2$N=9O.]TNA1BR>Y$>>ZGICY@3Q_"5I,9PX[7LV:WB1GJ MH8=HNMNRJE!K\&N7!Q*X)G4DG>6D0&-GMQBBDZX<^DVF MO[_$G+3TD-"^0MF@Q%]P$\PFL/O:1$M><`WT'KQ"T5!/P=1J'TJ+KQ+`_<(V ME,KN=@%(URW/5:C6SF(6/T$FYY*PCOXP9L)SP?0NUU;)PB,;\I=*LK#89[\A M)ZXZ(^X+\.DQ32BKU^)(2.Y0FK&2T_>8%I1ZZV?K0)G1 MF0+[9ML2!-7)MJ*,*SF'>*W>?;'I%3$[I,,&(TBOJ/9G>V06Z MM)HQKNMK[3D9P?-6L?#&%Q(^7'!4Y-*#!$/EC;B3-KE`6X[H,*]]PRUT6TM/ M7&4GQDADPI:Z!:5O*.[ZY7RSTA(MVZL1\L7B:F9-(ZF/B2=.MY"*Y%26/PBX MZ4MQM3;X2B,GAT8>[G1#!OK0YR9]2-.89]D#'FX>I&_&A&83G20JR-2C)CX= M=][UI:L5,KITXNT9>@A3Q48.4"UB:"&FZ>_%WK(CB$YA+N2>^X;6TBC\>_4\1ZFP M3*ATUB+1-S+[H1Y#V*X@B)%V5H&2EQ+O$L"V.LVJ\[.ETC&^?FOY\ M2A&]BJ,`VO*J]O3%`GV<0[.*/]6(_^-R70(.KG(V)&*]351XZ4('`2LQRIH+ M>-)1+04]_Y=S*[AA&(2!"Z7*!GWVA901HBS03UIU_1P!;.NH'92_,6`P,N<[ M-G,$/FSF"'[8S!,`V?B-R\#XQ"J-!_E0]%#N]9,Z`J#J8AJ]YU_0"[.O1!AY M[$O#)Z>/K,JKJ]+V6U_0'/#V_KA@$\M"*0V>8-41C)I."7P@0^"9@<-]LXBU MJF_P^1;%`IOJJR8F@+FA,$6.8AQ"!+I@S_,!BHEZ*&M]+#ZHU/KK4^"%#'AL MQ"H[Y57:MC'*Z;>CHZCK!:X^M.0'`#W6\.1-QCYO@-I"F)Y0P;X?;;=]VLS[ M_GD>````__\#`%!+`P04``8`"````"$`-(>Z'8L"``"2!P``&````'AL+W=O M1YA,)U4^ M?P3?FZMK9#*U_Z)%\DT4',*&-KD&K)3:..E;XF[!9'(S>UDUX(=&"4_I-K<_ MU?XK%^O,0K<'4)"K:YP<%]PP"!1L@N[`.3&5`P`%)ZLO$GW9`+GDTG8?=BD=S*!\\7D?P3$ M5U.%LZ"63B=:[1$L..`U)77+-QR#H4NE!]E^G`K$X>:\NDG55%`;Z.1N.AQ, MR`[29R?)[%;2K2OF'RC>)03P+HR0UN.,;E*,^QB],P[K!#,O\"WN1W/B!MJH@>8E<+QT=-#HZ+Q54H,;/@+GQ'6XJ-&PF9?XW$;]?O^V MI6V*&EKT")H3-]#"1FY>TH;6IO!H?EOU.T=)U_P[U6M1&)3S%+K1"2)(7OM- MU0^L*JL=8J4L;(;590;?/@ZO62<`<:J4/0_MAO_C2]$/;'5>1N(NC17-<=YOV^+R* M_OG[TX<\6@QC?=S4^^[8K*)OS1#]]/CC#P^O7?]YV#7-N#`9CL,JVHWCZ7ZY M'-:[YE`/=]VI.9K(MNL/]6B^]L_+X=0W]6:ZZ;!?)G&<+@]U>XP@PWU_2XYN MNVW7S<=N_7)HCB,DZ9M]/1K^PZX]#6_9#NM;TAWJ_O/+Z<.Z.YQ,BJ=VWX[? MIJ31XK"^_^WYV/7UT][,^ZM0]?HM]_1EEO[0KOMNZ+;CG4FW!*+S.1?+8FDR M/3YL6C,#*_NB;[:KZ&=Q7RD5+1\?)H'^;9O7P?M_,>RZUU_Z=O-[>VR,VJ9. MM@)/7??90G_;V$OFYN7L[D]3!?[L%YMF6[_LQ[^ZUU^;]GDWFG)K,R,[L?O- MMX_-L#:*FC1WB;:9UMW>$#!_%X?6MH91I/XZ?;ZVFW&WBF1ZI[-8"@-?/#7# M^*FU*:/%^F48N\-_`!*8"I(DF,1\8A*1!">1F,1\GI-\C\$29C.)\[$>Z\>' MOGM=F(XS?(=3;?M7W)N$5A5IM+VLBI'#WO.SO6FZU:`'4\HOCTG\L/QBU%\C MI`2(63P.0A'5!41RABP-O3-'HU8X1WL3XRC.Z:=IE`#)IPK9>57>!4+`".,3 M>%\<"UY%RI^Y9`,#!+IL&MB[0`8V66X?V()-]?R!%1L8(,54,I7GFH8K/RQU MGIW#A)1I]]M)63`CQ48M`9)-I$0S M!3-2+BV0`@B2T@DK;^6'DRQW0A)210@I"V:D"E8^@.BIJ5S'0$/YL21S44)( M&!>\7:8)32E)EQAT0@P(9<;E0M&X5J[XE!BS[/?K)\!F?5>0K&U*Q"`Q57#F M%07H+'/4*37FU-^A!G9+J+D=`#4##%#32J=.%*BE(`"ITBO]):S%WMSU$YJ5 MDYLX8H":3.*Y:G;(582`6.:N1ZEJ02XOYC8ONE6 M+R469.YB[NZ2;SF(N6SO&`16J1#.[@BK),C@)S1S!-<>(!=B8&"A$R<'>!6- MQ\+%*;$@@T_F!J]8G4K$`+&BT,XCD1CD0.+*(,Z%ILR"_#V9^[MRM4#)B'UG M*N%+$I-@,65^;5=,@OQ]0E.G4JX:2`WLVW,JO&ON5$F0@T]HVDJ*3;M$#$Q; MJ82U6D7CVMM[:,&"_-O^D&7/58IO+8B!E9?S3JM(6'M&1FD%.7LR=W;E&A2+ M!1C02RK!XA7F0#W%M:?0),C9)S0K)%M:)6)`+\\@<>'!W@!1;SNB:@7Y>C+W M=6_-H%J`N6R?F`"ERKUU05D%F7HR-W7%31TQ,+`H44!*O;V:THMR.'EW.&Y)"5BS"1>>_-H(X;FEM_RBT6,:"=E'KVOHT!I/?BF5)C[G^C=O-=(.5V:\Z[[$X![^/U MA5\_!)!>^/4#QUUPHG-H^N>F:O;[8;'N7NQ15F)>?YZOPC%;*>[-N8>Q*':] M,L=OT_7E.6!.OT[U<_-'W3^WQV&Q;[8F97R7&3?HX?P,OHS=:3IH>>I&<^XU M_;LSYYR-.5&)[PQXVW7CVQ=[0G<^.7W\'P``__\#`%!+`P04``8`"````"$` M^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8 M=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L M*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5Q MVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6 MF[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@ M>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT M)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU M)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P] M?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B0 M1D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q M*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[ MBV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@> M11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ M=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[ M^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]= MV684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A M5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[* MGC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*= MF5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F M%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D M,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$- MD*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%N MJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8 M[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@ MWA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[: M8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4 MX-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R M:W-H965TV*1NEA%GL;JP7:`% MBJ*79\668V%MRY"4S>[?=RC2,F?&C9V\Q/&>G]_9>ZFWN3KB\/ZW+7'*JE]Z/JO$^//__T\-JT7[MM M5?43T'#HEMZV[X^+Z;1;;:M]V=TWQ^H`R*9I]V4/7]OG:7=LJW(]+-KOIG(V MBZ;[LCYX1L.BO45'L]G4JRIO5B_[ZM`;)6VU*WO8?[>MC]U)VWYUB[I]V7Y] M.=ZMFOT15#S5N[K_,2CU)OO5XLOSH6G+IQW8_5T$Y>JD>_C"U._K5=MTS::_ M!W53LU%N?VUJI^W M/80[!(NT88OUC[SJ5N!14',O0ZUIU>Q@`_!WLJ]U:H!'RN_#YVN][K=+SX_N MPWCF"Z!/GJJN5[56Z4U6+UW?[/\U)&%5&272*H$55HF0[U82627P.2JYMH.I ML69P3E[VY>-#V[Q.(.-@O]VQU/DK%J#PY!5CP^BG_W,3^$FJH#TET.?PGN_0B;)M'2"YSXA0&Q(S4<)E\,%9R%`H#K<;JLG4 M4!H5PPD'0^_DG,`9@H.(P+F!8^.F67!.J>&(%FAU*&;8">H$Z]+L'D>H-;<; MJ2F)&Y>!1%D@;2Q2^L+US\PGJ%<'\>G/V$(JL')M)1KA=: MO8C:GQ#[#<>$6%+O9"[J^_2LNFB2$,\4!K4)(&:D4*C38AKAY".6ZD7$TCF- MM.$X990*`4WO_?$95EVK_I;D[)M):6:7G24YDQ1,HEP)WKMNS<[>K_C;-'+7WWS8$(;T1IXAPJ4\PO;J+GV[O::G8WM)24WUHQ4$TE9K-G-@6)+LS"ULO.5'(3M21KO! MI4^'$C6JIR5;Z&Y]NZ6FM[N6LL%CT#@:RMH2@OV85/H^#-ZJA`N9I+-'X@@0Y&0\:+`A(B=2V4) M_%1),G^\W0<'-AEM0U(#4DLR?4'0L21#<"C)))XC&/H"+C`%@EG74"-,CY.$ M(^$>IRMV:C:VDW6%0>/8%68D)!F"!2N4"&:S6X%AYR6/:0HCS,S4_=^I&E?, M--."6RUX4Y#NS`%O0NG3<48(,_K4FA,"TU`0`M.@+.%"^I*QYK:FH%_GDO#Z M=`!)+5[K`A>%XAV*?3!EH=)"1Q"@3[@@PZ:H197I%IXXJ=?,KP>1LX MS11ZJ+J+!9E\,FEPTQ7OA!2DU.>$D,R)+PI,@+>[I`8K2^!E0\^-MY?)@7VE M&UC.J>F1N&0(EK2$YAAF445P%%`S1YA&U7_7+#.PL9F\&UB2?5P)X5T(;M`9 M)L1\F,$$KJ'`!*Y!6<*%L))AYK9*`U>2U[N!)9FK!!*`#(%LHD$H/=`%0MDA MT/>EYB%[C*VY_C0W?/NJ?:ZR:K?K)JOF15]M2GB)/TK-M6LJ%MEP64;DN5C` MW9K6.P)P&WHLGZO?R_:Y/G237;4!E;/[&/IE:^Y3S9>^.0YW9D]-#_>@P[]; MN/>NX#YH=@_D3=/TIR_Z!\:;],?_````__\#`%!+`P04``8`"````"$`5*^D M^%D"``"*!0``&0```'AL+W=OD(SAQ#LZ%$JGA MS.[LKA;W1]62/1@K=5?0-!E1`IW0I>SJ@O[YO;F946(=[TK>Z@X*^@R6WB\_ M?UH]C.N'BA3ML+NB5%$9;7;D$Z5@,]#+G.W;'D&FY M*"5FX&TG!JJ"KM+Y0T[9B6WTX:N1Y7?9`9J-9?(%V&K]Y*&/ MI3_"R^SB]B84X*C+$4XV8)U&^DI*1$[Z[3Z%T&I#VH@&9]( M\'DB2?-D,LZGLRM86(PH)+CFCB\71A\(-@UJVI[[%DSGR/Q^1AB%QZX\N*#8 MU!BLQ2KLE_DD6[`]6B=.F(>(P77`I`."H>B@C&K7*WNP5_:&^%`>XL&YS/A] MF>PC,A[\2B8>G,MDL_Q]H:O16*F#P4]*V+<29BRR@P-7R!MK5$Z)WO]Q3O#*?#**ZR,$W#!QR%GM?P M@YM:=I:T4.'543)%71.'*6Z<[D-#;K7#(0BO#?[S`.L]2A!<:>U>-GY&PO=V]R M:W-H965T,..$UFO;G4QM M"]=/JQ-EC[S`6%B@4/.U70C1 MA([#TP)7B$]H@VM8R2FKD(!'=G!XPS#*VJ"J=+SI=.Y4B-2V4@C9>S1HGI,4 M1S0]5K@62H3A$@G(GQ>DX9U:E;Y'KD+L\=C6E';JM+PX5!3 MAO8EU/WLSE#::;()526D("\->JB)P,,`0] MM[\GDHEB;?OS2;"8^B[0K3WF(B%2TK;2(Q>T^JM([EE*B7AG$8@XB[C>AT7F M9Q'X[47>RL!1U;3F1$B@S8K1DP4#!_GR!LGQ=4,0[%Q1-?0^_<\F\$>*W$N5 M5@LEVGN)NS%@$.B5ZY3TZ(WY; M)!E3O$LJFA>^[L5U#R19>M`YO%5`NU7;+NU,(.I"+FT+_(51D!F4#``MV=E' MDI5DV)F#(0O\6_W-6\51>UQ.V.E4=(T=F^QD MR';=RR&J522_20:G]O6.2;)9D6'L5G$N2>],(.H`>;@;T7&WUAT1<(_+5PXZ MH:YE=?-4F!WP#II! MT*:]*_94P/W?_EO`YQZ&(V8Z`7).J>@>Y`OZ#\C-/P```/__`P!02P,$%``& M``@````A`!#FU\L*!```AP\``!D```!X;"]W;W)K&ULG%?;CJ,X$'T?:?\!\3XA-B$W)1E-;ZMW1IJ55JN]/!-P$M2`$2:=[K^? MLLO!L2$)F9?D\ M]SW1Q&4:Y[QD:_^#"?_+YK=/JQ.O7\6!L<:#"*58^X>FJ99!()(#*V(QXA4K MX$H/O=EG"GGER+%C98)": MY7$#^8M#5HESM"(9$JZ(Z]=C]3GA104AMEF>-1\JJ.\5R?+[ON1UO,U!]SN9 MQ,DYMKKHA"^RI.:"[YH1A`LPT:[F1;`((-)FE6:@0);=J]EN[7\ERR6[0\-M#L"15+8,OUX9B*!BD*8$8UDI(3GD`!\>D4FMP94)'Y7 MWZJ.#_DE)U*K[DVL!O5P2O,8O*$(6HVECYH!T?H0=)Z?:[UUW.E.8=%R;&)W M;LG9E^0#(8S,3K<[^I!+R8=L9S>;*=&*$82*Z<6#P"9^R*A(CU.%1I(FOK2J MJU/TD%61/J]RQU>#=(NO==CQJH'3VV=:G>E%D)[>*#1/1+OBCF\-S*#/P(Q& M77D$=0>*_I)GJ57WAEB#>C@?,BG:8U*=(=8@W>&Q&36KP-1QK-M#K-".,5,3 M&0NK04@\75SI+)4>,]BV%-HA[CQ_-4@33\R6MQ4_9%NTQ[8Z0ZQ!2#RY]KXA MW],?4-QG6T:2+C6"<(KH=&):84MV?&O8%,%IJ&N<[AQK$+[@1:3C8'@>PO-" MP>H]^YWEN?`2?I1G'0+O2NV_>`Y[DN5L!TO' MHQF(K_$@A1<-K]0+_98W<`!2/P]PX&5PWAB/`+SCO#E?R*-:>X3>_`0``/__ M`P!02P,$%``&``@````A`"A^M`XV!```$@\``!D```!X;"]W;W)K&ULE%?;CN)&$'V/E'^P_+X8&PR#!:S6ETE6VDA1E,NSL1NP MQG9;;C/,_'VJW+3I+A,@+S-0?>IP3G7U;?WUHRJM=]:*@M<;VYU,;8O5&<^+ M^K"Q__KS]7:J6-U)DI:5:0?ZQ;%HA&*KLF?HJK1].S5?,EXU0+$KRJ+[[$EMJ\J"[X>: MM^FN!-\?[CS-%'?_941?%5G+!=]W$Z!SI-"QYY6S$?L\Q!,G.*/NU MGX'?6RMG^_14=G_P\Z^L.!P[F&X?'*&Q(/^,FZ&2)-Z%!#(N M)*[W+(DC!?7^XK1+M^N6GRUH&OA)T:38@FX`Q,J8E#%8_2^G8!%)OB%+SP4F M!$S/^]9WW;7S#B7-+IA08F!%#)CEW(1$"H(%1-Y8!:XYA#51")P]L#3X@F)1 M7S.8]ML3IFQ@DFG#([\7WH`0$Q)A^/1-2/R0)+E+8AB=F4;O&T0P&E0%#E7@ M6F#?]4RUD<2\#$GQK:29F91H28;<^?^1BV!#+@U$,J!I4PC=$&FS1$LRM$'_ MZSUSOY0(-K310"0#FC:%T+618B=:DJ%M86K#=?JXGS%I8X/=8#!T+8PFRB4&+_?4+SY9+1?J''5SK$*X`YT M(R%1XW2WP'-:VP7O*T^7M\^B@E=$\`6D*1Y%XB%R;?_9 MC#A/!M!(/)XL6D\\5VQ7GD=&6WM3*EZ"5GU?TP4972@NHV1)Q,;HG(PFQNC+ MM:V,9>KBX:(Y>S`=\B@R'9$."'O*C:U/ATR[1N(1)M$CID(\/32%3]8>LQYM M=ZX$775%HT@\BB1ZQ%2*9XFF]$$MY-8\KUV>3*;V:X?U4D*\$\,4Z-6ED7C`7)>E[]$C>@"-EB4>/IKH M)UM#'EFF>'H2P@."BJ>1^(*1B].GDX-OD(%"UEH^*>25NV+M@46L+(65\1,^ M%^:P!0Q1^90)W0#NP6";Q&-\XMR(1UX`-XTQ/O$"N$Q@^08B>)$TZ8']EK:' MHA96R?8@83I9PA2U\DTCOW2\Z6_!.][!6Z3_>(2W)X/;P70"X#WGG?J"/S"\ M9K?_`@``__\#`%!+`P04``8`"````"$`_PPBRY@#``!X"P``&````'AL+W=O M@`E))E%(-6$TNY6V M4K7;[CX[8!)K`%/;F-JP*F.%K'A,WKDF'_S[C48L[;B;EQOZ4J1*:IF;.=#Y*/1VSQM_XP/3?I<)V(&UW5,\C\DC MW28T(OY^UQCTG^!7/7CV]%E>_U0B^UM4'-R&/!EV_)<7/#4\@\P1SV;D*.6+ M7?H)A@((HAN`#:*_=V$>0QO%[\,,G[N0STW:OB@OXSF[%.8?>?V+B]/90*0E MV&#=V&;O3URGD`:(-0^7EC65!5#`KU<*6T]@(WM#=2(SYY@L5O/E.EA0@'M' MKLVSL)3$2R_:R/)_!-&6"DG"E@3^KS@?/LQI%*SNX%BT'/#?R)&;;?*7GUH%Q!MZZ9+7ZZ!>9?NP)V6.RC!<<$V@DVK"$UK_M@Y[^" M^6F+."`"?GL$'2.2#F'S!QIZ(6#-="$6;(78=%EE!QP8Q@V=N(@(&]512!?K M?GXD`SP8RK#5LH!"_;TO=E%,HL&N%ST[ZD,$UI<5G`P&1O&!9!C_]W$M&/0- MXD9.7$1`H?;Y6(X128=P\P%KI@NQX+&0U3C,`1$HY/BKTDDZA"MD=8\0"QX+ M^9EGS`0B5FT=!!O'L03GFTR-$K.^1X8%CV4\.'X@8MG("`/J9J6;=LVPG[+) M[6K!8Q4;1P4B,"O8T-3IZ*2#N$HV]RBQX+$2ZIP+!X2,I+@MW$%<*10:=+HK M#=H1X[9KBQFI<0NEQ]S(L4?Q6PZ'%8+5L5NN-HS?I`3=:[CI6 M*1Z2(RUN([<8JR7?SV:KV0(J)K??@EEX8Q'RW383MRW`9K,8.#OQU9-YV_B:)%%/S4B2<.WFOP,UUR M=>()+PKMI?)B[RD45O:C_<6KO1'U$W"%J=F)?V;J)"KM%3R'I<%\#08IO`3A MBY%U&PO=V]R:W-H965T"Y3G',ZTUYW*W< M?_[^_&'A.FV7'3?9H3X6*_=[T;H?GW[^Z?&U;KZT^Z+H'(AP;%?NONM.R]FL MS?=%E;4/]:DX@F=;-U76P<=F-VM/39%M^D75828]+YI567ET381EKLM M\T+5^4M5'#L3I"D.60?YM_ORU)ZC5?DMX:JL^?)R^I#7U0E"/)>'LOO>!W6= M*E_^MCO63?9\`-[?1)#EY]C]!RM\5>9-W=;;[@'"S4RB-N=X%L\@TM/CI@0& M>MN=IMBNW$]BF?K2G3T]]AOT;UF\MNA_I]W7K[\TY>;W\EC`;D.==`6>Z_J+ MAOZVT298/+-6?^XK\&?C;(IM]G+H_JI??RW*W;Z#GV*]>/'L*YYPN`.\]%VWTN=4C7R5_: MKJ[^,R`QA#)!Y!`$5@Q!A+PUR,PDU/-369<]/3;UJP--`U_9GC+=@F()@<_$ M3!H7JN\Q!8HZR"<=I8\%)%HHS]>G0$:/LZ^PI?F`61L,G(@+9AY02'*&Z`W4 M<=79,*X1=$EZ1NCJ`:4++]@LSLN'LK]=L#,-O8C2D.S[UF]`:$:)C9B'%*)L MB*2(U$:@((2H_R-$]:*5&Z!:!').4U@;C.EF78R$&Q0WI,A`][F%=W#2X,I+ZM< M!F)H2=\/V9E*B#\((E9.A?W18A'R7^?5HRDQ M^SP/H/Z#.=2!D@\,:&H]2T#B)J-[:+44],,>"S9JUO"J!2N`C%L/H''+ M$\NB+$N*+313K6/W9VK4;Z)=N$0F^JD8D5%E65)LH9DRT9QH%Z-Z4/"+6-JS MY:R,^LD6;X9$$B\;\8IX!;_W3:D[&*<2I727NDI;77U^5[4>0+@]S++1HBQ, MBBTTPQ\226G4;J(]N"0FPS*<*<>D&$,SU2J%&GFB/8RF76\/@S'3)/;19:?1 M=(G]PI/6C1`!Z`=:;!ZE%!#!S=9%&P@W_:S@=FX]FH^14=?ZY-<#:-SKQ+(H MRY)B"\WP#7W4X.M5\(T^7N^3`80S-[@'4?_[Q[>:17P<-E[`/"VKKOS!_T\__*6[.E_```` M__\#`%!+`P04``8`"````"$`68MX[!,#```2"0``&0```'AL+W=OT,@+S0HI&H@W29MTC3MY;,# M)E@%C&RG:?_]SG9(L--5Z;XDX'ON\3UW9Q_+N^>F]IX(%Y2U"0I&8^21-F<% M;7<)^O7SX>86>4+BML`U:TF"7HA`=ZN/'Y8'QA]%18CT@*$5":JD[&+?%WE% M&BQ&K",M6$K&&RSAE>]\T7&""^W4U'XX'L_]!M,6&8:87\/!RI+F)&/YOB&M M-"2C9FOP:N@;SQWUWD[.F`XHMK:E\T:3(:_+XRZYE'&]KT/T< M3''><^N7"_J&YIP)5LH1T/DFT$O-"W_A`]-J65!0H-+N<5(FZ#Z(-Q'R5TN= MG]^4',3@V1,5.WSBM/A*6P+)AC*I`FP9>U30+X5:`F?_POM!%^`[]PI2XGTM M?[##9T)WE81JST"0TA47+QD1.204:$;A3#'EK(8`X-=KJ.H,2`A^UO\'6L@J M09/Y:!:-)P'`O2T1\H$J2N3E>R%9\\>`@B.5(0F/).!Q)`G":TE\$Y#6EV&) M5TO.#A[T#&PI.JPZ,(B!N!=FPCA)_9=2D*A([A6+Y@(1`JKSM)H&MTO_"5*: M'S%K@X$#<<)$4QN2]A"50,6;]0MGG\!VV?0(53V0=-(%R7)U3:#LKQ>LEZ&< M;!FAL]_Z%8@=47J)B&8V)+N$A#9BG9VTP"]UIP=PVII;13?W0.%W8 MGAO+>/:TM,`AN5Z+`KM:W(XRF)G6SO9HO(;3) M:=6,OG40P\4)]Y^SGL%(U.O^R0`CJ<,[\@WS'6V%5Y,2*,>C"%J%FZ%F7B3K M]#6X91*&D7ZLX-N#P"TP'@&X9$SV+^KB/7W-K/X"``#__P,`4$L#!!0`!@`( M````(0`MAZ"6E0(``(`&```9````>&PO=V]R:W-H965T,KQ7:2U]:#:%Y1"_I-*1IS1I/L+7"2 MZNVN>6!*-@"Q$96P+RTH1I(EST6M--U4T/UY2J8$D.:S3$`'SG:D>9[B19@L8TSFL]:?GX(?S,4[,J4Z?-0B^RQJ#F;# MF-P`-DIM7>ISYD)03&ZJU^T`OFJ4\9SN*OM-'3YQ4906ICV&AEQ?2?:RXH:! MH0`31&.'Q%0%`N")I'`[`PRAQQ1'0"PR6Z9X.`G&\6`80CK:<&/7PD%BQ';& M*OG+)X6M*(_52EM12^R<"@I MAGT*Y0:,W<^C>#0C>W"#G7*6/@>>74[891!0TTD"&9>2[MMS9G;)CMG9Y:0L M?>"2)KI/,_P7&I<,SER(C^)QA^N9?4X[N5X_4'79C[-X'`;QJY,_M^;J8"P` MVSEVZ^HIJ==O/.F4]80`X[6083@-_BK$U;5".I-/$?#Z0EI\GW7RGZRNKL]Z MBO19'^^SQK>L4SBQ?]Y,KJA/>8KT*:=7E/[$^V,EN2[X!UY5!C&U'HMZ\EW/0&ULK)I? MC^(X$L#?5]KO@'A?(($`04VOAB3.']U*J]7NW3,-Z08-$$32TS/?_LJQ';M< M2:#G[F68_KE<=I7+=MGQT^_?SZ?!M_Q6'HO+>NB,)L-!?MD5^^/E;3W\YV_V MVW(X**OM9;\]%9=\/?R1E\/?GW_]Y>FCN'TM#WE>#4##I5P/#U5U78W'Y>Z0 MG[?EJ+CF%RAY+6[G;05_WM[&Y?66;_=UI?-I[$XF\_%Y>[P,A8;5[1$=Q>OK M<9>'Q>[]G%\JH>26G[85]+\\'*^ETG;>/:+NO+U]?;_^MBO.5U#Q@3^O`WV^>OV_53]57PD^?'M4,%P>V`1-VRU_Q'F MY0X\"FI&KL_'<5\=UL/I?.0M)E,'Q`5FQ M(URZHX_T<(.5*54.)*)?#;HJ2GXE16G#45EZ.%,_&G"VB\IQZ4UKV& M7]F@"ZIZ*LQE!?B5%?S1S/46R]K,GHH+61'FBZSX6`]]60]^'^NA`T,O1H+' M@/!R?Q_'8BCKR`BWU?;YZ59\#&"ZP6"5URV?O,Z*JU4Q(W>7D:?P-HG$G9394QL$2@9+@H*WU$*:K$1/6B&^$C+-HG!,0$A(2$<((B0E)"$D)R4R" M7`!F(!?TF\ZE84:!-L-V>SY((3QI7"L2&J$F%`B)"&&$Q(0DA*2$9"9![H#% M%+F#+QNN-VI6XH<7#JZH]I2R;R.("^%E^&YJN:414M5"0B)"&"$Q(0DA*2&9 M29!;8,M`;NF/$BZ-;1?$LGUFV=X(-;83$A'""(D)20A)"'$=Z*&3F MYE+@>-92$#5":CJP1K4B<4.Z&TL:/5K&G5H]2ALAI3IK5`-!+N/9%/*9,2&J MPW'W=5/``@>Y1TO03"&%DHD5UX)]62M>#TUG4A1*-'=$-C9Q/.S<2`LH6QA5 M$U.4Z(IUGC=QK`4JU0)*2(9`VV5J5[(Y$W:U`@T5RCD**( M(D913%%"44I1AA"VF2=:ILT_%QHB74.N$&@&B[2Q>5HC'SA2"I:U1HK,O38A MQUO80214>8LZRF9S*[]C4HL'8IU-Q6U-V?U)VH1(?U+57D=_,E7>T1\\2CP9 M[!NEOXMKUP2&`W$S@V5.:4:L0"AB&]3MJ)`GE+`8>/HL$5'$%-+!'VO4K3U1 M0EI[2E&F4*T=^XMGBZ:_6A8VTR\RN33](M!4]R!P"`HIBBAB%,44)12E%&4( M89MY*O@)FT7F"#[4JU>33.JA<9?6OA/P:QH8><@,5<60HH@B1E%,44)12E&& M$'8#SPI--Q@+VITH$/DD\HA`9OKG$!12%%'$*(HI2BA**3QM-[QD3 MYA/)H4@^D5/-?+1.(0.'H%"BGN10U`$!90RC:F**$J*9)(=$:"&E/:4H0PB[BF>?YBRZ$QXB636GBRO0#):4Q@GN MTLIR`RG%D\=&BBQ+6D@9$RGMOCR#3:PK0*;J0)+3J3A60GVM)UI(M9[>:SU3 M=3I:QZ[FJ>1JF;R:IWEWN<0'BH!_FX%$9]8?E8V0,C:2]3QQW'4F M2Q\K9DJ@SXOQ(ZTG6DBUGBKE7:UG2J"C=>QJGO*:KOZIO<$5B3,:`8&L8+<< M%:B*'5T5'V:TD/)!))''[RZ^/2_FEEZFJG1$6ZTW5D)]C2=:2#6>WFD\4U4Z M&L?^_UQ.S[]]6CE+HTB*04S M5T>/Z]M7.4J7&<&.9\WR6$EI]0E%:7N+UK>O3%7L:A%[FI\*3$_?B4YQB$#+ MHT!HUC9(>X9N_%)(SZO()8@I9,[:![0GJI[6GE*4*=0R:WF^_0F_B/0<^44@ MY!>9Q&MC0I>@B")&44Q10E%*4880B@7^;1K9_%,[:*T%GR8DPIGUS%J,`B5E MK&D:Z4`BMY>1E)++'.2AUK<.I@0ZEAZQA^JVU*1/-.II/E7:Y2<#?V%-[DP) M=#2/Q\`^QMAC\-CMZ90>;R0RXU$C;1^9ITI(WRY&%#&%=&C'&G5K3Y20UIY2 ME"E$Y^D4G(IBMG_]JL6MX.0:ZCM"W4W7MT(HD!7A_*FB(Z0HHHA1%%.44)12 ME"&$PX:G]N9RQ+UUCF_O>5!?CJ5@UWQSM_LP:7Y\U.#Q8/"S6(% MWZY!@5>%!2[S6DSAQ*ZLS-+IFZ\&ZQWO!)R52]:+1*`M=?\>X)9+X+X* M?-)6DD`S;;K@:R^TWU8C@W%J+8"OKRO^(94:`]]2H4Y;R0:,V;0;`R7\"I-J M@XO@5=3J-+C?A)*V.G`'#'UK*]GXT($V.P,?VF\K"*&1-DWPZ1U:;ZO!(.A; M"V(?`J.N,6Y&#%[>7K=O^1_;V]OQ4@Y.^2O,\DG]GN8FWNZ*/RKY%?*EJ.#- M;?U!\@!OK'-X-C/A#[)>BZ)2?X`3Q\VK[>?_`@``__\#`%!+`P04``8`"``` M`"$`#`R^_9((``"S)@``&0```'AL+W=O M.-B7]>83R1ERR!GJN/OZ_706.-1<=Y5^_+\O!G_\RWZLAR/ MFC8_[_-C=2XVXQ]%,_YZ__MO=^]5_=(\A3_KYVESJ8M\WRF=CE/'LN;34UZ>Q]3"NOZ(C>KIJ=P50;5[ M/17GEAJIBV/>POR;0WEIN+73[B/F3GG]\GKYLJM.%S#Q6![+]D=G=#PZ[=;I M\[FJ\\WW4!^K$P@HF!FXGC$ MTJXZP@3@W]&I)*D!$[UZ:M M3O]1*9O9HE8<9@5^F15W/O$6EML9N:+H,L694+0=9?@KFC"Y;N+P>]N0BR29RAW(&F(E0=B9C.&&$!6-)#P M;_?.RKN;OD&2[IC,%LO8NH3/)4A&$K.!"4(31":(39"8(#5!IH`IA$7$!A+W M5\2&F"&QX5YM.5""902"2W"5P`2A"2(3Q"9(3)":(%.`%@@H2"T0_?L(SP4B MO1E#\2JY,-<=W%(9N]L#NZ7V$0D0"1&)$(D121!)$H!\(212`)$0D0B1&)$$D1213"5:.&`OO"$<1+H+!W=B2XD# M&XT2H*7ANQ#B:@$B(2(1(C$B"2(I(IE*--_A;-!\IUOE9`$*UPN"*.IAH&1. MSUZRT_F(!(B$B$2(Q(@DB*2(9"K1?(;33?/YNJ-$6G>4$4=L?CXB`2(A(A$B M,2()(BDBF4HT1TGKJYZ#UQTETKJCE'@KZ:@@,M4]8QL,J,Q<+0?;<_5R"(40 M+X=(F.8D%F1XL$38D3*.:\PH%4+<="9,`]%"!GV+%C*E'MI#N7O95E#C<+;V MA-*%%H$V#L2('DE*U$@B$E`RMVFG8=G&%AN*Z]R+"-F($4F$5M>_6/9,7XA4 M7.=6,]6&%AO22FG!Z0D"-)8\"IVX'@:&9E":RE:YTJ?D`+F%PK+AO+'-"29\0FE#*QV,3FCO&>F1<8&!"^H*0 M)N_C!6[3GA!.J=`(LM M$Y*-9,CU)(HXDM9CB8:M)UQ(FDHQRCCJK.MQ(:WT#7&AG3=$GI?JECRT@E!Y M:H/DS(RU\IF44F4!1B&W18\3VW'-\SWB$MWV:*LH(#C$*&/*AML6NZEK%E1%P1$E=( MV9X1G)A+R1$3C-+^$5&7P&8_-*(>:7*#H$;Z)Z5,Q(U2ID@K98&DSV9/%,"S MD"[59;&%&$4L)UY/64XPRCGI*F=P%J''Y7`;2>PDM`]D-QUP4O6]3 MI)6S0#*"J&$,F2(_V.W9PLB%B$L,%!T[6,1@?!]*Y)2NC)]RZZSH[96Y4V5< M8F!\/17)S<6UD'^K+I!ZO?=7ZJT%O4?18LYN6V02^;9`TD&BS1L/6$"TE3*4891SA%R4,E%"\7IGSCH^S.CE[3#,TA,<2FY5K&3:!!B%&$48Q1@E&*4891K2\LDA]P9F/D&MW!P?=H^A'-.=:7A)I![3KF4\ M6O"EE(P/M06*'(58*L(HQBC!*,4HTY`>'RA*+3[7MWZ'B!MI0I$K,]AG4@H* M,`HQBC"*,4HP2C'*-*3[3!IQ,R?<)7DK>'-:L#9?30N*C+0PGCOXCI#B.1!@ M%&(4811CE&"48I1I2`\1:;%_48AHMZYNQ0Y%1HC,!E=*R1`)18Y"+!5A%&.4 M8)1BE&E(#Y'9YY/FP)E_*HOP/0#)12@T8_,U.D9?2O%X!!B%&$48Q1@E&*48 M91K20T2:4#.+YF[W\N#6\XGULVJA4:1GD6W<5?N.D)(A0BC$4A%&,48)1BE& MF8;T$)$^U@S18O&I+*(ML59H%.E99)N/E."C#)9K,D0(A5@JPBC&*,$HQ8A\ M&2(G04-$O_2@+^Y/1?U<^,7QV(QVU2OYB@/2[OY.8/J)R=;QX!N3KMU'5^9P MI>NWT94%_R[%O`(J_1H6:'2GMZGAD&]ZO$979G"E MZ_F,*\ER#>\L8+5,OEK#\WK,L^4:GMIC#I_D//3."=SH]P(FU&-G"R[T>?`P M`_O=8T!CHEOPK,^Q+:Q?[_(MU]L^!_SEVN_CP7(-;Y"PP\%J#:]),(^6:WA9 M@GF\7,,K$^!3X0!\,G3)GXL_\_JY/#>C8_$$R6AU>UI-/SJB?[3L1N6Q:N%; MH>Z>Y0`?AQ7PWM.:P.[^5%4M_X,,(#XWN_\?``#__P,`4$L#!!0`!@`(```` M(0!&PO=V]R:W-H965TJ$KV3*:$NMX7_%.]U#2 M5[#T=O'^W7RKS=JV`(X@0V]+VCHW%(Q9T8+B-M$#]/BEUD9QAZ^F878PP*NP M274LFTPNF>*RIY&A,.=PZ+J6`NZUV"CH720QT'&'_FTK![MG4^(<.L7->C-< M"*T&I%C)3KK70$J)$L5CTVO#5QW6_9+.N-ASAY<3>B6%T5;7+D$Z%HV>UGS# M;A@R+>:5Q`I\[,1`7=)E6MSEE"WF(9\?$K;VX)G85F\_&EE]ECU@V-@FWX"5 MUFL/?:S\$FYF)[L?0@.^&%)!S3>=^ZJWGT`VK<-NYUB0KZNH7N_!"@P4:9(L MV!"Z0P-X)4KZR!]QS*]3/*KR33]-PF+CD*!]]SQQ=SH+<&A04D[<#^":8'$?ZX(37CL MTH-+BD.-7BUVX7F!VG/VC-&)'>8N8O`Z8M(1P5!T5$:U\Y4]V"O[/+R5N[AP M*//;R)',]']D/+BDLP/SV54^VH_*$1/:?"2$N\ZOQX,QG($W\,1-(WM+.JB1&SQ%PDX'A-?>*VUV[^@,!M_NHM?````__\#`%!+`P04``8` M"````"$`A[@R62(<```EF@``&0```'AL+W=O73W??]T_WCV_._S8?Z>2SX>GQ[L7^NO3EZOG'T_[ MNT_'2H_?KH+KZ\75X]W#]\O.0OATCHW#Y\\/]_OX7[X>GN MUV]TW7]-9G?W;/OX%S#_^'#_='@^?'YY1^:NNH;B-:^N5E=DZ>/[3P]T!:;; M+Y[VGS]<_C()=\O5Y=7']\<.^M^'_9_/O3]?/'\]_)D]/7RJ'[[OJ;=IG,P( M_'HX_&:DQ2>#J/(5U$Z/([!YNOBT_WSW^[>7W>'/?/_PY>L+#?>!7-CZ?[PC1I`_W_Q^&"F!O7(W5\?+@-R_/#IY>N'R^GBW7QY M/9V0_.+7_?-+^F!,7E[<__[\36;7"V-CI!Z5 M'IW3?P>B_;VOAA$;R>&WF#^QR MO(T3'HN)#,9Y_6@NOG-&?WAC.VG,NJJ]P7NEG3QLDU[WG]6;$QX&\X&ETDV;T^+Q MK1U:-,;*+\;,ATNJ3\OBF1;\'Q^#2?#^Z@]:I/=6<`:$EI@S M(,/W%5X;1OWADG:2WMJ8NAU]VVEH!^">CH#$0!(@*9`,2`ZD`%("J8#40!H@ M+9`UD`V0+9!=GSA#0=WZAJ$P:MKIR%IO+/0^947N9C9S!RPZB7C`8B`)D!1( M!B0'4@`I@51`:B`-D!;(&L@&R!;(KD^H,Y5^-T$G&U&$@")`62`.-VNWXCLR/R85C#!&= MB-PFYFIGBCO-PKV5+-WM*SF)>/M*@61`#7^X[/53A"BV:$$.3N>"R5P=N!-1<<>DB#)$.:("46E1KZD5HEHJ MCC2U$14WM46T1K1!M$6TLVAH($U`BLF!XYWH#0/9A;5TZ.;FWYJD#HWMK'=? M$B1=`R.3_3,SAF[8)Q5.CY.(6YY(/48IHDR0WWHN M(C95("H158+\UFL1L?4&48MH+5+A,`^()G-]MS9!OIDQJ^->L9@OU1T@M8()Q:Y>7QF+ MQAJ4#XF@085JT/)&;2@EFQEK4,6BL0;50R)H4.,V*+B>3]6QJ&4[8RU:LVBL M19LA$;1HJULTNU:CNF,[GA:YDY9$;YFT1JX.'!V:.^?"X%I/VD[URMYT$O$* M3,S,(X?SR7&&3N"S9NO09^+9;][C-R[$\VD5=ZP M.W99&)K*W)Y;\^.DV:R*Q:->:]%Q-X;U_N<_N>NWI;KC'E?LVC, M^T9$['WK>E\L;M1-:,=U/-[=:68R1F^89EV"R9EF'5+[F5IYD?D%TTS&\;/6 M2<07F]AZO)^M)FK^IBP8Z\7L'.^YB-A[P<;M?G:C![IDP9CW2@S[5T(M(O;> ML'&[H02S`.:9[?LQ]VNQ['>_$1&[WZ)[M9OO6.%Q[TXTDQ;K3[2?"^"[Y)HS M_SJDMCFU)B+S.[BY$7N::G\9/HFX$Q);;VYR"']\U..?LEG/4CN:S5@TYCL7 M$?LNE&]U1"BYQICOBD5COFL1L>_&]3V9JV77H)2 M1F(]$^1?L#F+Q%2!J&0DUBM!?NLUB\1Z@ZAE)-;7@OS6-RP2ZUM$.T9'Z^Z8 MFC1A?TS-7A+,W[WZ8\:DRR\ZVT>'W%1!H,*HR%:DVQ=/TAA18I&]6=&9:*4V M[)058RLB0\LYHH)-V;O#?*73M"4KQIQ5:+E&U+"ISMEL%00JRFY9,>9LC98W MB+9LBITM5RJ&W+'"X\R9+.;W0Y@LD_D;$XY'*VX@9]&<[L&G`VZ@;]$15Y1? M;6)$"=NB_$+/EKKLE"OVMYW)7(U$QBKQF",JACVJ.WS)%4<]5JP2CS6B9MBC MVMM;KCCJ<3`//4%O5O)X)D]"%#Q2+9 M-!-$*2/9DC-!?NLYB\1Z@:AD)-8K07[K-8O$>H.H9236UX+\UC#L):!MQ=HA7QM3(U5;0(?*##KDWBUTABBR*@I39(I86X(2 MJ[)IZ-549S13-M/?TO2&DK%(#.>("M?7Y#K`&6(;..:L0LLUHL9U%LPG.GW9 M-L^-*'F?N#"&1,T-^*KX-C!6UMW1([2TZOV(K M]@^HB!*+YLMC-#M9J6-NRN6>)6%W%ML@.0OGZ*I@4];55#6XY/(Q5Q7:K1$U M;*IS-5NIV+_E\C%7:[2[0;1E4YVKJ?ZM:LXBL5X@*AF)]4J0WWK-(K'>(&H9B?6U(+_U M#8O$^A;1CM'`4<(DY/KWB9_;!;JT7C],#3KD9KFF:J9'5N7`MY>2,;U\YUQOU7RC_L]E"Q3XEVQGS7[%(-OY: MD+0;KK]Q_2]N;O2S/2W;&?._9I'XWP@:\;]U_=-+84NX%]FN]?AW=Q:3QQR; MA?\Z_*";S.##4C2W^<&*P*9#^Z>8#CD[S@G)!>J)$5M35'4S5T2`*3BI>VC&B!%&**$.4(RH0E8@J1#6B!E&+:(UH M@VB+:.<@=RGJ5.4KPX,)RJ!#4YD@$:(848(H190ARA$5B$I$%:(:48.H1;1& MM$&T1;1SD#,64YT)'!^+H]P]BUNDEHK:JB-1G98*H@11BBA#E",J$)6(*D0U MH@91BVB-:(-HBVCG('=X=&JM=W9Z9:0PRS;M4/\M!40QH@11BBA#E",J$)6( M*D0UH@91BVB-:(-HBVCG('=8Z.3VAAO,U,C5JK%(3D41JP3%B!)$*:(,48ZH M0%0ZR+UFD](X_Z8ZM1F0WD')HMZSVI$@N<_"03S'_&>&BMJ(G7(Z51`L:U(S^H/ M/_B<"Q&PY=(QXW:3CO]--YWS*^84,P$6J221RN5& MK*(3^^FDAS.PL^X\J0,!4V)-<9::'O_266I6]`,_[2P[IT7YD`A:5+`_F\I> M+'4(5[+"TR)W<$RXU=\!?FX.VZ"MOS%T2.6!U:]@T=16]#2U>\!`1#S;$HOH M<149X6"JTNPI5Z2U>LTBL%XA*1AC\45#@ M]LO/S5*,"8^&Z:*,!S47-.*_8.O=7K&"G]A*%GC'D[8S MU<^V<#V)(E-&_4EK*_87I;:>&DG;TM##O*W7.`16X8-E._,$2B MXMD1(TH0I8@R1#FB`E&)J$)4(VH0M8C6B#:(MHAV#G*F\^RGP[!C3352&(99 M52\RBQ$EB%)$&:(<48&H1%0AJA$UB%I$:T0;1%M$.P>YPT);T1MN@3,C5V-A MD<1<$:L$Q8@21"FB#%&.J$!4(JH0U8@:1*V#W/Y[6T@WPY#.HH5SMIKIGV"L MBB*)D0V:33DIUYE*N2:BX@TL%>N,,D%^A[F8$E$P4[^Q%*)BZZ589U0)$EOZ M)E&+*1$%^D'>1E1LO17KA-P1-*%>_Q"H[[-GO0(^,U;4PN@0#2RW(K*J7CP8 M6^2\`A[,5.XO$17;2M%6ABB7BOT.4Q%<(2HV7Z*M"E&-%1M$K5/1[7P=K(Z? MP.DM;.AE&U>Z1TH5FD2VHA-]ZLD5#XGPD&E5]I"YO(:']UG@.>1U3SL,^=(- MRH=$T*""_74/#P3Z(>.2R\?:4PVYTNVIAT30GH;]=:?@9;!4@]&RP-,@=X*8 MB%6OSG.R&2;&T`NR0VZ,K!,,$5?TM*Z+D47$"R:QR#X]-9GKYZ93KC-V"LY8 M-.8]%Q%[+RRR+Y3HM^9*KC'FNV+1F.]:1.R[L8BO?*$?7VFYCL>[.^`Z)O^Y M[1A#=;/V:4*8MDCLJ9]'B%A%XI-*KX-81-P'B47T")34"^8J=DA9U>]AS)"( M>;&EVY"+B-M0L'6W#>HD4;)JM`V5F/>WH181MZ%AZVX;U!&D996O#>Z,T-F( M5^X1F'8PC[?0T/<#7D'^ZXM9)'F4!%'*J!?P"O);SUDDU@M$)2.Q7@GR6Z]9 M)-8;1"VC@7#:Q.QZXWWS^PVT)\`N;),![CI4!YZ(*_9#"&O+G33J*)/8BG8S MFL_T\3=ERY[-R-Z>3[YX9N=<;]1]855V'Y[H&H9"36*T%^ZS6+Q'J#J&6$ZY'.F^YHC.^"1[GJ]2YI MXO2ZS:/(Q<2VXD)0@BA%E"'*$16(2D05HAI1@ZAUD#N;:=TZL_F5_C-RU7\= M<@-U/4A%*QSB@3Y'>8BRD18:`N*K9> MBG5&E2"QI;NA%E,BPD!=5&R]%>N$W!'4J9:?.AF:W[#TP':H'ZA;53]0M^B5 M0%U4?$4IVLH0Y5*QWV'J[E:(BLV7:*M"5&/%!E'K5'0[G^X8;UD^1JZ63X?4 M^5M=8$2[DZEH#H@CRV=`!#?#Q)JB+<'<#!>+F8I#4Q;0BO7ZRLYI4#XD@@85 M[,\&ZCI`++E\K#W5D"M=T4,/^;`>MKE6HT++`TR!W@NA,CEF=YP3J]+H` M3)4.O1*H7.MSIXIUZ%.')D7MMECWG.V)`>YPB): M:6963G2FK^0J8\XK%HTYKT7$E]Y8Q)>^TLF/ENMXO+LC;M(I_^$P0RRWBDZ MI'8*_2NQK?C*3F%-R4_)B:VG(G5U3D]9U>]AC-3/:4,N(AZ'@JWW=[E`OW%= MLFJT#968]\_66D3>IS5TZOE`I[LCJ^J_'"1(*L+M,+$J#E8Q4FL@/5K0F.M)M)L@2AG)BLD$^:WG+!+K!:*2D5BO M!/FMURP2ZPVBEA&N1Q/5^49C?$,\UG0W1(MZCS5$B&)$":(4488H1U0@*A%5 MB&I$#:(6T1K1!M$6TF*G@*Q$55TS15H8HEXI] M\RJ_4(B*S9=HJT)48\4&4>M4=#N?;N1O63Y&KI9/A]RP2'^+-J+$K:DX'A8- MB?"`9E6<0%GJX"!E`:W8TXCJB9P-^=*B?$@$#2K8G_TB@WZPH.3RL?940ZYT M>^HA$;2G87_\I(-^(KYE@:=![@3YV00*G0U@J@PE4!8JO1-Q14_KN@2*B'C! M)!;9LRO]RJVV$3KT%0KAQFQJDR%9\9:.PIGKY M$UO/Q*.GP0T6ZA?^E%7]'L;\R3EMR$7$XU"P=;<-ZE92LFJT#968E^O!_0#Z MH6'K;AO4LX\MJWQM<&>$277T9\0K1U0C5_>(#O7S)XL3\E]?S"+)022(4D82 M466"_-9S%HGU`E')2*Q7@OS6:Q:)]091RV@@7ON/Y$\6F#^QR*30>BM%G4@B MKBA;7"Q(*L+=)[$JNQDMEOK;F2F;\6Q&W9,.+!+WN:`1]X55V7UXKO]]FY*M MC'FO6"3>:T$CWANKLA>_A+-_RV8\[MUU9U(:_76G,VCGY4\676;$V8I/R1+> MNR*K&L]GLDAR$`FBE)&LF$R0])[>S7(6B?4"4"_-9K%HGU!E'+"-?C M4N=/QG?!H]S=!2WJ[X(6T8&,!R)&E"!*$66(3,YN7; M$AU'N>J_+O=A@IG>QJ5^(HEL19,(.ZGT5(NMZ)5`750\.JE89Y0)\CO,Q92( M,%`7%5LOQ3JC2I#8TE=8BRD18:`N*K;>BG5"[@C2:6%T/SKK9+@T5M3`=H@& MEEL1654_4+?HE4!=5&PK15L9HEPJ]CM,W18+4;'Y$FU5B&JLV"!JG8INY^LL MR2O;#Z9#EAU2@;IZ^B!B%1W/1I:/-=47X4G`FK*!^C*X4:?0E`7]4ZB>R-DY M#LMU/-[=$1]*S;SY M66CSCR+KX>^0NU/`.PFVXGBD+B+N@\0B-U+7PY"RJM_#&*F+>?]NE8N(VU"P M]?X&%NAO)I>L&FU#)>;];:A%Q&UHV+K;!O5N1LLJ7QO<&6'R`?V(X96;1)<^ MZ$<&RPXY9]03\E]?S/4DVDT0I8SDN)L)\EO/6236"T0E([%>"?);KUDDUAM$ M+:.!R(!&T.EU':>==RXR5M0VW"&U#:LC2;2T%258C07)9/-SF+Q'J!J&0DUBM!?NLUB\1Z M@ZAE-+`>==[DE5T0\R/+#KF?W-#__&DD*M[38T0)HA11ABA'5"`J$56(:D0- MHA;1&M$&T1;1SD'=8KEZ_KK?O\1W+W`%4GXI M--D)]$-)I3"A[,E024`E0W4HGT2M'BJAM%)HTA1HC7))-,A#?NAQD+"@!RT& MZBRF5#+4H?0D2&B>-<`Z]$!(:!XYP!)Z"B0TCQE@"3WF$9JG#;#DEDIN!TLB M*HD&2V(J20:OAY[:H)(A/_0H36@>S<`6T!,UH7E"`TOH/:2PH#=\ADJHW^B$ M@B7T"E)H7G+!$GH3*33ONF`)O7X4FO=;L(3>+PK-:RY8#L(0^XQ&:CW1@"7U))33?ZL`2 M^J!*:#[9@27T%970?*8#2^@S*:'Y6@>61'-:/Y1@PA)Z\8_&9ZB$7N.COAXJ MH<^#AN;CGVB-/H9))4,MH"^#AN:SEUCGEEI].]QJ*C$?7<$Z,968+^$,EEDJ$6T"=<0_,A4FP;?K\':P`=$JC`8+XE58#%UD3!=9#-8H5V$Y M6%"MPJHKN#H=1IX_OO]Q]V7?W#U]>?C^?/%M_YG.7M?'?Q_PZ>&+B5R[O[S8 M?S3AU\/+R^&1XM++BZ_[NT_[)R.@_-#GP^&%_T(C=?7GX>FWX_GNX[\%```` M__\#`%!+`P04``8`"````"$`02_#\I0"``#/!@``&````'AL+W=O9IBB) ML"@*)!TG?]]=T1;L."B;N:4.,_;@C>FE3E]E8[>KCY_6NZ-W;I:2D^`H74YK;WO,L::JI8$AL]=PF+)40MX;L=.R]8'$RH9[ MR-_5JG-'-BVNH=/<;G?=C3"Z`XJ-:I1_[4DIT2)[K%IC^:8!WR_)F(LC=_]R M0:^5L,:9TD=`QT*BEYX7;,&`:;4L%#C`LA,KRYRND^QN3MEJV=?GCY)[=_), M7&WV7ZTJOJM60K%AFW`#-L9L$?I88`@6LXO5#_T&_+"DD"7?-?ZGV7^3JJH] M[/8$#*&OK'B]ETY`08$F2B?()$P#"<"5:(6=`07A+_U]KPI?P],BFLSB40)P MLI'./RBDI$3LG#?Z[P%TH`HDZ8$$[@>2T?1:$A82ZOW=<\]72VOV!'H&)%W' ML0.3#(C?-P1.$+M&<$ZAIR%7!YOPO)K,ENP9"B<.D+L`@>L`208$`\U!&,2N M%T8P"F-E,9.[$#B52=^7&7U$!L$Y'9\DG\;S@3N MH4P7E0R8%)P.F#1>#-F>T(3(^JV<2O^]@ M]A$I!)]+A=+R23]Q6JG6DD250QM$, MO-@PD<*+-QUD#E/%>)@D_6,-/PX)QR9&XZ4Q_O@"PFSX%:W^`0``__\#`%!+ M`P04``8`"````"$`:GA2J\L6```B@P``&````'AL+W=O'YZX?S__E7](_K\[/7M[OGSW>/^^?=A_._=Z_G__SXW__U_L?^ MY??7;[O=VQEI>'[]W[YN+B]?[;[NGN]=W^^^Z92K[L7Y[NWNB?+U\O M7K^_[.X^'RH]/5[,+R_7%T]W#\_G6L/FY1@=^R]?'NYWP?[^CZ?=\YM6\K)[ MO'NC]K]^>_C^RMJ>[H]1]W3W\OL?W_]QOW_Z3BH^/3P^O/U]4'I^]G2_2;\^ M[U_N/CU2O_^:+>_N6??A'Z#^Z>'^9?^Z__+VCM1=Z(9BGV\N;BY(T\?WGQ^H M!VK8SUYV7SZ<_S;;=.OE^<7']XK]?]GK]_V/^*7A\_%P_..1IO\ MI#SP:;__78FFGQ6BRA=0.SIXH'DY^[S[R-WKZA'JF.; MSW\'N]=[&E%2\VZ^4IKN]X_4`/KOV=.#FAHT(G=_'3Y_/'Q^^_;A?+%^M[JZ M7,Q(_.S3[O4M>E`JS\_N_WA]VS_]KQ::&55:R=PHH<\!)1,5%Z8B?9J*L\6[ MJ]GES>**K$]47)J*],D5ET=5)+6'_M(G-W4E_9VPN#85Z9,MKM_-KU>SU5J- MU$3-*U.3/KGF<9VD-7IH*WURQ>,Z>6,JTB=WTG+J1%-G-/_T=%`3T;CZR&[. M^JE$_\-UC^OHC">0^A^N>EQ79SR%U/^1#-K%AW;69Y':JUQBX_L+,^D MF365CNPL3Z69S"5[N4YYEB?3S)I-TYV]T*'B$'F"N[>[C^]?]C_.*)R3?U^_ MWZG-8;91ZCCF:/-]%!H+0A1]E);?E)H/YU2?XLLK1.#U@>=!2[( M/;V/:"']?_A(J5$^XM&]92!.FWL.80FN$O@@]$'D@]@'B0]2'V0^R'U0^*#T M0>6#V@>-#UH?=!9P'$+A"1RRH"@[O%'S&E&U/IQ3?++6R+4[X+=:AD("C_@6 M2``D!!(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@G4TY3TP3T\J+>&6.L"2``D!!(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@ MG4V<@:=SR0D#KZ3=@==D2<%-%L'JTEL$O1#[*P`2`HF`Q$`2("F0#$@.I`!2 M`JF`U$`:("V0SB:.+^B@=X(OE+3K"T.L10`D`!("B8#$0!(@*9`,2`ZD`%(" MJ8#40!H@+9#.)L[`T[GTA(%7TN[`:[+4%V5U,-T""8"$0"(@,9`$2`HD`Y(# M*8"40"H@-9`&2`NDLXDS\+1WGC#P2MH=>$.L&0\D`!("B8#$0!(@*9`,2`ZD M`%("J8#40!H@+9#.)L[`J\O_"2-_$'>'WB`O\L^\R"]2?>A'%"**$,6($D0I MH@Q1CJA`5"*J$-6(&D0MHLY!KGO45<^^=D\?5U4ZQEL9C*RE@2A`%"**$,6( M$D0IH@Q1CJA`5"*J$-6(&D0MHLY!KB_4+<_VA4Z!O%-9RY^X1=\/Z1K!D_]6 M);W(4\MYC[:(`D0AH@A1C"A!E"+*$.6("D0EH@I1C:A!U"+J'.2Z15WU;+?\ MQ!?F9FC[0B.=*3_LVNK"1]X1$@`)@41`8B`)D!1(!B0'4@`I@51`:B`-D!9( M9Q-WZ-4USA[Z7TT*ZNL@V9'U89`=MGHD5XS5VMUG`I76)<\M:$U:]Q`O716* M%!N,$,6($D0IHLP@*SN3"Y)V^8TO1)4(S59+MXNE2''C*T0UH@91BZ@S2#?> M=;>Z/**[#P'P[=O#_>^W>QISVH(&5N""/`/I4BP'JK7B^3NB?CEAI19"QY M?6I%@/5VO5XB[A)75V-[9@PL97KRV:]E9KQ5SPE_NOA19K;R,NRA432G.&"9\YZ) M1$K**O8R\/$1K4D&9*`U*;=&QZO%?.7-[LQIB#^M\P$;ODPQ(`/M*-UVK*_F MWJ6[FFQ'/6##;T^/1C;7#G9,J1W'"G#0I#3OT:.2&GK6? M@YX9J>G0TPOQ`@NYWK5^:GWM3?:(RZEF/PG]\8Q9:,IX(D)L/&6DC?M/S#,N MGK*=L]"4[4*$V';)2-N^6GO[2\7E4\9K%IHRWH@0&V\9:>,KWYL=EX\8=V;8 MW,]U61?XX\^O!RUN"LP@)QBNO<6X-4)3`Q#T,MS_T!"*?(?O2GB3.5+%X[.M M5S;;R@FW>JQ4=_F(H>ADV78IIU=NU=[:O')N^ MNKI7-VZRZ6789"LFI=K,M]PYENW>NA/LM&S='+-U!M%W!+B!6T'20+_O`0O) MDX<04<1(M,>"QK4G+"3:4T09(]&>"QK77K"0:"\158Q$>RUH7'O#0J*]1=0Q M.FAW?3J1]3LA:&`&<*X1[5;B:H/D_A2PE!TV8`<.68KW)N_\%''Y2)0\7,QC M%A+KB2`98;">&JG%_!"C%O.E%Z4R5C-E/FFF,H_V*3@U:(*&(DRS,6-*X]82'1GB+*&(GV7-"X]H*%1'N) MJ&(DVFM!X]H;%A+M+:*.T4!H4;E*V]?3EVUUKJ7;E.-3D^VT_#?SSV=;4T\F M=@`D!!(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@G4W(E*7<1GA]S%AJLA$Y2\G,+`1--*)D*;<17E,KEIIL1,U2THA&T$0C6I9R M&^'M/1U+C37"G8(JSWE"0-!I42<@F$RI[4/_SK15:91#6D8FH$]"(\/WCFOO MTA>I\GZ:^',\!@L)D-00^E!G_85G(%/%HP9R4%<`*0VA#V6`S@7N0JQ4^:B% M&O0U0%I#Z$-96,V\9="I\B$+KM-5EO,$I^NDJ.-TDR=UX@[>/R&;&LP!A8ST M2=*[]$5<:L]F=#YH3;B>++*4D;M\O*-3QE*V08AF.4N)^@)1R4AWS9]P%1?; MIOR^U2PDEAI$+2.G;U?>J;AC*=N@W3=WEI"N4V:)$O=V)XV<),45)"FTD'0O MF/LD-,29W+,KF"I4KY_[=K?,!N2K3*>D!GODS@B:-\Z,\&\*1SV-G2LMWD31R#W&7'FQ;6LJTOXF MNXBI*"AD*:='5]Y.';$4U1_LMYDRH#Z1BMR(U*"%$PROO&TYDXIBT5_L.0M) M?PI$)2.WBUX@JUAJLHLU2XG%AM%-/\ZM0=-=[*3B8!>=N:1N@,Y"QK4W+"3:6T0=HX-VUZ=^,O*7XL,"Y;8V03.0`2&B( MNY%<>UM2I*0FH@*H38"DPX:\'2N;-I2#V@)(.6S(V[&J:4,UJ&V`M,.&O!VK M&S7D3A0_P_F3Q8^I3,K\J4V$YJ(L_AZ)\_P`&W`]F>(AHHB1:(\%C6M/6$BT MIX@R1J(]%S2NO6`AT5XBJAB)]EK0N/:&A41[BZAC=-#N^E1E]HZ_5"QT(M"^ M5!CD^%1++>27H0%+"0H118AB1`FB%%&&*$=4("H158AJ1`VB%E'G(-<7*DEG M^^+7`K'2XNVY&KD'-?_A^U8=$ZBB?5!#%#)R3C'PC)NE)D\Q,4M)\$\0I8Q< MB][1,&.I28LY2XG%`E')R+7H'0TKEIJT6+.46&P0M8Q XML 15 R46.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) (Management [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015 Law_Firm	Mar. 31, 2014	Jun. 30, 2014
Management [Member]
Schedule of Other Related Party Transactions [Line Items]
Legal services to these law firms	$ 42	$ 258	$ 232	$ 577
Amount payable to law firms	$ 43		$ 43		$ 116
Number of law firms related to entities			2

- Definition

Amount for accounts payable to related parties.

+ References+ Details

XML 16 R33.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Receivables [Abstract]
Net revenues for settlements and filings of prior year Medicare and Medicaid cost reports	$ 10	$ 105	$ (287)	$ 611

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail)	9 Months Ended
Business Operations - Additional Information (Detail)	Mar. 31, 2015 Segment
Business And Organization [Line Items]
Number of segments	2us-gaap_NumberOfReportableSegments
Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of operational areas	3
Number of community hospitals	3
Number of states	2
Number of licensed beds at community hospital	183
Number of nursing homes	2
Number of licensed beds at nursing center	166
Specialty Pharmacy Segment [Member]
Business And Organization [Line Items]
Number of operational areas	4

XML 19 R42.htm IDEA: XBRL DOCUMENT

Insurance settlement - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	0 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Insurance Receivable for Malpractice [Abstract]
Insurance settlement	$ 1,000us-gaap_InsuranceRecoveries	$ 0us-gaap_InsuranceRecoveries	$ 0us-gaap_InsuranceRecoveries	$ 1,000us-gaap_InsuranceRecoveries	$ 0us-gaap_InsuranceRecoveries
Insurance claim, malpractice description	Claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006.

XML 20 R37.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 35us-gaap_AmortizationOfIntangibleAssets	$ 36us-gaap_AmortizationOfIntangibleAssets	$ 106us-gaap_AmortizationOfIntangibleAssets	$ 108us-gaap_AmortizationOfIntangibleAssets

XML 21 R47.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	9 Months Ended
	Mar. 31, 2015 Segment
Segment Reporting [Abstract]
Number of segments	2us-gaap_NumberOfReportableSegments

XML 22 R9.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Mar. 31, 2015
Equity [Abstract]
Shareholders' Equity	Note 4. – Shareholders’ Equity Stock-Based Compensation For the three months ended March 31, 2015 and 2014, the Company recognized $12 and $9, respectively, in stock based compensation for options issued to employees and directors of the Company. For the nine months ended March 31, 2015 and 2014, the Company recognized $33 and $40, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the nine months ended March 31, 2015 and 2014, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the nine months ended March 31, 2015 and 2014, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#@E)SX-"B!4:&4@;F5T M(')E=F5N=65S(&]F('1H92!3<&5C:6%L='D@4&AA6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%-U M;6UA$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG M(&ES(&$@2!O9B!T:&4@86-T:79I='D@:6X@=&AE(&%L;&]W86YC M92!F;W(-"B!D;W5B=&9U;"!A8V-O=6YT6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQB/E1H$$P.S,Q+`T*(#(P,34Z/"]B/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/DAE86QT:&-A3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A M;&%N8V4@870@2F%N=6%R>28C>$$P.S$L(#(P,34\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%D9&ET:6]NF5D(&%S(&$@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($%C8V]U;G1S('=R:71T96X@;V9F+"!N970@;V8@ M$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S M+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L.3`S/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XW+#DU,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C$Q/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH.2PR,C$\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($)A;&%N8V4@870@36%R8V@F(WA!,#LS,2P@,C`Q-3PO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XU+#0T-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T M)2!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M-3(Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-3DV/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPU-3(\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C4Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`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`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,3,X/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W,#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#,P.#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M."PX,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@36%R8V@F M(WA!,#LS,2P@,C`Q-#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B!.970@2P@9F]R('1H90T*('-E='1L96UE;G1S(&%N9"!F:6QI;F=S(&]F('!R:6]R M('EE87(@365D:6-A$$P.S,Q+"`R,#$U(&%N9"`R,#$T+`T*(')E2P@9F]R('1H92!S971T;&5M96YT3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31A93=C8C=?8C=A.%\T968Y M7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VL@6T%B'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M$$P.U1H M92!(251%0T@@06-T(&EN8VQU9&5S('!R;W9I2!B;W1H('!H>7-I8VEA;G,@ M86YD#0H@:&]S<&ET86QS+B8C>$$P.T)E9VEN;FEN9R!W:71H)B-X03`[9F5D M97)A;"!F:7-C86P@>65A$$P.S$@=&AR;W5G:"!397!T96UB97(F(WA!,#LS,"D- M"B!A;F0@97AT96YD:6YG('1H#(P,40[*0T*('!A$$P.T-O;G9E2!D96UO;G-T6UE;G0@<&5N86QT M:65S(&]R(&1O=VYW87)D#0H@861J=7-T;65N=',@=&\@=&AE:7(@365D:6-A M6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M(%1H92!#;VUP86YY(&%C8V]U;G1S(&9O6UE M;G1S(&EN(&%C8V]R9&%N8V4@=VET:`T*($%C8V]U;G1I;F<@4W1A;F1A#(P,4,[1V%I;B!#;VYT:6YG96YC:65S)B-X,C`Q1#LL("@F(W@R,#%# M.T%30R`T-3`M,S`F(W@R,#%$.RDN($EN#0H@86-C;W)D86YC92!W:71H($%3 M0R`T-3`M,S`L('1H92!#;VUP86YY(')E8V]G;FEZ97,@82!G86EN(&9O<@T* M($UE9&EC87)E(&%N9"!-961I8V%I9"!%2%(@:6YC96YT:79E('!A>6UE;G1S M('=H96X@:71S#0H@2!R97!O6UE;G1S+B!&;W(@=&AE('1H6UE M;G1S+CPO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#(P,3D[6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!C96QL6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/DUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.S,P+#QB$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)' M24XM5$]0.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/DUA$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#QB$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%1R861E($YA;64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($%C8W5M=6QA=&5D($%M;W)T:7IA=&EO;CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@Y.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X M-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@=')A9&4@;F%M92!I;G1A;F=I M8FQE(&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q.'!T)SX-"B`\8CY.;W1E(#@N("8C>#(P,3,[($QO;F6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%-(4%`@4D1!($QO86X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR+#`P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#`S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$L.#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L.#4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W,#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X-#`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@U-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@2!O9B!T:&4@0V]M<&%N>2P@86YD(%-O=71H97)N($AE86QT:"!#;W)P;W)A M=&EO;B!O9@T*($AO=7-T;VXL($EN8RX@*"8C>#(P,4,[4TA#2"8C>#(P,40[ M*2P@86X@:6YD:7)E8W0@=VAO;&QY+6]W;F5D#0H@2!O9B!T M:&4@0V]M<&%N>2P@8VQO28C>$$P.S4L(#(P,3(@*"8C M>#(P,4,[5')A8V4@4D1!#0H@3&]A;B8C>#(P,40[*2!A;F0@=7`@=&\@82`D M,2PP,#`@5V]R:VEN9R!#87!I=&%L($QO86X@06=R965M96YT#0H@9&%T960@ M87,@;V8@2G5L>28C>$$P.S4L(#(P,3(@*"8C>#(P,4,[5')A8V4@5V]R:VEN M9R!#87!I=&%L#0H@3&]A;B8C>#(P,40[*2!W:71H(&$@8F%N:RX@4TA#2"!O M=VYS(&%N9"!O<&5R871E#(P,4,[5')A8V4F(W@R,#%$.RD@:6X@2&]U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!42!P M87EM96YT2!4#(P,3D[2!G M=6%R86YT965D('5N9&5R('1H92!5+E,N($1E<&%R=&UE;G0@;V8@06=R:6-U M;'1U&EM871E;'D-"B`D."PU,#`@;V8@=&AE(%1R M86-E(%)$02!,;V%N('!R;V-E961S('=A2!T;PT* M(&-O;7!L>2!W:71H(&$@#(P,4,[4TA0 M4"!21$$@3&]A;B8C>#(P,40[*2!W:71H(&$-"B!B86YK+B!32%!0(&]W;G,@ M86YD)B-X03`[;&5A$$P.U-O=71H97)N($AE86QT:"!#;W)P;W)A=&EO;B!O9B!%;&QI:F%Y M+"!);F,N("@F(W@R,#%#.U-(0PT*($5L;&EJ87DF(W@R,#%$.RDN(%-(0R!% M;&QI:F%Y(&]W;G,@86YD(&]P97)A=&5S($YO65A6UE;G1S M#0H@;V8@<')I;F-I<&%L(&%N9"!I;G1E$$P.U-(4%`@4D1!($QO86X-"B!B96%R$$P.S4E("@U+C(U)2!A="!-87)C:"8C>$$P.S,Q+"`R,#$U*2X-"B!4 M:&4F(WA!,#M32%!0(%)$02!,;V%N(&ES(&-O;&QA=&5R86QI>F5D(&)Y)B-X M03`[4TA04"8C>#(P,3D[$$P.U-(4%`@4D1!($QO86X@<')O8V5E9',L("0Q+#@P,`T* M('=A$$P.W5S960F(WA!,#MB>2!32$,@16QL:6IA>2!T;R8C>$$P.V%C M<75I2P@1V5O2!N;W1E('=I=&@@86X-"B!I;G1E#(P,4,[0V%R M;6EC:&%E;"!0=7)C:&%S90T*($YO=&4F(W@R,#%$.RDN($]N($%P2!N M;W1E#(P,40[*2X@5&AE(%!)2R!.;W1E$$P.S(R+"`R,#$R+B!!(%!)2R!.;W1E#0H@9F]R("0R-3(@=V%S(&ES M#(P,40[(&1A=&5D($%P6%B;&4@;V8@)#$L.#4R+B!4:&4@ M0V%R;6EC:&%E;`T*($YO=&4@:7,@<&%Y86)L92!I;B!F:79E('-E;6DM86YN M=6%L(&EN6%B;&4@:6X@87)R96%R"!A;F0@='=E;'9E+6UO;G1H(&%N;FEV97)S M87)Y(&]F('1H92!I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VL@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX-"B`\ M<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B`\8CY.;W1E(#DN("8C>#(P,3,[($EN'0M:6YD96YT.C@E.R!F;VYT+7-I>F4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!*86YU87)Y(#(P M,34L('1H92!#;VUP86YY(')E8V5I=F5D(&$@)#$L,#`P('-E='1L96UE;G0@ M;VX@80T*(&-L86EM(&UA9&4@=6YD97(@:71S(&EN65A$$P.S,Q+"`R,#$U+CPO<#X-"B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA"!$:7-C;&]S=7)E M(%M!8G-T&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY.;W1E(#$P+B`F(W@R,#$S M.R!);F-O;64@5&%X97,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T M)2<^#0H@26YC;VUE('1A>"!B96YE9FET(&]F("0Q-CD@*"0R-S(@9F5D97)A M;"!T87@@8F5N969I="!A;F0@)#$P,R!S=&%T90T*('1A>"!E>'!E;G-E*2!A M;F0@:6YC;VUE('1A>"!B96YE9FET(&]F("0Q,#4@*"0Q,3(@9F5D97)A;"!T M87@-"B!B96YE9FET(&%N9"`D-R!S=&%T92!T87@@97AP96YS92D@=V%S(')E M8V]R9&5D(&9O"!B96YE9FET*2!W87,@2X\+W`^#0H@/'`@#L@34%21TE.+51/4#H@,3)P M>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@ M070@36%R8V@F(WA!,#LS,2P@,C`Q-2P@=&AE($-O;7!A;GD@:&%D("0U+#`X M-"!O9B!E"!P=7)P;W-E"!A#(P,3D["!A2!E"!A'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA#(P,3,[($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]B/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`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`Q-2X@5&AE('!R;VUI2!A=F%I;&%B;&4@86YD(&-O;G-U;'1A=&EO;B!W:71H(&QE M9V%L(&-O=6YS96PL(&UA;F%G96UE;G0-"B!B96QI979E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#QB M/CQI/E-A;&4@;V8@2&]S<&ET86P@1F%C:6QI=&EE#(P M,30[(%1H92!#;VUP86YY(&AA0T*(%-O=71H M97)N($AE86QT:"!#;W)P;W)A=&EO;B!O9B!$86AL;VYE9V$L($EN8RX-"B`H M)B-X,C`Q0SM32$-$)B-X,C`Q1#LI+"!W:&EC:"!O=VYS(&%N9"!O<&5R871E M6-H:6%T6-H:6%T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q.'!T)SX-"B`\:3X\=3Y#;VYT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0V]N=')A8W1U86P@;V)L:6=A M=&EO;G,L(&-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S(')E;&%T960@ M=&\-"B!L;VYG+71E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(#(@>65A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.3@\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Y-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.3$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R,3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-#(\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*(#0@>65A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XV,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,#DU M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-C0Y/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,3DU/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%T M($UA65A2!F;W(@86YY(&=U87)A;G1E92!R97!A>6UE;G0@9'5E('1O#0H@;F]N M+6-O;7!L:6%N8V4@=VET:"!T:&4@<')O=FES:6]N7-I8VEA;B8C>#(P,3D[$$P.S,Q+"`R M,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN(%-U;DQI;FL@97AP96YS960@ M)#0V#0H@86YD("0X,R!O;B!P:'ES:6-I86X@9W5A'1087)T7S4T M864W8V(W7V(W83A?-&5F.5\X-#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!46QE/3-$)VUA3I4:6UE#(P M,3,[(%)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS/"]B/CPO<#X-"B`\<"!S M='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!!(&1I28C>#(P,3D['!E;G-E9"!A;B!A9V=R96=A=&4@;V8@)#0R(&%N9"`D,C4X#0H@9F]R M(&QE9V%L('-E2!H87,-"B!E>'!E;G-E9"!A M;B!A9V=R96=A=&4@;V8@)#(S,B!A;F0@)#4W-R!F;W(@;&5G86P@28C>#(P,3D[3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE? M.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@ M8VAA2!396=M96YT/&)R M/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+51/4#H@,3AP="<^#0H@/&(^3F]T92`Q,RX@)B-X,C`Q,SL@1FEN86YC M:6%L($EN9F]R;6%T:6]N(&)Y(%-E9VUE;G0\+V(^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@56YD97(@05-#(%1O<&EC($YO+B8C>$$P.S(X M,"P@4V5G;65N="!297!O6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DAE86QT M:&-A3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(X-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ-#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@ M86UOF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P,3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-#,\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#,Q-CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`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`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.30\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.S,Q+"`R,#$U M/"]U/CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!R979E;G5E M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(U+#$Y,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P97)A=&EN M9R!P$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#DX M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.3,\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y+#4Y-SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPU,3`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C4W+#0R,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT2P@<&QA;G0@86YD M(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Y M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-C@\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\ M=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T+#0V-CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#(Q-3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$W+#(Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV-BPV,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X M<&5N9&ET=7)E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-C(\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,S-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/CQU/DYI;F4@ M;6]N=&AS(&5N9&5D($UA$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#,T,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-3D\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH-3$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$T-SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L,S$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$W+#(Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`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`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+#$P-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q M8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31A93=C8C=?8C=A M.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M M4U!!0TE.1SH@,'!X.R!7241/5U,Z(#$[($Q%5%1%4BU34$%#24Y'.B!N;W)M M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED M=&@Z(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.S,Q+#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S(Q/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XY+#DX-3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT'1E$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-C0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L M,C0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#4T.#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V,#$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,T/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Y-#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S,3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT&5S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\8G(@ M8VQA'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1% M3E0Z(#0E)SX-"B!4:&4@8V]M<&]N96YT$$P.S,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DL('=E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.TUO;G1H$$P.T5N M9&5D/&)R("\^#0H@36%R8V@F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-;VYT:',F(WA! M,#M%;F1E9#QB6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,34\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($EN=&5R M97-T($-O$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XT.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D(')E M='5R;B!O;B!A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F%T:6]N(&]F('!R:6]R('-E$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,R/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C

$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE'!E;G-E/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C,Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q.3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A M;&EG;CTS1&-E;G1E$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,Q M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($UE9&EC87)E/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C8L-3$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($UE M9&EC86ED/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#$S,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#4V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ+#DW.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XU+#4U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV+#8X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#0R-SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XU,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ-3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#8Y-3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PY-30\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Y+#$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#@T-3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V+#$R-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($AE86QT:&-A$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$S+#@U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"PQ,3<\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0S+#8W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U+#$Y,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR-BPS.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R(%)E=F5N=65S/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S,CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT.3,\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8X+#@U M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T2!);F9O'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*(%-U;6UA$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH-2PV,S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@V+#DP,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E M)SX-"B!4:&4@9F]L;&]W:6YG(&ES(&$@2!O9B!T:&4@86-T:79I M='D@:6X@=&AE(&%L;&]W86YC92!F;W(-"B!D;W5B=&9U;"!A8V-O=6YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQB/E1H$$P.S,Q M+`T*(#(P,34Z/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/DAE86QT:&-A3PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@2F%N=6%R>28C>$$P.S$L(#(P M,34\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($%D9&ET:6]NF5D(&%S(&$@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8V]U;G1S('=R M:71T96X@;V9F+"!N970@;V8@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@S+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$X.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8L.3`S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XW+#DU,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH,C$Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH.2PR,C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@36%R8V@F(WA!,#LS M,2P@,C`Q-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#0T-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@ M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(L-3(Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L-3DV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPU M-3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S.3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q-3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C@L,3,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$W,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX M+#,P.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3,P/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH."PX,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($)A;&%N8V4@870@36%R8V@F(WA!,#LS,2P@,C`Q-#PO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/&1I=CX-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@ M,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!';V]D=VEL;"!C;VYS:7-T6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/DUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P M.S,P+#QB$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DUA$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#QB$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*(%1R861E($YA;64\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W5M=6QA=&5D($%M M;W)T:7IA=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Y.#4\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@X-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@ M3&]N9RUT97)M(&1E8G0@8V]N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DUA$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#QB$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1R86-E(%)$02!,;V%N/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,CDP/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XX+#8R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L,#`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(L,#,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$R+#,Q-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,BPU,#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#DT.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@0V]N=')A8W1U86P@;V)L:6=A=&EO;G,L(&-O;6UI=&UE M;G1S(&%N9"!C;VYT:6YG96YC:65S(')E;&%T960@=&\-"B!L;VYG+71E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(@>65A$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.3@\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L.3$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(R,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV-#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#0@>65A M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,3`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,#DU/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(L-C0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C4L,3DU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*(%=E(&5V86QU871E('!E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-P96-I M86QT>3QB6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE'1E M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P97)A=&EN9R!P$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T-CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-S$V/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,C@U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV,#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(Y+#4Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M,BPU,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4W+#0R M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(U.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(#QB/CQU/DYI;F4@;6]N=&AS(&5N9&5D($UA M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C8X+#@U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XS+#8U.3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XS-C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XR+#`T,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XY-S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(Y,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@Q M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#4Q M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PS,38\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE'!E;F1I='5R97,@9F]R('!R M;W!E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'1E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$S,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XU,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-#8U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS-S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-S,\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,W+#,X-3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPP,C,\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8V+#8R-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT2P@<&QA M;G0@86YD(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$V,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!T M)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L,S0R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8U.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,RPU,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,3`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,30W/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4R,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-#$\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,W+#,X-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPP,C,\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8V+#8R-3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT2P@<&QA;G0@86YD M(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0U M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,S,\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,3`T/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!H;W-P:71A;',\+W1D/@T*("`@("`@("`\=&0@8VQA2!H;W-P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!E>'!E M;G-E("AB96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ.#0\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5S.CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5S.CPO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B M-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E M,6,Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!R97!A>6UE;G0@<&5N86QT>3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E M9"!R971U3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W M-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA M&-E<'0@4VAA6UE;G0@07=A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQAF%T:6]N+"!296-E:79A8FQE(&%N9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N+"!296-E:79A8FQE M(&%N9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE? M.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@ M8VAAF%T:6]N+"!296-E:79A8FQE(&%N9"!2979E;G5E M($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!0:&%R;6%C>2!396=M96YT M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\F%T:6]N+"!296-E:79A8FQE(&%N M9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D(&]N(&EN8V5N=&EV92!P87EM96YT7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!0:&%R;6%C>2!396=M M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E M9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O M'0O:'1M M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!0 M:&%R;6%C>2!396=M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF%T:6]N(&5X<&5N7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!O9B!,;VYG+51E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&-L=61I;F<@8W5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^2G5L(#4L#0H)"3(P,3(\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!P M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6UE;G0@86=A M:6YS="!T:&4@8V]M<&%N>2=S('-E;FEO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`@<&5R8V5N="`H.#`E*2!O9B!%;&EG:6)L92!!8V-O=6YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X M7S1E9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y M+U=O'0O M:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3V-T(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E M,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31A93=C M8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q M8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31A93=C8C=?8C=A M.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!C;W9E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W M-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA M"!$ M:7-C;&]S=7)E(%M!8G-T"!%>'!E;G-E("A"96YE9FET M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S"!E>'!E;G-E("AB96YE9FET*3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X M7S1E9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S65A7-I8VEA;B!G=6%R M86YT965S(&%N9"!R96-R=6ET;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y M96%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B M-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-31A93=C8C=?8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E M,6,Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6UE;G1S(&1U92!I;B`Q('EE87(\+W1D/@T*("`@ M("`@("`\=&0@8VQA6UE;G1S(&1U92!I;B`T('EE87)S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3`\6UE;G1S(&1U92!I M;B`U*R!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&1U92!I;B`Q('EE M87(\+W1D/@T*("`@("`@("`\=&0@8VQA65A65A65A M65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE M;G1S(&1U92!I;B`Q('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA65A65A M65A7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E,3@W M,F4Q8SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-31A93=C8C=? M8C=A.%\T968Y7S@T-S9?-F4P93$X-S)E,6,Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!396=M96YT("T@061D:71I;VYA;"!) M;F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;F1I='5R97,@9F]R('!R;W!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@<&QA;G0@86YD(&5Q=6EP M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!0 M:&%R;6%C>2!396=M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\F%T:6]N/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XR,#$\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E;F1I='5R97,@9F]R('!R;W!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@<&QA;G0@ M86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM M/5].97AT4&%R=%\U-&%E-V-B-U]B-V$X7S1E9CE?.#0W-E\V93!E,3@W,F4Q &8SDM+0T* ` end XML 24 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Expense (Benefit) $ (169)us-gaap_IncomeTaxExpenseBenefit $ (105)us-gaap_IncomeTaxExpenseBenefit $ 816us-gaap_IncomeTaxExpenseBenefit $ (200)us-gaap_IncomeTaxExpenseBenefit

Federal tax expense (benefit) (272)us-gaap_CurrentFederalTaxExpenseBenefit (112)us-gaap_CurrentFederalTaxExpenseBenefit 591us-gaap_CurrentFederalTaxExpenseBenefit (190)us-gaap_CurrentFederalTaxExpenseBenefit

State tax expense (benefit) 103 7 225 (10)

Net operating loss carry-forward 5,084us-gaap_OperatingLossCarryforwards 5,084us-gaap_OperatingLossCarryforwards

Net deferred tax asset $ 6,961us-gaap_DeferredTaxAssetsNet $ 6,961us-gaap_DeferredTaxAssetsNet

XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

Shareholders' Equity - Additional Information (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, amount recognized $ 12 $ 9 $ 33 $ 40

2005 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, options granted 90,000 0

2011 Director Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, options granted 0 21,000

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=ssy_StockIncentivePlanTwoThousandElevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ssy_TwoThousandFiveEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Components of Pension Expense (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Interest Cost $ 16us-gaap_DefinedBenefitPlanInterestCost $ 15us-gaap_DefinedBenefitPlanInterestCost $ 49us-gaap_DefinedBenefitPlanInterestCost $ 45us-gaap_DefinedBenefitPlanInterestCost

Expected return on assets (7) (7) (22) (21)

Amortization of prior service cost 22 32 70 95

Net pension expense $ 31 $ 40 $ 97 $ 119

X

- Definition

The amount of the prior service cost or credit recognized in net periodic benefit cost relating to benefit changes attributable to plan participants' prior service pursuant to a plan amendment or a plan initiation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 30

-Glossary Expected Return on Plan Assets

-URI http://asc.fasb.org/extlink&oid=6512136

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 60

-Glossary Expected Return on Plan Assets

-URI http://asc.fasb.org/extlink&oid=6512171

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(3)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(2)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 70

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6414718&loc=d3e28014-114942

+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

acre

Mar. 31, 2014

Mar. 31, 2015

Physician

Hospital

acre

Mar. 31, 2014

Commitment And Contingencies [Line Items]

Real property 24.74us-gaap_AreaOfRealEstateProperty 24.74us-gaap_AreaOfRealEstateProperty

Number of hospital facilities 3ssy_NumberOfHospitalFacilities

Number of physicians under guarantee agreements 1

Number of years required for maintaining practice within a hospital geographic area 3 years

Expenditure on physician guarantees and recruitment $ 15 $ 16 $ 46 $ 83

Castlemark Properties, LLC [Member]

Commitment And Contingencies [Line Items]

Promissory note Principal amount 600 600

Promissory note term 5 years

Estimated fair value of the real property $ 500

X

- Details

Name: ssy_CommitmentAndContingenciesLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenses on physician guarantees and recruitment.

+ References

No definition available.

+ Details

Name: ssy_ExpensesOnPhysicianGuaranteesAndRecruitment

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of hospital facilities.

+ References

No definition available.

+ Details

Name: ssy_NumberOfHospitalFacilities

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of physicians under guarantee agreements.

+ References

No definition available.

+ Details

Name: ssy_NumberOfPhysiciansUnderGuaranteeAgreements

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period or be liable to repay all or a portion of the guarantee received.

+ References

No definition available.

+ Details

Name: ssy_PeriodOfPhysicianGuaranteeAgreement

Namespace Prefix: ssy_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Promissory note term.

+ References

No definition available.

+ Details

Name: ssy_PromissoryNoteTerm

Namespace Prefix: ssy_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Area of a real estate property.

+ References

No definition available.

+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_NontradeReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=ssy_CastlemarkPropertiesLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues $ 25,196 $ 26,303 $ 74,913 $ 76,500

Provision for doubtful accounts (1,845) (1,837) (6,060) (6,125)

Net revenues 23,351us-gaap_SalesRevenueNet 24,466us-gaap_SalesRevenueNet 68,853us-gaap_SalesRevenueNet 70,375us-gaap_SalesRevenueNet

Healthcare Facilities Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 15,695 15,954 49,229 49,796

Provision for doubtful accounts (1,845) (1,837) (6,060) (6,125)

Net revenues 13,850 14,117 43,169 43,671

Healthcare Facilities Segment [Member] | Medicare [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 6,573 6,784 20,536 20,407

Healthcare Facilities Segment [Member] | Medicaid [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 3,591 3,287 10,562 10,131

Healthcare Facilities Segment [Member] | Self-Pay [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 1,565 1,978 5,555 6,683

Healthcare Facilities Segment [Member] | Managed Care & Other Insurance [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 3,911 3,855 12,425 12,427

Healthcare Facilities Segment [Member] | Other [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 55 50 151 148

Specialty Pharmacy Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues 9,307 10,217 25,191 26,385

Other Member [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues $ 194 $ 132 $ 493 $ 319

X

- Definition

Revenue from Financial and Health Care Services

+ References

No definition available.

+ Details

Name: ssy_FinancialAndHealthcareServicesRevenue

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the provision for bad debts related to patient service revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755891&loc=SL9156442-115640

+ Details

Name: us-gaap_HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_HealthcareFacilitiesSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_OtherMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Dec. 31, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2013

Receivables [Abstract]

Accounts receivable (net of contractual allowances) $ 15,650us-gaap_AccountsReceivableGrossCurrent $ 16,753us-gaap_AccountsReceivableGrossCurrent

Less allowance for doubtful accounts (5,632) (7,279) (6,903) (7,244) (7,239) (7,761)

Patient accounts receivable - net $ 10,018us-gaap_ReceivablesNetCurrent $ 9,850us-gaap_ReceivablesNetCurrent

X

- Definition

Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Subparagraph a, b

-Article 5

+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations
9 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Net Revenues:


Fulton Hospital
 $ (9 ) $ 3,255 $ 6,721 $ 9,985

Dexter Hospital
 186 47 764 560

Memorial of Adel
 10 (62 ) 63 (66 )









$ 187 $ 3,240 $ 7,548 $ 10,479









Earnings (loss) before income taxes:

Fulton Hospital
$ (299 ) $ (601 ) $ (1,196 ) $ (1,748 )

Dexter Hospital
184 34 754 516

Memorial of Adel
2 (82 ) 34 (94 )

Life sciences and engineering
(31 ) (40 ) (95 ) (119 )

Lon sale of Fulton Hospital
(6 ) — (197 ) —









Earnings (Loss) before income taxes
(150 ) (689 ) (700 ) (1,445 )









Income tax expense (benefit)
(55 ) (301 ) (291 ) (556 )









Loss from discontinued operations
$ (95 ) $ (388 ) $ (409 ) $ (889 )









Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri, LLC (“HOM”) sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of March 31, 2015 and June 30, 2014 and for the three and nine month periods ended March 31, 2015 and 2014. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $197 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the Fulton RDA Loan described below.

Fulton RDA Loan - SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton.

Dexter Hospital - On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and nine month periods ended March 31, 2015 and 2014.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and nine months ended March 31, 2015 and 2014. The components of pension expense for the three and nine months ended March 31, 2015 and 2014, respectively, were as follows:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Interest Cost
 $ 16 $ 15 $ 49 $ 45

Expected return on assets
 (7 ) (7 ) (22 ) (21 )

Amortization of prior service cost
 22 32 70 95









Net pension expense
$ 31 $ 40 $ 97 $ 119









SunLink contributed $84 to the plan in the three and nine months ended March 31, 2015.

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance $ 7,279 $ 7,239 $ 6,903 $ 7,761

Additions recognized as a reduction to earnings/revenues 1,619 2,596 7,950 8,308

Accounts written off, net of recoveries (3,266) (2,591) (9,221) (8,825)

Ending balance 5,632 7,244 5,632 7,244

Healthcare Facilities Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance 7,055 6,760 6,649 7,286

Additions recognized as a reduction to earnings/revenues 1,554 2,521 7,805 8,138

Accounts written off, net of recoveries (3,165) (2,552) (9,010) (8,695)

Ending balance 5,444 6,729 5,444 6,729

Specialty Pharmacy Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance 224 479 254 475

Additions recognized as a reduction to earnings/revenues 65 75 145 170

Accounts written off, net of recoveries (101) (39) (211) (130)

Ending balance $ 188 $ 515 $ 188 $ 515

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of increase (decrease) in the allowance for doubtful accounts.

+ References

No definition available.

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of direct write-downs of accounts receivable charged against the allowance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 310

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35755819&loc=SL9156395-115594

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_HealthcareFacilitiesSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 32 0001193125-15-189219-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-189219-xbrl.zip M4$L#!!0````(`"A/KT8$9J;TVZ<``%4/"0`0`!P``L``00E#@``!#D!``#<75MOXTAV?@^0_\#X(4B` M*;ON)(WI7O`Z:&"F[;A[-Y.\&+14MHF52(6DNNW]]3E%RK9$43)U(47O##`] M+=[J.W5N577JJU__\C2=&#]4EL=I\NF,G.,S0R6C=!PG#Y_.YCF*\E$/O&WJG67AB'/*3WG2Y=NTGDROC26?_(R%15PNS&&=EP:%!.!L$"$?R?V M)9>7E/SO\MWI[#F+'QX+XS]&_PDWPYWP!#-NSF_.EX#]N_$M37*X>SJ+DF?# MF4R,&_U4;MRH7&4_U/A\\=*GNVQB@$R3_-/9$CS]\WF:/5S`)]A%O)#.677G MI;XZV7+_)$[^KL7W>K_^8>7^GZR\F]BV?5%>?;DUSE-.B;FM,=4=K^_.XZ8W MPZWDXL\_?O\V>E33"-41@*8\1-'L]&:NW#Y4M MRM7H_"']<0$7&F[/\^>5=N7S1.-\5-&D>"Q51G+YYG*&QM57FGX MC&[)N%AMV`*_N*@NKMP:-]XJJUOCU\87LZP9K+ZBFT%6FS$"Q2ZRY^9G%A?U M8ZSVV#S+P'PW/;>XV@!;/8T>FQ_25QH>2*)XE#<_45YJP!0G/U1>-#]376M` ME,>C#8*+1PW?2-0#F/UXH[K;%UDZ41>+VUZ?FD^;GQ@7V876E`NX0V7QZ/4! M\`SO/Y,FJ/;WY,_HQ6#.G_+Q'JZEO=>ZJ%`M?,&EK^X*'2"R,C*$ MT4@Y4ZW2QBA-"O54W.@&JG1R>QU`_Y;_$$$P^B^,,;W]]MV_Q;?0=DHP(_"_ MA%J84?9$.&9<(O//D-# M]#^_7KP'L!(#^+?+("GBXAGBR31-OA7IZ._?'J-,Y5?SHHRT$'UW%(;`@K#; M9;!Y^<9EG%^^AFM`?4G\0`B&A.F&B#N^A=P0A\AU`L^R*7S3#F[IK3C[;'/. M.+9^O6C7_FU=_@60P=W%#1CAMT);XK7*1G`A>E"[X<86YI2N*`'%MF4NR6$V MS]1[4G!`;RQ;NHB;'OR'NB:R/`>ZFP0.*!,+/"ZK[B9GG_&YEL+NR+HP@A;X MVRM]>RF`TC.\D](?V_;!].4R;`FBD&POV(Q*ETK'0<3&)EBXXR(K9"&2V",> MH5[H4O\5MM@/-F2,Z4^=,(5IYJ?SN^)^/G%&92#/;]1(Q3^BNXGRR@"]JRP8 MH=H/[H4]I.`W'#M`GL,XXD($R"9.B`(S]$W/(5Y(R"UT-;NUSSZ;E-DKV'=" MU;M`0#E,R6S[B3`I&":="HAH`4E3XH\I(-,4%NU40%0+B)L?0H&XSHJZM"BA M+8I0;5*<'TLB7I0_.LE8_Q'\WQQNG,`MN5-X498]0T3^6S29[QA>#Y($]KD, ML'!1(,(`@DCH(\>5D-]S2-Q7S,G3P$J*4DHK5WBX;?#P0VJ(Q9U+G MO@13?A07V!8DJ?K19-;)0.[OQMJ"K)05\H^:MG8)DF*Y7T+7%A2K0)GPUO=! M=>]W^PO)0`YV)<(DU$F/&;H!X+WEM)Q&6L6\H>'OH#MDIJQ3B*P-Q(WS9->9 MNE?0N^.WF[_-[_)1%L_THM:NR42W6!F,Z&A]/N0]!#6SSE1T=7^CHDF0Z^FR MZRR=J:QX/AAG-'I_UD]05]@A(P@STP9;Q1(YIN4@Z3O$Q\3S?2%OJQE>?F[R M)3/=T.J-.OLUO8ZR?<9?Z\"67-$M?/3VI4.?\O@RB2>?SHILKO;67K(V6=_0 MG[DS+Q[3+/Y')^ZEJ:?:*J353B&7`*R"+6]Y3"=CE>5ZT%D\?TE&D[FVT^LT MT_KK%$46W\T+[8>_IU_31`L@2R<3N.5E\O>8?7PDKV3"P(P)O!J.CX-V58)7 MQ:/*?H^CNW@2%['*]XO(/8B$@JX0VR(K$MG0^B:(:?+P7653/?W;(SB78(_; M/$2.2T+$/4LBFV*&8%3G8M^6CF,[VA#T:`XW0%MJ=KF2X! M`ID-U_17!7`@OHW"&BY^R-L(EO;J9,][;@\L!C*+,<@DG:KOT=.0`8J4>5Y/$/5:GL[VF>?U7%U3WH M[@`[#0P.,<8WA=@VJ-9$4LYZ7$?/^T_L].%J(-7BO#YYW-CX58`WJHCB1(V# M*$M`7?.5A.0^'L4#!,L%N!TA:U4`[R.I^=BE)'2X_0H>UN*K.6-#PVM*.Q[' M.C.()M=1#+'&BV9Q$4V6O-?P@/(RE'#36M7@=Y%L'_8-.GB"R9JUF>G-[=^L MNX/&"(,>0KC)-RKP1H1O0H!@NCY%,#RL'$;RPN2U!=GW<*RB#J:S2?JLU(TJ M_=:'R.+!&3->6Y5[%\=F=1[>+$:YT,[(9AWN;XGHH/Z4GHV)+1&G6"#N6@ZR MF$>0PWWJ!8$'7:K1@L5":*V-6H95#=2'5D,Z9=4*2/:H!/HM3<<_X\ED>``) MF"V7JP.WE];6)Y,VS#E!QCQ`7%0O9PJV.JFP#4,]'WY19STB&*S7U3.K&!.K ME@$WM'UM9G`&F53P-(/QCP))E!E'56`S6+!Z.<6L+1JT`%*O^*ZF%V&(5]T% M(AIRZD2D+G99J_+>!J)YZ/JF%;]E,,X=;.#!Y:!.K,V/;P'1TE&5CPRPAW4= M/Q>RI:LJ430,=RI%^"/.1VH"SZAT/NAA#['//MNVD.OCGJU`CE#2V$?:@)O& M`$WUBTV6W",>C#W;(B[):@&Q.:BT7Z99O&C(EKFZ'G4`ME4A?4E^P&]I]CS(A%'7BMMLU1TM MM[CF<2O(R8.>,BX3__LT^QEEXSZ=44OC+;>)6:O#ULWM?R]Y&+(-2YTZU/KA>\3#D^W\3YWS7X MP2)DNAK9KOJM+8KZPG-29-&HF$>3J[M)_%"5$,W5E^2;`KCC_U%1MA_N6T*E MC3DM20PHEGO)P1/<#WTO1*8C".*F])$5AT]EV4J\)H;-8WB9*RRJ_L0\H%H\C$$A=>7Q0^' MW4ZCG/M"96%\_U%T2E<08%NT4JI5;/U'&693;NVW)ZR5-,K=3DRT=:TGC#+= M2Z)<*!EBD.D>>ED_5%LB&DB,Z1Z\WAG6SAL,.<1T+R>L\]$6@AI\B.E>5%Q7 M,GV(`,,M0:7H3A:LFC)OX5I.'6"ZEX3F,^#U`NHA!)CNH0N]=MO&>?0?8+H' MKTN16P_DAQMANA>4CC#8_B>(,-V+2D_E2MY"5N_$F$,6CD_':L0UDX46@2WL M%M0XW6#LF-2(Z^:4I9:B-@/2)<9N.8VXYFCAY6"#R' M]IXF$SD&':?E^287H8\DTZN-+'21'9H8F19W6DI=:EK6A[ZX@HMZUBJ=-@J M[5&P!]@,A"DD$BX%!9&,(<=E(?(9)X0&MF697C6SVZXNN:XH97W[8( MIGDGQ6IGMX/7USI]SP(11UFYW^)5#B@)K8M"_QVBKOE4IA6"=R<:NB`T(]BR MV[K/AJK1+S!DN-_\1$<:LRPF;NXY']5*3.R%#Q_7JJ=W!7Y:;8)\13"[.S&5 M@PK-_2L/4:;:'N/%AJ_K*%O:[.4DXT,K9[18;,[(DQYS,K*?]F#7P<*W3"2I M5^;L$EG5)P_(C=3S M[V"K;_R+DH.'/)M0'WLCX,*M6.4N^Y6M@&\@ZIM8$W5U[V5J'&M*_K*2YX_H M24_CN&F6I3_!V7C1#*[LNZ%U=_A-O&9VP&WB8X[`.0!^:?O(LBR!3)-R3+@C MB?M"D;V8Z5_9X=H>Y&;QG++W0\=U`\<$C3H&1Y08826X*QQ:>9076:^]O M`/Y6A-8DCEH`M:&N?6HFKMJ+!/ MZ#NKPWMV/+?%=+%E.:Y`+A$4\1#BK4U-@AP;FSI>>8YO+GM/0<7@W.<:\".[ MSY?D50]N6[K/KD[K:0"_SVD]K2;&RBE`?*S3>HXR1=C3E&")7.]3M<1JAV^> M$OQ:SNB/U=)&UOU15H=O"1M;=+_Z74H8=[$^*8)AL&K/=9%KR6:)X;LS:E-S!&B4,DT>I\F2KZL7(S0ZTX9(_S9;K7B5YI^BO)F-22Q]*1 M?B74/4T_+27$S:.=8W`=DYEWZ;/]J:RIQ^4RGYK'Q_)U9CX!DNE7T/(M%4]FM;MUI1V9^( M];T'F92L[YA9:\2L@V1][T$@PV9][\-*3$TM5ZN+'A;W>Q]2T-SO4F"Y20R= M3UZ:*^N=^[Z-?=3EQ;=ZT?^[W/OJTXGZO M%TZ?BON]C^#)]*9\<^M(J5/N]SXPEMSO-K&FU=QG71BW#6JGK M0ZLU18AU\"K=GN73?4Q*G8+[O0]4A:\ MWJ&GI'[O0X^E/LRK=@;'R:C?>X@[FOI=FJ*YXKYWZO<^>EAS\S(N93M/U0?U M>Q^H]:0OM^V&,Z^ZYG[O(VW`36.`MMSO@_7`>BN>73N6;8#\Z'VHKZG9&4F- M*GX`+.E]#'`A)S;%JFIO9DD_(GMX#]BD/EZF7GLV//;P'B1AE@?M-/BO05*( M]V'R)>F*:=?T_A04XGV@U13BNFZZ1PKQ'F#INC-AUFLG>Z,0[V-$J!FCJ:R" M]'X%N_ZX6.B)N5A.8Q`#YF(YC4#$45*@([-G;!!%KUPL=/A<+"W$U#D7 M"QT^%\N[8NJ!BX4.GXME24R]<;'(TLCJ[(F'D;$*2^)/D\TV,-7[WNC&LO(5)) MB%3GF-6CD^4+RV$2.0&CB%MA@)S0TW0.!,3CAQ[US.IL+F\2Q5-C&HT52'&L M,L.(B]R(7YIFS-))/-(=]T-E`.H7(YJFR8.1ZNDCHWC459F_&&I1&P0_J/O" MR+3CUGLRB]0PIG$>S699.LNJW3!&>F_WE/ M;NC/&5%BJ/CAL3">-9GU#!J0C@WC3CW$B2X'A58:H*7R_*U?WI%N/4E;W`$# MNQ+>+D7=J^+?)X%HUT6X@7:@H>';2"BN2\'%HP7%^(X8*<&4KC!1F*:T1'^$ M(R\$55345\ZW@.Q0'IB?7!X5XTYM27('>5QGZ4BI<1YFZ=2'+#0O8DU%?W7O MSG/P;)"([FH)%)MX(163$_E$A*34VB^U#KB#N0,91N@)&W%"`@1^WD:>:8?4 M]QUF2_)&V\9J)3,ML*TM9JXO=OP6Q8G>0E"]I5HC*5=+UF]U%7@O];K]9P?! M6;P,\F5,6Q(=),66W"_]9KYD@0U2J%+_;=H"SX=:^+ M_3H0A$H:`3^>S(M=.!"H62';=DSO"JG#-NI#PH1)?)`V_5-9'LF0S*T M3.IP.Y#4O>7ESD>$S^ERS7LSCMKX3A6Z?A@\P(]XK,;N\U]S/:WS>B2[H[G^ MRD+YX^(_"G^1=F;PC=7IJ?:(]EDAJC(3B!*9BG+(SJL_>Y5-JR4BLQS[Z84T MAO@NM*S5PV":DJ2+`A`A9'JOLB'"; M@!JSCM=MGO`B-\KCT0<0%,.EH+"]25`[(%T5V'^7(V8U=F!<&#VHK_/IG3Y( M:EG"^]$F;113*S*AMG(Q2^*DU:FU'2%M#T6EW`:N'.S=0%2BV,.5?!3[T&P: M^SB235:QHW%]'(^K=V,>YD@V^]X-=K=F<,D30#.N)SD2W(#0]%AO>VU(J0H3G)M^Z#0R;=HHHF'=MU9T:.Z2KW4M%J(M!'`YOF3 M_?8:]]>5]MEG0>V-7^$^T?YU;=! M=^B/)`\!//#_[%UI<^,VD_Z^5>]_8#G95%(OZ>%]C#>ITD'->-(DZ+,DB15GZD(DDDP#Z07>C`?2QS3UE@\#A2J_K M58>M/5$\#^1GQ_+B:0\@O@TGEI^Z@]Z[$]\=NR/+CWM3RY\XT;5O1C%0%C>\ M&AI=41X8`X,;R#T=Y*[3Y3H]7N*Z`T4W9=4`&10!,IX$]LP!M@-EE<27J)*^ M.4\.@-STRK$IIV#]8:GB&%\9][9[A\K1OA.9W^/0"D(PEZSPY3IV'J.WIOAL M<-DA2ZM8R5)7(P@5K9Z=HQ4]MA(E/`^M%NU=,O:%($C,V-1U?/@08\@K!G2C M(?;-B9/0O_7QMP.8)(IDR.:@+P.MJL+)O*EP'4W#TWU>YZ6>(O9E$ZF^^$VL MA`)N0=%"]KCJNK9]HK4&]09.N*`OU+=?2<0&]Z@;+%`[WY_N`1E8)WIJW]0X M4^N``2?)!M=5.P-.4U2E(W0EHS/HI-LJ3I`K]UQ[(KAR39J:A<.@,_H[<4-G M#UEQ]['B;E(7&W;;,HF7AD5WWJMQVOC M7@6CH?5*4$QYS-L:#O6F!6]PHO'$'AV7M[09WIXH'&^;1E9V1(OIAB"I1H_:WW(E['@C6JH6 MQ>NIM-O(,:0LC%2QGS8A9KG".,0\;THIZ`Q-6*XSED[IC?40A$!UZN'?8M*4 MB]\DL`_U!5U=[9H>J;*'J[;"6B$U2`[;`XV-3ZP=C'R1Q?I'?AJCJ!C""G=*]$SZY MHW9>&.D8%JM7"Q651[WB[B15>NFNN(VD85HJ3EQPG5\Z_HT\NC`Q3M1^CRY, MF"Y(E2(%FY.TXJSJ!KD;-)Z?K>@M/?P4B`:KQ#6OI:(BLC2R<.#8\(IW6$;O MZ8+44S5+M(C*TZH^"._0L8R-84AN=%]X#6[ M+=UP6C%AKZ9+^A)%E8][Z422PKN@O6]@WW$:2V5Q/RVOGL//K^!VL M7F&JXQ'';>-*FSN1Q7*!U1*TN]"VD8X?N#X8>ZW7\>1`4A7Y373\$I(J6Q4\ MVR6[4'(;>P>(A;`O#1T\CTM!/L06;4/^D$@^^OF=R^8456[WDMG,<_%BI[4[ M4MAK*UI%VU>&O!&@XK"F'.WV(FNUQ:6[*@' M56T;%00>0[ZV@)1IV.!:"Q??\=@9Q2LBX5IYB86&A:+,[VUWHFZIDU)$KG&H M`LKM[38J#Y`(W5"7%&E904 MGB9V8=W!/8DN%5&?FQ.SBV`M=^MKHV@I<["\E<("JU7>LL>##!Y+&4(.S78$ M%4`L-W*_P/9V!+\!I/2C:YL>+-]AX+LC^@H&`(0VWD9#IQB?GH7UMW&%)J?P MHE+DO=T_V06DZ?;8\J`9^A*VF9U^IUJLC2CQF%=.X8N%;"-*:O%F_9/D9914 MDJ&)%^6]I`3>U.5(H(55)%6;]]M;Z_&Z1Q_,0Q./V=VE2N'I5]TTZW$G=3,&B!)E&5]"T\YYO1 M(XT0CV50E!7W9JU4(TV@0M1()=7CD:F11IA'QQ"W:GZV%F@1D5=W2\6V*>T2 MT1K5#"J'T!E-D(IA^9)2B:EJF99H``?4"J*@')56:((]L%RR7(V>V50+U+X9 M0S1$628I&PU%$?=B:HG=OB)*HL+QAB)S8$AU.4/65<[4>K+,ZVJ_UR=)M<@] MMJJ6CD>VV*XU"(W$&[#<-0>-B-#@.:.LMQP969!T66@.&1)-@Y?;HBQJ;<=& MA3%JS6$C(S:D_H#,MQT;1=0-K4%EHR`VI(2%(`FMQ2;%@@=J=LM#OQ$6*F)A M%/;9CL=DATALUUQ9+8T3%*:W\ZNGG= MU0AF"H;T[()9174U*7.[`[.1S.DH M2V*2UL#ZALHB&\$JI?.E\^W3]E>O>#H>W7SXR_"R^8@:W7X?< M_?7_F!\9H?AAT/ER??/'1V;H/H**_^H\,]^"1\N_8M(FAK=W\+P^BR]*_3S@ M9RPB^,*%]J,F.-H#5H`_X, M(_.86>JSP*1INK#$YB?7P]J-('B+7 M=JWP)1T;SO+,\E\NF6N?0<&+QNFB-__W`C#C"@@(FDXC M"[)QT>[HYZQ!:`0'@+D>9A@KCPT`7R2ABYU=TX>#9Q^FW0Y`:J`-,@751A9> M)L*"#&:]D&./<5V(^0P.DG_&[B`:A2[L\2C MC[AE(2:">\ETJB)*9CK7`25.@:X$\X:.P1=!;)=45[6=4J\V!Y MI-QP-'6<^+(QO2^(:Q3_?>+?N/Y?A'6P*')9F!FL#`-*T$H9]0E^#9*(>22! M*![A[;P4,6F!5DS.=!O\4.(U5%-SV2KZB-\YZL)UAA""OA\,&2029/A04DG?&<"1"`I^B@*U@`P+>HC874 M.)X+^R;D2PL+1(/N2;+^H@1(6P$,H1;>]]R_<-4"&A\2O#U.0'6EDH\$ABXJ M>_L)U@@0&!*[G&G2<7:JC7(2T#AWEL'`=V;L!<^`+\!+!3;"T01%'%EU&1L2 M4#/Q=;(=;T9WA,8,D;P7PAXPJXB=W1)V7K1C[E/+X',0S5QDOK24>6:#50P; MIFS9$#6000%V`!H`N)[$T]!QF&G6XCAOD0%V!E'XS\1W2O+/$_D7J8P1=@M\ MWQD53)59,!%V`O,46QBYSXQ`W<&G3+O@ZZD(0ALI>U*+,LZ9']?@>3/T'H9* M#%2)*6_UH8DB^*ZULW<['J-N@?F[]B-,2`Y\_,GQ,=\3D^;UVLQ(A:>A`Z*9 MR2+&YIHO)'=A`+<%B_J(5/U$+3@+'!\,,5@#R/3\"[9R!#22GRAB^@ZJQ\7'^!4RS4HR6RH6$J\E0]NH]T ME]GK#1*/-3K06@]J:` M`'QRF&_.!%HG>B\7<("MU%5JRK.DA=#Y.X%7'3N?:K+;!T'#RG-E),>P2W=0 M:XY#*[$3C_AM4U`?+=LAZQ682C1C/`.$SZAS`[81O8RF8*6&[@A,D)0/9FG" M(F()PTA`6#VT=J`9"PVHT.;(.HO[E+RQ94UE+8742,GG#<8;@'9*P$(DUDF^ MO#'6`[3(S,.+DTCW7R#]4W=6Z*'72,G[9U-K"'=P^?H#:T)^ZD`V`]@MT6JC M()T^N^AK@O6Z?+IOQ-]@A4(1(:M\.C_4\+.3$5W2H*%GM-%)@S[Y&;JW4KLU M-4P8$!DP*M#F#ITGUWFFFS\+=.SC#'-0X[?L66J@1IFMD,R069.P(F8P9=#( MO`E!%EXP?B(R7J`,&-:!@1/;);4%\"'@(Y@)6+\SM4WM8KH89PJF>(@LJX4I M0`T`>",S`;"1U`@`<;>H$8`C+AE3^704QD"0!3#`^[DE$)9LA`;7@,H92JZV M$_R`QR1H4R8P_-L'+YT!H*IRGD*LE.J)2I*O`&YKSE;*!`5E@D:5`Z)1F1PJ MGD0'HVF8;S5LYR%F@<5\;H2;"6JKYI,+=AHF?TQ-C333/#%Q@U(]5&R#EVQA\&=N8-+"'!N@`XFT=<+[9.T\ED?6\Y9 M]_9;W_S&]6YO;CIW]_#2"*BP9I%S`=:6YT4@3X#%KQ<\_3ZS;#O[_NS:\?37 M"QTF%I2M._%_O<"`>R>\8!YPBQOB4^5AAN4O=O:^:E#&(&3%]OPS3VG##T$< M!X]YG^KJ5_;U^REV_6%^BL(E/*6_QE(7ZTGQ@^?0FOUZ0?]??GBV2V\Y`V'GS\RBG')*TO.JK,0+L9._?[X>FMS]7:<' MP);@QTPD'*8B(:/$-_)F0N9#.F;T0JT`LQT6QX9>'MY8`8+F$CXI**Z+9;," M1JEZ;NW\LH%N>GV]@Y5I`E0'L#3]T.N9YF"P0EW%P:NZ:0N+Z,8<@`$D.(\5 MDXB#G[)N!'*]4:_*6?+NCQLM0.E72T@,[;>2?'P&]ULIENLVR=[[8JW\\TC% M6V?YTV-W[>0H%EE5;L'F>O9]_>D\Z:T!.*N*(3VZ)%=>Q;GE]_3<(0IB*PDR`=976HFC%6DF@]T#D*7P@IU MVS_O;6&40$_80?+@.4UIIMU[;*=J/R-X1G"5?OA`G*F6C6K!>>O[O/,6?J\X M=A=:9?5PZW+`X]*8&/HFCRBH?73*= MX@M]XGD:/*YHP:4^P]#`A/I]8YP)_C6B866N3]S\,8HJ"!D2398%U6#3&`&0 M!QN01H()K`E3=X2NHE;J0XR>L^X8?IN1*%[F9Q\=@+$K&JU`#@Q^P0X><"08 M+T#C:4(LTP-+E<>0=F:8LKAP<"WHR?SD,X_QG/YYK^(\"H>.RW^9:R*+VT/G M(^+82!P9`W3+):%1N6OP+$L+%U'7W26XSN'I1M25+\;O[O]11VO2T/)A%C[. M5IH3*R4PB_WY0-&HQ(#E\0`%*R"#>>AI&V/Y'?2YS3RLX`-I+?%MF%,2)8>Q ME`4IQ+?WP7'0/W-FN3:Z50*U*Z/2,F9-HW)LYD=!(:Z>/PHJ]?(LF#+O)4H] MWTEY+N*LC>&,4R?EB\?`CZ<1C8?[Q[^MC%W#-FC<1.JD#:S@O2P;DJS^@[HY M_ZA+Z)J\S9!\#.NB(X)&UL;HK1K1HH),`\/+);6W"6>?#X4W+1(J$-TY(8FI M[[M>@EZZ.\>\+TMI\2?(\)^+.0/$W:HH27]*\L5O_"4O%A"L(*.26P&CN!// MN1VGZ4#N@R0<.='R[(Y#Y/7])P%0==74#5GF-*G7!1(ED>O*_1YG\KK:U4U) MU'MRXTD`U@4QI5A%(-@8IEMH,L+E=IJ)KU`[H*=`46#X(W6LAB92U^J*I"+# MEP3D=?&`EE!`3LU#VQ#?Z*&M;^^A+1W.3?K<=2U=U^\<7O->Y^U^LNI:/]DA M44I?J"XR41>1/Q5.L8N:B8SS8V>"V\-%R[GVF_=#/7<>\WG,C5R=[E.TI;6B MG>6[:%R(=[P<5%E%DS9ZM46N0CO3JNF'N;ANGE:19Q5)/1UB9?X7: MS5L?;_3[DUC%.+G(!(D5]:[Q[*XVD?K49O`>O((+_,;Q4VV+QB,:[>CTV.G)LW)R M,=3"Z64\$>06!%$?4R#)^XEP.^-WQN^,W_'B=_P[X_4^%5MZ0.]F439F6;#J M@5)6-$>AH;0ZB/BM%,H&*XHUYZ,X.(6:4?,5\['M9=?KJ+LCUDD_"ZPN[ZR3 M?FDO&R-AN\?]MYDPE>75G7?E[29,V/WH<"UAY_UG6^W7,WYG_,[X'2]^[WW_ MN=:G']J,\QUJJ\T\`2\C#W.4WQ2%,BL(K<[S].:-F<0*ZOO>>DJL6G<&[O>U M];S'3"V@H5Z8NZD5/EJCE^/3308KU>WE?6#5Q+/B^U9-(B:C.\RU:5,4JJRD MMR#=WC';4M2+[2ATDF"\ZU-L03J,OWU3=H1QF-BWALB3A'-"[!/=;I_Q.^-W MQN]X\3NVW>=Z)]YA$%M>QJ)DQF9?4PP>#U$J;JK*ZTVH3; MN4XH*]5=PN6]&6_O*6'V&<$S@F<$CQW!5]+>+R:)?DOR8YI&V7;L..+G3U[GN@!]PW8[9TPT1 M6C5,&*9P\=O]O[[>7'_]+^:SV;D9?F;N_[@?FE_NF>NO/3KX9<,LB!B&%J8` MOG]Y?`B\ID0^53:F&0<<_HGEG?[`*)!F&;@1B/+^\.QPB]6 MG(1`8L9T->72%DS%4*6NQG4-0^!DS92YCF1T.$GH&7VE*ZB*:C:=2UM=DTJ[ MA!H3Y+!%+`"29W`G:;%'Y1SN3.A@'0";%ACP`G_"Q4[XR-C.0\S2@@,8D.V1 M)-7!S`DMDH/>"/:1M8J\!: M66H"&DH3?&?IO4\M+[<67K:76G-(\FIO.0.O M3+IZQ?Q^W1]^_L@HQB6OE.3)2Y.KWF5U/;!XB>M3\7W(`:HM)KKNI+'X80S: M+.OH]\_70Y.[O^OT`-@2_#>H28>@2:;%VS3BY7'"'NG,Z(,FJ<10YD-J['DM'*MZ8[/'D MN%T43XYD5:[9;_!]K=;RD8JS*AR=H?U6DH_/X'Z[DVP+DGX=\V*M_/-(Q5MG M^=-C][K=;MI'L(0IB*PD MM#I<;%?"6&7W#$HMI@N#5<].N"?KOG=&\(S@H1'&[PS@`4B'^Q)/`E#;C`\\ M2:[M01X-FFI9O*%(#9**NGF2#EUPJ!HO)";\RF(,=(O M%LEO`))\B19(HSE].=I0BC>Z9WG60:$\O"/F.MXF_K7K?\L!,"^CUTJ%3.T( M/:X`"$.X.8@V!7$E$Q*Y\+$/8[C.U,:DT.4_B1NYA"(O=LW^>ATELH"M&6&H MC3G3068DOVAUSI/A/,V5W('T)87`@8G<")8;3%`\Q5F*INL_UB=)<_\4MP-R M-'7ML!Q-0WA[CJ9>7:)DZ5.7GRA9LMPO.V=L.UN:_I0GB!'IM,&JC^Z'JQ5& M_IWX*_W$9.$%A"C'1AD^\08933&PS./&[SWO^2`Z[,3MR M6S1:6!Y;A@>'?$R_M6=!&&?73.MCC9SFRE@5YHA:G3E2^M3,'&'F"#-'F#G2 M8'.DLN=JO>:FY>#^I$99:(\Q(E4>3D]>!R=P`=LMUQSL)-#-Y["ODWP_B0!! MM-2RE]:2F+KSYJ6IBIQ@5-/NH-U`MXN__X7'+@TK7KN@P!LEQI@.4XR2])L(6O%RUU, M'3C1+I^;Q5O*U+F1JZ$7EN^LC6LCQ1+#7_EBG?FICRQ17O=3T^8&I8J/HF7_ M.4-O8W%\B3.+RXUNVH5MRMU@&#RN$'E#]DN)6?%W4XQB&H+Q23WPS21_E/AC M'-)LE>VX(+R^N"#@1LBFY9:S#!92*GESK)K<`UBU/A#^,2=.2?1D1^@76:6W M1WZ1-30)4J#C:8@Q(C<:IA'"@`MR]V)'U6?Z,@F1;T:VV^MBR9#9,GY9@W>$Y,1?^QS+(+ MECA2Y)%J\HH^DGC%TC2^-S!U7AD*QD"U!&$D"?4INR#*&W471JYO^T3BH"L? MK-I9:E8_K$N=7.&HNO+"W]2=8=WVT5TP=QWT*;C(24PR!&[IT5AN/K?2-RI* M?R2E#TA*TQA/P'P?DSY/3C";!SYM&4/N\?B(*FCST(TPLA^")$9/4]>9P@AS M&P;#,,)DB3IW!77$D_+==M..5?'4IKX5#("*%'&PP8!V8 MBS@9TC9X69\LZL6)(O(HS$57[#N85)3XG(0[5[$V)8&%8BH"4(+)OW84HTC' MPC^PDQ`?!SPY<1W8-[*.`$`.T0S/'G`8O3)&A'T7((LMCJWF7F3[BI=DN+K_A-R!3%XX).C!IMOL M`\)I5T5R:L@.+I^;LIG2@4W97NDUMLM1HE3GHV%3,\]4%7Z87'1L M.&!R07)<-TS-\;$4F!OH6(C/3B&C'X2@?(`,W4`&D5J?B6K3*6SD.1PG]4DV MV<&WQ!WY(Z%(W(I1[HHA4OPD2TR_;):5[::H[#FV9K;F([&'NC"#3SA>&%=1 MVJH:_P`FZ]L>_5UBTFC7)J6_<==J"P)J<+%13NKN"C36K*;Y^>D@E MF2N]JV#;]9O/+WN'3J^F''C)0BI^=:0JJC\49%'1N@;RN2X6AKG(#:$J03V` MH@^^-=0:[#J[8-ONU7)Q2JZQEDER$+C\D\.9]S5W%>I$&1- M:$2GU/KJ:2N-%1K%T$Q.+;L+=OV@%B5.[5[/6%'EY.+J65.A5G5.D4KFY^U2 MV8;D$M#8C9.0>-&"D%B>8(7&SQR:>S9I9@)J'/XG<>?55$$\5-1U3K@WT.-T M,,A=`[ATRZ2!EQO*?;SM&BV99CVR^FG?RYD4/2RPRM;34LBX;@2//@QBE#17?6;)QJ7Q!2S>`,M1%&;7WUF[9$5F5.4QO'S@X&6NM< M./E^8=%5B1.41D0DZL+-VA5G-?7.Q5G5[F6+2,W3UP[V2W*&6'*X MK>UZ&XNT-HG>6:2U,U"S2"N+M&[$'3MGI.E:YQ17N60[K7X0FV73-8NU=DRG M)=.LQUKWOL6:IG:P8"M;SA=J^YMFMJ#0VORCHG=^^`BQ(GE!URJR'4>A/M[$.AUC1.DVH0 M>&B.RM;V\*K6.`_,X8D5G5-HNF=]RW(-G&TLO-HBG99,LQY>W?EKR"DNL#)>B/,VOKJ-ZV)KG)R MV;?^Z@=T!V_OGLN<*A:66TV+KQYP`8;%5QL:7Q4Y4>F\E<:IWT<0 MTF6'E=NNK[$8:X/HG<58NP,UB[&R&.NZATWM7+ZO(G>.V1V0[-M4D,%`$4J. M+*\SNG>TV??J%V/W._GX^[LDXA]M>_X^:WA^0_O1N_[CP(T<+XB`M=SA'W'/ M"YQO'^%E]/L8N^^'?NS&SR/7PV'?CO%C$#XC)_!C>/(&3SZ`EP505P;3Z MHBG?DQ<_DMW(-F-3-];@Z#:=^"F*,I(M%HW@`2;Y$O21R M?1Q%*,<,)9J7`[!EK5=;7RZ-`^]:67+JE6U(Y:S3.US M%.-9Q*$KW[G@4#P-@^1QBJ+D(7+'KAVZ&'X+GH#T'C+0<`2C/$U=9XKL$!.1 M_MT=XS!"P01-E^V\483#[ZX#:W1]Y(#,M^'_,SO\!K8-?`5#Q%.,_O;=&(_1 M;0ST'UTLUI;OM7F9SXM<0OZS>1#!&S`7O`^CP-)@[JD[IU\]!?GC4% MT4[1N(I7867'UWG;ZO"4EQ54KK+NT?W/U]?6EUMX"8Q4SYY'^`R0Z)%,#0?X MR(>LI[TH"+^"=1N$L"?D^S5UE M\/#P)%X=1A(D:?^!Q+.R"GO)O\2O]XE$D.H!\8:IV"R#7Z8'%2;8\0 MM)T1S%ND%2.H-8(2Y990%"$/()A9`FSJ&4V#:.[&0"6KS!'&`L9&&$]$F1C, M#US51C'IUDZ(3#1DY`$C]`G1/>!Q]'9EB)%7*\D+:,9/PHCHA=-@]A+I:!J, MM48\',(V"%[X,97`(!-!\[6)$+7'_V\[A,_%`0SB!"$8W?/`)_A>$?O;Y'Q) MK'!&DXPFX3%K58.;I"+T>4EJ1'PF0%9^[#W#.`[QX.`?#I['U+E#F.`,CUV' M4N^$*G]+/1'>)2_B\04C-::NI>K:[9S$=#V@L"]3.YS9SO-N76T2)"%3U1C? M>IF:;C#8EQZ:+\@(C-)QXH"E":(-AEC8HAR\Z.7"DS`Y!R0D/`E$!FI2P79MLDPC1L1B;9O`,0,03Q M"T5Y&?TL3R]^LQ]>VL-]O.H#05/[^ZHD)9[=;3LB=9;D[EG7=S"2!$&D46#R M3K1]A#8>M^:AZ\$H\)IQ@7ZB0^:V"EC)J>I(%T<]W#!('YX'-<#&WKK#N6]' MTR<['S#UC<,+Y_ES_^I%[1PY(AX"^A;;A0H MDJC?_WT[.$-C0/O,]J(/9[R\%5T2!HHV%-0>/U1'0UX11P/>ZFDR+RBB(/=Z MNCE4AVET291,V$MA!>*](5K'Q`WVR/9^L"!,>+8@VM(:* M;@Q47AK!`(K0'_*F8&J\(6G*L*=9NB4/?AI$`VWST?5Y8!;O20#L$F5?I!'6 M]_3L3F#!?.3^![\7\\\3>^9ZS^]?R?W(`VCB9@0M0Q>B^$*K"*.$^)-`VLJ: MM1U+)@CF77\,!_"]\FLA$"PT=D/LQ$&8A7L6X=,EP\@^KQ_?"#LAF`-P^%*W MPPS/'K+P%/%0C-W)!!.^@#S["4W<<+;E5,M"6M%2@)-H5;`XR"G?62QE:D<( MDS078J?:/K(?'T/\"+@EP_VB2'2MOTBJ`6,0)XD'/WIY<`R&!4`BG"^&NI-A M@GBKQB^,L*.E*IV$7$CE$''Z87)&L/>\M5(88?=:)3E;K*KKKRV5N"0W%^OO MV_PU7REU"*VN%9BLEXQ30VSGYA(A0]=/W0-^%'CNF!+R@^W91$)$4TPBC';\ MV@K@Y7\G/E[Y44@O]!))\8LBIW@016T=GQS!DST+$C\FJ)S;SU24;^_A/JS] M#0QKG=-9GA<\$5A'03@(DH=XDGB6X]!5W6`'N]_)JK[@T`V`<3K$38('./W_ M2:7`2!)4T3*'?-^2%5Y156"/HC7BA_IHH/RC;L)?JY+@ M$#C7,0:_!C-\'431*`QF?4"!ZR<@2W*I"J,,7"^!_;B=9EZ!XZ'I'J:YC\BX MT2K&I"V$B;*JBX.>PO<'BLXKO8'.FWU=YK61H4N68@XUJ77:I(/B<3YF.BN-W1-]JY>> MP%MR`"U_;('.G]K,.45'QY?!LBH:JCD<@8+1TWC%,$'5T!29UWOZ<"".+-7H M&X426;[^>74WY&^_6'U0H?T`-$$O4XKO;JQ/MZ//-W^1[WT,CX(Y1)^\^O0' M>?O')0+3Z//->Q0^/IP+'/SW6ZJ`I\HXB&+`\N6&V$N_A-&N!I^_WL*36U;= M);H>WMV!X;6<:VU=N;)^B?@G_/#-C7DJAJ,X#+YAGAHQ='T+"7N#H\2+T]3, MS#-&.&^>Z0&\.&?*XQ4J@)>#/"LIS0,!%NC'.?^>!.0`D^@6-5S>F(91%OJE MTM%/%[`?_H]CGK\*SDY3_0W87$')T3"PKZ/`E'+CG40WN58W[.I3SKU'FGUQEO.U8X,^\(IN!MOO/YNMO;L9"^X9L[K2'TB M1#7CLRV$+ZO]:)NG:H&XAS0Z!\9'OHR_J&:??QX2%9\^'*)WV>*VU>T-2_+H M>(WEH2ZR4I";=LPI=_DJ>HYMF:VYA+.?#4G7'[UA(\2+PY\]&>6#WOR,UZP M-M9YXIC;MY61!6C=.EQM4**0BKR9EEUXEHKZ[R.B<;T&J5 MU7&R@^\=&]V[4-^Y,AJZUKFBY:I6RYI(35/4_L*S('33NU'6&#>0OW6N0<%Y M\384#:ODJ'6N,,IY\;ZG!Y>N7(FA5FJ#;S+"S*='0\9K#KT?F4/O!<2_E8.5 M/>?;:8-AD6&18;&Y6*S>7MY[9_=\KFC?LEUWUNH9,G`'L=!\N#A$_+DXI/65K0Q/%8-$L-CB_'8%E_=3TK_ MVJ'O^H]1UFT&/>!)$&*23Q[,,(KM'X6S*=AS[+F3/%>]5536T3U!/D2Y&O*Y M9)XT^Z%D:#3AI/V.2H9&Y$2S',]P5?#HQ$Y3E[!B:B@FBYJ)P+NW#AIN@#CNL?8,[,P M>$PY0M?N!*/(<;%/:JS0?DC^H^MC'+K^8ZT9T;E<1Z/E8*B*1\KJ#)59...Z MSE")Q1NAGYCU-$,1N@Y\%-D>K0=U2B_0X9EH-:/NG\CR`B-L`TU>38E.]'YP_8QQ,W_JW>.G'Q`CYU5K+D6J;K'0R6 M9+82+%5EU]2[*#X9%AD6&1;;A$6F$'?2,TS\P6@2!K.U#B0K_4=*U8$+5^>L MH^I;%!C9*.<"1#70*$(=7=I%H3%*&1X;']N'Q)WV?'T+D M>'84?3BSYG,/\RYI_^!,;?\1\SY^\EP?GRV;SBP&V>H_64'3OUU=![.&S3=X M'H2DQ^^5/R%MQ?LQ^-W#M1'@C7LCU1>,X=]7I$-A;K!) MH]?`1V':OP(&(1<,\B?G83!QXZQ$P\6R<;:;XQ_9M'$N;5V$9)%T;5UKXTK_ M(.T#\Y:UY)O5?K#PBY\UA74C1)O0IJT!7R@`L3=>I28VO3^TEYVFO;V7G5)= M5S.'>),6BYDX0A. MJ$=[Q]-U/12T3IJ&C]LY=EQ`R?,&.KY,;>#RSG.GD-$/0M`R0(9N((-(K<\@ MJL).8>,N6%SM.1K$Q7R2F_RIW,#\+AUL'V_D$G?DCX0BD:H]F;:3*CH[>L]3 M_"1+3.;CL(>Z,`/2'#`SKK(0!:UU`_8O*;FSQ`@T-@U22.5DMN8]:V_6;SR][ATZO MIAR8]R65W62N?B"+2N?:IYWKQ8MB-:S!T/D!%%U"M8NZJF0#/`^)OR/U7H-5 M;\](5.$_](OF<3&UF@8'58):AVE"R87LVJZG65&$X],;EP>? M;I-3BQ=N:2JUBQ*G=J_YHZAR8(7&SQR:>[8?IV41_TG<.4E/:!S+ZUYGT`9ZG`X&N6L`EVZ9L-L>'=-H MR33KD=5/*VED++#*ULS6S`*KS0NL*C(G:B6W\ZP-L)+*B<7K"#0,6,5LG&I? M$%+-X`RU$49M??6;MD1694Y3&\?.#@9:ZUPX^5SDS-/V8ZG2G.4$I1$1B;IP MLW;%64V]%76 M.;E[!UR4.*'LD%L-H=:;:&MK;I=2V*;HJB)SFMZ5VYV2UD0+ MOR"PLMBX*WT%(=4%3M8;8=;65[]I3725D\N^]5<_H#MX>_=KC__N[`%O1I M'_LQ=M\/`B ]@'W@1O,@LKT_PB"91U>^XR6D M7SE\39;O^@D>9UZ^P(_(MUX0`<]=(N%H4*H#31@IJL'W1HK"*Y:B\3W0G7EA MH)J2T9?4/H52./M(-C';PTUY\U*_^*]_7MT-^=LOUG_9N_;FQ)%=_PGF.W3- MS=QBJ@QK8YX[9[>*`#DS6YG)W"2GMNY?J08:TG>,S?$CC_/IKZ2VLO'S<75]7?\WA9PZ=5UAZ[\]N.? M>/?3%]:^NKRZ_IVYHUY!U^#?SVH/4_L9^V\.ROLRLX^I+X':M\[5WS=P9;I% MO4%MN2^[M[?=ZWBP%&/1AD<<%!]%[Y?TBZCEHN>[SB]1I";C]/O6P`B@S@KP&3-OUFH[I[PG(>&7<%<\ESP,_<`QJ#I-J=J=HI-L&;X<>!L)$: M_$4MG#G>.Y0VM[%7-Y#P?/@*;5A%.1RXFH`Q0[Q#-NVQ>_Z`#`B;\<'_!1[> M[SO`Q]`2?1]&DN?JW MLS9)9^N=M5:*$S:6!X5`($^3`N?>&(#;294LC4-L+ZP$$+6AP7RQT== M?9[PP2#Z3-?^\;%9_C3;WY[U''<@7+PJ=>I-QYSA_77]T]I8E>@><_DMV_H^ M'WJO0Z_Q@*2QB5TM>5:2^3"UT=$MY#VT[,AKQKX.D::,0HZ/]^%=-HM-=_PR=654O"&X]SH$]\Z?88X? MBIWSG/.\79C^YB'%KBW<7&GA%X'E.S;[ZG@3Z7-K[S:>$>5 M72M7C^X=6M;F2UJ]?'2HKXRR-K7FKA$_IQNKK/9D'CM/]NHWR(WW!XUX M=X"H>NW=I9]7:P>);CVV0.V[&#NNY/2>JC401^C?WEVIB4+V@B)'EI-3>W<0 MMT+V"K:O3D)*HV/>[@P^ZPC#9WKTRCCU0.\I?*"W0/&;>K!=C[GYVLBUF&LQ MU^+Q:O'MS\MKS^R:UV6M0-]XF^/8;J4RM7+E;2+/W)/?KD[(,>[-:6Z_&M1,)Z/)5G=2\D<7+7EO;( M"^L&L9X8.JY`/+DS%LSG3YG1%/EU^75[N>[M3T6[,MT]X"%V&R$7RLV]HA]V M+$U-WVOEJAU+8VA&M+B58T#*&)_B@'/=G`%>UH%;U,/;T_"%1I[A0OD7G<;<];,+%X> M'+%+.13,ZTMA]X6J'B'LD;2%<*4].FA'5#`/\=#R:JFRORD[9*F:>VT]NR^I MC.PE[??L>HXC$+IT;.9Q2V`@M,^G0*]'HAW8ZGYA+\]`85YHO%61Q&3/S*'" MT88=1C,S5B.?]1PX<*I8KER+N19S+9Z2%D_E(+PN8.!R&6#@L&/05S22/>0S M5JUQB&]:7RU673_)V3*T2F4W1_T\[COL72+78J[%7(NGI,6\IWC^6):&_#:- M@9G`WBB>8(6>L,50^AD;P.>0@RSS(.%ZKQ:KW#Q)L:K9^^WD`?$1 M;Y^Y%G,MYEH\)2WF`?&[?#*,SX/9T'7&RYKN[#0&SER=\Q!#WZS"F(W=)$"\ MC305_1`?:6>5IK&C!_0G&-^>6"9QKL=3T^/+W0Y/:JV==AP;>M]ZU`+ MO6AOD?C'(K2JG.X^O87K4/7/O+)91_3%N"?<^`K3*,$PB+#3J)==VQE#(/X< MW]C\XC$OZ'ER(+G[K+&O@EO^/3;_0>SL=^EY3N!*C5U>MH%0(;ZQ_>7KU??X M8^?+9SPK#8B8SR&VY9;U3,WX<%SN><+WD*3TL=EC&W[@C_P9&1H'MO2?IR*G M!U'Z2(^#R06NL+`/)9#J6]*6?>SP%T)]M2G;JA_@9.(Z3W(,EP-#9S5-;^JH ME%G*J`DW[",8-ZQT1=\"YN504L/,%;T#87P8\\5^F-/K^+ M@>QC:T6\5WV0V%T1^[U(4/2$/RM]I&:^^_6:9LD>>.GI1[''@B/(9AA8+/`( MYBVPEZCKP%*`DR>N863:<5$GONC?VX[EC&!](POS2]22O"+ZP6,C4`0J$;`=Z8"_[]U&O M2X^=E\$0M93=I MU?I>W/J,TEB1W03VI;1_39<(+L.$JUWD7>&[U+I7#GP@7>R9.P%S4I,$7I@6 M(#Y(`+KLK*KINDY/&V#DU@A<`\VG'Y6[_UJ?$O+,$]<8_! M@L2&7\+S(X^8C$1FV%\8@JAK9LW$83?@=V$7`,+*R%B;6HOA,#>^,QAPVA?: MN+D]$V'<&(";T+IB-NB.*;%I7!$Q!41:\!7LZQ@#I'F;WO:UV[J\_9IBLL1F M.8?H(QU.Q"'(\@!D/OS`>&B#`&0N@J#X`8ADBB!RJUS#*J(4:$<9.V%=V8WH[`$&QI'&" M"<*%/MGQK1SZ4YL/E9`V6;QB+M8$,C-'B(9F5O42FV<")5YDPG1*6=^(EY@P M[I_K&_$B$W[AJ)$;\;I&3,GN-\ED]VZ<[,YNQ`AG9H.S>Q@>)DY>%&@/Z>\0 M(84_PO9$P=S$PN"*@OV^\P!;Z*)#S?34(L"HG6<1G6TD[+.*0R`A5(_[Z1>P M.#VU,\-B\_ID14:SV2BQ[G"H;)%=B)X;@,-(^)^&AE?558RJN`-*?*QV#M_! MM0NK\S]XV'-]V9?@*OQ(,J5!"F+C^\&8;9CTQ.4>GMI_@EW@5AOAQQ+/`@A7 M%BD+;"*Z1&(,.D1'(L(P5)UTU%$?5)(P0&5+"0VMWB'7/UQC=(S>%4S!]L,3 MY61&EE6&O'PD]7PG'DM#T2:1VX0SH<"3-XIFP7%M0;'*-S'PV;V)@ M30-?_LB3GEENX35Q^.P5%'+9^GD#!'!OXQ-/;*#-A$JVI@'6%Q:^G.^#X_KC MHZX^3_A@$'T..]LWRY]F^_2RGN,.A(M7I=ZOI9]+A_?7C4]KOT2+[JDNOV5; MW^=#[W7HO+-[J/`I(J:VLOOU+>X$,1O?:2>(/W=Q2Z"+7?9;R-S\!I&(/C97 MP1$J[8>T#TQG^;*?G<&\T?WN&]T?ARV\%;[^FLE-M^=Q/5WU\<^>S;7]H*X(TNV.:G4TUR+ MN19S+9Z2%M_'L?F'\&?Q$MDBRC6OR]JA//.QXE5!P6Z%.LF>Z]F+KA^P4*_H M(_%NP[L3R[G,]9CK,=?CZ>DQ",ZM?[I.,/&^1=G"G40NQ-44B8W?6HX7N.(6!#NWG/ZO/X$R^T=$3=42 MQ9)*%ZXS7DP$#@U7PUO^]%.XY]R3_9M[S$+&"X'FM1C^\5$XUMW/KF$4Z1^C M:NC%_]%UO7QW<]NY*]DFOQ'K++&E:83?]>S$(+'$U;(5IW3\<7WB8I^FU M[,&%2BVQ1]?37.^IYK.K;$8)K7*E4KFX,(IUXZ)5K-3JE6*K9IK%3JM2-8SS M>N7\0K_#&__$)12NH'6,>/4A=,8`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`?TH7KDL*8IA*FHN]7&JS8-.32Q7TOF!;1GUWY)H8-U-7.W]`R%_ M;V%!,ZP+=F'QT?;>BE;KW9K9:A5K]6ZS6*DVZ\5FJ]LM5AJ&T3'+>K72K<'> M;GS\<\@M3_SCMSE68@[;JG;N!=5N^U_!W:X]Z,"JW!JSG9K1Z5:K9K%:/[\H M5EJ=1O'\0K\HGK>Z[4:S#%2;76#6_/AGL0CABJDK=I?Q%7/>`/ MYO$&13,SX*#^\<\FZ`!&C4UC0Y'2^NAR%VNS>S^%2U<2(.'`415&\1;JYY4^[/!.=UQOU>KM6*58K M'1,MNE5L@7."_YG=BU;9-"M&8]]H$CR^+#YT&/K,J2/LA@Q*$E[6(\8K.*VM MP+TD&C5/"VIB1X):DQ7.RO4R&PK8-;F5NH*B-$,W56U:C#SB/L^J:8=<0A:" MF,*98:3(POTIPG5%-DU4U9?'-@]BMAW&>KBU94%$0@-((BS0B1;P^5J8YHX07BU_F5I2#7/8/1]0:X5&A9J-1+$^/C3_,*W;#IL[=>_H<]=] M+L)4/')WH(K*1K.:F/Y)X,*!4^`:Y0]<6O08'J_%CB98?S?PP6VR9X@ZJ#+^ M_V%I^A"P:#T3MO>H+B- M,C8Q6;X\L(*L*F5-]'&1<566%VCCV4@=MZ9OBU&<$9>VYZN&%6(H7#>LSDN5 M3IB',G#U,$IXE]@*84XA"JJIQX/N/1;9Y'E7J) MI%0EC,>.BWQ8\A<6[(9?;#BIAY<`\UBK0-4IP.+#"S@LP`EMS%UI85%TO(90 M'ZE)%JDYB><#[-$)K`&-UT,FT#2I1'-Z0<$2@@F7WCWI(U/&B8T9)@<7 MZXM*0,?*F2Y,CSU*RXJ9"'QIX7%Z'9SNJKT[O:^>M M]GD##AD0L,/VWC9;Q?/FN0X?:U6S4S;+=;-^.-M[8V9W1]T443D,M7-@^SLQ MYR-S`V".JLQ+#]U9N,(4BA66>HYCS7&L.8XUQ['F.-8CAGW$*H-K5:NO#T4Y'@`JC=??_Y\NQ7]6G!F68,0^-B6]A:$-H\" MA'VXCKS-W3$<^+BP&`%7CF[A&UJC^NX6_AZ$/BWG?H5MA8]O;1]7,<$7^,A` M85XE\4D?@_9=L?J.\*^G`[7/]??>4Q7,U6=6)VI9O*MTA%?[^[)F&CL^M+VY MA%7]``J*'4_D0GF34?OR,?<#5_HR:YR^IUDN-++7]\N2%+DOL:JUMROQGL<4 M>4QQ?/I[FYABVXXC<^E,K5(_Z.T\NV#-RH[S)T_-)YY2EERNP>WZQ0U*+[X2 M:U)>@>#`@:09/Q5Y\MGC7'V>.]8!,("@F&3>SF0 M6)(M1*J$<"J-Y"6&A&N'`\./[L1QHZ8TR)`3>+YC:PCO+*4YN/G:_CH[/-9$ M5"E"(2-%8@,(K6"$^M@/J*\79F`UZU7VW7']$1$4CW9G(ZQWC6P&E,,DPJ""8(1X.157+.HKF/APBE## M8:_+P/:EQ5PQX7)06C12CPASH#"T'`571&43V#$B(OZ-9:M"*"DL!OC=Q0L* M,G'RB3"EH`9%H0`R3(((LPA3@*/_S2V+W?BPH'SVEQ,@X/0SFUB!QXQ2]9/& M'!>(%&22<.T3*]1*^B?&EV)O/R\432(XE"!=/F)I*3VP]\QFU@?"0D$DBQ"6 MOH)D@\!R0@9'RD0Z(8(5]#X*."6MI;+6_E6Z*;&.P*OH/M`.F(WL!Q:"V/*B?!(-_L`2Q0\`\_76?D\G&)M283UWDB>":YM+.& M5@43#?W'C*QP:1\X\@C.&G@J>1&G_3D&L*);3#F?M!+@!SMZ&`%B.HD4)$3] M84Y?BB5@J/HR.YC_1_P,:6KE&%'!0BW<<$7=1U9,RH;OQV(@^_#9&0ZQ'5@O MD!:Q@6&6I@E@-7L7)@A`C(GMD&0-.4H+%C:"_P$ MNIISQW4)+TJ8[=B_4!H9>#;A(M*+%1KZI\2=0*D+H9Z$<.I#HMK>=:+:'B=X MMK25PT$N%DF[8$M=N)=]!G4S&NZOF$<"P8@W(ULYK,#,OOE8@S8!2N>VC?,`]B\>T53\ MT-8&TH,)3R+*+933+;V4#1'E_]H.NIZ$/^E%\^\E7.CRU7FX^S1BUS%W`0XA MKH0(@[9LY=#A)[`1S*[`S/.P>#5NLZIJ""D:'+[LJZP,O"61I:$"5`X.D.H( M/XC0<]EBI#YBD@`0`O=%?$T_AF.)Q#C3W^#^L>`(T`_CS7"]@2_O<0B*POP` M%[<_S-$.7!6)):)7W_F@\N;AGC!DHX"9O$+X(%OUI\45%7UC2=Z3%CW;UF@S MP9!XVNQ1)8UJP/$3,-:_Y^XH^34J8AB081'Z'.AVS[_==EJXJV(X,6_TZ5F" MI3Y4@DA<;^0I:'?$+03W)%M))"F-@J0B4/N\`C5%1F5L]`7Z+E((I;N`)M!] M(>F!RQ]1PVJG"OWGW%Y$6U:!HC>E^#.=MF^\VUX1[9!&YGS#!P5U_7P@QC)_ MX)S'X"TZ4+(?&![TA)L(`&=.E.F3(L1+0]AIZ$B`'V#S\)_IS(@'PN4'KP^8 MZHX?7`$Q._!ZY,_)[L%0N4-'0( MUAA&J*>#[/+-;BWLH0OO+^=YC5,+SV(7%$9*?++DEPK7[`N8F/?<)S<([SRD MYT\VTB'AGZ62PZB#)%7I'>2VK77.75T)&6W[C5.'<:#"FZ=#)X;OVI':>#4:1]D;;-7 MMYG'7K3JW16O7?7R<-43/X_/G+R<;8J;,%MLQ/';X/8QX^@%Q^\%M^_=/RH< MOPNBJ-91G?@X/,9L3%'$W<.)LJO1]%,Z39?5BLH28G'M6D1 MLDT+=RSB.D;!8D:W0QPPG]V8[JAEI^TE$M_]@SIRA`BX8(U#5W+G5D4&O>\5 MBVT*^X2#9;.KVSQ=IJRXF2T1>,;K#!T*&(0&"[-TB.&4&C55=LLZ?J3."I^8 M"J4K'T""..0MH0A?3$M78793@X\5T+JHM='DQ8Q:@DY%`Q7!H]Q5HR3WG$MV*3P%&5+:]U>) ME^3$(,/`08(KE*V3BD>3!U/8J[S-19T_JD<2-MX3"PN'R]"OX#K"RC(#HW4\ M*@X!%@3;:)%]--X=?PM@53YX`G-YMPJESF`(F;>ZELCWE`EY7E^>_\%$K67T#9C M6_MX9G"LGURJ6O.S1N8$W,=;IL?)!ACX+EWCFY9=>:TQ!V.5<@H6#[PH40&6]K4HJ'7DJT/&)-?!XC"`#M3LA;@8:96M2:< MZ31LFSSC`X6PP.$4 MR71@;R:8&!FE-$=('?3(^T[G]9N[>'(%8IUC+`R8$T8YQQ'%,S=0#,;`^,J< M3OE=Q-8:8B2%+2Y0\#B629@/OO!;-M02)SFO@1/=J0.?J$F'"6 MA=^NE@L$P!)$"<=WY=XM%S1\<2W\7[(XCW$6D_R/3R:(<)^PW0:C!=RNXA@_V?;EJI5`7(=D8J?YB:U,$:BI M3@4OW8T3@G`HQ+3R6)3`>X`M8($T8+B"[I#P[1/FSL#6HC8E$ZQY3H*BG`2Q MG19'`VXC_!$`=8@CD^=BHD$S9K(Y"]T%A44B>VF>P<@((GTD-.O&[IH1$/Y$ M[HN"GQ-[O/^>6`:WN`\Y,QH!]O]:^B08GVU2"?%YEA="^#E.Y)A,Y9/9LRP( M=_T'"><=$APMTTSL'/(1)Q6)083#[[Q$S#8':JL.C@MK&A=FT@ M9="S8QAM_(RA;5#VY\"E[W^XSX=&S)7//I*#C)9N6`J%GZTD/7[AW=K-X^ ME>Q1^;D[_S*I<`;&UD#3+&$TLE1!%6608TN%R00IUBUC,![K`^H,Y,!TUP]\ M*R3E%;SA72$*[Q1'64<<9579!D>YFJ#RP@9EA3;?%<4/Q`CT3A?L;LB68)E* M]`1V?J&NC'T-/+`;73K>#!;M06D31ZH^%K6!,-8FL"ZER4BP![HBB*HD*H.! M88TUU,B2B5C@2HFT\LB+E'W"7,1G@@]YX5\[X$1E.0P]C MVG$<>N`PD:Y!P:5#TDDLA(=.Z/4\#70[+,&LCJQ)I8PD0= MFK#N[(%@#T4%[%K-'*NZ!6M0!I:!%2#(IE'@6`W22KVW4"KIB0)'OL7?0F`4>KMQX&?H7/G[7@+FE*98ZGHQ4H%778),8:X)M&!)H1M$4 ME:$FC]0Q4@U$%TE^#45%7E3LV5*`4>F;=,<0DD&F-5U^I1U4A_HBA^T%.YB=-+=R9_F>G6/6SN:0 M')MHZDB3+?`D-,.&Y3\V09)45=`MQ1B:EJ3HUI#Z%$IQ66Q'2]F2@)UGZI$+ MX.^%R_((]@-RE/HD;907";QWR92,DA'Q,C'5ZJ*)>=Z64M08AE&I,2JG]+-S M&X1`]15-0;>8-`U$6(9K"[15#[^TA2<-?B9!.`J6M_%\N4C+)EM(*$87S:*3 MMXF$515%&N%47)F5B/YOZ,7NQ7Q^6/HGLJA)MC46AK:B"JJFC05+`N-N;$Q& MQM"6AA,)]CR88.4&VRO*LK2BL5Y!6HDON55],8S9+`3AEC?,7+IOZVT?="4DZWB.G@-467'+P(?Z9K6(+1RV9N@WU1)+/EZ M^5&OR08QI<>\X3:2)EEG'TU)K[#75H:_XG#@7%^R%FJ#Y_^`F7+N4U@<,--L M[+I'ZTQ:*,*@R#6Q%(O:GJ(U$:K/I##K"N2>,:ZET5R)Z"^Y*,\;J5C9M4GU M$W7;"7>PE.QBGA2.M7/.,8A-LAW%W?LE4DK*BK5]IMT/FUWB0U-2AKJ!F[:H M8GP!@W2J+0QU11Z+0T49FC(-TL$=1>6UF8HJ_?PI"&;1-5;0M5"B,1:GRRO1 MN,*X*^>1G*>";>LS.%S=F$T90ZY:U6QNIN6EP'/1@+F$;3MDFQOR<4CQ5%H8 M@@9^&*5@8RW:MMK=V#F\MN]N)`:KB:5TU/8T56:70+)(;OT26(9@*R$YA\BX MW(1SNJ6`*."O%+WN5Q!4RM0N'Q\7'F;I6NN*8Y!!+(532L/>)C-_"?^/*H6N M$I;D35W=>1`.G!F>+FFEN2XA#_2B4G@CF27M$/A36$D7X:43QNR#G96V_H^S M6+K)(2,6QI])K504Y"!144O4H>VES26)G8()4_M[*W)V,YUM*MF(MZBI/G44D?T654.INM%&!6&A3E,*9FVA8[QZ= MLY+,]A\IQ`,LAK;6.:HFA!(>1<^OR%M6Y7_:R!`U2\Z^G<",4;!<'H/(67P* M@^5CFO>J7$39V:J+.1.YPW)J2[4!G#(TU4Q9]482,UZQ7S'SLQ),WGU9\%!6 M#5D1+4&W+=@AC+$I#&S1%";B2!R-!Y)NRVI[VK-KI;)@QBL$FPSN_*PN*^$< M0LRDS(M:6"]<"?F:HJ-YI/J2D/8W@:Q#8J.DE)'67-%275HB%R7A9*P+@I\) M!,?L0P;*&6:@G(@>1J%,P$130@T5A!2")U' M:D1&22'LBX3D?^$H'`\IMT.L*,3SR0%1(JA/-FL$4`I+BJ#.*T$:JYRIXRV[F[HGICA7=B!^$`$@(<9"SXJ-B MK>IO?UX4<4QX+&2L)?:P)@3Q7(`J>%I: M64U@9;&8T-^.T_E?WE'PKP2]#$1CD4"CX03.*%XGOH6G]9F$&(J#FZWSG&B3 MFL8I*R7&J#YL`TS,/`8^00IAEQCUI%@_3I++(X^=L6Q>^GR4P?P8"4[E;#EU M67DH3')(2OZ?T%-`<2'SF)?B5')==B!ZQOD$F`WQSV!"<&#D;KI<\33L':'X M/K?R&3&3I^!!]*S.>0T0076]^KKB:11=U#_A+$.J@D$S)9'5BQ+PFW0. MW(HZT$9`IJX2MMV2$W54<@@`0?4DW[)52-%CR`J>!R@8FVMSM\!98`75_ZS/ M%T)G"55Z"TQK/'YLWUY#3<16+_'R#WCINYB$3TZ&$#[]4RD MGQ^=V2SY_,V;Q?>_GEGRCVDKFRF!F#I#D&'01'A5H==,L7D(NU\W?]RZH4QR MC[+^EEU]W[_ZH*_>HBV16;.W8.U.=:]JOE-L=Y,L\:P16,P:@:UP&!8G/7W1QX_`0L2P;7RR`F5BWG?;?' M:^RZ?LS]F#O74'MS&_@D#G;P15RSV:K.:X:RU:V[;B+;!*V&V4S#W,/3*HN\ MINBG0ZPJ&OLEMOLVR3:*RYL=WOIXU1VKDZ_PFB5U3=#?3K1L[EG@VT>T!#I- MET^0:DG9LX`?EPUV[2[FPJ/SW#E5)H%\:R04(Y?"679.`RJ\)9V@,6>>GC*09%Z53Y/J3GBJ M;=%X1*-U3H^=WGK6Q%.C6-).;J>2U#U;ZMOHKL?O:Y33@5,C91W($JSDR%J6 M7?W.LJL5['^M0MOK"U\O'CW_>O[U_.L*_[KO&6\^4_'*$]#U+,J#61:\;C5C M01Z.0DMK)A=[(`I5BY=EZ\@I-*P]IYB[YLMNUE&7'=9)[R7>5&OKI)_:*\9( MF%([)--FPG1>U&M[Y>TF3*H?.MQ(6.]_MM5^[?G7\Z_G7W?Y=^S^Y\8S_1PB MA28>:JO-/`F3DKI^Q(8+ MB_B9N[QWP@=G^MP]W63QRKY/>3>LFD1>/F[5)&N\U-!I[4-1J/.*N>?8[;'; M4O046R=TDF0==11;4IHY;W\H.\)JIO;M0.0ITIZMP#Y?]WE M7]>\S\V'>+\&"!MY,$>S;AFQPBL-G>G<,V$JK^K-%(/OES#=Y$VMU29<3<(, MD5>,%GB173+>%-#%>*9BX1Y*^]=_8SNWSYZ#/0=[#N[+B/N9(-16C6K_2,%F M`8H=@8U3H.5@3N!^-R0(",1ZZ$:(_8;XOG@[W$5Z=CO3>`FFG3/[:QD1`'$* MDUXZ?GOKS+@9:2=$W_9N8T+"B[+7(4"XPR'`<^`S>/(@:@L:= M@#X/X]MHYY<#AN9OP;6^7MQLO!S:3:R372] M;.U+&,0-J-'7RX<')WP&YB%\/FU;D\<:SR.-PZ0X40(2?6KHSH;^-G1GHP:Z ML]87]W#Q+Z`J5F-TYL#\CTYE-'?EWX.\4`1*QC2HY"^*LM6U2KE?=7> MGC2,B'ZJ98.]Q6*LZ3YC`4WW"I+K$JOSQKZ#(%T+1VZ6_,_8P>6%/B@'%_4W MGXH'F:^?K:USW+])8G7>$FO+?%\"T,F<2,^_-N24VFO0L&Z_E>ZK@%&+>CI] MS[NWR(M2,_AW^R7,VO]!\F-3U<<4^^PYN%MUW63TN-C(D\8`L=D>Q@2YB`41 M61P9G$;O"1M>)MWY\F8V/&&U%UW2<&YS!0TVHGLQ'Y1/I6N.PU#H;2B5ZO+>GF:3OX5>'+L^%\SG?')4#)7#DQMZ M=<_]-YEI0C"%@^*>-4FL)-:N?^@:J0HOUZ^)Z#.(G!JOJJW&;*B;2#:/,8O\ID--?1;Y,/JRSR+W'#Q>#FZE'^*2 M?KAW487]>B;IZW5#[IHLZ:`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`!+D;=W$>7A4]NMA\UET\\\G#X#&1&\<+%]O# M1N3JN;=`+#E\_6/HP67/KA-R?[HSC[2>Q4OH!V_&38,HAD>$[F,0QM&'-21A M`"$ABWL_<^E?/^$;WO\@F\9/\`A"I2Y)*94KC6E?)I&,I(+([4B$N]<3F9*X M*HDS[PD__NOG*'K^YQ4EWO9G22SE*NVQ_M7]'@\6P?3_/\*MW+_P\L^!?_?5 M#1\N;F&]."0*FUX%[_5C^'#ESG\]58D@3R/TF31.'?L&+DF^NOHQO9 M4&^0$Z*B2#?B&>?-?CWS9C>:)5F6H=R,QR-=M?6!H`]$45`551=,29X(ACXP M+7&H#C5]3XZL:E_R4'1E(,8A.Y;C`[TO?S3%$K&"(NEN&''O. MX6OH3%WN:F2#WG?\>L&&PV>935ZV.I=AJTVKON\&M\<54[O^[?*R.8E^:U)% MYL&N[)IH[X!HI1/(Y.U5Y$,G?/"F]XZ[X+X$<0>SQ!)OUJ\Q[:K@'X#HXU+N M%^""AMV3[6Z=!WIA'#6>L,J2S--'HWU?0SVAG,7QI'A[_K4A1=ZDJ:-L]EG3 MHH%]Y<7?K.]E7I%:C<*\`PHUL8>)>H7E\MF-(FZZ#$/7C[D')UZ&6>U36^7X MO:D>]##CH`Q*M&J[?S^H19:@NJ-KJD M$X_I7$[/P=WJQ9633<7C*9O.FV2G4L8+=QJ'@>]-:>G\E3L-PEET[F-&U'MR MKUSOX7891N1$3<7YEMV=7!F.37.BJH(\-"5!'8Q-P1S9MC`2%=&41A/%&)@' M/+E"C6SCQY63(V6CV_@Q+Q@D%8PA\6P:]0\K(HZ5T[^L.8&430@\DLX)QR:% M2V2F0H2V;7.FRSP[-!V?#+@W^?T3O\ M9?S;5?9Q],M/W*/SS(Y_A7CFS4OHX\*\+),26)!F8.'2G[GT\!A[S[D_#\(' MLF8P`N!.[WTP).Z>R2&S,4A\\`"#PFD;+CP8G[-([K2G,?<>GY0?X6_G7\?# MW]YAS5U<'.JW>V]ZSWUS\-B;,XW)D<`XX!;.-R[PN8E[&Y8PNPT\!R=:G!/! MXQZ=,$X.2MD/;@@#\0F/GMSPF0P/5J\/$QLCP61L<#7>#S<7>&A?7=F%D>5D M]BORA5!`GL!.^D7<8Q@\>1&J%7@:?`&J$L8/HT^/_^&XEO`OO!0FB;M]_B][ MU]K;-JZT?\'^!R$X"^P"9B%2I"Y=G`*ZMEWL-D'3?0_.IT*QZ43GM26O)#?U M^?5GAO(UCA-7CGR+=H$TL2F*S\.9X9`S)#6PI'?:Z&Y2)-TD3E6"'CQ\EQ6C MI(P'Q=);/7F;I'C1K7:?E$MY*7T)?05\]Y,":5?YBM!DAH@>^RXIM,MNF=W( M?(E%3*O,QK=WVK4-!_3);1X/E>@O-P7E M=D7Z%UI1:#?05SV4MV*LFM8?#P83Z-$A=&V9J[="%4,98W?`E[,^A68DN=:5 MT+I^`C5@'Y=S75GJ2S\#(807#R:8MED"?<:48!1:OP,Q9 MG=N0F[D<)NE:_R.SJQ(@UI-&#Y)OC$KK9\-1G$Y0X*J=OLIZ`6D+BSB'"5*% MQ?*>VB"$*O?3?(LP@K\N0YRBV)]UT,E2R)5CW""Q]UE-MQC8IE9++FBZ':VP79*&HWLKR7>>SQE:YY]/F(HY%@Z%^E;F+ M=6PV:M#R;@;Z/GL]V$&5VJX-,[1L9:[TI<3C.A+4V.&H2G.O.`4&1W?*D">5 M1%0#'#3Y%GF"1HU+\%7@>QB&E6ZHC,?**#S*$]1R+?-O"1CD(S%JT?*F"-76 MK3<.=*8;(!86`85?XCX$OI",=:U_L_Y2J&7;U_*'9FCZTE2BNJ`AJG9^<&.Z M\Z/#A/W8[HU-'?2XJ7INX\*N<[[%[/'3&)VGR_[5W*7["WWI]^"UQB!>T@4Q MGGK;M>>)XS2IGIJ_Y`*TJ)L,0>'_>?'Q4[0VE70#$?JZX1';$PY,)85/7&%8 MQ')URW:%;S'/J*:2M")D>QA+$^?OX%D4LKA,YT_-RQ=NV@/>\G%2>=Z[8T^* MC#-J??WK.EA&3XQZX.$M%^^X">^=2L3V8!8,7$W%[4OF=O\>)[F\RC,8F\K) MU0`>A*="^'2$10)PDM2`/Y:]2RA2K4;LE18]X&:H"X^$(@H)IU%`7,\TB,XI MD.593BA"D`D!,D'GM.R*<%U1/DR'JL5QA"_`PJS2Y_3"CBSJ\E`G`14&X3;W MB1-PBS#7=CG7#>90^RO[2B_>&:MZL=[J!3(7-^B@"P:&,LC&-R4,9[/]4%^: M62J*;,.R/:83E]H6X0%GQ(NL@`2V8(Q[/G=TL>]-3L]ZX_.=3,H]`A=R.(2I M_E-E59WZQ9*$&AR6ANI:WRO+@>%&-?/.3(.=G M/\X+]9\?5]%9?GQD?6T;L]I+/,_FU<=[B:=HS^`]GWUD[1F\RTK0GL'[\I=X MBEJQS%TBK[5/A]'%:SFYHD%H=UO2%I>>5G;GE,;PRSG%]\!1W5PEQ MX+:;JW3.,( M3GHXI>'ZG/8)M`RV#!Z:P?86SX/>XME&$,\H:-9&$-L(8H.W>-:\]F/_@2:S M8_+#7`5R@/#AZ450:O>JHY_$>8S'HL[G'CZT.K;^^H)I_-5!MCJ.:/BHPG,? MV<\V?NAT=/IJKK9D]-7$#YT.8^UQ6(V&4XXN?M/RU_)W2/[.R_MOXX?'%&EK MXX=M_/#L8C9/F?"7\%.SP.^^G@WF?(V1'P^4=$V1-R& MB)O=9'I"46++/*D;D';`RIO>>'DT2*T.,TYBL]FQ:/264>+9%>Y[U^Y=0PFL M(^I'$DXV9/KJ@L30S4[M#6=MD%A9@G,-$H-LU+_0\M0BI_5'OU-#BBK?QHBW M67X[GQA=RU_+WR'Y.R_?_]D8<AAO/9F4<&$O.F( M_KD-U^<4GVL9;!D\-(/M'M.#[C%M`XAG%#-K`XAM`+'!/:9&O0G'0>),=L/K MS4>#E9]>.*%VKUKU;V%OHX?G%SVT.]0X3.;V`4%3Z^3R(G;O9T,_@CO'3WED M/]OPH=TQG==S1JWQ:K;3VAV;-=.OY[8@>3[QFY:_EK]#\G=>WG\;/SRF2%L; M/VSCAV<7NVD9;!D\-(//[#%=O35[^XMN%Y?C7G?O9&\\D)?]CVD9I[<)%'.+ M0I9%^+T[&..VS_=9UKM/!H.&[LIU'4X-S_2((:R(<$,(XNA,)TR$%K5\X7/# MW_==N?H35^4N>%(W(Q=)4<[NR)W?H#M??(B'65XF_U67+;^V>V@M<[ M;A$^0)3]=&.BZQ,!]=4B4CP_>N:U1(E_'Z=RB1#]$4+XRQ*R4\*+O5G?%T5^ M*'UEF^+GOCJ^^5[U>E/D/4S87KS<4;?YU%9FC"?%[4L>]Z3V*1[*_8O7CNOR MK`-F=ZM'SRC^N`?0IV]AGQ9Y?UP`03+7/LN!N%&VM'MD]NL?P*@ MS\N^_RE["2:E:G\DX'(6IV?E+?/5"7GCD,]M'?M\PGXM?\<0-OU1WZ7!"5`M M`V)T;''4Q\B>`,#S<@/<;G<\'(.[*WN:N[3*7<\=V%,O_^+8>TVGVQVP!R3KDE M+8,O.X@\DYU3.]-FD:QS)=,"7.SP^P@7WAK*Q^&>[3BV81-*79UPWV+$#KE' M0NK[/#)=6_!HW_DX50+,AH2<+W<2P`]'62IQ#U#6UT853YJLB-+Z6:[R_E4^^.'W#;PXU;D9->`?J(),JBU/RLV']R M8MW[%5_+63P'VN.W?Z#\Y/)#Z@)MN$=/+>+YM'7"99+=7.\4*K;K^?VD$;KP8H>S6W3-2_4F?G4/8A;EJNYAF$J6[0K?8I[QE7ZE%^^NC'_/0#S;O`66CVDQ MSO%4N6M9E@/U9?'R6:?4-$T.@RD1MJ\#"CL@CFZ&Q.0Z-2D7W(B\9[-.AW%^ MFZ0$?.6W5*733#^H1.VM\H_[T&!2)/^5;^GB[WX\3`:3MT^XXBJ&_RDKI>:\ MF65DXJ4QOVES?K1B3I"2FT78_]&4T*7&FAO:BLR2).U!C6_MGVNU_6.J_1ZG MT+T3ED$C\:7R3>\-D/[!\5C0)8@J/`65-`=Q,D0&M>3VAA: MDFM)66C)'/,()E+=B58=L8\'W\7#++W5,G@-YMS"1P7>Q26'HT$VD9B"*_LE MO!C/R8!R9:8-DR(>C?)LE"?SQ>D^O*K0;B9:>9^AZ_03YMCF>,+&K*)"PS=J M,J3%%#KYAM%1#<;2JQ\"O4^7KDY!(HB-4N) MP55:\$^/)8Q=`K+J8)'Z"C=.D^JII,@XH];7OZZ#"ZTGN\DP'A3_O"#&FE+J`3=#77@D M%%%(.(T"XGJF071.P>!XEA.*$$T+:"6W.3"M5\A_#-*"BNK&,S_.Y65^&Z?3 M:,7LP`DW[56_)KUP(+MEGJ5)MWKD,_1CWBN@C^&E(-'%^SA)_\B*_=)%#6'1 MP./$#[@%-BRPB.-;!C$CVV(N=T*3>5^A&+MX!V9M1M;+@UX0&B4I"&`2#Z": MQ75RUU70I_A<78USC!R!1%G;NHP8&Q6Q?OX#VKT!]!MPK_:FIZ MOF1N]^]QDLLK&%MD7DZN!N#B@/B$\.EH%Q?LP*R@N:6.6&%E>]"K9`5RE./I M@&ARX/>!Q%^@^$JT^#1ILB_>.9:]PM(V:/=M0RQ+V*Q1*AC:$":H0X_-ANP# M>V5#3LB$[(,4-"&6:9^R"=D'36!"!#>/SX0PW;0:A6XHM\,Q#FXP]H`4#`2A MCLV.V43L@08T"08[*8NP!U;``K`':K"]!6A\!H9D,,XIDN$(P5[$PV)>()C! M!-$=P0FW=(\XW#9):/FRIJX(^JZ@`1K:J.!&X0+F, M"QG(ZM\7(*F^P$2@(-1U0N*[!I`D1$@&80UWEZ?%E M_"OX"?[Q5!>G'(,;_2W!*'(_R[VXAY&1P_*VO?R`3IFZN4K;CL@7)OK3>'@C M\\O^]&#QWJ=Q7L`4S%=[JSW9:X(DK':9G8^?HC5ZO,CE+')\X@66P-BT06PC M8(1'06B&NL\B&^=/N@JR4].LK/*S:-:!7Y=Q*9M`J2I^#B;7`T/X@46$8]F$ MV[I+[-`(B.YS*V+"M3S;G<-DJR"KEJ\CFD?Y8'!"(]H`-E7O<]@L80<`+R*! M&8"$F]PCGK`\$AHT\*CN6X$>5=AP&KR*[2&&=933KOV0#1OIO0]9,4K*>/!R M`RA,T:B6+KEGXV'&+C)K.&'4@OMQ=8F*E2VWA<+S=@6B=AK<@A^WI[ M[.L"O0YD_V[R/@8K@6XR8\X).\KU5[FW]H54>(CRIOSD_?N/>^$,_$=&Z>[N M8\.#Y4,NMAHL'4NG%@\<&"=]^.';+G$B1HEG43-T7-=WHG!N6_BV@^6^+$O] M[M_*LMBS9>%Y0+6F97DT&6H1;HCR;/AH$4^"\RRK@E_B[[LP9G%JJ@522]2S MQ:;!?#,(+:#(#0DWN$,\$Q3&$J9PJ6G=1MCTPR#-TNTL=V!'VL,NF`?M73XJV8 M9--E-/(@C^9%9?+H6!4F8[;3'*O&U#8:YZ[H>R'2N'AG&GO4\UGZZ+0_U-LN M^_N13%.'\;6>Y30"TP@=X1`W]"CAU-.)!_012IT@#"WFB$!93H:6DU!P;IZ5 MS?I,'*GB[T#O5O+*IVN#2+IYYKJ_%RXIZ+[%:#/:OYR>CTNP+\4)_&WK!C.F M?QO-J3-326PP^;`>S%L?0EO(31CG@\G\ZRN9XHW8E^D)XX?Q@1G67$2>`/@P M/>>F_)@693[&@A^+8HR3UB`N)=V%"0?FP]\I,QT8_1=,,,^CY)\6$PK^9*%8%+*9#=;N8$/>-=7?-ES2Q#; ML\'6EK(WXED5C#^25%[V_5SVDC**N\D@*2=>EN?9/49I8KS^H)P$LNCFR6A' MZ7A:%YR0.S30.8@XC0@W'=0%6Q#+8ERGW#6I-UUNX1?O\+(+Z,VNU/Z5Y?^/ M>]R@J6H-_H\LQ@,IM7A8760S7P%^Z#&\BBD#D6^R7Y%1Z?,Z-YN+(Y+ZMVWTTTW'J'VY"T M7VS]YU_QL7"0J"M.M-D2F+98`]-^@7;V9!\:,M]X]Q!.A6>Q7;:G;AK\?3R8 M:$+MOV/PFAQ:!\W[)?YU?L<'-"PO<:/@XDX/#7?L3;<__L,2NKK1XY>;1Y_! M)OP^!H(,O3-[Q&3BS4+7?E1NGI>ZCZ`=TWS"'8WP"QC=V=#ZF-'=HO%/#34@ M.4EQ/6YI1N/\V8BGRYGIPO\DM/6`<%\'?RRR7<(, ML#$FV!O+M.<13_T-O';3`+09VE.$+$G)97_Y*55=8W*P/6QPZ2MC\SEP*X6\ MD7$.-D;K#[)J!R\XG_A4/!MIU"8H/E?V>C7/P9'[51H-QH=$WXN?.7.W-GS=UQ]/$/J^1X#B^OH M%LXM?#>PE@=HII_6`#TCI39L4ZQ(GF92?1:YVYO7+='C-MW;/UQ MZ[H.:A_+:ROH\6]J4%OM^S+I(W=X1HR&@6T3&MDFX;K)B,,#GW"'>[X-HPBE M4;6\-IOIP=L-6F-YK5FT3'=LZY%!TN2V8WJ$6S[\8)Y%;-\%=#1T@1SY?#EX-/=V>`I77^2""_Q2LI3#2 M2K'9TB%^`D.E>K(Q(I9>\MR@M#T3,%,7TU#1EL@>;&>YBW,3::$F MD&Z>XU"E'*C)HLBT!O<^SGN7RB4HWN/Y<<7'M"+\?;[;_F];=TS^'539KJ_WJN#:5X&?1"R82/;;$?(.',?G/QYK75!;R[PMU<`UVRC?A!_ M94?&=H[HTMW7<'0;U^/!LN<6&M&9KDV1031JTXGF<$8L/+)'E.WRV$&[(W[Q MO%MI>GMLE''TY"=)%+]P`L-SG*R-'3:W.9D2 M-)_;V#;Q=NG=&AL^RH,7+`0MW)C3^25,WP(74S]8\]N`RK-P=#X)^AIOV?VS M%]\?0A_78S##]X3YD)K^!]H/4Y1/HXN$\PH":2)7VMPP2V"CD!?27()Y/IED MDN9#,#'O"`;9*)FHA=A!PP;;`C;[,:WG+TDSWTX&T=/RBDG4,",]61S8JF=$CBV)$U=6;XPM0><: MD>-F]\BB.UAM#:VG1HV(6=V(E,^G")^,")DSUG*>Z%-2B\[W5"K.&N4/@R4O M?7C&2#A0V/1#0:%P\WTD^L%"G)R9133SAXCR]R\PNW$J;WY.B[U'3G[_T]NM MD>U*X-17[`2W6L7^M[5@T/\:W3)DG'+*DB8,3'*:/G."]4UE?K0OWC/_(^&# M2%=[@2@W;BZ)G8=18Q.N0J=QYS^$_G=_P8[_DT<>+$@^A;-DQ69V$F_"^1)S MQIC.G;FCS>G$UB@:C;711"?:>&[8,VHZ8Y,P>?&S.RHPT-286$/$,_)PPLY[ ME)KY`]^K)#-O>R>%>@`OF?U>Q6X4LRW'C5\^K;RGY',4 M?!`_XYDV>F4=-2J"!IDZY7<87JI!/FDY=$R7ZV ML<(`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`4/N@%4V]J!:\K[9W,A"FN7&[9SV+F8,=IRE\Z<@?.9D69L-,"S:?A MG3"?0@A__?P<^#R`"]6SML1U87[9%]ZZ(_IS>;N9X`S.VX1&J,Z/+ZG-J8PO M((`K@-]F%9/M7YM"A2@M-ZBB1NH(O1;$F"R/OA$]?Q:I-;G2>_9$!";3);9U MG@`N#X=WQG+R4877IM`!@Y&PZ#B#'11@:Q-&O$7,61,;'PF-RG MU3F[7D8GS`5&1W!Y.PWF75FV@NI10W!I(N(IY";1N^D'GIME=UV-13$-CX0A MBE#>+VFO-2>HN?/$$GPDOB"S426A`I4B)EM>;=6Y!VFR#CS>T;*L0# M.[`7,F8J*,(Q.C'M4*J%D"$&3BU!^V009`B%4_`AO:8!:/OPU6DK<'%A@)S, MO^J^.>\1R730"5S$AO9HVD#*I8,^X.(ZA=A@FLHU;364G+K?UNK&GN\#:@W9=NK`<"D]9"5'@! M@VG1V*4<^;W]#G7][L1Z3([M-V(5IQFMD%LYC$:L1X0JH7VHL(J:C8>]RJ4( MDM.)F7C8RUQ"4TMQ?-#,*HF3?8:D%$F*0-A>\+3A]J`M=$P\D):TAHEI\IB1 MS_TXN6'BYL&&J&@->31W:$-%NT]S!XZ*]E6!-'&`0G1#&&^B.DH9$0!4 MM'*1@LXU(AU1T;9L1.!1T9[CJ52<=7=4M#(FQV^1\@H%2D4K01B#I**5(3=N M+ITR3HT^,M&>([!*3+0H9:*M<'$KCXA6!DHX\14Q\A&GOA#1RC#%_(1'[=>6 M4:,B**6#X']!K$4^M$PA3:W9;(2IKDV(8VIT:B,FI/E8,\V)Z5!#GX[F=KIR M[$(N=,F+-YX`+T/]/"Z$;4`["1H*!2[ M9UT[5*'833WOPT13"!R[,EP,=KXU]2*5F&2.71GSY!R[A:B&!(Y="3,3'+L6 MSE^9R>;8E3!/DP$5*,>NI+M17I&%S3IM.J5P[)XCA4HAF79ZLS&5S[$K0)<^^T4F9*N&Q[$H(10DZJS=B4:!8=B7(A#LA M^970%N!!&),@GD[!B;Y7/L&EV3A:;L$#Q!S2[<"+9->`=C MZOQ(Q+!B`\6B74S3M:WD(CPYLA82)\M.\ MA2`;!PE",-(<[-Z8`@DBX:3:M&X+YK8/6YURZJ:W)88)BR'U0#(=<.J*4!`P MYM@#N73`J9M>GCA9TB)9#CAU1;"#;#IK`Y2,-$Y= M$6S?.&,]X&P\E%'+Q*F(;CLZT+<(G668:IKV[A!X"W>:A M(-MGU17G&:V02SDD5MT#H4H@@Q5F<5B.)`PV M#4L)A+!I68AFO@W,^G*`N>:E")?S%F/'&?:REP-3SMK4SK)OD;5X3U;26(M% MR)KFMYJ328NS>8IW.&.>8C`VG+=CQQ+_]Y?\D^^^%_\K63QZ3]Z?[QY7J^?W M5U>_?OWZ(_$6?SQ$/Z\FG_Y^]Y';>MTQ+8=\N-H]MALJ\1[$->>'W]_B8.F_ M]WX_!_["7_WC<6Z_?RW]I[0*Y,]W;P@C&;_L?S/Z[2?O/FZ>^<<-W0=1-Y*. M^^&J],]]9/#,WB>;^55NZA^>Q6%Y[^U7[&]-V1_E>0SL;(4TSN.X^W3[0R]< M[OV,,/>,#[W<^]&'J[W!/UQE&CQ7G;DE#E*=J44496"BKL<-^/G[[M'S^#WX M:+GTN7;=@%N'($K6L<L6)$FA((ZRZV`5A?^.DF=_Y087"87,R;MX M*+"WB&+?#39@N/D^6GJ7"8GL3'KQD+CVOWMW"]]C?X"73,S"!S_TF-3#A[OT MO2\3'6GHY^+1,65"].(+W3MRX6>04-B!8)VP99LDV9K=T^#=,\\N"U8OMX]N M_.0N7BYS6>>N[OJJR]U%Q-Q=^`%;YUYRT>I,\V3ZJDY1VIJ.<&'J>S4!#*0Z MRW,4LCC-7;2.N?NTYV>GY91OJ%79AO;`=23O(4(!_H(=YK@:L2\#G:+#'6<#J M5"DO_52?2GD92*@++KA4RHL"5WO@4BDO"F\2\:927A32Y"!-I;PH?+6#+Y7R M,AP=JI07%9IK&U2`-Q[(H%(;#KR4%P#2P1;-9YK9B"#[-S(!';8G;K(*O"+:ZCA9Z5!S3,J4&4C#1K8) M2W/;YB:!&WYVG[R=ZK[^BKX^1NO$#9=S_Z?'FYNL7K:=%/GO+U2+A#@4J.]T MJ,6[5;3XD=/:GEYG`3]Y79P:"2:_$<6Z8P,]UG!>\$]ALHK7_,%]:QH_^8M' MUPN877W\Y6[=T,_1ZJW@\E#5J!-JTMWNB"W'1'W8'7<=Y+\E_M)W8[8S-N5T M'L//W3H,_/#'SN%DF_)WYI.*Y)---ZLOZ]@-ILPP!)%H9C5:KQZC^.T8WZ`! M!@M02L_-ZQD[-J%`,Q..Z?EK[/+6$@]"KYN4KZ-ZO8XNSF5390)#TR=&F3ZI M6KLUO8/K*'Q8>?$3?[.O+\]>`5M1O'I@Z'K+&1DDVB9JAUK_`!B),X"DLR,6"*H;JKA@**B94-12(:BBP\%#E4-++H>!A`7ZV M!]BD"[#*!)QE`3G9`:P^54543_6G2J*&DPH%%5VJ)DJAJT5TJ:(H!3B9@%-5 M40IJDJ"FRJ(4P%H"F*J+&I`256&4BM&UCBK`>P]D5*D]!V9I%!#Q4%5@4QOD MI)H6)12X'6I1%=CT6HTJZ79@^E0):9TDI`'&@DI(ZR@A#3`F5$):]PEID.&A M$M+D)J2!Q`+\*!O,8!=D90(.;H&-,4'6ITI(ZZG^5$+:0"+0@-&E$M(4NEI$ METI(4X"3"3B5D*:@)@EJ*B%-`:PE@*F$M`$I426DJ1A=ZZ@"O/=`1I7:`H++6&!(P'K M%ONORKCJ/N,*"T3@MQ"Q_5E[B*`8YTA0+'O]"G\VP^7 MMY_^;IE*G^&$:K@*G-*?M08G=B!4KC5""!7A&.[H*?[J\^(T=PLO=)F*"C<1V:?S*/86;M)P M8,9GHG#9KU/W?78H8!B$63[9!!@$:PYC[H;_RKOV?WO)3R,3SX'\+O%&2>"NFMW_<_T7Q M)'"3DG3!:Y_Y&XG,K$$Y5YN@D(,M:ME`E_M)R-D\Q.S"TN.%Y,.[$P<&')T: M0+VR6L"9K)-5].3%8BOAN\JC_ZPPU`*&8&)&:0AZ^@JD+)(.E-1Y!%#FG(DR M'>>ADLC7D#(=4)4$R72T/F>L6TCUGVT.I.+^'2$9"E--2/O:A%0F7O8:3*>= MZ0U'MW$?.M.GMS;)*O">W/A'=@W`]IGK8-'F75J:G"M!'>HN#;QNU%U:?Y6G M]L&^*$S=I?5!2>HN;4CA[.Z1H^[2%'!J`D?=I2D,U<$03,PH#:F`.'@EE2>, M7UKPHH^YX=(@HMA?H&M&4;JHS;@>5`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`V"HWK>^_[(:*G58O_X/U!+`P04````"``H3Z]&["<"-2TR,#$U,#,S,5]C86PN>&UL550)``,[^U55._M5575X M"P`!!"4.```$.0$``.U=;6_CN!'^?L#]!S<'%"U0QW%V]]H-=J]PDLU>@.S: ML',O[9>#(M$VL;3HDE(2]]=W*$N69(L2]6:*1K\DL4-RYAF^S0QGR`__?%V1 MWC-B'%/WX]GP_.*LAUR;.MA=?#S[9=8?S6[N[\_^^=/WWWWX4[_?FTY[M]1U M$2%HT_O=1@0QRT.]1^N5NG2UZ=U8Q/:)Y4%KO0?L?GNR./I;3_QT>O#5[]?3 MA][E^;#76WK>^FHP>'EY.6?,B9H\M^EJT.OW(W*_;AF[ZOUX?GEY_C;QGRGU M7>>JE_SJAJ$M80=8NNI=7@S?]2_>]8=O'X?OK][^>'4Y_'>R-%UO&%XLO=Y? M[+]"82@)-=[TIN?3\P3&/_=FU.50>K6VW$UO1$AO*FKQWA1QQ)Z1)1"^/C%R3MEB`&3>#**"9]]_U]L6OGKE.%7AY4U4?#CX_!*#[(;7%0D]TI5/QCYL&0$R3&\SOL0A]ABTPHQX+"#;$XQW.,G&K<*[9] M1!P3BZ&*75&"@+=$'K8MTCBR>UC?5FA$/,1<&`//J#:4PQ:;YOG&XLL[0E_X MO>M@AFRO-L^'+=;E^19SFU#N,W3M<^PBSL=KL3U`U_*1XP1];)'ZL[DTF>:` MB;\H+"&NCYR8JEB>'9^@\3S[_W5Q5J3:-NQ6^K0,J;8!BDV?NC!;^'@^0:[0 M1#Z]KN&/BBMK-09TM87%=4N*`:O7I/S[LAJWTHRJ9YH!-T3,">4Z131=N M0&GD.B/;!D71X_`MPL_6$T%\YJ]6%MN,YV$%?HV`'31A]!D+D=]1=DO])V_N MDZAV76&TR=K1!1@RF>A$8.NPV)%DILJ-+C&-YV`RT!>AMNL;6&J\''\JMK+R MU"/>G!"^(`?45X:`^O9/['PBH&_:NNK%1('`705P2* M_6A%F8?_&\AQOT"+2(MI'T4$K4R&TO2:@_I`W<4C8JM;].3MEO'DEW6Q%1,X M(A@PH8>M`XKL=#1L"=HCLVPTO1T]4$OL/<''WRC[AMW%C;7&GD6"_[0Q4IMB MHZ4^_WDRB1AJ&WTAK78@WEALA>VEAFUQS4>Q=^"@5RACR/!*ZD M5B`JTVD2FG#B/5JO+?5:8?O-0;FAJQ7VA-`X3/R;P-.P0*Z-6X)6FMY1H,8. M,O$UK'Z>;Y'Q$\&+G;MEOVI8LT5YU&"J2?N,P/8GW.S>!K8%EP,;K7GTRA%K M#N3N?"'1_/5FAA:M+5H5*!X);OCK6%@SR#5R(!)L<8]T1WMWG,'';&&YH>$! MDX93@ATKM/TG#'%Q^B<^)HZ=XLHQJD?TZET3:G^K)IXC\M>R/+]:'I`;S^L> M8I2BT#(F$..:/7D,QZ4 M/L+0J,U/R_+*\3$>8=DH2;U3LFAG*E7BH66YI+Q[;0V%;"(ZD+73L7FD6D:9 MX=7BK?5C/K'6D8;.KB.L7;FT6L:9X^DY`O*2U#LEBW8F=R4>6M<'LQU@1Q@@ M94BW;1%M?4)3M!9'Q%N#K6U;2(&D?M3M3`1UPJ$$[#ASXP%(IB0!-9#KB`#V M[;>"=G,1^%OZ@ST&CL"58F1]P`GP`C)+T2C;\18>MN_&(:I$S^$7_\166\3:R,ZZ<9G(B`^HD2L)T0^ MGA44'FCD.[:?OB)/C?O,*IHP,!\YB>.Z0@"2\IJX]U=^L.K?HC5#,*;%<(:_ M"8IBX1)!.A-&UP@VAPFQ7`_^)UQ&ZU4NV&::URR;L;=$3,1;,[04D=;/X?'L M`^7;2";HR&(1*+6B!>GNL&EB81B:8;R'T(ZH&[@(9>"**VK!$T:O9?.<#"_3 MP5?!^I`JHX_+($\D=IWG>\Y5(%5J4`=^D>HDK`'X)1:@9XL$]H&(G6$;8/A7 MB_A(`E6MKA94\9S,!;!?3`>O460PK(>[:-'\(997HRL(OE+7+@TB44D+#O4I M&[)<"+)&BSHD\`FL.KI!45S*`[:>,(%-KTC/*ZZG`TT***#Q\30A*WK\$18PG=A-MZO[%Q@%B!#+ M1=0OGC8*%37C*0.A"UPK+[*RTEW@7$WHW5ES)RRT#@I-N*R2FCA>BSS0[9T$ MH",DAG'^N%&I60[1P4$,?`%DZ!QQ'OBOHH[>3#'_)OHZFT/E:GH$+G&?PB;* M9>ZP@DJ=PB%7HG.KZ,"0R!PO=%YDE]7#M6=A%SF?+.:"NL53_OLYMK$<0F%% M'7@.K9*=*CD1QP[4'7D>PT^^%P3O4;'&BSP;2H"5!5B5B"$NP]Q0XSNY)`XO M1RPM(HO9$1/PY\')9?JVM;#$@(ML5M%:'WMH%=6?,[HZ<(9'Q*C,#]VC#&`& M-_[]X^+BK/>"Q*UVP6?XM&:8,L#_\>SRK.=S8(ZNM\<"7467O\3LP`Z'IP!6 M176.(?_=-,A[BVL2N:(K/Q[9WIX2YQOEK+)$?3T@B2I9D#-V@'4S5]YZ41I;[90?^TJ#97Q-\ MIOIR:9!Z6@5_4Q;-3F!OS!PP"GO&?C1DK.*:.49R(&<>0\1XWY\:7H5#^7A% MN#@U]#DAIS%J@RP9Q3%>]]`QEHU!AH^:;*3',C%F@PRAW%,:V;*7K0T89!<4 MHE8_LHCQ&V0%*/=ZWDE>C-P@(T#]:#OM\5`)EXJ5`(,6O6H"R0)MT*I7#711 MH&DL"H/T_(JBJ!.K&LO)H"VCFIPDD2>Q!`S:-%2.BI7.?<(C\MB)9)#-5%8( MS25]Q6,F963UNRVO9D^%]QR5AT$ZL4YBT)AJ3T:'B2BQ+\H@4[T]`:EDX\4B M,\C.;T]D*G$KL<@,TH1;'&5ELUMC^551JKN;L)]^/:X+S!Z^#ZII2=F#G8V+I1CQL3NSB'!_YR:XYU1H0,!; MX=R`<)*7%%=Y_T?P^7`8F-P2$1U=EPUC`C^1N/4Z&%OAT-H]VC:G[-IRA$=; MUK]U6]63!QDI%'>@WVPOVO)!0XGOWMV^79LDIKRVX-IL'L45L)MNI26'%'KB3+89G">,L M5-7E,VF_E!9._?6:8*$BYVT%^Z6TNDX5'%A)?^C>WF%D(%U)R+471",CZHY@ MBJ:$G+7;&QF5<63!Y?F]C(S6.++\#LP-28!'QP_KV_5[I`768O\8F5][;-EG M^"$D21L='[29AFBYL58SK<>DG(^2TJKEPS,R+23'8Y#*#=LW)XQ,@U8$>W"Z M*TF`[OA*H8A6YI&39$"?!NA\$U^2ZGP:T`_L;4EV\VF@W8]_D%PV[T961%PT5`&XK2,3,3":UP:$66"5):^KX_)`XN:.A MHABP9>0533G0&PL1DESGI#HH-(>ZBINY[@A]@1GO8)@"GI90U\Q;PB:P1E.1 M9,_$9G6+MK]EP9EEFM`4Z)%BXMZ=(@Z6L@W6A.!:'O&17TW3,;^@'+L21Y+4%A3-Z)[SGUA<8SGR8LR%`!)*NJYD7@=#BPE%-+B#4P: M6=O*4Z1D`WI#"2KH1'OA%,IKO)&Z?4L"RMSDC;S5L24!96IY$L]1MP547HW= MWE6232*K_&7EA=CVY%'L+)$?+ M)SE:FC`"S3R=/H:\BM>C2D?;.AR;`@JA'%:0:/V(`<6W>MP+!^Y6]/JN&XA9 MS9;_S%XBQR,B6BZ^1S9GJ0/ MR\BAL*W_IW8JI7;JC^)L0$Q[E^XU,R>-U+*.+]KB25U3,^OB9F38WBE2:JB[ MM;PF(K&&NE$R MFGU612<("V:*P,ASQV[`?MY-*J6:Z`;&*!1<"%\95:J2EE.+[2R)7G:9`!\, M>6`U"`,A9#0_];!,"WHOZRP/=>^^W]P>-]*7WKA,\F9ZS8"94Q&1VB90+X-` M[^8\6UH,I>Y.[*P>$49XB>C'A8NCX+^#M\_X3(P4MAG/PPIA1EINH+PY\$)T MB;X!/(?%="A1AUP$%T;GO^M;4$G'1CLBA+Z(HZ*,D1*S60"K5!N&/[ZL8ZW/ M93__=<3TJ#12&5!'7VXL&Q@H6W4%'<_S9&/0CM!=R[]*+D/T5H?(:8CJ%U;J MK`2BYU9``OM/T>Q>8NDVFX%G+JD'[Q?0H6G<89@/Z`&Z_H#?Q)7="C?N5FA( MQUZ=PV;X)D=9=-MJ>@XD'&%GR1C+>)Y)2ET=H5+E+N#*?E9+ M"55F5YU.)D@CKZBH*I0J>WO- MP*'.*E^=U6N3L9([>RH52JKC1EYJN=&#UI+=)U5$RZW!Q>D9VM-)OE(/%<@Q M543;[:P*PCPLI_?]U@R.TX_U)H>PD=I!$<3TZ#)ROR^"F#$X33XC*ESLHU>8 MT%#/LM_])37)0+ZK/:ND;HX/GTK-83I1N-.3-+-+)(JDV?5R0P>)3MS=ED][S=F<'+KH]$6_T(6 M*P/CL'*7<-V[=]1GE5"EJG8+TPS9U'4J84I4[1:FQR5FU2#%-3N#Z,X7R;E? ML(M7_BI*,+P5400K"\-*RL0[OQR6W+*`RS6L^8F/G`4R?:=J?0D:Z:2I)Z&# MET30@@N0F9Z3U7%L&^PJ,R69U>'7ZQ&+>!NQHEP->W.7D MLMW-J`F^KC]')?D9_M[@$8:XIM\AG1OUU_"1*=MJE M(9*OB^DQ"(SM(K*9!^RE$FY$64.Z)8Q(S@Q#-I_Q[@Z:H@#H*<*K)Y_QH+0A M79(3]F+(;"B'H+NC*W66TF6!9S+:7;EF'#KP3LMW=_)@R`3,\>B?)(+N#G69 MW6A(-X0FU^Z^F=-ANVC(?!@(VD\61_#A?U!+`P04````"``H3Z]&9""U:`0< M``"(WP$`%``<`'-S>2TR,#$U,#,S,5]D968N>&UL550)``,[^U55._M5575X M"P`!!"4.```$.0$``.U=6X_;.)9^'V#^@[<&6,P"6U6I7'JW@\X,7+?$F$K9 ML)WIWGUIL"3:UD86/:145>Y?OZ0NEF13%"53(N6H']*)S,OY#F_G2O[R]]>U M.WB&F#C(^W1V=?'F;``]"]F.M_QT]FUV/IS=C$9G?__;G__TR[^=GP^FT\$M M\CSHNG`[^,V"+L3`AX,Y>$4>6F\'MW#A>(Y/&QL\.-[W)T#@?P[8G_:`?OKM M>OHP>'MQ-1BL?'_S\?+RY>7E`F,[:?'"0NO+P?EYTML_([H^#GZZ>/OVXGWF MERD*//OC(/OI!D,0=FQ3BCX.WKZY^G#^YL/YU?OYU<\?W__T\>W5_V9+H\T6 M.\N5/_BK]1^T,"U):[P;3"^F%QF(_SZ8(8_0TNL-\+:#H>L.IJP6&4PA@?@9 MVA=QHVX,=T`9ZI%/9QF$KT_8O4!X>4F[>7>9%#S[\Y\&4>&/K\3)57AYEQ2_ MNOSMZ\/,6L$U.'<\X@//RE5DC?&J7OW\\\^7X:_9TI0.V]\5SY+UX3+Z,2I- MG(\D[/,!62%/)>`,"DNP?YTGQ<[9I_.KM^?OKBY>B7WV-];A+QBY<`H7@Y#B MC_YV`S^=$6>]<>%9_&V%X8)^(ULV3!_>O(NJ_^466<$:>I0O]IWG._YVY"T0 M7H=$GPU8L]^FHQSU)/!8@RL(7'\53C@_GKR7K/BEL,7+(\F=THJ_SWPZ05D7 MX\6]X]$1=8`[021<-3'V*-SX!D>#>6P1=4TWP"RNG?1"QEYMH.AY1]-\V&+Q])\ZQ#+123` M\#H@C@<)&6_864*'E@QM.QQCX!Z_FBMWHPX8^QNB6X@70#OME6WF=N#"\8+_ M^[$X:_;:-.Q&QK1*5TT#9"("\NAJ(>/%!'I,;KE[W="_U-PQCNA/'=39BFZN M*^3:5!"[^U=`3\-&QE&V&W7`IO`94GY.H866D;PZ].RA95&QTB?T*W2>P9,+ MR2Q8KP'>CA=Q!7(-*3EP@M&SPUA^C_`M"I[\1>`FM8]E1I.DM<[`F,C,(%*R M#HNUQ#-9:G2Q:;R@"@9Z84*^OHDE1TO[2[&1G>>XSM4QX2NTJ?B*(>T]^JMC MW[E4SL+(I;3$+3*_;4"-;4BL<]T]_,#X(Z?7&>YLTGL5XUK-LB/(XA2J<2X MP`]MT?Z6'@L>H60T9O:JUIDZD#LC?*;YZ^T,+AO;M&KTV!+<^']M8>5TI\1K M$!YQ<[3K>V?S)V.\!%XLG=-%0Y#KV"!6D"<8$N8B8__,^&;2RBFJ.7SUKUUD M?:_'GA;I:YB?C\"GW8T7QUKZ*_70,";*Q@TBP/V,4;!A:KH;L,`!OL&ZA3EQ M-#V&\VL>VJ),XUI,5<.\F_FTJYR/@)5M85+)=]PP!V);)==`V1AZN4Y-0-[, MXJC2=<-<*+..3J&S?@HP"4NW,#6.IJ=A?@D,<2UL&Q5[-XH7S2RE6C0TS)>< M=:^IJ<#O1`>R9@96U%7#*#E6+=+8.(H[:QQI;.QJ8>\2]M4P3H&EIP7D%7LW MBA?-+.Y:-#0N#_(-8"U,D"I=-ZT113:A*=PP/VJDL#6M"TETJ1]U,PM!ON.8 M`P!;LDPHB)U/HO)9T/R'D#F`!2#$#6>A[6HYGG]I.^O+N,PE2,,)FJ"'=A7% M'I[;<`$"UZ]&W6'U=FA%:^!XM4F-:C=):=C#^1JNGR"N2&:N:H,TKF@3V`J> MX/F.,]4HY340TVOOLH@>*&4YFNE2@Y[-TB.BKZPI=?D=4?>7^?Z;ITDR:\-H MZO)I&/I)/4RST$_381J%)IJJIT6$-%&JZ#&7(\5E&6((EYSI],/O24]4BLSZ M;B@X.*(,(DD3+GB";MA&>97+QLB:1V')LB3-,W'#1Y$3F=)8,.0]L!R7C@1, M)(^O\7%P0%-Y'06$/0:L)>9D7Z\#.B^W7Q`)0YYX`R_/WUS%":I_B3_O MB(GD_S!0/EIB^Y1+5%#(QO!T$3$O+J"#93'>VUC:YG(I7Z835/[^5L4`SC:0 M"5+^=K("])"UMF6[?$D%+:Q+1)OD5$QF^/#5*5H6XCH[%*GT,\1Y/%1_2)J. M50DY+3BNL\!H+2E=)-TBB:-_@+`-\:>SJS=O+M[0_VCE4&'ZR.0L:'\Z\W$` MTX^([NBO_EUD1*;-1SPX&VRP@S`]B3Z=O3T;!(1"0YMHYVN*-7NZYC%,DMDJ M$S9=O+EB3.HT7O%QEB)]>U)(>0)@BO7=26%-3M<4W_N3PE)H,K`2UH$4XW]W M$V.98)P"_%D3P$.?!Q>DC'"[%?<@S'3@1)UMUA`RR^8QU4&O[0M-4.=IA2( M,PKB`.OP1H#X`B.>.?/8%C4-I7QBQ2-80Z$-LFYK"H;SG@HYR"L]?+C%=#!> M8LE'5U"PQ>[[V'D*0C/5'.VB>Z+8@(*A4->^/NZD6[_MGM7L&$_.`LXLQQ(Z6.V MDSMO2<<-8MIQF9=)MJ8"(FE+5-$#;G)@C!=#&Q:?+L+B*CRJT$^2O8HE3$XA M/2;!AH3IK**N7(7;*?I7YIG?=/*TCK*7\M(\/YHB^31EQO0+2;Y0]B633J'UF.MB:< MGV"DC>8A+!)_30[6,8!ERN5%DT.&#-EE:IK'30Y0,H2S"HVFVL.E2H-+-%F4 MVCTOS0]Z$=M=,OOL<=ZDJB$CYD48*$C*4N33@D_^R*/C%"91"@S]G():?'`Y M,NZ!!8=K=HV3%-69XOII'Q$2L!WBEFX85U+DYVOH1U#NXBPJWF':*V>+]/$W MO9?^!T*N)IOJ#F!W2^50L&6K;P(]%D`Z]J(W#PZ\.*+2G0J7$'0_M0&[J;^D M]WRIT_3I]M$(?31"-SE$M$(^AS]:@8Z?EXQ?%Z`63W"D&[^J'"+:J$9(PM" M.Q;"GB'QG>AV\"1,_R#*LDI-'8AVYS6APN3AN5Y83&\62+&^G+-J%NH:^JTW M4HZ\XV#6R0+1XL4M40GS$0M[$IA^EZQQ_GI="5RFA*YHBX.2V[MZ[WP?]V#2 M#MU'/O21#PT-H92XW(=#E/+Q4$CO8QKJQ30H";3NHQUX<3M"8['VV`5S>5?N M4^U"4+91S-MSZG8AIEOW2]"Q!'/2*-=J.\"XUH.U7K;W9M0;M!Z M@[Q(_HM7:AR&I?^JZ]D*8)A[R,^8J*JA&S8.[9#&:T"U.<9)RK>0I(2%?(NW M9&4M7@BZ4)@10>""S1712:,PN&&O4$?HU!1[E%Z'Q)^10XR!MXQ>5;G>IF4F MD4`^?`'8%KD^U;6OA3ME-!>17.9O5]!PI_@Q#@]#\ID69$^632`]+FUZVA+E M#!+TI.(F:/;`[.[53+:"YR]HOD(!86^4N"RBN?A2:.FZ"@C--'U/>XO.T%SG MA71*5]7K\>"=5SGE8V\/UBX]R[D;JL$RPM8OH8CR#\3$R",_6;M@+1-CK;"# M:#=O2>M[RJ4(WHPW1`DN]&RI$Q9R5W"J8^T)NZ2:X;VLJM<%9U-#L[,)@;"J M&TJGH2).8F/OJ2_C\>0]/T]FP7H-$8]M!!6()$C:(+1L\/VU7N$;U'PY"\" M-ZFMX";:W1MPE*CT/NH9Q,^.!4E,"B_@7*K>B3RAI48UBJBZH51E;S^?T#\I M73'G8L;M!IW.@&M@,U-OD1IT;*OF<")="W1.Q21G;+!E"O.1C9K$AY#*&0HP MNQBFV-@F7=U4;$+C5X4&3AR?FJ2JK\`#2WH*TP[9`PS^"N*1QQ8!)L7!^Z5U ME"04V(X%'%N00I`KH*Q+#$NZW!50T&7(O/1@BBY7*.Q?5%H5,5%S8A)R9;38 M$X&[$R<>85&:P'XIO7;R_!KFKW,YB[A\2YUX:T\3E>Z"ZA7<>KW;8T15O677M,\WFRZL^VF,M6T";ZI9=2-NLA[9`W.U" M>N81PUMNT]"?GMDD`X16!>VWRM?P#E?6G;OT8&C;_)`_,ZO&*AOWSFBEMU0- M]L&J>4O5W.0$4".65)_.$\+[Z9VZ]5428=V[,_.Q.+?(WQ83'\F034\XP6+ M^7AA*2-'>^35I1L4T9.2?Q-@#`MO2JW6A@YKI!R%493(R+,P!`3>PNC_1X$N M:-)<'OQ*=PXJ.2R*;+156^F#./K0A=[;U;BWJ_H:Y M3"H2JGY,/UQE(4R[WZTWP_6VIM.S-?5VF9J)!H)[$G22GS@F*=&)UXX*+Y:/ MD>=8T9)CT+!-=KEQY!8N(#W`;7:]5E*_M)*A^#\C9+\X+HM]&7D^$8..YX( M@3Y)?M)A7=KUS1?4=S_KT"R2SLOTZ\-R>E7FA!XYM3A?NE=]>]6W1=6W<(GQ MM=F]F7W"&JL48]+-4[N\5$,)X&Y3/Y*@+R\$ZY+R>R%87HH*GY$NK9P-/Q]+IH;^E_7*1+&BTCHHOV?S$3Y0G>!@ MKE"U*5@'+LOLS\Z8`E`U&C(,[_7V*_@_A&]<0$2R2946#$,HNDJJM)IA6%). MEUXA5[65'P:IIMOT1EY\#O(IO7N-+Q8M4;LK-Z,'*VL-'RRCF&-B0'1EBB?R@ M6-M&FA(1?*?.EJW)$S;72+"H_A&MW<.KE@'E4K3^'$K%(RXGJ'0A5T[-.!?J MOUU(H#MBY/FBG/XD.KF4X1H*ON1\X.MA^@V\4O;/=MG2E13BFEIWEC.'\I%^ MBW@KP(566^VNGF9Y(%`OM0=1ECJY*JBFDEO`X0ZB??$WQ04Y=U]W98TT9G".NAF>WK)C,T5T4%C M>!V$Q+0]+*?""Q.=Z&FNQP2C!16F0HF"_IV*V/YV&F#@WL)GZ*)-N-T'_BH4 MEHI]-2J:5?'Z$P;LNL!EV.\71#:.#]S"?MGF5?P:5-VFVG*32$@=Q0^KGJYK MI");\F>`*:;):&7?#MF:'7IV^,]?$?[N>,L;$"[S\)?CGUSO;82&V`BO M`7'(;(,AL,?>/P%VV#2?`A]>2:$05->/[182"SOA2ALOLL2%5$OA*VE"/\9[ MND*':Y;L+X4G4UP_[2.J+V-(?,;/N\4"6N'+MW1SIK^!I9SUMZP-XU&RSU/V M*N97NM>O@[4*U`=M&L`%0@)V?]-:95B*I'($!T"QLO[EPG].M?.ZX+.3?:<,1"M>WK'I0#!%0$IY_\;48HD1@XJ69, MP7KWNG%PJ$^(#@J9FJ8@&C$-KA:B_9JF(/H*7IE0<3"?*D`K;$+%)D,UU`E& M%H0VF:-K^(U`>XZB1\;@:+W!Z#ETT/#T2OFZNKS.?J*IT\X$NB:WJ`DT"R6H M@L(ZZ/Z*L+^DYX0X!VR_E)X+IJ!'%5-TCS"T`.$G#)84UDGW-X^P",R%`VUQ MQF5A>:VIC@E9,BF.N;*].[]WY[?NA1,JY29[9ZIZ&V4D,9-]+T>-:]8HJ-W? MTNR@%@NC)Q2KPC.-G%#$BKQ'XH0"68XT$I]0Y$M%IX#)N<@5D8M,B"<0^E-1 M&]UI\!.4B([,.&F>#LOB%4WSZ?@ M=8EI?7AC^^&-5YJ$,A-CVXP'R3>K:\]K5PVSP&(9XWQG^&TN(M^':#"[M$&) M?259E`?>B73G,4\QEC;XYQ\7X'LU4J"ZM+]JMS'PW`,\G!RF=#6(>/9E,DEB MB/M(X3Y2N(\4-F+\^DCA/E*XCQ3N(X7[2.%Z]!)H72S1,Q6RG(A4^I=]"NFG MW^\\GQF!>.-_\'/SU#S`)7"C/CD"!Z^$XA`\9O"G0OS0^E?@$(<3LRI104N` M3_!$'-NA!WE)#!BGX(]R$4D?\M,!F[5,:$AG_4X5XYHZ[TD21X)TWI]4)Q*D M\TXE99$@)Q8(5"$2Q#RC9\T0"9ZT=+*A/M)Q$=HB?7K?:47?J>I+433%/O5^ MU`H@N6JF=O>I8%(7:>DYOPQ'_=,?H";=1==3"E]PR%E_@UY63J M[]-NV'+7-0_8J7A00N>T?83[Y*`!`_!UWFOP%?@!VWX9/5(`?G@:Q_0A[/DWU[0Z31GXBW4E[3UN^W[-UW%=UW M%6_PU^26[;US?99CA[,.WYXN]/0LV^0QVZ[@I[E*(G94&,H'&((QHLI!7-'V&1/8M0*;(6%Q17X M,*G(S68W`9?=;AT*AY0?`'3^YL>Q`.%7CFBIR[7I38]-6$^ZH%MA-^&6-H?HV M@,.%#_&]L_!7_P-!43BX9&63<(V\>Q3@6JAR5%]M(4JI)*)X)#C^/`)S[P;-HEZZC0*UM60U>&77)Y@C!_BE-0 M`1/'5*T!;*P>("`%MRD6E^LM[*=D85=Q^IR8Z;*:^'1BALQ*$)E_*"8PG#!!_!R M[^!U&B02.K7$`8S%=70P,3NGA68B3L&.T:OI#I6"72.Z6(.,%YEO$E#*6C`( M(;G>9G\1&(,K-*#B39"=AW;LKR`NZOQ`W\B^_U&U"3V7#R5$RO%7=*%ZJ^Y+*X>=S1KTY(Z5"J@1NA27&-Z'6WJ7P^::TM MX$1M[2HX6NDT-UEQ5<60&CJ'R6KNL6R1U`ZT!\U+7QARE!0AL7*X.W>78@'O M'0]XEI-3_J^WLV@7-#2E7$AS_#_=M@Q"X$&VW=Z/FN)^"'(=.V1,N/P%BDU! M83/H%JK/A<4[3+LF`\`-PAN$Z0[WR%*'EJ4&J^+R>BX=WV!(MXK0GP@W+@Q/ M(,^F$@\]XO\0A;]*556@T*?/)*6I2B)&R]71P>R=7R"ZE83EGQ7PEE=2*\4Q M\\2/O!:5UGBC-YFC\)DXO,M2G;@@%%GOZ->-X+:!"@UH,?\`%U+1\QEZ`7R$ M12#V2^DU5,738@HW;(=@D_M0/)$S4\FWI`5Q1(#X+O!<&8U4\GA89!RM5%6% M+9==DT5W\MT-FV7[?DD%K9>L7P>$\H8DYY!(L!37T6N;%$O(>U$[!7*==I.< MG#7R>*A&V!\E#.IE(G@6:Z%,H-WJH1BH0++7[DBH8>"I?/J*)[@A\6AM,Z)D M.]=^5;#,/:0\\22Q;DIH6R;;O:4PEHD5VBW8!QZC.C(;WU-48?*?H)_H:#[N M:UTF)QH<"Y9KKC`YN^!8P'+&,)-3#([E0&*6-SF/X%B,52Q#VC,,*MY`+=(Q M<_M8_G@TWR$7/H8S1SO/U@XQ&>,E\.+%F9-2Z4A.,"2T3/A/EAUW4#GUF<9SF(P;S=OE9 M4RJ559I1I70D=<_,EJVU44%$B%,,,IID*%/]]`<`P3M`@@P&'-E_JI02Z?#/ MZ9_CYG#\\__^OO?0*PXC-_#_]&[R8?P.87\3.*Z_^].[/S]>7#Y>W=R\^]__ M\M__VS__CXL+]/"`/@>^CST/OZ'_V&`/AW:,T9/]/?"#_1NZM9^Q%Z%;U__C MV8[P"-'_.BCPT7]\>KA%UH<)0B]Q?/CYX\=OW[Y]"$,GE?9A$^P_HHN+M*6_ M)#K]C!8?+.O#K/"7A^#H.S^CXJ^N0FS'Y&GD$&U^1M9X,K\8SR\FLZ?)^N?9 MXF=K\G^*3P>'M]#=O<3H_>8G\C!YDKPQ10\?'CX4X/TO]!CX$7EZ?[#]-W3I M>>B!OA6A!QSA\!4['[A0C\-%Q)A^]*=W!83?GT/O0Q#N/I)FIA_3!]_]]_^& MDH=__AZYI1>^3=/')Q__X[?;Q\T+WML7KA_%MK\IO4B%B5Z=K-?KC^ROR=.1 M^W/$I-P&&V8E!061]`GZKXOTL0OZJXN)=3&=?/@>.>_^A3;XSV'@X0>\14R' MG^.W`_[3N\C='SS\CO_N)<1;L19>&'ZD[W_T\8Y\2X>VL*8M3!:TA?_)?\W\ M[!VB3_[YX48*:%V2E;ST,5'2H_^@?EI2$W^/L>]@)U64OMY@+B:=69H)I6*# M34F@1VT>A$+@3-;6CIZ9P&-TL;/M`Q$\F7W$7AREOZ'..;L83[B1_R?_]5\O M-QO"A)@P]3[PW(V+H\OG*`[M39RVQC#^Z9W""Q\S_>DK)00ACH)CN,&=3))\ MGHY:_-5[IB_M/?(*#3_8O_CSXSOD.G]ZYSI_G:^)8R^G?YU8R\5J-?_KY*^3 M=_^2"T.I-/1[*N___G.BR+#88A*8\*T&@%8_@)=AV0/M<),J2GYL0E#[D-@[V2-Z7M!\I&^0C'G^C>?K.?/7QU#$/LMW"G^K!^WE0T4'6I ME;5>6B7.1(A+&B$N"Y0N)^&R2K@.B20#R"'Q+0$Q1/`-(,4#]FC/>6^',:$L M5^[2=[X2$W3ABX(<."JU*Z?LC;.E-9&QC#>#>#M&L&UHZ`D1][2)E(8H#I!G M?T-;-]P+00-Q4MVU&^BJ:#]()C_@#79?J;*_A$$4J75SDI<`."K61-DK%\OY MND+(7.((,9F&=(!#("UWA&$F$;WW<8R"+2(\8:.NH^TAV_.";W16&?UD`B^; M'55$P@:+F<&XKSCNRK?"*Z!LR_50]L"5M6SB&I%H'-/ZHF0\^WS$B+HRBE_< MT"']71B_T5XO"(WHYYK_*UZ&#U^F]'][!OY-8PXO52 M<1"=U5U[/,N9FS:-BFV/4-8ZLGT'%=L?H50#\A/58<0>R=0`(SR`$5E\N,51 MA.R")9V"`L"A8E"N52++K`E4:B,=#[RGS?S$!M5T6D?:`@\1PQO$JAHD M8`;9E`SB$?&&!(0N/B_AO;(10>CM."X-/+9W;[MD`'1E']S8]HBZ^\!_C(/- M'S(O:7]1)XE;M5%VT^ETG>ZJ9$(1E8I<'W&Y(Y1(1DPT$$T'AFQ5(!^(U`L" M>9/(!>6CLI.6**AF(!#6>4PX=AY?[!!_H@DU-$"0Z,!&`=??Z8]8]N'57M;) M/B6-E-UQ;EDI`U/!B$F^2%*/BK(1%P[$P3,`9SPLPMT4))(Y1+(30T:2P'OTZHMJ+>M7G61HIJNR8NK..UE- M<]8R^6@;A"AM`0E7D,^Y^D5F4F[@7/M.&X7/9(P9-09IGF;Z/-L>;>2,.!]C M.XR!D,XITD]XY_K^V<"*$O_T^_;F3>KG-&X(.RYVC5S4Z=[.@N4'Z MGK+E"3'J9SSCY_TFN(Q%I7`@7ZZFD]8S1 M])BJ-(.*"D,T9)-P0?[M'#=LS!H'"-LA#971QQ"_8O\HSATR*UXT$ZE[^&@P MN;G1Y-]#-\9WVVUTDK?E4HR+&9EJZEDJ5K9-TB%,L'8N`M*0V<.$OO:8E9(F MOA$I,?81P3M"/&^'QH=7PH$?@?LUM^].][(ANS$\BMXH;>?C*2.2,_K<9_G=896ANT?CA+%RT* M2N=$6HE%7X2QB#6`?J=-(-:&YJ,EYS1`LH1TW._M\(U&FI:X#!%^^A&81IT> MANL_G(CPYL,N>/WH8#<929`?J@,(\JN_7A)&.Y357SQ[5_G2];]KZ/1KC:H? M5)J/%YQ"Z?N("M!+CQ/UM]3T/[>72UV#.K(8(LC0MY"!<+>](7V3OW,)BRZC M",?2D6[S2SH'MHV:=!FWS5+'SP72^)F+1(E,H)GL@#BM&DXLWTC1-A95\L/2 MT+/=)""$(E/9N^T#MKWKB`ST<)K6(_NPLL=UDDBB@W+HLO'Q^NG1U#:R?LBX#Z'-=]6+Z+\D':*=2Z; M,%TL5D6JP9>".`%'PCY#7+BQM$,=))Q+MV19E)[1[M"=CYJM)E;1G\]\_DU8]+IVT\YV#3"X8RN%[.JS4([>O>[-.BN?4'9X0R+Y M2;A80$_Q)/)^-L;]VP.\"#L<'?(""TJ,$#RNG11U'93]9SZU9F5>Y,(,H<:I MZ!@["JB,(8CV@8D,H:VF$M(SCU`A[ M?AN5.KQDN(=>L.>PC472+NSR\_5Y?/E%[1G,S0IH^B]\TGT_5TGJ0PI"(1D8F*0M'O5"QBA\P8%E/ZA_M^1Q,X("TT4UT64V MF\Y7K0&!B30B%O0`UQ8'S@BN3PCH@;"-_G*$@,PO,:R%];E-!F#\E1WNW M+,;!T4S*:/XI0EPP2B73M8(8H]\3Z0`A8'#,5ADSPQ7,=$Y?"-SFK_8WE%V,$KM78VK`DH*=3AYO;!2 MXD4OK%`3^Z$@>H3L&*72$1,/=VKU#.AGC>@148CF]"2'=B"/L9X!^KP9>GZP M];P&:%WE.0-TJP1]0W_`N6C(U9Q.T:JX<*-N)7."<*=#JIU$@(?DTTY6KA;6 M>MP:F76?.6W;5C^?)=BN.ZT0YJ98654BB67,XZ_Z(=+.-AQDBA7%'M[;X1\\ M0]+%T:VW:9A<-3VO?5K5H(SJNMQZO++&Z80JE8=R@8A(/._$0S[/&@S>!!!> MR[QJ,(R6%.,(W=Y>&3"W4J!:/JMJL\L0Y`_V>S?>)[<]7+'-G1WVZ;U&33LN M*F_I#@3M*JG.SB?KY9KON^12V4I=22[SE;54"1<`&S.#0E2($E#;,X/B5`@.L)LT MBLQKCPE]MVH&6A7(](JJBLFFF`UOZ)SSR]7H4!C:FE89%27SV:(\H#6WH0!6 MJ:2$3]MDO=W_2G/S%J,81B&:K.4%T3'$+9G%W6280;.Z8LI9NM;86BL0#^5- M@&->0?"9S5SLZ:`^K'?Y;Q`P?3"")J_ M0^\,/F,6@1+/3L1E%7!%M(Q[-$+?W/@E.-*;@D/T*D.GDU%21ZL21VP,8'ZP MZOC1310=L=/^(4M/PW"DJ$*7X+P2L>21.U4B#IPG_;&)F.)*00'00^1G$H+4 MK&`$1>Z.<13;K-:^ZH7;QJW<28@DQ#:-,;I8@[03,\,`()O+"1 M156C`%-)<2`&.0;KEN)F9<4'RC1A4HSI5WI@*I+B43;T^ID#9-.<`F5&:#V: MS6:<332M]3?B]"]H.ADANK7%GB>__=>CC]%TS'XY,X1G*D,X\-%;=HT1F84] MX-@-,9V3=5F%5):@EX6J:G691^0CO_Q2+^J`N7S#UA_/8P1K,"-H9&571Z\0 MMI,EH;ALS6.,!* M6PUF@D7=!-?\]A9N!&@6MKAHE75-5H%AF1\%GNNP4,#R=JMY M7*V/@W(DT4'9F5:+E=7`DD2:,3SI`T[.E`9P<%PINUPS6PKF`.(+&S8>;>_N MV7-WHJ3'YF?U,J6N0)%NS-G# M;7"]"FDD)C*&,9^/^')+@N$7=QN__">VJP>@.KX,S:F:1LH..5O,&TDV0D0V MLJEPQ*0C*AZL;QH<.NNI[NVWA&_.D9TYG/\_Z(U(,H]M4K=MI9_83";Q\<;_ M0ERF%QM+KQK`Q:(^ZEW#:CQN9R+QSD2V@3SL#UO(PIFY)!3YJ@H%:Q8RBX"/ MF-C$Z47`PJM&$##71]D3)^O50HF`B6PC"=@7MI"`ELD$K/NJ&@$K%C*+@$\O M;MB/?_F;1M`O4Z?#UN_$4F(?$VTD^7J"%G)O:C+W:FZJ1KVR?8QAWA MU>LW.SZ&;OSVN'G!SM'#C3L7<0;1EE'^YEFR66-4]H5 M`I-),>=\=A../"9LY&%>,.G#HO:(TMFX,&$E/`2A'>.O`9F_[*B2PK)=[<]K M#0(2)3J<7%UDU2BX+':3T`47!U3,:F"`5D^`^MC8XGQEDC79!(8[47RW_24( MG.@Q\.0'C5)J6GUDHFK6599(F)I:DP&HD*@"'$"$JN(9,>01!(D^CQ? MZ#IE?Z]#AO/R1QR^NIN&LBJEA[3[>-JRNF-,)XNRBZK$C M[*"H`8A>_ZXZ3=V]2X"AO)N>^K[^3K.J<=M%T-+'-7N\2`?U6P9G\V7N^\ET M/Q5FP$F!(=!98G30E&CRM"HYI$8`H4ER1=L73.8MMO=D?^>:?<(^WKI2MK2\ MI9,TS:IT&5"D>PG\.C\NDF;RIWZ&WG.Q9ZJCW63-CZJ M@3]-[:M?^CS/"A6DI"DLU-,K,J@XO5P9#IC5!]BY^:'B8I04K68`[&T>8Z($ MZ05O24M=^YR6=_7W/,T**8?DY70Y+5.)"6:C'";:P'YH2.C)AA:#;&I?I.:V M@AY)P4XP;(SB8(_#!^PEFX4O[B%J7B1N>$,K\Z1J=-A%S9*8N314$@>]4#P4 M1*LG1'W<:G7",J.:[0+!H\_X6;V8@>1AC>P1:Z!^6&MI\3$?%612+8(A@%G= M@>EB2K.;%4G28(@!BON7I=\VW`4B>U)S,7^)&JJ5WR>SR807\:\YQBW0-1^# M0!*3^-R0&HOU#X)+S.$67#J*\[49R'B:5MQG;I-+`:T_<"H@JQL@G?V8V)VJ?9@`/+S_?[(C-WH\A-AV[OR_ MV*%+TP@?R`1OHO09&UX'XXI)>!3X*&T`/6A?&SPO_&1! MW0MLFE^+:$8+W7YV?:(.CH@A(M:$.=1K]V0Y(5ML!D_3SSC:A.Z!#@GOMD4% MF>9*?M$B`HRNS7JIEUE;69:$LH46J`N7&)OPV03>#FF'O*]T\[[2R1LPA[5J MCBUGKH+5X-G[Q=[@RWUP])N6482/@[$RUZ%#98^T]%6-@50:2L290+6^X!BM M;@/;1_8NQ$GA1EN*"H90=5^3DZ=B!WBBW/#1!27P]7:+-['[BN\Q\08_MG>R MXL7=9(!1JD6Q#BM[D[6$9VD3K&L;H:P5E#=C`O\&M43S.!7AO]'C,'&`XA>, M"&OM.#GJ\M[]B?WJ$+I[G+SVWH[0X?CLN=$+=I*#MAC]N^UYZ#$F=(_1OQ+# M^+;W$SIXQPB]IN.(("32B+B(;HP9-")69),\/JA\)^.#!OWU`_&C](S+$!Y: MDVEJ4*DJVB$]43H#5@@RR=":-3Q*SYW]`('G-&NU39@]'$48]%C9(+SI'2Z$ MUC4K?+#4!N>$`4=-@!&!H:I5ASWWY5@M"B1-&#S..,T&C-L99,;M0R-4>$K+ M?%F-OT)S&4#6*#K:Q"B?E5>HRV_`T;&H1H>-C\E!@5. M!U!T-SE;3$L+2*NK"(XZ*+P`QI>B%EU"L&S=-BM.9$HGTQ\@X\W7@/0QM,J' M`W3>0=W;Y%RIV0">+E_M/6Z\M4#Z.!A53LZ9BD($R1PORCS1K^VY+?V-['OT5KZ8C20Q4>A4@MU1%+]4,1FLU M65B%9-/";K3/A"?CH\:N$@-!&.[K:H(#ZMR`63H#H\\J2K MS;YOA/?NA>W[=!^F^*V+NS0'N05TI;)VH7(QMU79?O#=]#T.W1AOXNPOB4'M4(5/$R]8:,?CM@;16@;8?4A@F ME5Q0SI_<+`:PAEA6[5O2!^$X0UKOYIY<$WNF,"Q9-3L2;3'DP3K3E>6OK!IL)@"2+WMS)%)`8P MA22\_$2'[Y>^`4P9KD87;UKT8LX(\:;,H5`O[%8)NYO<2&XLF2I^V<:IHD5, MH=97@KPSNPHO`1,LUZ3#='FZ[LFQO#5S:-;7`C\6T^INVD:VBEV`^.;ZV.'E MD>[)5[G'@W=Y"J2(\&D3 M*&F#'LFG?^`]^;`<7R`N5H41-E5URM"\-G`2NS5/DK23\#T='V1UI._Y=A@N.9 MR`6;F56S!0R7#B'>N,G]F/C@8?K#I>\4.W#IUU5X52NOVO51]KGY-*WF611+ M"UEPP6QGMR@:BF)#@[:JH!E2NP6I/N*I^VN9?HIV&B0K[3OY;K\&T<&-;4]8 M_U;ZF/9LL[H.JIE&X_5R/DDSRZ@8],+EZ,X=.Q7#I(`AE0-4KG<80%970'HR MO.2TR+.Y)-!!^L:L9.+=]BK8TQ+;C$>L5#!VV-4KCR]VB)_I;4KIQ8UMY7I/ M$ZJS/SU)4_7H5"S*Y(X050*]IVK\A*AW MHU03RDO92\],'93H0W>^X*(6F%5Y-:\H0J0!%L6^'+V8Q*]T!`"V>`CJ:[/, M+,04J64,6%P\3X2JQNZA[6Y,,$_4*B`9-(CWD`X=O+NKK+Y0OYRW!&T>>"MA M^X<+U>>V(0O1UW;HN_XN2JW%#9(G*\!>F#DPVUH#4D^;#[&T-(PZDCGJ.5K0 MO:`UK/J*7)G1NUZF?"VL&$2"5'[*%8_VZBS8..+G:M32O)@&:;^&>)T&7S8J M^B(/UNA3-5:#K0N`F[,2NCU9Z/X9;$7P/-$L6TP\@_&-&4S22Y_3P?`O87`\ MJ"P\=I$"/3B4JZ9>$W*^6C0%E>3*[VRRGK1BQ#KBV:QA#6L-T!%>.P5:1W(M M9C6&[?2.3U;.4S+O[>)*K;*@F=^F8(?$D?FX>1+(KL!E;Q(-6GFO9$@@]N?!B'P;[^B0T9M01YYAWWINY`2)>B-!7S75,[/7 M5KXH5.CEV&)0TJ!T#2@[E@)]]$27G7BUMO1EOOZ,7K#GH"U-8[<]V/IMIS.E M$B9.LNLPBSNJ*CS@5TQ^\163`,8O_Q;>EWJB1/V+-Z>HJYPC,UU9ZVRQ)HD# M.]HDG17S,"!9G0F39I&?'$[C/6:D?8U&GYD$X;(U6B+>+#O#=[=%:`K(F/F`@*:RCG&Q$\+%4U*QXE&>-/.'O\2>BUA\J/7`?L5"CJAZZ M=EA<6$]$L2)J'UN11_*6T>^T;<0:AUM_T6BSI@498X97)Y!'.L;J:UGC(TE[ M)=Z>TDR-&]T+W2Z7UGC:/UR84.I7AX&LLQG(R"C24DOX!(L/,3GC^3"6'#=KK*:[JG60HZJ>XT3L?+:3J7XF+9-@)F@LF$*I.L=XHT M.,1)"2*1BQ+!J"`9=JMY<,C6Z9"US'8Z,#.;TJ@:J_]H(\*;#[O@]:.#W62@ M07ZHCB_(KS)5OI!`9GM)@=4OY'?5]9SF9S6,#1H54.[8UHOELD*F1!@O!8R8 M.+WT&1"9U0?9N5FBY&:4&NV&T,V'_\1VJ,:&_$D0+F3-*_O+8CX9BYE`99G! M@YZHA"QH1J6?`S77$C.@;`)]_I\P[]IW!!<@R9_3[/NEQI5]9+9:50=4/$1> MTPP4[1<=#83(ZHI(I\\+W:GJ\77P^OS]B8AM^"[LSYJ]F[:I?'?/>K6H#FSH M^W">W%U[2TE[G5Y;=(JJLV;X!IC=7]NA]_:`^04-]]BWO?CMSJ0W.(1+W;G(-!F^30,G&(RT-W/KM= M0/]\?3!X5L.7@YJ3*_`IG8JWV6$8=K,<>)KU3;HX=OC[*EDT)+\N)(/*U_$Z MB]`?!SKII[RS348VRRPXE$X2$)DHHNV@3=90GBJA.2?BO/@G)?SL#`II)"FK M@/)FBKG4D$N!YS4&BS="T&`'2?H2O!"#NAOL3(%)DJ?>+32U"#$@.#5KJ'S0 MB?2!Z[;P),[E,B!`#6F#QA`E._!A6I`:TB!-B15&!2HUPC>%*@6S061-I*JF M:K8<4),^KC'O0:9#EYR>>86+.0VA3Y8-@RY+7@3AX'O;G[%MA>_/.!-$#HTE8UF2[WB!^SNGX_DV]"Y%/DC=E_I=:&R?/1! M1.J>"9ZHK_(MZ.OI=,;GA5F3Z(6UB<*D47K:)VF5_*;0+/T[;U?S%%&K<285 MXR1M(MXHREI%I691WBY@JKY^:[%H]AMVW`T=R-,,Q^0?KH,4;!BA[((O5BOR M`F6B5-X&FZT.%+"RN>L0GPQD<+(_>,$;QKR$[*UK/[N>&[LX:KX1L_T]G0.6 M-F64SP?/%N-TZ,)E7H2\X'!!*O!5F`/#32[TVFQ"NI)TL-^($AZ+`RER\"IX MRDY:&O(H6>G\62!)%NX5:3"TO1O?P=__#;\)DAO$SVG*"Q$VKCQ'7$W2:[1X M&C47A)@D1$3ISQ49`)'5%9&._)%&=TH32>3@M?E[L-\'_F-,^C8VX8CNCG$4 MDZA"9B'RK]7TDEXF-&C2)6%T6J8%DXJ86%ZZ/D(%R6`L&0RM=2):C0Q2<-`* MG=JLI(M;PB.8M3]KY4O',X#327KNB/L*S)''T_2W%/77Y]/U(X9"A+K\](OK MX?"*#+YV02@?\92?TNJUI::5/_YD/IF4G)>)0:D<*!<^`8S5"8P^?Q8Z4-FM MZZAU>?<#WKET=\V/Z9%I/*;5O\MM=\B87I:'\[D<=OX:RL-/@6-U@Z// MQ\5N5'9R`7"0M:*_'8DR;;D.Y8=TK@*56E9WC_&$7_J>"(#/93@!AZ6,0]O: MC=!I2@LU=;Q#;$GQ&DUW_OW+6^1N7-O_Y6A3#F%,:^,^X$U(VMW7ESB[OJU[ MHTE=-=6TLO%D,EGQ/24NG1Z,.*3RT2YK@"\,9DUHWDVN<'V[_ISNYLJZ:C#4%ZVN^QZ^^.;O1"U;C; MTB,CE_O@*-^.D;^@LP>6:J&\([&89<>:2L)8$6LB;H02@4!=\T``^>UPA%J' M,-A@[!!B'0Z>BQUD1R@]Z63OR(P]BE'\0@^B[`^V__9/$8JP[P8A.[4&VJ^W MNFBICV\VG#$<^^Y6RS&T/@[-+Z)#AS'BS&IB%QDS$G%0X]Y!T%F]T(&RIN!T MK9Q)[6$*8^A1Y<:2@"TO`;,GUT0]4WRQ7#3W4%0H55@PU%=[3_/<4TDI1>]: M+U;6VDIFG6E5;79]7-8(FVSPU+$KFE&6-J1USGD&S"QZY#`O,Y@EE&FM2)\>7Z/K6D?JSYX7?",:X`CD M`IK.X2B=,JO;#6)80K1S8WSKOF+GAH0N?^<^>SBYR>)R0^+9D>5_D=E&&+M_ M;[I3JH<@C<.7[MIUN`YWO,J"$FGD@K6"\F:R.V(*+:%B4U"WF9_=*#.>'*F, M6M=XI[_7%\=`/>UG&,T_O?UF_U<07GEV%#5,X;M(,(/85;743^U-ITL51J/G M-\2:0*P-T/G_V>Q@#6D'`_@M-D]?,X"[31;FW68_3 MDJEM73"3:QQ#>Z!5H&4#6@-X6')21?+E=C*,<7E,:+WEHZL4,_@H4DVY'[&F MR[4:/8N]B`&W>9S5($H,[F00`UC=1`1%DDLM.\1ZXM&+`__7(#JXL>W]AO?/ M.*Q\>^ECNE<+!3JH%H`+2;(XF(A!J1ST>R+I/(22K@*>C&6B'4OS&M_) M@*RN@+2L;S70(UO.DD$?C)X/CDUW]UO867X*A)PE%;I\_FF)FT0,8ND,@-P\ M`UB0.=KM78W#8B6%E&=O\W&Z7,Q*/B0UTM!#>EH\0+ETE(N'&?^>`7FR M'Q[%[I[AW=INB%YM[XCI=@_-U0HQZ0@/(:W'"5.GNIVZE:#HB:K$DF3 M.!]MC_QOFPR\&YQ`\H)F$HJU4/:_R6INU9E':)9<(>@RRA$OY(N:]#+[?)N9 M[]>UW,*JAY)#V,'*[$!`1T0.16XS0="D:_;.*M,:C`%"KR!POKF>]/.E?]9) M'=ZF>J">67S&E;X*Y.N]%+?:%-?FRQ57*'EN$1JDGU[ZM068_(;EEM-JW60` M>+R28AVVPY96F18LQZJ^'5:\MASX.-P9+6$-:0G=G.SD]B+BJAO46';+"DCV M%&(:O[M6]+.6X^5RUIG@8,4.=1A#@>/&LUE8=O`$XT'R^=;U\4V,]]*Y6NTY M`%9FC:M?DSB95`:\/K M"3[B'5T/D:[VM[^C>>V_52'5"K*+^73,=^ERF6B;"451(E7O*?&!X4TJ\'*A MB$L%W"L8&*MU&E8=^PC*#$QW%=1,-%ALH&,NF?T\+*;=6" MHW3]5?K!!VT$)/H,B4#]5DEKPJ_\2PX?TQ5#U]^$V(XP>N_@Y*>?R.\:JE>3 M=WBY=4:1H``B^M#PWOMWU[\^O/LI/=X=(?JVI%)[Q$NU8P<=?0>';%^!R[OQ MMT&X3[97GO#FQ0^\8/?&%GNO"7>"/6F:CG.OB.%=>CTY?^]R$Z/W5,Z[7V^> MKJ]^I;\@ZGQ[<3R3"1]IT?7C`'GV-[JN^@4_AT<[?$.3Y0C1U/SD M@'H8IYL=EWL7#P^7[W[Z@)XH MHDP1:@COZ)`X8D^:N/L<$'19M8JD M1L4+W]TG7^03WKD^O?T`?7/)@UM,[$FLLDWN;G^C=[<3*EOHO>@O;H3N-G%` MH@2:D*;#X+A[(:'P$+/(@:;CGUAS9'B-62'([!E),XL1PIZ;S#XR'9F(34@B M$WW4WFQP%!7^^O[=U>6OS'%"\H1[2$X:$1^EIA!7;B=&W(7V/O&QK$'J(N4+ M`3+WB]`S,:[#EM*/3('MT?/>R"?8DR\1\]-->VQ30Y(_I9^`J."&:(.)9EM: MOH!^DCASR@_T"LE7VG]Y;R/R;!`54<<0@QJX MJ%D8!26',8MJC"1NJ'(%P`@5]K*@!E!P=LUWL?CMCG3WV/U[0L6\=TA=4_=! M*Q-,E!S"HK17LX>^4>@YQGKE8>O@5H=8^Q%#N2?_)1KR;6E^BO0^[?U)7_7) M=NB9?-E*T:E2-:XKG:BJ\N[A:ER>KXHB-6\U2P=(S]YG#;-A`FF:57@`RA'0 M:K"D&A,=@2,%4[-52J<\4+/3"G$ MGV=JC5!)L60J/4)EW5"JW'F"6A#;7E-0,\;:"[;Y9(<^"V[*]G83>X/?G:R! M[L5(>.[/9F;$O&')*^17][108N!?QG'H/A]C=L=[,'"P[-6847&R#P+U.\W7 MZU6W$#E"F4*(:X2**M%,D1\L-I[?PAW#HMDA\!3^=HM^O3^,F8'O'H>?[,C= ML`N1>WMK68I1H:JDFOKIPEE:S5$]!I&6$&LJN2H;9BIY5H.P:21[V>QH('3J M;C2O6\E8_GYVO6.,G9,97))C&H>+RG4X!+7HQ6+>F/$\[F\4QF3^NO%<%CEX M9S;7;`7/9[H%G"B+G5S7KSB^VY)Y57E@\<"6V@BHY$)A):\Y13X8_T]0NLN: MZ$0:%XH*E"+#U^0^$*+%J#:[N"=>!54A"\A^_`K$*&HQ&[]&);:_FS#7TF:> M1=D\3M$\@8&SJ@&"D3PFGVIUTV-U]UE4%WF&QN)^$XGY>MW63:&[4Z#5M68\7\HVSP>.& M<3/`,QK5S+E@+_J<$#\,FA\^QG;,TC)::M_)GM;._)H*'3+2TKMX.:LS4>!E MZP:!9O6`II=O4F>K^<^DXK)"N[162[#^]I1W! M+V%P/.3[..+(T)#MKJEQ.!:?"5&7O08>%+*^FS7";Y\!S*DWT5!6=T,!19@S MT[0A8)WS0_UCQK_;EJ.$.C7XAXJ$MUT/W2W6D[0D:'4@,4)<0<0T9-.=7,?2 MD;OG-U2.$:6D&=G\"?Y@H[$?1#BR`_\@_SB1O1:`](;W6_`SF>?'^$07W,%X ME[3^#Q7;&23UP]0K:PH5UYFF_[`AO<=W``KG\N_PCQ/)2V%&;Q3/'0$N@C_9 MWY5OLVAZ0WND%*K19?FKG,5-Q)ET*\5@&*V^&/4RO-$-ZZR4&\80)K7='-'X M"BR7NE^$L)RE!1PEC@9^`\1P,"M\,N'P5;/CM9`'_N:&PE&M>]MUON+6[B=_ M$((I6>L=KI.;3:K\((,R*H;M[0)SHB>@(A,,.88H/O_&?\!DP.?26O)7=O0B_Z;-K^GE3J,N'0*O-<](Q*\5^%R\ M5B"7BZA@J,*A`P.>I05"-JS.!06Z(5+H_W%$./`-F%I*_EGA6+M]8,CF$++[ M;HQOZ>T0U1N_KK_S!8V62UP[B]%*QFZZJ?<"677DO(D+UH;@@KSW63LH;0BL M\SNG/2PU>\`2N)_/EPG=PX@P!">S/KJ0F5?]_!*$O]G>@2ZAN)OV-4#5][52 M6E$I9=\=+U99/B^772P=2^M3%<0;L%QX%@-8`QE`'Y,[.G>9PEUL",U=>A>2 M*ZVS)WH2B(^\^0XCOLE*P#PN!IY>O?!4B)27MH,;H)_ZA69=($$$@`I#9%0O MHA_@DKY,]&->OE"V&=#^O.:K\QJ54;]49SQ>);?@B=PCTGNOU8"0*D&I(!!P MAV-@C)8,(]1%2$I\2N\T:C<$3+==G@S\$@91AYFTTLM:.W<5C;K,$K,EKERWZML0A/(^A7'?:DJ M?!60J")]U*]HFL_&4IK2I5F3%K2&QFU5<-O)&MX%K1YB1B`Z'2,+0T^T79/B M2A/]FJ**U!Y`,8456N0;:O)/6GI*;Z0H-JWL.//9(CL?FTA(=SWAYK6G()F5 MH&"^@2NEN492B/RGXO\UW(/,9A.Q=_[=,8X(Q5@R*W[F-]L+YR+-;VB?T3:J MH^@?L]7<6LS3.2UWC\!'02Z3W>2H>VH[(+8RB^]\5)#);NI$OR=B0>:W`P*U MJA^Q$U`]4UXETN63WG;K0/9Z--.J)5JS1P#Z.]JN>EGJ>7X@AGL/?1]LC-L3 M0C5BOXAZM(RB#!._$IZER!\:TI++3RBU8GS=COV>'AU!-T]$)`]K=&VQ!AV6U2R^6L\$\8M> MF:CSS$]4_7T(7,SS'VW/IKM6(_3-II>$483/29XFZ+)@LY\5:=%@BOX$B?#F MPRYX_>A@-^$&^:%*"?*KO]Z2B:27%/`45-(1/:'!^07-JF_)3M--&Y.H0&CU&`>;/UX"SR&?Z?IO1WE- M[M;7=(;]%EV4_6BZF/+%ZH)(%B0303!KML/"2]9K[YXN;]'MS>6GF]N;IYOK M1W3Y]3-Z_/7RX?K7N]O/UP^/_X2N_[\_WSS])VBOH.B:I?Y!Q5@F\JPE?U+Y M=8-XU_GD\7RUG#3Q#SQ?\CR(DY[K!R=C4XID)[,!D_/J&-)+#]H=('T0AG"\ M=?7J_=:J3JT1XF+`.[9>+M(0LE3\24*+(GXS"*#>'U5?`"5$ M]VH7\W070T0,DWJ@=B:I=1^%9&++D"G2X M='BV%/`DEP3>A_0%5>A&O,#?71!.[@WL2.H.)B%'Q0[&\$*]1Q&\`\V3SE%W M/9G-&OEB4M=R*DY^:Q8ASQ,ESZW!Y%'L8206`2;3W;94**ZY3ISR3*:75!A" M]E&UPZ1B*:S0WE[S<(3TS:HZT/K\UI(-*]$+]AQVVI,T+MPU`P@"I[!'$B9Z M6WB`)+M;=XL?-RXF)J#+*M?^SO4Q#DGKCWA'D]NDR7:J;VI.NE-42]%#IVMK M/K&2Y#LJ&45<-%M0Q+EP%"72]6;AG07L)`.;BD:7=/6T`)9+!TS+.PMRJX[< MKB"'SL_KR-=BXWF^#HQU%>]D$8ZX:4K[T_ M'E!YU6SK^6(\G:6]=M%ET9:KD+LK>J:5S`Z9%O1AS/5`STP19'--4)BIHKNC M![/B)+/B71J[4*H"RG2@U\EBE&M!'T[U0(DB*-6D4,L%8N``9DEA""W[(=RP MX@PA+!]\#&URZ"%*#<65?2"_BM\^TY*`[D$0"WN+`1KJJ.BF?BV0M1@7`DE0 M"R2C0B1)&QJA0E/PPZ7A#2*,!UY@^\AI!@XQF.KB\K(!E[()3>'W]?>#FRR[ M?+9C/.G@)=4W@5E<44=Y87YFY1MV$N+FHA&5;0Y13\+,N/GO0?@'C4@;^^#2 MG3V<0W4D4"&I*?'6-C:*[&0*`6]\-W9[$;#Z)C`!*^ITZ2C6+03,11M&P),P M)W>WDOT\F;:71M\^TVWC8:;HCE1!+L[L-@ M@[$3/06?\)\C[#P%7UR?%I>[V1_"X#6I+B=:W5!^5_"D=/`?J$$95/?^0MH&(3 M`,MMYT%O]?GN8(MK70F=+9QU,M[`H8+U5H469AOT704.Q<*%TM.!2@(("QT$)FH(!0V9)P*4A`G1%_1A,@@YYLH M'$@,`S)_(&I%]_9;PY79I4=TCO\+[:J?<)W,ISD[Z%5Y;_JWJDY'P%S_X?,E MHB)`Q^`"_RB-L:L089S8W]&T8UJ[2OHI"H]H=>*\7?7)V7I:2T"A`J"\N"\$ MJ[$RZ.F:MQX-Z:VY&35-17Y=)E\%'S3Y6A+.!4\"4;%KJC,)RA,1(_-C@K_9 M\3&4'GC0R])>Z$J)W/L,3;*"FV)V!H]"ZA5:3_]^LZ1`3!1EIX7WC5\-@N=- M6><2`T"S7IAEWO`@$.<[)15;R[4U7H@H#Y0W/12BRD$M\+JE[0XEHP!TUG-! ME?:CO^*'@9C0XYSL=#&>B3O`O'J_B5UA7ZA6&>KP_1X'\XK#Y^#\<";Y4!R5 M48T0SCY@O5<K>EAX*449LQ,9)!8'`UYP.!S&IH7[<[^WPC:Z,PH\*5?F4[T.W MV`*B%RSJ MK0JI)@Y-IJO9).E:N4RT(4)9)9"`BD4NEZNWDQT8X*0(D`IE15Z86)3*!:SO M,C!:JX;V?]G[P_];Q,O"!W1Y%V4JIGVQFIU@.F2JF;2$E/0QK5UNN6WU$TK3 M28E!@,60AL%B=<"BK\,4.U"YAQ2@'J)+Q(Z[L5U'WO^5']#=V95:5_S4XA5[5 MYT!85E%"=;)/D$_71;*1,8>7"((@W4DH)B447!`X!T^"9'6&I(^2$GJ4F2E" M/R!!6YD)2\ENA:WN_ M!A&K)7*WO72PU\"RAL>UT2"*`#.'E7VE.*+[;9K7L96"*$1,A=C0"KCJ=@8`3X=(]>G1V!R*9`,D+M5D002Y"`\ MP/&5';W=G=LPR1%::I0O7O`M0I1>0DN`WKG9 MGP7]Z`Y^?9I$U1O_%4?Q"5VV2``\S05:*7=6B_E\K43OK!%3N^R3K;`8T`K` MS&YP=`5&RRQI-I/[=>!-@HQD=N=^:KY>J0W*1;YM:@<^F&&$';C($B9VX`HL MZ$=W4SMPOAK0OP,7"8"GN4"K#L/0U52)WEDC9^_`>W+Z9"M84BNH8@?FZZ]KH)I6-5TMY_S*/?K!PT2*WCW]4[7/R,BE@`U6AP!C5<#` M##B;?3_=E)=@!>EH"!;2%]Z%).3&_!^%*KM_L;TCOMM>1A&.(_;[$#NR>VGZ MR=+9+4?KO0ELCQ%IC.26L/90V"#2F/+]I&$,Y M6)N+0$??P6%VXY2'[2@N'.Q&%XA?"4_'GH$9^Z^G,*;4\?8V.5"@"-(! MN/Y^H`FY;>M&K>_I#0#-RJC?FC9=3#*R9S*S82T7^Q/\^L^PB!F'TU.$5-HH MQPJ[PJ/JGA4&*A@'B&U$`0?G%\%*9X&")_4RJMI\AUYADG>83$KAJF2HM953 M\3"&W!/?=*,H"-^0'\08W8>NOW$/I(>#OR.JP;4JW!`:`H8-,6ZY^5"?P1\[3_1)IG> M;:^"_?[HN_%;FFDMNJ^LX6'=*Q]23=0O>5];_)11(HQ=B9>*RXX[:"X;,12N M20'7W19EXK+3``"7BPV%S6K]9F!+)ZUDRI90FFTQ(+%3P?P^Q/J66=X]C>TI6)1 MF,BEFW*82X;A_4!`*_0G4A$3B[A<>I5H*ADN$`P$UNKP5:$C0RL;JP&BV49# MQHFD\(#S"3O195P;<#1]QI8WH6)&LUK*@\GQTEK5(@>7C9[IY9-V+!A=`L6/ M(4%7HT@*F@I'E[%@N@`82X8$7HTH[5\;/*ZHL;<6712L=H88\_481O2.=<)B M'-*V%3YL_1W@N%)32+E6S7RR'DLCBI^(11LFE[D<;"@Y$:;:*WP,A#1VS53'<\M MQ^-9;7?@D(GG"7V[M`%D9RW`A(.AD5<"1"X>,?DH:P#E+<`%C:'16SV^.W1H M4:=T-=@H6@\D)8:K^(`/0' M4GE`R30#X:OP+&H`I2VYIM7C2JDVS888L,=^))U?XV28/P#4\R:MJT;9]=2: MU9)J(B8"IOOLHWZEBTQ$P/6!?2!4^2>%H+,C*WMZM;,JP(3HD.[*B=0-YU9% M3VKL@@3-J]\,/K%XUO]=+>5?>M+S_+W.R9"L,J1#&&S=&+WWS@>I[13NR9`6 M94CW'!+X>=P&GA3[3QG^`3K.3/0MF3]+:O#*G]/T!(%F=(>GH;1OID7:ZSFI26#I1'K=*SL,W[9!^,T.:]D8"B^`$*FJA?H)MDEZ,*G`(B(-E<1!T^%FAB/S4+AWGTEM/P[<++M,,%LG<3TPAH5E`^9,N^31>\R![&H(Y9164CT9/ MQG7:I**`[W\8!)K5`YIVMHB=34@5@2U`>!+N;-_].YOZ7`5^%'BNP_YQZ3OW MQ!O2:='=EM<(MCVVR,-T;RF[,(QLG1P<0F%EMUZ,+9Z`5VQWA$HML\%5L6VZ M%)BUCO+FP:L\`!C/TF0\;7%D2#*6HLY@W^:'BU&?W6A#QE;'$-.;8-A%,.=P M8%$S/TKD$NBNS,/E8FX-&,1R50RXN0?6J,F]/W;D1M1:Q?9^V!#5P,7!HI7, M[B"!BQ8I2HIG_4;4PA[Y[C@X1K30UC&DY45EGM?^HL[@TJJ-^KTZBTD:+E@! MIT3J")7DCE`N&6CG9V#$;"/HB;:*_$P$LED#H&Q6=M`2/]6L`\RX+B0#YU4/ MQUHM)BL1E<[-G=9>\W14A0IOIM)%F2&FD.(JV!]"_(+]R'W%^8;N5QS?;9_L M[_=!R'K80A'LIR`I@=WTG4^0JIMH_555=E[+LA9%2I::+"=IL#T@.K`C38\0 M;UQK#7(E'NLR6H'QFY+17-8F..E/9T\M/)QH6L!`$L5D(,[WR++US&8O$K^B M/P0(]5!VU?5D-B_S.TIV/[.-W4PF*&<'0%D@9+Y'Q;=WX?O@%A\4<$UNDB&R MF6@;OV+;BU\VA*&L",B;/*>IX6G=F4UR593/5J^G4WY>/G&7ETQ<4M?E37.: MTU"0"CS/Q25U>=X@*M:S_S(F%7[=-.P=.Z M.\.Z"LH]Q&0YF17Y41`U0E?@D\]3D16886\VX1$[YO1\K=7H2,YC`$+6U M&?$+@#SIL9XQG4]74JH8L50S`#[Q>HV7"S:)-@HK-W*3P)$G\'=/.-Q_QL_- MG"D^IYTJA<:[A-S2H@D5\05^4_?W*M*AYD3)P*QY M)E1Z!F+^4U1`>0@]M>;SXJPG>?V\\X+&*4]_%!.]*-IG-_VA6)V@:)O:B&A0 MFM#4$$/T,_?V&^7*C?]OKN_9%=-N+BT>I_!%B+8R2M?:T$5`B#FX$ M1DRV0.VX\9&HCK9!2$]!#B`LZJ&G&`X:AZBU?998]9 MG2]198\3!6H>Z)ZFK:HGK^?S):_+5:0SOVBSV9E'XELV]6X>Z#13.>H]U:-> M$O3093'FH;S=O"[@P(?AUHF-?+RC->UE(W6MIIIU#XXF7=LZ7`!*9PT#6%]K M4*59N8DBV!DHK$I$&AM8Q?HJ5]"ODAR@]9R3$257 M$!?>IP.SE$&TVS2`/D+?$O"D;H8AI@F);$ZS)Y;*+#F+V_JX[N%]@RZ*7C*? M3!8S?E'!?3FN:AY_#X:EQ&$N#S&!@*=VAX7(2;T_!#Z;0-`CN&7`8&-PS"[M`-G$*A\GJ)1/=G[=[@X'N]`^O+@;=K<&F\S9*#K@C;LEOSLPK%3.,V:)6LEYHQ`?;-*H MYR'V^($?2R+.3P9/!95#O,'N*W9T!["!/Q"/8XDI"O4CJ9$D!7E7G@HN$RI$G#XAJ-@69!I!O^-7>X\OOKG3X7WQ$ MY["_T*[Z)0+K1;JW2YY$]'WT.Y4`E4+1&X2E"D+;J%[@*J71?!4JI#]_#FA8 M:?DH_"$`GTY:5LZBR<\&%1PBD0'LUWV`5#V[`8ANWRZ[C-(R"I<>:QU36Q7,Z7."%FC\7C,*64. MD4J^)^=.;A\@NAQL-RTGD>XM)O6>F@]_J[RIETYMZJA?"C&QIAF]J-1L9R#? M34]KE(&>$1\UX&TY'`A&!>LYO*B-=@HB&2`\)@ M2XA,)K>VEU;5>'MPHS]H80WQ4%GY-=WI`0HZJ>['6FMZ@]J4>U8F-BN9\H9" M*GA4**>B>:M]<+"3&MA,+F*":340`GN^WU\::@2?\CJ0_H#144#U:,8J[DU66=A@0LA,2#&B/8V MVD/`23`F%1BLO``5`T+NDZ!8LB\"R%0)$PJ\%$$&&DJ+S\S\$LHO:&]Y2>\0 MND$3]0,6UCC;QRE5-2@7-1@A)A9LZ#P85*L,57@LT8[1)HB@!]`*SED9/+<9 MR2B6R:]?;GS%!(9UN9-XODAK[[?PZVQW+[<>VQH,YJ*56^@"^6*;X.C'#1V7_!6]I)+JT6%[8Y9W6HDX-GM) M!:)4(EA_-1!&JX[QV7;8\@X[^_%($^=MCYX:?['#O;UY2V^@!>98JWM6.-9L M+PB./;"S!/0$0MM]LJ(G-3)*T+QZ6=!Q6I*@(`7\RM:3$5G=$.GB18-+%>D@ M@P_,`M+A-2<1B)^%84*N0(`D`TT[ M=NF0TN8]!3_]Q"F!3@LQ*G`K*Z`=+'`ID[E2D@!`_M_T^A[4?TK&'@7^Y9A+G;%GZG M\"7;)``QID4M]3LQEVEF7=GS"K)&B+?`KA3,?P_/LD&-P.AWBW>VAR(0V>I9UG0TP#QLF0\JV,DDQGUZ*_ZEX=QX!P$&L+"N58=!VG0B''4"GCL_ M%TS16!3\9'IW5U5AH,14)G&1%H#T@N@82FM;]9%@`!L%:BG[J;5:MW>/>0.` MU:/.;H66;M-$SC:XM`II92:#8>V!EW*]VS8D;]<>T\J_T[M"R1%\`65)1Y4ID1`OS0;J]P=D'Z.!`->B7M M6Y.T0$N9#N<\F]!>T7M@>+-2=?/`KQQ)D%Q^8`IOVLXG-!II@$1BF7SE6PHZ M"M"<@-Q-.T7/6TRL\729)">7B45=#^6N9\1=`^4VL]ABTBT" M9S5$>Q0R['Z`?L1/TD&-TN2'AXLC&Z)_QUMVX\NZ_ M]46M`X$V;3J4Z;:R5:%$*$JEHO<%N8@+_@EJV#PL8JN$&'.IL(,`5=4 M[#+(P.`5$Q9?^DZ:%I>G#325+%=[3_LP0$$IU?MU)ZOY,NO]F5R6<)Q*1KGH M\R_BR#O]P0%/C`#<>+CI#*BM(FHB+=CY;IS>BR*P`&!_WH&O>3>N:C"(WOO1 M)O;D*LJ/;E2?TM@O5YKNL+:S7)7X=,:C&&T][4D8K/26G#`1<*;D][;TOI,P M++1@4*B5R['_@21C:+)8P_KC?V^$;NO&W M0;AGJRGL`*A@H@M+_Y/Y4PX0I]D8-H1\=J-#$-G>+V%P/$0W_L8[TNP`\4H\ M^3.9!#S&=IS<^FE[M.#9XPO&]*#YI>.PQ0W;RQ-6(O70HT\3D)"E#9XR<6>+ M\;P>ZE(]4:+H"&6JRG;CV"-$793I.T)<8\143E:[,J4+>6J1@9'2T`]E"3Z4 MZMZH_LBJ/:R(([+>;PD;R7\)`N>;ZWF,4*U>7GX:)"*65%`EPV*]F`L&:*DL M'D_`@\@)V&I$5\&FG^%"=Q.SL&X,0YBB/#:IOP'+F,Y=R,2:SUI98U(O?")4 M1J)4AF&$4>NZQ`888&L^;^+&CXDI7?+EDZL(KK_S_K%$V*;M^OZR-&_A]U94 MM53M>#%;CI-M_2+#W*PU?GL%PFE[:,<;U)O0I\D2Y5ASMT5Y:_SR$I2UE\-+B_MZ?W0?T]63&J&@LH).#E0I'D"IUGTK"%/-%A6><.8\-5E M@#DE/>.D&J2$U#SG*+I[8.J!42'\@,P4!@=JG004-HS4I@ZJUADT)+"[F&1' M[VY=']_$>"\ZN]!9!%C04--/U?'6D^5<,-1)+B9KJF=`6T*L*:C(<@Y#U&95 M\(90##_GL$9M]>)D:^B-4=VB03UH=;`I["*(6H4`M<7$+K)`%DXZ*-@ATV$E M(+_M!%O*[3U=C048*E4CXR]XM^Q;87 MOUS9(;X+=[;/9ZRJ,4)5$E"$4%2OPV+^;"J*#\EA`-[0""5-(=H6*C9F3G`X MBV$$H6$`PT#$A8X$D46%+E;^06*"^OY*#Y%F1XG.VQ:4%8(=FJZL,&D+Y]S& M*N6\#8AY>MRT8'#\4-PVZFGT05=4Z"$,\M_C<^0Z+ODXDGJ6BB^! MK9K(-%*]\HS,B,?+^FHK% MO6L;;;RLKV8TV@EV%,)OC7G`![IWYN\*2<>?WO@?U68FZI)`QAS*ZG7()YQ/ MZD,-+@IE#17SN-GT/'W"D)G)F0Q3FYD,8AC](XO.!!$/*+I9^0>("P/ MV(^8JI=A2#XJ2_".B-K9,[SXUN4W.W04APTGRH<)&**9 MBD;%]E%1`19)"@]R)1#3PIBQATX[UD$DRY=(WH^@S[OWAV$IP]#&)Y'#E#A10POHU]DXHN6V&^GC M^KV]IH/Z-1/SV:KD^(51-/2E-L.`L_J`T\P,JEDS6F@OK ME9[1RK)"PQT&4MFZ*WG_@@B`+I[7'X:E#$,?"P0.4W;W*EH0OVY;KI"M5K3V M1*<+ULF@D[7MD$RT3FFGL*[6LJP&W]-I-IREQW#:HL1@]"N%EF$^R@\5C^X. M+*_]%_)@'-WX]SAT`^>7,(@&#U`-+?T($4NN?H>=R-5\H!`V0ER?$4HT0JZ/ M$IWH;XA6/UA<&\J\M4"W*>@Q0D'2#-K1=K#S0\:P=LH.$M1:OL@0N:BT5*OM MQ6_W1(&]O4GWIX6S!847=.>@-FJC>B!SN9RO+)Y_F@I$!RY1<]&1`0%-RH!2 MB7GV",R$`KBM+]O(8;X)O?T3G> M:%)$O7KO=+VN;LD"7O$^("A+$92V7EG%V4K]:ZLM0#ESM[VRHY@&(RIBP]"P$ZXH*J.]G3J>5.VG,&`/V!V,I@M'.$)$S"2E1PP[#@6#S MQTO@.>237?_MZ,:RH[P*+VAE@TP+]1G$;)+U/+FP?T*).'09QZ'[?(S9.97X!C9OG/MT?H\\FU( MY7=U[TBJ*J:ZRS6=KF=\4A'4F/ M$Y+!@+PK'D*L[EYZ`)U52Z"-I[/%C&<7_7I_CQX^7R(OT-X_:T?,@PH]`?,' MRMM%Q891VO((L;91H7&4M0[9KVLWFU5R%'HY,GP'/V#@R/K^H0P+,RPX'#RV M^V![Z>9XX=X_X`UV7['S M$W4ND`AZCIB4CY(&M#'82(G,9*^_TW,OTEJ!E:=TCWSRII7W^9;YC69<`N(B M``TC/;KSVGT[EKC'3:Y+'[<(=_!`Q^I MGPC'Z@1'E\]+':GH]6+D`XRFGX@P_(!W;-[]:Q`=7-+52.?==#E"NA#86Y3F MT7)?/56=;;V:SN9\QXXV!;3BIP?FI`"3MX72QIH7]5J7MLX[?-5C'JOL!48L MYYU*^71P>I(%0;KLT';P5WO?LI=7>TQGAUUI6_WD_7(UR\?G2PFW@Z^:'JX.17K%G7WSV^[9^#Z@>I M_UV#2]<:52^7LTHOC.7OHT2`7B\^47]+3?]S>Z[4-:C+BB$.,:K,\SB^N*\X M2P?-,SWDHTC55W6/&A7U4EW.FJ\FJX4@KVM+,YQPDDWI9BE/^A.ZSH-WDN+- M4K>H\#1[M)+B!3@X/`MXGLTUGO?`JV5@V)&UV4"PB[4@!G[_CMW=2XR=RU<< MVCO\]4BUN=M^=KTC^2W+XHWNCG$4$P0D%DJ&,UVE:!PV=E1-?=EDF6:'I2T@ MW@1*VL@NV8A00?X(\99AQIUGM08C<0,\74/1GCY='*GVL9-!]*TIV+(2VUD, M/(&ENJE/I5;6[!0&@Z_YGMA+`P7*-UO39,Y_ MLB-W8J4:9,ZTLM-I=S?MS.QL.?__MM'4U>`,(AC']Y]_G# MIW<3$/LP"./E+^]^>WQ_\7AU=_?NO__KG__IYW]Y_WXRGT^N81R#*`+;R=]\ M$`'D)6#RY+W!&*ZWDQD"&,2)EY#F)O=A_,>SA\%_3NC/8$(^^MOE_'[RY4?0!HN5'TLUW'\N"[_[YGR9YX9_><-BH\/I=6?SS MQ[]]NW_T5V#MO0]CG'BQWZA(&V-5_?SCCS]^S+[-2^/P)YRU<@_]#"4%`B?< M$O2_]V6Q]_2C]Y^_O/_N\X M%9^M$%B0S_"6`O_#I^_RZO]Z#?UT32=1'-S$29AL[^(%1.N,Z'<3VNQO\[L& M]3B-:8,KX$7)*IM"23$A/]+B'X4M?NQ([IQ4_/V13'E`NY@N;L.8C%'H13.( M0]K#5>1A'"Y"$+2C7K'M(_(Q\Q!H.10:'20KD(2^%QGG[(YL<&MP$24`Q60. MO(#.K!RV:)KF*P^O;B/XBN_B($3`3SK3?-AB5YJO0^Q'$*<(7*8XC`'&TPT] M'\C0XHL@R,;8B[JO9NUNS#%&_X)D"XE3$%2]TNTY2",P7;"_[\IGRU[[9KN7 M,=7IJF\&Z:$/8[):\'0Q`S&51&[>-N2/ECM&A_[,L?JX(IOK"D8!$:UN_IZ2 MT["7<53MQAQC<_`"")YSX,-EG/5T$0<7OD\$Q0233T'XXCU'`#^FZ[6'MM-% M40%?`D(.F"'X$E+(;R&ZANESLDBCLG97,/HD[>@`%D36!I&0=5CL2)BI4F,+ MINF"J`SPE8KM]B:6&BW'7XJ][#S=.C<'PC<0$/$5`=)[_F<8W$1$SD(P#OU? M,SXHC2@@$IA/-GTB-N)KL``(@>"K%\9E?6FE7E"T3+VY8?@*8?`:1A%AY(ZJ M@,N0#/X%QB#!Y5==L5+IXB@,/0`BV%^L(4K"?V0X[A?HD5-YWT>!H)?%H-V? M.5;O8;Q\`FA]#9Z3W39>_[`K;_(.^F'F"7D^F%]?W$./;M#9OW^%Z(\P7EYY MFS#QHNR;/H;3%!D]C?*OLUE)4-_<2_OJA\4K#ZU#?^6!Z`$F/1U@VOV98_4N M)C^IE/4(DB3*["V]L*C/8-G;IM6BQR.Q6_PZ%J^,[HQX#;(C[@GN M^M[9_/$4+;VXD,[)HL$P"@.O4)#KGMN:;Z:J7''U!-Z2RPCZ?[2#YXCT]8SG M@Y>0[J:+KI9^K1YZYHG`N('8B[XBF&ZHFAZE-!B`;;`^PISH3,_`\7K*;%%# M0ZV@JF?L'A/25<-'0,L>85*I=]PS`H6MDFF@[(U[M4Z'P'D_BT.GZYY1D%E' MYR!!X5%/TNI%0T]X]*P[O4U%=B=V."L MGX$5==4SEPRK%NYM',6=]PZPMXE[*MG/@66GB-PKMG[H+#H9W&WHJ%W M>9!M`#O"!-'INF^-*+<)S<&&^E%SA:UO74BA2_M<][,0U#LN$-C4K%#WI,\& M%*0*B`,:YIU_2CLW%Z>>$4!(($0U>HUH/#]$S1$H.LV"]C'P/RSAR\<`A!_) MJ'Q/_Z##\_W[3Y^+D/U_)1_]?D&Z#FCWMY&W+)N+O&<0_?+N\/N/O=-SE2(: M!7Y+QL2+_@=XZ"8.KLG(,4CC%M6C\F#>D@]^+P?E@C$H%\\X\T[LD:1FDPZA&I55R>/1F"/#GXWLC[XDT*R`K^[I_ M:O)9?P6H_RZZ(_OBVY_!ED$6N]S1Z".B$(PS>V`6L8RG:4(O65%K*9]84:5C M47X;1@!=D9FUA(B/:[/4L6B;@V5(M[@X>?#6K+G(+-8_=42ZHV/TN%T_PXA! M5O/['3WU4_\"-6GSD%\V1/X\./*;U^:*$A\WV?VF]_XJC';2P@+!M<;141(! M&8M[`E$`4':=\_.G3^\FA/X\,/,^9Y5+7T9<`A`&64E:,X2(4/#+NR_O)BDF MO,%-[I\]*73V1)L*GB\C//R#K8+INQ$FD8Q2`?7]")18Z*R@^F&$ZO!$JN#Y MTP@/5YRH4/H_(TI\4;N"Z?^.,`D-"A52/XY(\32,'4A$IAQ!4E,@*\SZ%L1_ M_KAOFSR&Q5(U[T71:9C0]C]3,>G3Y/UD5[OQ-UQ,=FU-RL;^N/#P MQDI,O.VU"!<;"5[*J2D<'O]MCO=5:S& M`TC4J&=6L<0#2D%0NQH@98!3WA+UZ3K-/$S7@*Q&,JWIA"9_1Z"\G%J[-3=# M<`-0LIU%7KX=_3T--VLALV::MXS--%F1PP:N"0LKFOK@I;@*<@]Q?K60#*0< M`J56K'"Z"VR?>2&9FL7=LMKIP6-.7M$*/\5U4C;-]?N>-NCB^&4XA>S1*=G' M&F6L4ZD$ZGY9>U0_P-C7()Q1W![M64J?*H!;'+^M,HE:-6B#?YJ5BL:DD%_T M:'KQHBQ*A=[@1%M"\%^\*-UW*.C5M<(5/^"&QXN@ABT.BO-&.`3[Q6S06J:A M(&?]+C6!>)&(:@R%@VJ#TF"B5LD*'^J;SOXNS&.R0XLV$+A9;R*X!>7]SOO0 M>PXC(M#)=!AY/1O<5`E3F$3O)3LY+FV,?"0W;\7\D-"M5-4.3R]DJ"':$HJX MM->*V*"Q-C7)275XLXI#M[3:$'F12)+*U2WS)MYZ!K+7')*ACOX0M)`:.=)3 MC5UV,%2K`S\0+:I&D4%5JFNK5I"H9\$1<\)7J&B9'QT6AD"U\E''*ST$RM5`'\[),2M]FU(C`:ND)8HW-*UE MGF*92&RU:2R>-RHU#5P]F"&X`!AGUO]RH+?S$/]!QYI-H7(U.X!SG$_D$,4\ M2YBDTJ#XX*MIPBHV>*@EPI6:Q]AE[5"=>&$,@AL/Q431)`:W?U5H(Z,+(#T-6+"1I3QUBTC*NW M%PS,MDQ,Z79I`=+$R">.#S].P-5;"KK8=+V0<"JSA&-@K@.B&)A0!?RZ%7.O MC1='OZCP<2O27AN?IFMO!\L7MV+KM6$1QFY4*+DL0"J@)([JKF!R68I4@:E# M,%T%HLOBHP*(2E;2"BVW;L"VG'(,7-H(DJ+6C=FRK*X&),<;OH/H.Y?E=FV(N`$0%5YM M)/CAGX>Z`81U_$0!;ZYF/#",F]B6Y^9QT`4ZX;T45Y,BF`!.5-K5/`F&URHG M6+Q;QH23.B$T##W[:0>J<]1-$X\>2LP@UPHB-PTX>A`IW$.J`'/3AJ.]\GA) M)RJ@W/0.:BZ^KK'V%9QN6GSTX.0&,%58H* M*.S%0ZD'6.\B^=UZHU[#V<*XK5&"YZ:?57X@RG-I(\E8(YE6ERO#@IDJM;QELYGNI\'%U$>K@HY+/K4)L M7'1J5W=/R]-!W&*?58/'I;I0>!.7\EY&4JMB_DY[3=)$F M*[(,_\$=!$FE@?#QF#YC'X79!L*_.BVIYO25UQ-2Y&3SU/6;DP9QVUL7KM^H M;(L:1P]?H017^QNEK)'Z2-`+Z$OR`K= M*&2+3FIM+NX#R5+MV<>EYF2CW?! M$SS86S71$]G,J`]=PB6-6$GI7)!9DBA9`=SB0Z#]TL.AKTAX7G8(5%^'49IP M]7=>:0/3?"<"D97_:W;X^U3E*/;C.7@!\8%-2KV>E8S>7AAG"XY(:/&C%]$@ M+N';+H(*!@#.P;DBX$S1THN+C?4;"$(*&$$O_S,,;B+@)PC&H9]7F0.?")68 MB!Q$:B*R!Z9TWA]FE>NI$QM#QV9C1GX2ZHJY54RM&8(O(0UQ64!TZ04T'H@W MOEU;M9,FO?2%W!+EA77670)"(Z@%<]Z\D4V8#"99F&A[1X1MK)7&J\\>AXF@ MP1QH/74V3-S(*90=G-E1U!J09BN#Y;0X:COSVFC'/K=L(;14;)N35`E%+JT/W1T].>_3GLGP+WVFM!KT1X".R.51`'BE;9'.8&QL$=<@A@L MN$EC>:7M4(Y31)0(0(70%X#X3X>Q2EIZD"<[F`OPN-0V2UEY)[X&%J;8C+Q<9/5RZN8^UY!$D$'%-;R`.7>'QV;-4B$CBIS.J[X1*SR:YB M*8-^;CJXA>@:IL_)(HW*N\[<8!9!%2N!+-3X59A"^"MIOY052M/-)@JI"4)T ML.V7LD'I7T&X7)%3]8+(+=X2/*3K9X#HM=)*XE6(0]-M94"<'A`G.22UFQDR MKR)OA%X;-D,F9![29IC$GG_:]4@O'7!X8KGK,5TZ&(D/4M?#N720.C@$70_= MTM^'JN@3UQ/@ZV`CEK>[)F=DL(ZC9$NT!8UY.72"(.2K%1,3ZW4YH) M(JP_0P?P,A9&ZGK6"0TL#UQ"Q\L=,7AL^,J)ZV_F:8#$C"[H]F:>4Y-((9;$ M]:?T--#J-2Z^VV-\3LU*;E2AZR_Q&9V+';,SM7JGS\%I:"1HW?7W_'2.G&:0 MI>LO^ND(*UU#\EQ_ZT]+.A:D6NCV^I\3(>7'KA_OA3+K6="N/+RZC>`K4?*#$($:@$46M!^HA424!8VV M,,F:L)()C?1.7\@DOV@JZ1>R,=,W,Y,K#Z$M&4QA,F*ENE9R>?7-U>]?!L07 M$=]"2!]T0S0Z\1KDO[78XS1A]28SP/0%`OX%)$9!2_0V0+N+Y^341J%/]D:* M,I]Z<36;-YLIGERZ:T4LW0VF^&0N6[*)7VY_P_0UP\)#3DXR/PE?LJ=C.!QH M-#!L_F37C/4;&A"_=_$+F64=QI/5P+#Y:S>>HH8&Q._.`=QV/%D-6+KU[Q/R MIFCFH:3XY\(G1VF>.S@3#TK5-ON<"+Z?>:RV:LM`.KJ9M\T>1W^"1;,$;8)O MLIU%7IS=!R&?;F@1EAURCQL##1Z5);:%L!-3G"8MW4#W`0@*5UFV-R0I(M/H M,L5A#*@!AC,;56K:YHBF)Z>W2Z:+^AN@"@QQ*MK@9PXVQ<12XH);W,"BX;6M MO$0T&[#\+L=.6U=_C^.PBK5$!QE%7E12=$>C%=>Y,4G"CF)M`Q-*TE5VL!/- MX1:BFOI&=M)2K1!D43;6M%53<&OI?N]RM'1'=/W^IADD^7MQNTN=IV1N[X9@ MF^/#_7N@9F:ECHVCW>W/TXFA:*\_\W9,KE3<*4?)25R?,`.FW.39+I.)`PM= M$4D3.GB['"@CQGI&@7;)5,X'Y39FW&Y)6(9_9*EHG`K8,4VFKB8N,(R=1A4 MMUOJYXSB82#?\>ZPVXD,IE:$".(4@=*N6+N"%`1A3F(-8;V87Z;+K>R)#$L] MT0EA#F3WW!FN-&D5`YY`3A]/]*:D.DEY<6,/,-*L.;>>'T:9-O,(EG3J?P,T MH)U!D[R.`<+*<'KZL'@:DRG]*\2;D*Q'UL`)"ALDY3[TZ963X!($5(S<[TM` MEZQF#T0^I(C,G.45H%L2[5>!O,,Z!@DK&O^5;'XB6AK%#':_VW"\Z()JFP(2 M#HI:B:4<#*0RFU#?**G"PP"H-<8HB# M6>U\FRYV><-V:I$L],5,VU9B9/)9<`W77LA[[;Q9QD2\RX;FFHV2[6SED2/= MW\K.%$D%JP%2Y1E+MY"W",5U;(FSJJ)00[<2[#^N/EJABY7X?''UV8HN M*+&D.5B"4WG,NOIF11=LI&*XJX]9=`&M*7V[&@1I8EHQ%"=7'[)0M4QD,4@HI7#L@U*)U M`[8_0Z0(KKR9[F$PTX$*->54_HI@NI&9I75;&0RG-'GV8@'\A+-B=?B5MF5F M4E=X[C)7,[NKWH.8+LK'#]B3N%.+EH:R-JO$1.,';PV$7H>VK1D8SMLT2F`L M/6:9Q>QE?S*2ZILY%.;:MX=.)=UZ$;WY^[@"@-YEJ0),*OD.7VZU9I_`Y7.D MSMW$]<`J=W1P[UL&]YP*PJS`HF/W;F##O@\7X-$/`:$O>U0H7I)Q`XAT+/,L MJ]8T0"1IB:BU7E0>&-/%10#XIXNPN(F8#9`4DH-`EF84LF5>[4EQ:+R":UI= M=?7>F!AX?(2SQG4;?$])#^U&TO43RH+BO@NG82@=KL:+#@!NXS*Z MJU&KEL>JHS/$U1C9@8Q*'R]IMHK8'7X*BR-;+(^KP#H>PW@68WA_#A&68O-N M33CHYK0^7D#<,`.^#-Q--^1X!\_)74Q&.9>1[(QD%K00*-,BX]7QPL89I MS`UCX16W3WN91_J:[%B\]RI$->QS((_#X!4?3+30&%!X[A%D;H0=W7@HVNZR M@\]`3(/1IS'CE0M9Z9.*@1)T/P^\>^C%DMZ;I=P,U!A#C,80H]-$V)$0(WO1 M.X;>@R)*6YA=M,L-5.'ATT3"HK;?L'+C5:[ZVQ^*KUX!#'Y(Z'/PA*Q#"5%LD5"(07Y$:"7T`=7$"=79*1" M?GA7J\;LA$[MDTH'@;[@/`=)BN)IG)&?/2FES*V@B6'P6+Y;1,%7YJI1:0R` M.H)KEZ8\358`S0CB""0ARC?F?$C*S4+H\55JX<2]2;+I[;JML1<(1;N@^Z_: M]P*IVH'J^LTO`]!J[8['NY]E6\Q\7!'P5S`B_&+Z`&ZR'&341!0.C1J M15XAVQMUL0IB6AM%;-(HC!7?*V3E&:I=TFGV?+]`R(N7><[\RVU5II@(%Z\> M"D01FN;:MX*.C&8>R0?VV7U8NC=\4GA,L\,+?R4%$WP7S[)GSZ M'C5A7"ICK`O1 M-4R?DT4:E;4-O`.U>Q"/$%4]ZU;8AW%!"D,U4*MG0'U1>&ON@#AY'1LJ!#Z7A@([H`(_:_5)V_2'-/8>]+ZEY/M1;LL(QZTW; M?5X:9>Q0&2V(EL%PR)JS]DA=]#TW\X@I6@%-YE7MZ>=DAQI#W7<\)TF%9R`X;K.6':@RPW=/.D*,'=54 M78CRLI_I,PZ#D)QD'!E?L9*+P6MC6-B9A85UUAU:R,:;[)PEZ*)DV/J#+9AY MLLT8F-XB0<.\^@S'Q*,HX>7![2>A#R&RHR. M\M%1/CJ&3\1BC0>3HY.]*3Z&A/I%Z'MQOW9W";@2L?X^-:]XUV8G-S:#'(3?'/ M+-SGLY]\A3!X#2-Z=_6.=!,P`?=$&S^8*Q>^GZ[3[%V& M^HSA,-6BH8'Q>[G]YOTO1%>1AT4BK4X+`^-0]'*+M-K`>*F0EK[7I-O*:./H MB\L[XQ_10JG#=<&T`-*&%U'4'6P?\!,J@Z]FY M6ONWE?175S5=\:`X/&><=?.V!$_1*S[.-8D0./K'%?WC;MXZ'OWC!OSC M@PG"KZNVAYL#QQ0GJ71F?JU3$KI4A_U\XN3O8;Q\`FA-C[M=QK;ZAP;>T[TB M!T7HKSP077EX]>KMCHX'F/"]1BJU;`6A**\I3F$##IQFRP=&JAJ0O)+V(W@$ M?AI&0?OT2D,@N,7MTRZZ-\`J:8/B>^C%>.9M!:0VBMBAL;8W\FBL%3D!&BUE M;JR3(,Y#R2IIF^('&/O*1-<*VZ";GIB2==4H8H/&++._PL0]+&$Q$ZP!PL MLWY_A7@3)E[$[9=NL5R66C=EVZ&GIA@PSTR7K;`2,;*.3?-T=M7.HPE* MZ4'/%X">X5"GC]R&PI=DSBEZ1F:S*3U9[:5BUT-I5!$THS:Y'EBCBJ:2F=SU M>!J!T9*_NSD>\*&(C?``/6;4PI!\6ODF?WU!M^^+.,C^_2M$?X3Q\LK+=OSL MFZ'XHT?GTMDZERX]'.)'LD:\8!K_Q4,A7=]S(J]_5N)"4-T^;]<`^RC+V:;^+R08/<$+QO%DL@$_S!LX`HAD$ MO:6:VU#6QN"YI!_/:0[6;V$C&_ZH M%!-)2HU@6M`&O3=O"1'GTA"O*!G3!25+N!,+*EAQ*Q.I:;JX(K)XR'4FUXL8 M$/#J[16O"VPO(4+PE0!#3M3:%C9=W$1A%AUW&4818.1-9XB%9MNW/2@''!#5 M@7R4;&M"B<+`*34S%%YOWC8ARO0@T4&A4G,H'-W1U/^M.-JO.12.OGEO5*@X MF$\:K'&;,+')$,UZAJ`/0("?X"7X#8/@"=Z&,14F[M8;!%^R2'J67JE>UU8@ M4%):&$AG`EV3670(-`LE*$YA&W1_@RA9DG-"G!YCOY2=9,T@)HHIO(4(^!YF MYU*1%+9)]V\QII=[%B$(Q,EHN.6M9H$IR5+)_M(H.T98C1%6@_!I"Q5U5YV. MNGY_%G3$>TH2!OEL`Y7FB M.,97*IB-NV7L.GF(-*TWG6(N3Q^M=C[O"K2SE.=[\$)4B)ZUU-]T)U6@C)*^ MS,518776`KZ^ZZL"SBWQ?PRY'US(_6>W)/TQ[MD8-FRGG+-Y[331X;A)2GB^ MG"D\@PF:MX..R)$M6EOG9UA`[T:KT!RRQ2E MY)QF`<1`\WPR1C:2T?TZFY7W=L;;.>/MG/%VSG@[9[R=,][.&6_GC+=SQMLY M1[^=@X'_80E?/@8@S$DE?^Q32#[Z_29.J'&8-?X'7_=/S3U8>E'>)T/@8)4P M'/9.G:9$Y[GP_YZ&.&3<$U&H8"6H-GW&81"2@UP2=\TH>"[Y&,SB*,BS]K6WB8(\:X>[L2A(M[SOQXJ"=,L^WS+$CR6ICN&U M7>+Z'(NN'6-AAIT\T:U`Y3$NIC,V3`/(N8?#G&F\!\\TUW!!,VP^KD;V"XR# MY=)IPG6>3O@J)6WVSH$!1_SX0-P8)>!NE(`K7N8L;"GHX&(^:&``_)V\9_6; MEZ3TZ*#T*#'0J&"?_F-YAKG;8:WME!X/].E7G'A11#^:>5OZB[,_*E6U#S%9 M<2$,0I_-C%H=^UR<@AM^3`$VOE]8I[%8/7?QG\,XF-W]F2NZ*E08DY>-RC+WS,$3'FB!AC!GI'9\P182I'A,A&Z'H@E^%T M$6Y.I3%=A$ZD"MFR4T3M&H\@2:(,M\&DBMC15B6H))/YFQ=MJ(DT]&5Q(>KU M;9BMZ]3!%T`CQA3X*$M:>46F0FY'DOSU+EDMFWN%]@RK[Q_,`735W&P$,>D$ M.I[EV?Z^2[X%3]Z;D8A`,^O[*D5T^&\!&00O(K3=O&U`C,$EB,&"^ZRBK):- MG:J@*1,%+N+@GO2DRX^DKIT`CWPU$&HN,`8)?@#\Z!1&43NG7#'/E:,Y136L MWBE;5`^W0":FCE>WD.,KSR$MF1[>?50P!,T!!7LGCG2.=0\ESD#YO[9 MK(63=+MWU0_<#2_9H>*J9[@E:J)-R%7W<$NHV.?[\=S%MF7B*[A>ATGV'@I9 M7U5A9&;F MT(XL*6R0E-V:P+\1F0#M5L;%$@'N,_4:E0V0FL1EY)3R%8LF\:)7Q=T^4*4JRIZ!["8^XRKJGD+G'CKQE4]O,-44A0. M7%7+6TXNT3GKRA6'A)?=_$M3%$KKAI5A\73(_!A'+3BJ59U6#P]K4+4CJ6JYF`XNDT3 MLC\56?B+JSV8$#L'5`X(J"WAEFQC7J3+L%[#-O"X>:-;=1KB%:5MNJ!7GP29 M:[C%AT*[-!F6I)(!L:!,:S*-IVF"$R\.2(>T&VY,A*R&K0QC9?)8808I1D$# M(%8!6\##G)>K^.6&I^0++>(F-J717*X&Z\&)/!K/-8"K'?NCY5P#M[I8.YK/ ME8';UW/.TWJN#UU7&QY,O.@4D>+FP^"+N:/3870ZC$X'@^C)-$K9LCRGA"-J M&NQ^:I9]MW9MOU582AS3R4;)^0%V.:&@#& M`[KLX_LTB7"9NK-&+SE4BNN`Y*QY@+&?_\,QU.BW8R>]1^PMLT`CH=7IH)C! M^/%[[_4V1.LJ0#'S"HLCVOEU;(!8G]-":RBCH&UZ:VLPSYZ-IXO:9PJ,R%H8 M$(=8XEB55AL2+Y?;^C<"+X)&`P:6=17`,$U6`/$Z/]"R:ZM41*KA M*WJ;I5U;-N4?_I;7S/VS?[JX:C?7W7B:.>E:S237M37]?:\.*FN"NHI8EVV7 MAYE4+G!5#38%9@L]PE6EN2NDBMJ"JY>_C$@<"NN9@PU$"1WE@D+N%7]^!2L*2=YY3DT8+R6Z M+K>XU<4HX:%Q1UHP7L<33@:]MHI?MBVJ65XKGIDT_])2<"J&41ADP&3;LL"( MPBD\#+J%1D=N<3NT([):R>'X0*^?+Z6&9WYY.\E8R;(FBRV+EP&;"&1;8QP0 M#8EL5_\0W7)0JFK`_/9KMF7X9*>MKJR+@%:K8S63:9Y1C^8PX&#+*FF5XO(@ M$DYM7FF+C_#B)WCA_ST-T2X[RRSR,C7UAGRZ$:21TFC`BFSD18"HC"\@3@$_ M@?)^*;MFY7U9B'7`JQF5U5NR*+>*'Q]NE'%"NK9(>VW\>6X8K:HFO$;T-19R M"NW>IY.=69(*5M^DODPQP0:79ZA(K!37L1N6)Y*.]V)B.?*HJP9W54FA8EKI7+VL MVA4L-?NQJS=6NZ)7^I%>T;#$,@?5<7*+_U$2+R,H/^'Q3L\9.W,"/G96T)B#1U#G312$*$C3'-=\B_.P0 M13;=C(*GL^Y87)[ORB$;R09B+_J*8+K!1(.*TNQF,-E?LE0&*0@JH`9RMK*) M(]MFDQG)XM-MQ4JT3]?1X;+>K5F;J[WEZ#>4X,ZPCAM&6^R>\J>$QFU#Y^VP M&)-.BFY%P3%U7-ENCUW'RG:]?K_X&BMW(,T*`\M;,*6S[ M;4_9[LLN:]5;+D2=]UC.*`KQ5H[%$*RCKQ^F!%"B4KV?QXT_+>!F()8]`C MF8FB&C96D!!191:&<=HHC$9=%A.S?KZ+3.FQ4:O+KM5SJ`=9$-B^BC\Q_H_=!R>PJ+7-*X4;= MVCSQ;:`3G.>[*_">9!G(J7\.#U:J'^PZ+0SQB3K1"M9"YWS7ZWX2I(&L4Y?2 M@&O<*E*H.:2,64+OJ0H*X[H3P&-/9-9,[4>:/ ME)5G#P/RS_\'4$L#!!0````(`"A/KT8*J12R8!```,RQ```0`!P``L``00E#@``!#D!``#M7=USVSB2 M?]^J_1]P>MC-5*VL*$YR%U<\6[(=S[C*$ZMD97?J7J8@$I)0H0`-`-K6_O4' M@%\0"4$@)3MT'5]LBNAN=*-_^&HVB<__?%I%X`$QCBDY[PU/WO8`(@$-,5F< M][[=]T?WES_?/ZO?A],)N"*$H*B"&W`[P&*$(,"@2E\HH2N-N`^ M6*(5_`>808Y"0`GX_6)R"]Z=#`%8"K$^&PP>'Q]/&`LS(23=NY/W1LF$QB0\`^:M2X:@D-0@E$J<@7=OAQ_Z;S_TA^^GPT]G[S^> MO1O^KTE-UQN&%TL!W@0_26))*3E.P>1DGE"V&,@JAH/??[M-&J7WU[^`A/;L:<8B MO,6A[F0\IP-,N(`D0`9+A,EW!XJ8]Q<0KG/Z M.>0S39T6R&J&[_MOA_W3X3:7V*P1M[+I$CL?YYLMS7A,E#Y+!".QU)!0OGQ[ MNL5$I(OBE;T10L$&JKZ!).I+*L1P8++NYZOP*)I0Y&QF>W\8)(4&=2#1*=AF MFYRCX&1!'P9IH3+JM-(60SN&"-O99(&=`ST%2SN+*K'S8/*` MN+!S)65VRPC$`;>SZ2+%-:QB`P=V'EFP@T.LV0X665+F$9`MD/@*5XBO88#J MX%`.=RM$Q#5EJRLTAW$D&^7/&$9XCE'8`U`(AF>Q0%L$,2E(?E92/D-"J-`# ME_ZM[JS7F,QI^E/>4%J<,1JAJ00G4!??)C=[5!7I(#Q0Y(,K&L1*64C"+T1@ ML;F1%;"5KK8'<'C>^4.:5P,:Z9')^):,!9:+:;+[V;^>28KKJ7.FM@ MW#*X?7@J'9<+`FIZ)"$B:MJ65YQ& M6$VJ(;B`D9J*P/T2(<$[5Q[#E6,HQW2Q1`++%JKM5\V]Q[GOFS@7O-E2[*?. MV=[.OI%KYA4:10(Q(@UY0':O5LG<;OS@Y\:`+9$2N[:6O;RGG/X$WWPB,0RRE=.[V=_5 MS.WNCTWG0N7_@"X2,KT7R*H`11U=SV\,@B^17-(S2G#PJV96K9?7BJ\)#]P"`HM0*(&2/4`N2(< M7*$Y8DQ.*[]`3$Q1/MP=#)O"\!=*PT<<17((N5'1W`66_A]QCIIO1VJ*=$/L MM`RQ3+J&6"$?)!5T0&@*A%M*%E.D'CW,1#U_VSG=;GU?=JL2TE=2@!+3N;&I M&V^(;%`5EKU'0B1/G'@]=[HEN-WZH>S67!@HI'7.;>Y<%0&>PJ>F0[-3@-NU M'ZNN5;)4]D8W_S9WZ25=K;#0EW*^O-2;ZP621*CQ_%M3I-OME6"?(3U]0F#( M[W#0?$\8J?#\&#*QF:7UV)F98#9!J1U=4[_42'BJ0[!O$B@.*W*"9UWE;#A MCG`Q>).(ZYXS/F$L08^ZLAS@^"@<&*'C!<.Z-2`2"/!;JQ4XH?NX$Z'CN>) M\M0`@8O?[>M*(&\[XM/Y]H6WDC6A:%6#$;5M/[:;&X'5Z*&EAPC>;<0O>7W-U=( M0-SE$OL[V[ZA4^^0A7&$[N;V\K+O&TIQ0Z$22=RU.^R#K":54[AS#]EAXRC8 M\!H,ZK"Z45"))NY&03#Y6"?Z4?'E:JXQQ/^\[^-T0\,TJ M3%:%:1TZO3BI!:35=$BHC00SCR_)XO/J_KYL3K^?>F45=OW^>-Y.(V]&X,T: MW^/W\6H%V>9NGC+P"R2;'8T9?<"JPUU3=D7CF9C'4<9=1LAS5N5&U6'Q1@G" M1",UOF0Z@40ID&L%Y$^0Z54(ZA#Y3(A,?6+T?HF+*EE#$/I*=^.N$KNL@3L# M=N8(IU!FH^YP]KPXNYN/HH@^JC2EXPUU?K+=&*O$3)MA3`YMN1+=4/;"DZO7 M`NLP86X054*M-2?(;CEV),1D&>W2M5EJ_+[\?)YEQ:ND^(Q_+Y,7Y'ZP-F[, M5N+"/^K%@@[_Q\._XP%R5E0&J0^+&TF5`/2>1\P&0>?A(WKX*Q)R*;12CXN2 M%]7+!#53,@:]2K*J-.6GM`!YGB`\9K$:O.[@5$)3N\%1CM*%+J4C[*U?2KGJG3N/<"]4P8#-+D:W5*HMCGZ MY[\I^X[)XA*NL8"1+O'I_\<2ZX3*^TK@NI*ZI.H"LFZ@JM"#17(KK1^D"NCB MG[IAXYF&C5_'X\S_=<&SE]>-D$H0NHP0)3\'2(>`9T+`)60K'"PABG3J4FT4 M>/&[D5`)"Y>14-0!="4=&(X(!LN[JUX@\.9S.[\2KRU>?^6YX,[?Q_1W^CZK M9V??2^_V;R64:KX#V_GU>'YU9!Q[^;DVO]OOE7"D.UNY`$+`*%(1U2WY7); MQ#"ZFT5XD>$C_-06#A=V-A-HOZJM))+WJ8/"LL>KL&^UH6#MJ+5F';L=_V!>.](E< M@S>YCF#X_\'UZH\ZXVB"YD`?7W2F3NXY[W&\6JM,PN0>9('B=Q]\-%@SND9, MR#75(!.;":AP;Y^TI(%4:K]4JTS"DJ&Y5(MO^MGI,7](AI.G5911""Q4)9>% M&*#DR.4?C*+>H+V&;WMQO]V2WF+W52[EE9@=P1F*_"R6I!:+;Y6`5V)LN8_O MMUER6&PV/R5O,_WSP#SV2/[:/A;IL[2<,@&(]:2F'0>F@>1,MEL::$$.%O6K MG_'UU:W^\%W_='CRQ,-4Q3H:%`U=3X.,KZX&SH/6=NF@Z[>>[#9`D>"YK'XA MJWYS6(]B\VH5D_-KPJB:Y9-JEN''0S1IID4S%:P'Q?FB(F-0E7ZH#83R07T' MX$#=J0N#?6?>.=6Q\64_^H60!HI83M#ST\1DS'\=U"BE8_F\U,AXU,5!E9.1/2K/6/25SOJ3T]'U`J<]USO3$PMGT&7"XH_ZO`DRZ/D3-`SD=V_$6BE MM@X]`&=W,8Z060.G3U3"Z,,`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`[,EYN.`XP)+_$D$&Y'$%J M8R>-8'&R]C2:H0[3:Q@3\B?P4OG$L^I%XWO$'G"`LF]L%_9[DK^*.>TZC@0E MN]9]]M(VK?L2#2P31W@%L_1?8"1=`/76X`%)@BIA=".#N[-T"XKBI'E,SEF6QQ5;-IBLKG6"5\ML"?Y`L?I MP6HB&C,:(!3R*;U`WS@*LR]UHYO5FM&'I+\:;>'/[FHQ!5MDEN MJC;9\Q6)[,BH2IC'5M:B,$[V*$4]#8N)7!!DK6W,E2Z:5CUNR13-]"OV=%5C M;#2M-.86/EYCMLK.L)Q2'?>VVN0@;:=IR;`:7L@URDA4X&4Q5AJKSUZR&)3=;Y72*8#(XE:B!U56^3N*V[2^T5N/(E2: M/'BMV.$B:ITUB6)6&[:+VJ1YFN3"IU1OY?5)`2K5;#.66V_]2%S>72L2VQ/4 MPLQ#Y;R*L*Z_D:YCH.HUURY)KZ/!MHZMV958[*9J6[1EK`4;,UUUCC--\R`V M79FI^@/M8W2..->KDUL,9SJF.\'\._]*R:5^S$TT(OZ8+#FH=UGQ"JC*\PY M93IM6$7_MJRLE+7+:WFF#]]^W7G?0%27[U4,.UZ';9MMX$7>MH&H^'1.^=.\ M7Y[2Q+[L\[J[1MX#1+R>UB@E:>\E?.%0FE^2=J&U7E#N^O:-)7N[/F>+8HF% M\O=0_Y4B<(CEH%,-B_K0MLFT-5*I22)_6V7'X^9]=&W:3=P+-09D61MJ+3M] MI-,EC3DD*LE#CK,5\_Q96F5I\C&38G-J+H2RQ?Q$UAA=21,BJM?RHU@L*;-L M=(\CK5WMLUXG-Z!^*^LZHH]&7K6Z-898/4(V/QFIOS*O4T@LYKS3T;;4N>82V@07H\]?RV$@.:IR:U2HV.W-\0/M_#Q(WM^5E_\' M4$L!`AX#%`````@`*$^O1@1FIO3;IP``50$`!``&````````0```*2!```` M`'-S>2TR,#$U,#,S,2YX;6Q55`4``SO[555U>`L``00E#@``!#D!``!02P$" M'@,4````"``H3Z]&["<"-`L``00E#@``!#D!``!02P$" M'@,4````"``H3Z]&9""U:`0<``"(WP$`%``8```````!````I(%`N@```L``00E#@``!#D!``!02P$" M'@,4````"``H3Z]&+O"&:P!7```FDP0`%``8```````!````I(&2U@```L``00E#@``!#D!``!02P$" M'@,4````"``H3Z]&H-H'";HM``"Y<@,`%``8```````!````I('@+0$``L``00E#@``!#D!``!02P$" M'@,4````"``H3Z]&"JD4LF`0``#,L0``$``8```````!````I('H6P$` XML 33 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) (SHPP RDA Loan [Member], USD $)
In Thousands, unless otherwise specified
9 Months Ended

Mar. 31, 2015

Oct. 31, 2012

Debt Disclosure [Line Items]

Debt instrument maturity period 25 years

Floating rate of interest, spread 2.00%

Floating rate of interest, lesser 5.00%

Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated 5.25%

Loan proceeds used for acquisition 1,800ssy_LoanProceedsUsedForAcquisition

Debt instrument description The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%

Subsidiaries [Member]

Debt Disclosure [Line Items]

Loan agreement amount $ 2,100

Date of loan agreement Oct. 31, 2012

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Loan proceeds used for acquisition.

+ References

No definition available.

+ Details

Name: ssy_LoanProceedsUsedForAcquisition

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

When presenting a range of interest rates, the lowest effective rate for funds borrowed under the debt agreement as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentageRateRangeMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 34 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Jun. 30, 2014

Current Assets:

Cash and cash equivalents $ 4,885 $ 3,587

Receivables - net 10,018us-gaap_ReceivablesNetCurrent 9,850us-gaap_ReceivablesNetCurrent

Inventory 3,936us-gaap_InventoryNet 3,757us-gaap_InventoryNet

Deferred income tax asset 1,861us-gaap_DeferredTaxAssetsNetCurrent 2,978us-gaap_DeferredTaxAssetsNetCurrent

Due from third party payors 1,525us-gaap_AccountsReceivableNetCurrent 2,786us-gaap_AccountsReceivableNetCurrent

Current assets held for sale 0 270

Prepaid expense and other assets 2,705 2,547

Total current assets 24,930us-gaap_AssetsCurrent 25,775us-gaap_AssetsCurrent

Property, plant and equipment, at cost 54,567us-gaap_PropertyPlantAndEquipmentGross 53,466us-gaap_PropertyPlantAndEquipmentGross

Less accumulated depreciation 32,030 30,389

Property, plant and equipment - net 22,537us-gaap_PropertyPlantAndEquipmentNet 23,077us-gaap_PropertyPlantAndEquipmentNet

Noncurrent Assets:

Intangible assets - net 2,873 2,979

Goodwill 461us-gaap_Goodwill 461us-gaap_Goodwill

Deferred income tax asset 5,100us-gaap_DeferredTaxAssetsNetNoncurrent 4,432us-gaap_DeferredTaxAssetsNetNoncurrent

Noncurrent assets held for sale 0 6,111

Other noncurrent assets 1,522us-gaap_OtherAssetsNoncurrent 1,012us-gaap_OtherAssetsNoncurrent

Total noncurrent assets 9,956 14,995

TOTAL ASSETS 57,423us-gaap_Assets 63,847us-gaap_Assets

Current liabilities:

Accounts payable 4,429us-gaap_AccountsPayableCurrent 4,530us-gaap_AccountsPayableCurrent

Current maturities of long-term debt 840us-gaap_LongTermDebtCurrent 561us-gaap_LongTermDebtCurrent

Accrued payroll and related taxes 3,415 4,186

Income tax payable 32us-gaap_AccruedIncomeTaxesCurrent 73us-gaap_AccruedIncomeTaxesCurrent

Current liabilities held for sale 0 4,842

Other accrued expenses 1,981us-gaap_OtherLiabilitiesCurrent 2,314us-gaap_OtherLiabilitiesCurrent

Total current liabilities 10,697us-gaap_LiabilitiesCurrent 16,506us-gaap_LiabilitiesCurrent

Long-Term Liabilities

Long-term debt 11,474us-gaap_LongTermDebtNoncurrent 11,948us-gaap_LongTermDebtNoncurrent

Noncurrent liability for professional liability risks 992 1,268

Other noncurrent liabilities 755us-gaap_OtherLiabilitiesNoncurrent 807us-gaap_OtherLiabilitiesNoncurrent

Total long-term liabilities 13,221us-gaap_LiabilitiesNoncurrent 14,023us-gaap_LiabilitiesNoncurrent

Commitment and Contingencies

Shareholders' Equity

Preferred Shares, authorized and unissued, 2,000 shares 0us-gaap_PreferredStockValue 0us-gaap_PreferredStockValue

Common Shares, without par value: Issued and outstanding, 9,444 shares at March 31, 2015 and at June 30, 2014 4,722us-gaap_CommonStockValue 4,722us-gaap_CommonStockValue

Additional paid-in capital 13,478 13,444

Retained earnings 15,639 15,486

Accumulated other comprehensive loss (334) (334)

Total Shareholders' Equity 33,505 33,318

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 57,423 $ 63,847

X

- Definition

Professional liability risks, noncurrent.

+ References

No definition available.

+ Details

Name: ssy_ProfessionalLiabilityRisksNonCurrent

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph b(1)

-Article 7

+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2510-110228

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name: us-gaap_OtherAssetsMiscellaneousNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 35 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Long-Term Debt [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year $ 840

Payments due in 2 years 798

Payments due in 3 years 1,971

Payments due in 4 years 610

Payments due in 5+ years 8,095

Contractual obligations, commitments and contingencies 12,314

Operating Leases [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year 795

Payments due in 2 years 351

Payments due in 3 years 221

Payments due in 4 years 95

Payments due in 5+ years 75

Contractual obligations, commitments and contingencies 1,537

Interest on Outstanding Debt [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year 709

Payments due in 2 years 697

Payments due in 3 years 642

Payments due in 4 years 498

Payments due in 5+ years 2,649

Contractual obligations, commitments and contingencies $ 5,195

X

- Details

Name: ssy_CommitmentAndContingenciesLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing after the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueAfterFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fourth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the third fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=ssy_InterestOnOutstandingDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=ssy_OperatingLeasesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Basis of Presentation
9 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

Note 1. – Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2015 and for the three and nine month periods ended March 31, 2015 and 2014 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets - Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Jun. 30, 2014

Goodwill [Line Items]

Goodwill $ 461us-gaap_Goodwill $ 461us-gaap_Goodwill

Specialty Pharmacy Segment [Member]

Goodwill [Line Items]

Goodwill $ 461 $ 461

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (Tables)
9 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:

 March 31,
2015 June 30,
2014

Trace RDA Loan
 $ 8,290 $ 8,624

SHPP RDA Loan
 2,002 2,033

Carmichael Notes
 1,852 1,852

Other
 170 —





Total
12,314 12,509

Less current maturities
(840 ) (561 )





$ 11,474 $ 11,948





X

- Definition

Long term obligations.

+ References

No definition available.

+ Details

Name: ssy_LongTermObligationsTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Jun. 30, 2014

Debt Instrument [Line Items]

Total $ 2,873 $ 2,979

Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite and Indefinite-Lived Intangible Assets, Gross 3,858 3,858

Accumulated Amortization (985) (879)

Total 2,873 2,979

Trade Name [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Indefinite-Lived Intangible Assets 2,000 2,000

Customer Relationships [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite-Lived Intangible Assets, Gross 1,089 1,089

Medicare License [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite-Lived Intangible Assets, Gross $ 769 $ 769

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated amortization of intangible assets, excluding goodwill.

+ References

No definition available.

+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ssy_MedicareLicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Financial Information by Segment (Tables)
9 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Segment Information

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of March 31, 2015 and 2014 and for the three and nine months then ended is as follows:

 Healthcare
Facilities Specialty
Pharmacy Corporate
and Other Total

Three months ended March 31, 2015


Net revenues from external customers
 $ 13,850 $ 9,307 $ 194 $ 23,351

Operating profit (loss)
 285 146 (716 ) (285 )

Depreciation and amortization
 258 201 143 602

Assets
 29,597 12,510 15,316 57,423

Expenditures for property, plant and equipment
 63 194 1 258

Nine months ended March 31, 2015


Net revenues from external customers
 $ 43,169 $ 25,191 $ 493 $ 68,853

Operating profit (loss)
 3,659 365 (1,982 ) 2,042

Depreciation and amortization
 978 546 293 1,817

Assets
 29,597 12,510 15,316 57,423

Expenditures for property, plant and equipment
 195 768 32 995

Three months ended March 31, 2014


Net revenues from external customers
 $ 14,117 $ 10,217 $ 132 $ 24,466

Operating profit (loss)
 226 524 (1,215 ) (465 )

Depreciation and amortization
 378 185 210 773

Assets
 37,385 12,023 17,217 66,625

Expenditures for property, plant and equipment
 162 150 24 336

Nine months ended March 31, 2014


Net revenues from external customers
 $ 43,671 $ 26,385 $ 319 $ 70,375

Operating profit (loss)
 2,342 659 (3,511 ) (510 )

Depreciation and amortization
 1,147 522 641 2,310

Assets
 37,385 12,023 17,217 66,625

Expenditures for property, plant and equipment
 456 433 215 1,104

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Business Operations
9 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Business Operations

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

• The Healthcare Facilities Segment is composed of three operational areas:

• Three community hospital subsidiaries in two states with a total of 183 licensed beds;

• Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to a corresponding SunLink community hospital; and

• A healthcare facility which is currently vacant except for two medical offices which are rented.

• The Specialty Pharmacy Segment is composed of four operational areas:

• Retail pharmacy products and services, all of which are conducted in rural markets;

• Institutional pharmacy services;

• Specialty pharmacy services; and

• Durable medical equipment.

SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Mar. 31, 2015

Jun. 30, 2014

Statement of Financial Position [Abstract]

Preferred shares, authorized 2,000,000us-gaap_PreferredStockSharesAuthorized 2,000,000us-gaap_PreferredStockSharesAuthorized

Preferred shares, unissued 2,000,000 2,000,000

Common shares, without par value

Common shares, issued 9,444,000us-gaap_CommonStockSharesIssued 9,444,000us-gaap_CommonStockSharesIssued

Common shares, outstanding 9,444,000us-gaap_CommonStockSharesOutstanding 9,444,000us-gaap_CommonStockSharesOutstanding

X

- Definition

Face amount per share of no-par value common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockShareSubscriptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions
9 Months Ended

Mar. 31, 2015

Related Party Transactions [Abstract]

Related Party Transactions

Note 12. – Related Party Transactions

A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $42 and $258 for legal services to these law firms in the three months ended March 31, 2015 and 2014, respectively. The Company has expensed an aggregate of $232 and $577 for legal services to these law firms in the nine months ended March 31, 2015 and 2014, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2015 and June 30, 2014 is $43 and $116, respectively, of amounts payable to these law firms.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document and Entity Information
9 Months Ended

Mar. 31, 2015

May 13, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Trading Symbol SSY

Entity Registrant Name SUNLINK HEALTH SYSTEMS INC

Entity Central Index Key 0000096793

Current Fiscal Year End Date --06-30

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 9,443,408dei_EntityCommonStockSharesOutstanding

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ssy_DocumentAndEntityInformationAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Financial Information by Segment
9 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Financial Information by Segment

Note 13. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of March 31, 2015 and 2014 and for the three and nine months then ended is as follows:

 Healthcare
Facilities Specialty
Pharmacy Corporate
and Other Total

Three months ended March 31, 2015


Net revenues from external customers
 $ 13,850 $ 9,307 $ 194 $ 23,351

Operating profit (loss)
 285 146 (716 ) (285 )

Depreciation and amortization
 258 201 143 602

Assets
 29,597 12,510 15,316 57,423

Expenditures for property, plant and equipment
 63 194 1 258

Nine months ended March 31, 2015


Net revenues from external customers
 $ 43,169 $ 25,191 $ 493 $ 68,853

Operating profit (loss)
 3,659 365 (1,982 ) 2,042

Depreciation and amortization
 978 546 293 1,817

Assets
 29,597 12,510 15,316 57,423

Expenditures for property, plant and equipment
 195 768 32 995

Three months ended March 31, 2014


Net revenues from external customers
 $ 14,117 $ 10,217 $ 132 $ 24,466

Operating profit (loss)
 226 524 (1,215 ) (465 )

Depreciation and amortization
 378 185 210 773

Assets
 37,385 12,023 17,217 66,625

Expenditures for property, plant and equipment
 162 150 24 336

Nine months ended March 31, 2014


Net revenues from external customers
 $ 43,671 $ 26,385 $ 319 $ 70,375

Operating profit (loss)
 2,342 659 (3,511 ) (510 )

Depreciation and amortization
 1,147 522 641 2,310

Assets
 37,385 12,023 17,217 66,625

Expenditures for property, plant and equipment
 456 433 215 1,104

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Income Statement [Abstract]

Operating revenues (net of contractual allowances) $ 25,196 $ 26,303 $ 74,913 $ 76,500

Less provision for bad debts of Healthcare Facilities Segment 1,845 1,837 6,060 6,125

Net revenues 23,351us-gaap_SalesRevenueNet 24,466us-gaap_SalesRevenueNet 68,853us-gaap_SalesRevenueNet 70,375us-gaap_SalesRevenueNet

Costs and Expenses

Cost of goods sold 6,181us-gaap_CostOfGoodsSold 7,078us-gaap_CostOfGoodsSold 16,253us-gaap_CostOfGoodsSold 17,838us-gaap_CostOfGoodsSold

Salaries, wages and benefits 10,729us-gaap_LaborAndRelatedExpense 10,591us-gaap_LaborAndRelatedExpense 32,135us-gaap_LaborAndRelatedExpense 32,105us-gaap_LaborAndRelatedExpense

Provision for bad debts of Specialty Pharmacy Segment 65us-gaap_ProvisionForDoubtfulAccounts 75us-gaap_ProvisionForDoubtfulAccounts 188us-gaap_ProvisionForDoubtfulAccounts 170us-gaap_ProvisionForDoubtfulAccounts

Supplies 1,877us-gaap_SuppliesExpense 1,808us-gaap_SuppliesExpense 6,017us-gaap_SuppliesExpense 5,790us-gaap_SuppliesExpense

Purchased services 1,208us-gaap_CostOfServices 1,289us-gaap_CostOfServices 3,410us-gaap_CostOfServices 3,884us-gaap_CostOfServices

Other operating expenses 2,695us-gaap_OtherCostAndExpenseOperating 2,994us-gaap_OtherCostAndExpenseOperating 7,035us-gaap_OtherCostAndExpenseOperating 8,967us-gaap_OtherCostAndExpenseOperating

Rent and lease expense 343us-gaap_OperatingLeasesRentExpenseNet 366us-gaap_OperatingLeasesRentExpenseNet 1,020us-gaap_OperatingLeasesRentExpenseNet 1,079us-gaap_OperatingLeasesRentExpenseNet

Insurance settlement 0us-gaap_InsuranceRecoveries 0us-gaap_InsuranceRecoveries (1,000)us-gaap_InsuranceRecoveries 0us-gaap_InsuranceRecoveries

EHR incentive payments (64) (43) (64) (1,258)

Depreciation and amortization 602 773 1,817 2,310

Operating Profit (Loss) (285)us-gaap_OperatingIncomeLoss (465)us-gaap_OperatingIncomeLoss 2,042us-gaap_OperatingIncomeLoss (510)us-gaap_OperatingIncomeLoss

Other Income, (Expense):

Gain on sale of assets 13us-gaap_GainsLossesOnSalesOfAssets 18us-gaap_GainsLossesOnSalesOfAssets 13us-gaap_GainsLossesOnSalesOfAssets 18us-gaap_GainsLossesOnSalesOfAssets

Interest expense - net (213)us-gaap_InterestExpense (234)us-gaap_InterestExpense (677)us-gaap_InterestExpense (714)us-gaap_InterestExpense

Earnings (Loss) from Continuing Operations before income taxes (485) (681) 1,378 (1,206)

Income Tax Expense (Benefit) (169)us-gaap_IncomeTaxExpenseBenefit (105)us-gaap_IncomeTaxExpenseBenefit 816us-gaap_IncomeTaxExpenseBenefit (200)us-gaap_IncomeTaxExpenseBenefit

Earnings (Loss) from Continuing Operations (316) (576) 562 (1,006)

Loss from Discontinued Operations, net of tax (95) (388) (409) (889)

Net Earnings (Loss) (411)us-gaap_NetIncomeLoss (964)us-gaap_NetIncomeLoss 153us-gaap_NetIncomeLoss (1,895)us-gaap_NetIncomeLoss

Other comprehensive income 0 0 0 0

Comprehensive Earnings (Loss) $ (411)us-gaap_ComprehensiveIncomeNetOfTax $ (964)us-gaap_ComprehensiveIncomeNetOfTax $ 153us-gaap_ComprehensiveIncomeNetOfTax $ (1,895)us-gaap_ComprehensiveIncomeNetOfTax

Continuing Operations:

Basic $ (0.03) $ (0.06) $ 0.06 $ (0.11)

Diluted $ (0.03) $ (0.06) $ 0.06 $ (0.11)

Discontinued Operations:

Basic $ (0.01) $ (0.04) $ (0.04) $ (0.09)

Diluted $ (0.01) $ (0.04) $ (0.04) $ (0.09)

Net Earnings (Loss):

Basic $ (0.04)us-gaap_EarningsPerShareBasic $ (0.10)us-gaap_EarningsPerShareBasic $ 0.02us-gaap_EarningsPerShareBasic $ (0.20)us-gaap_EarningsPerShareBasic

Diluted $ (0.04)us-gaap_EarningsPerShareDiluted $ (0.10)us-gaap_EarningsPerShareDiluted $ 0.02us-gaap_EarningsPerShareDiluted $ (0.20)us-gaap_EarningsPerShareDiluted

Weighted-Average Common Shares Outstanding:

Basic 9,443 9,443 9,443 9,443

Diluted 9,443 9,443 9,481 9,443

X

- Details

Name: ssy_EarningsLossPerShareContinuingOperationsAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ssy_EarningsLossPerShareDiscontinuedOperationsAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue from Financial and Health Care Services

+ References

No definition available.

+ Details

Name: ssy_FinancialAndHealthcareServicesRevenue

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

+ References

No definition available.

+ Details

Name: ssy_HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.

+ References

No definition available.

+ Details

Name: us-gaap_GainsLossesOnSalesOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the provision for bad debts related to patient service revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755891&loc=SL9156442-115640

+ Details

Name: us-gaap_HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section E

-Paragraph Question 3

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InsuranceRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LaborAndRelatedExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_OtherCostAndExpenseOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of expense associated with supplies that were used during the current accounting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_SuppliesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets
9 Months Ended

Mar. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Note 7. – Goodwill and Intangible Assets

SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition. SunLink’s Healthcare Facilities Segment has intangible assets related to its Healthmont acquisition.

Goodwill consists of the following:

 March 31,
2015 June 30,
2014

Specialty Pharmacy Segment
 $ 461 $ 461





Intangibles consist of the following, net of amortization:

 March 31,
2015 June 30,
2014

Specialty Pharmacy Segment


Trade Name
 2,000 2,000

Customer Relationships
 1,089 1,089

Medicare License
 769 769





3,858 3,858

Accumulated Amortization
(985 ) (879 )





Total
$ 2,873 $ 2,979





The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset.

Amortization expense was $35 and $36 for the three months ended March 31, 2015 and 2014, respectively, and $106 and $108 for the nine months ended March 31, 2015 and 2014, respectively.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives
9 Months Ended

Mar. 31, 2015

Text Block [Abstract]

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives

Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives

Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services.

For the three and nine months ended March 31, 2015, the Company reported $64 Medicaid incentive payments. For the three and nine months ended March 31, 2014, the Company reported net gains of $43 and $1,258, respectively, for Medicare and Medicaid EHR incentive payments.

X

- Definition

Electronic health records incentive reimbursement receivable.

+ References

No definition available.

+ Details

Name: ssy_ElectronicHealthRecordsIncentiveReimbursementReceivableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Tables)
9 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2015 were as follows:

Payments due in:
 Long-Term
Debt Operating
Leases Interest on
Outstanding
Debt

1 year
 $ 840 $ 795 $ 709

2 years
 798 351 697

3 years
 1,971 221 642

4 years
 610 95 498

5+ years
 8,095 75 2,649







$ 12,314 $ 1,537 $ 5,195







X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-K (SK)

-Number 229

-Section 303

-Paragraph a

-Subparagraph 5

+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations (Tables)
9 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Net Revenues:


Fulton Hospital
 $ (9 ) $ 3,255 $ 6,721 $ 9,985

Dexter Hospital
 186 47 764 560

Memorial of Adel
 10 (62 ) 63 (66 )









$ 187 $ 3,240 $ 7,548 $ 10,479









Earnings (loss) before income taxes:

Fulton Hospital
$ (299 ) $ (601 ) $ (1,196 ) $ (1,748 )

Dexter Hospital
184 34 754 516

Memorial of Adel
2 (82 ) 34 (94 )

Life sciences and engineering
(31 ) (40 ) (95 ) (119 )

Lon sale of Fulton Hospital
(6 ) — (197 ) —









Earnings (Loss) before income taxes
(150 ) (689 ) (700 ) (1,445 )









Income tax expense (benefit)
(55 ) (301 ) (291 ) (556 )









Loss from discontinued operations
$ (95 ) $ (388 ) $ (409 ) $ (889 )









Components of Pension Expense

The components of pension expense for the three and nine months ended March 31, 2015 and 2014, respectively, were as follows:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Interest Cost
 $ 16 $ 15 $ 49 $ 45

Expected return on assets
 (7 ) (7 ) (22 ) (21 )

Amortization of prior service cost
 22 32 70 95









Net pension expense
$ 31 $ 40 $ 97 $ 119









X

- Definition

Pension expense.

+ References

No definition available.

+ Details

Name: ssy_PensionExpenseTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes
9 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

Note 10. – Income Taxes

Income tax benefit of $169 ($272 federal tax benefit and $103 state tax expense) and income tax benefit of $105 ($112 federal tax benefit and $7 state tax expense) was recorded for the three months ended March 31, 2015 and 2014, respectively. Income tax expense of $816 ($591 federal tax expense and $225 state tax expense) and income tax benefit of $200 ($190 federal tax benefit and $10 state tax benefit) was recorded for the nine months ended March 31, 2015 and 2014, respectively.

At March 31, 2015, the Company had $5,084 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At March 31, 2015, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,961. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt
9 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Long-Term Debt

Note 8. – Long-Term Debt

Long-term debt consisted of the following:

 March 31,
2015 June 30,
2014

Trace RDA Loan
 $ 8,290 $ 8,624

SHPP RDA Loan
 2,002 2,033

Carmichael Notes
 1,852 1,852

Other
 170 —





Total
12,314 12,509

Less current maturities
(840 ) (561 )





$ 11,474 $ 11,948





Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (now known as Crown Healthcare Investments, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at March 31, 2015). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds was used to repay a portion of the Company’s then currently outstanding debt. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.

The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ended March 31, 2015, $750 and (b) for the quarter ending June 30, 2015, $625. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At March 31, 2015, there were no outstanding borrowings under the Trace Working Capital Loan.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at March 31, 2015 and June 30, 2014).

SHPP RDA Loan - On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at March 31, 2015). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare.

Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Insurance Settlement
9 Months Ended

Mar. 31, 2015

Text Block [Abstract]

Insurance Settlement

Note 9. – Insurance settlement

In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the nine months ended March 31, 2015.

X

- Definition

Insurance settlements.

+ References

No definition available.

+ Details

Name: ssy_InsuranceSettlementsTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies
9 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. – Commitments and Contingencies

Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of the sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not either pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation in November 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the settlement in the quarter ended March 31, 2015. The promissory note is included in long-term assets in the March 31, 2015 balance sheet.

SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred.

Sale of Hospital Facilities — The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and various and contingent liabilities. – See Note 3 Discontinued Operations.

Office of Inspector General Investigation— In March 2014, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD has cooperated with the government with respect to document production, as well as conducting a joint medical necessity review of a sampling of medical records. Based upon our investigation and evaluation of the facts to date, we do not believe these matters and any results from these matters are likely to have any material adverse impact on our business, financial position, operating results or cash flows.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at March 31, 2015 were as follows:

Payments due in:
 Long-Term
Debt Operating
Leases Interest on
Outstanding
Debt

1 year
 $ 840 $ 795 $ 709

2 years
 798 351 697

3 years
 1,971 221 642

4 years
 610 95 498

5+ years
 8,095 75 2,649







$ 12,314 $ 1,537 $ 5,195







At March 31, 2015, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of March 31, 2015. SunLink expensed $15 and $16 on physician guarantees and recruiting for the three months ended March 31, 2015 and 2014, respectively. SunLink expensed $46 and $83 on physician guarantees and recruiting for the nine months ended March 31, 2015 and 2014, respectively.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Gain (loss) realized on incentive payments $ 64 $ 43 $ 64 $ 1,258

X

- Definition

Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

+ References

No definition available.

+ Details

Name: ssy_HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets (Tables)
9 Months Ended

Mar. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Goodwill consists of the following:

 March 31,
2015 June 30,
2014

Specialty Pharmacy Segment
 $ 461 $ 461





Net of Amortization Intangible Assets

Intangibles consist of the following, net of amortization:

 March 31,
2015 June 30,
2014

Specialty Pharmacy Segment


Trade Name
 2,000 2,000

Customer Relationships
 1,089 1,089

Medicare License
 769 769





3,858 3,858

Accumulated Amortization
(985 ) (879 )





Total
$ 2,873 $ 2,979





X

- Definition

Schedule of intangible assets excluding goodwill.

+ References

No definition available.

+ Details

Name: ssy_ScheduleOfIntangibleAssetsExcludingGoodwillTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Schedule of Discontinued Operations (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2014

Net Revenues:

Net revenues $ 187 $ 3,240 $ 7,548 $ 10,479

Earnings (loss) before income taxes:

Earnings (Loss) before income taxes (150) (689) (700) (1,445)

Income tax expense (benefit) (55) (301) (291) (556)

Loss from discontinued operations (95) (388) (409) (889)

Fulton Hospital [Member]

Net Revenues:

Net revenues (9) 3,255 6,721 9,985

Earnings (loss) before income taxes:

Loss sale of Fulton Hospital (6) (197) (197)

Earnings (Loss) before income taxes (299) (601) (1,196) (1,748)

Dexter Hospital [Member]

Net Revenues:

Net revenues 186 47 764 560

Earnings (loss) before income taxes:

Earnings (Loss) before income taxes 184 34 754 516

Memorial Hospital of Adel [Member]

Net Revenues:

Net revenues 10 (62) 63 (66)

Earnings (loss) before income taxes:

Earnings (Loss) before income taxes 2 (82) 34 (94)

Life Sciences and Engineering [Member]

Earnings (loss) before income taxes:

Earnings (Loss) before income taxes $ (31) $ (40) $ (95) $ (119)

X

- Details

Name: ssy_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTaxAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disposal group including discontinued operation revenue net of expenses.

+ References

No definition available.

+ Details

Name: ssy_DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: ssy_NetRevenueAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Overall income (loss) from a disposal group that is classified as a component of the entity, before income tax, reported as a separate component of income before extraordinary items. Includes the following (before income tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 05

-Paragraph 15

-Article 3

+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Tax effect allocated to a disposal group that is classified as a component of the entity reported as a separate component of income before extraordinary items. Includes the tax effects of the following: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e38679-109324

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_DexterHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_FultonHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_LifeSciencesAndEngineeringSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_MemorialHospitalOfAdelMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) (Carmichael Notes [Member], USD $)
In Thousands, unless otherwise specified
9 Months Ended 0 Months Ended

Mar. 31, 2015

Installment

Oct. 22, 2012

Apr. 22, 2012

Jun. 30, 2014

Apr. 22, 2008

Debt Disclosure [Line Items]

Loan agreement amount $ 3,000us-gaap_DebtInstrumentFaceAmount

Interest rate percentage 8.00% 8.00%

Date of loan agreement Apr. 22, 2008

Principal and interest payment 185us-gaap_DebtInstrumentPeriodicPayment

Carmichael Notes 1,852us-gaap_NotesPayable 1,852us-gaap_NotesPayable

Note due date Oct. 22, 2017

Number of semi-annual installment of interest payment 5

Scenario, Forecast [Member]

Debt Disclosure [Line Items]

Carmichael Notes 1,255

Payment in Kind (PIK) Note [Member]

Debt Disclosure [Line Items]

Principal and interest payment $ 252 $ 247

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Debt instrument number of installment payment.

+ References

No definition available.

+ Details

Name: ssy_DebtInstrumentNumberOfInstallmentPayment

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Statement of Cash Flows [Abstract]

Net Cash Provided by Operating Activities $ 1,292 $ 3,319

Cash Flows from Investing Activities:

Proceeds from sale of hospital 6,090

Net change in cash in escrow (160)

Expenditures for property, plant and equipment - continuing operations (995) (1,130)

Expenditures for property, plant and equipment - discontinued operations (11) (83)

Net Cash Provided by (Used in) Investing Activities 5,084 (1,373)

Cash Flows from Financing Activities:

Proceeds from long-term debt 175 0

Payments on long-term debt - continuing operation (411)us-gaap_RepaymentsOfLongTermDebt (529)us-gaap_RepaymentsOfLongTermDebt

Payments on long-term debt - discontinued operations (4,842) (91)

Net Cash Used in Financing Activities (5,078) (620)

Net increase in Cash and Cash Equivalents 1,298 1,326

Cash and Cash Equivalents Beginning of Period 3,587 2,497

Cash and Cash Equivalents End of Period 4,885 3,823

Cash Paid (Received) for:

Interest 614us-gaap_InterestPaid 854us-gaap_InterestPaid

Income taxes 203us-gaap_IncomeTaxesPaidNet (1,625)us-gaap_IncomeTaxesPaidNet

Assets acquired under capital least obligation - continuing operations $ 41 $ 0

X

- Definition

Payments to acquire property, plant and equipment, continuing operations.

+ References

No definition available.

+ Details

Name: ssy_PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Payments to acquire property, plant and equipment, discontinued operations.

+ References

No definition available.

+ Details

Name: ssy_PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuedOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Repayments of long term debt discontinued operations.

+ References

No definition available.

+ Details

Name: ssy_RepaymentsOfLongTermDebtDiscontinuedOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: ssy_SupplementalCashFlowInformationCashPaidForIncomeTaxesAndInterestAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables
9 Months Ended

Mar. 31, 2015

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 5. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues before provision for doubtful accounts by payor were as follows for the three and nine months ended March 31, 2015 and 2014:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Healthcare Facilities Segment:


Medicare
 $ 6,573 $ 6,784 $ 20,536 $ 20,407

Medicaid
 3,591 3,287 10,562 10,131

Self-pay
 1,565 1,978 5,555 6,683

Managed Care & Other Insurance
 3,911 3,855 12,425 12,427

Other
 55 50 151 148









Revenues before provision for doubtful accounts
15,695 15,954 49,229 49,796

Provision for doubtful accounts
(1,845 ) (1,837 ) (6,060 ) (6,125 )









Healthcare Facilities Segment Net Revenues
13,850 14,117 43,169 43,671

Specialty Pharmacy Segment Net Revenues
9,307 10,217 25,191 26,385

Other Revenues
194 132 493 319









Total Net Revenues
$ 23,351 $ 24,466 $ 68,853 $ 70,375









The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:

 March 31,
2015 June 30,
2014

Accounts receivable (net of contractual allowances)
 $ 15,650 $ 16,753

Less allowance for doubtful accounts
 (5,632 ) (6,903 )





Patient accounts receivable - net
$ 10,018 $ 9,850





The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and nine months ended March 31, 2015:

Three Months Ended March 31, 2015: Healthcare
Facilities Specialty
Pharmacy Total

Balance at January 1, 2015
 $ 7,055 $ 224 $ 7,279

Additions recognized as a reduction to earnings
 1,554 65 1,619

Accounts written off, net of recoveries
 (3,165 ) (101 ) (3,266 )







Balance at March 31, 2015
$ 5,444 $ 188 $ 5,632







Nine Months Ended March 31, 2015: Healthcare
Facilities Specialty
Pharmacy Total

Balance at July 1, 2014
 $ 6,649 $ 254 $ 6,903

Additions recognized as a reduction to earnings
 7,805 145 7,950

Accounts written off, net of recoveries
 (9,010 ) (211 ) (9,221 )







Balance at March 31, 2015
$ 5,444 $ 188 $ 5,632







Three Months Ended March 31, 2014: Healthcare
Facilities Specialty
Pharmacy Total

Balance at January 1, 2014
 $ 6,760 $ 479 $ 7,239

Additions recognized as a reduction to revenues
 2,521 75 2,596

Accounts written off, net of recoveries
 (2,552 ) (39 ) (2,591 )







Balance at March 31, 2014
$ 6,729 $ 515 $ 7,244







Nine Months Ended March 31, 2014: Healthcare
Facilities Specialty
Pharmacy Total

Balance at July 1, 2013
 $ 7,286 $ 475 $ 7,761

Additions recognized as a reduction to revenues
 8,138 170 8,308

Accounts written off, net of recoveries
 (8,695 ) (130 ) (8,825 )







Balance at March 31, 2014
$ 6,729 $ 515 $ 7,244







Net revenues included increases of $10 and $105 for the three months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($287) and $611 for the nine months ended March 31, 2015 and 2014, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

X

- Definition

Revenue and Accounts Receivable [Text Block]

+ References

No definition available.

+ Details

Name: ssy_RevenueAndAccountsReceivableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 0 Months Ended 6 Months Ended

Mar. 31, 2015

Mar. 31, 2015

Jul. 02, 2012

Dec. 31, 2014

Mar. 16, 2012

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale $ 6,090

Contribution to pension plan 84us-gaap_PensionContributions 84us-gaap_PensionContributions

Memorial Hospital of Adel [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale 8,350

Fulton Hospital [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale 6,090

Loss on sale of assets 6 197 197

Fulton RDA Loan [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Loan agreement amount 5,000

Date of loan agreement Mar. 16, 2012

Fulton RDA Loan [Member] | Fulton Hospital [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Repayment of outstanding loan 4,745 4,745

Early repayment penalty $ 237 $ 237

X

- Definition

Early repayment penalty on debt.

+ References

No definition available.

+ Details

Name: ssy_EarlyRepaymentPenaltyOnDebt

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash or cash equivalents contributed by the entity to fund its pension plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_PensionContributions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_FultonRdaLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_FultonHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_MemorialHospitalOfAdelMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 136 198 1 false 32 0 false 13 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation false false R7.htm 108 - Disclosure - Business Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Operations false false R8.htm 109 - Disclosure - Discontinued Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations false false R9.htm 110 - Disclosure - Shareholders' Equity Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity false false R10.htm 111 - Disclosure - Revenue Recognition and Accounts Receivables Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock Revenue Recognition and Accounts Receivables false false R11.htm 112 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsElectronicHealthRecordsIncentiveReimbursementReceivableTextBlock Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives false false R12.htm 113 - Disclosure - Goodwill and Intangible Assets Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill and Intangible Assets false false R13.htm 114 - Disclosure - Long-Term Debt Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-Term Debt false false R14.htm 115 - Disclosure - Insurance Settlement Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsInsuranceSettlementsTextBlock Insurance Settlement false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R17.htm 118 - Disclosure - Related Party Transactions Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions false false R18.htm 119 - Disclosure - Financial Information by Segment Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Financial Information by Segment false false R19.htm 120 - Disclosure - Discontinued Operations (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlockTables Discontinued Operations (Tables) false false R20.htm 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlockTables Revenue Recognition and Accounts Receivables (Tables) false false R21.htm 122 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and Intangible Assets (Tables) false false R22.htm 123 - Disclosure - Long-Term Debt (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long-Term Debt (Tables) false false R23.htm 124 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) false false R24.htm 125 - Disclosure - Financial Information by Segment (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Financial Information by Segment (Tables) false false R25.htm 126 - Disclosure - Business Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureBusinessOperationsAdditionalInformation Business Operations - Additional Information (Detail) false false R26.htm 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperations Discontinued Operations - Schedule of Discontinued Operations (Detail) false false R27.htm 128 - Disclosure - Discontinued Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformation Discontinued Operations - Additional Information (Detail) false false R28.htm 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsComponentsOfPensionExpense Discontinued Operations - Components of Pension Expense (Detail) false false R29.htm 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) false false R30.htm 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenuesBeforeProvisionForDoubtfulAccounts Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) false false R31.htm 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryInformationForAccountsReceivable Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) false false R32.htm 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryOfAllowanceForDoubtfulAccounts Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) false false R33.htm 134 - Disclosure - Revenue Recognition and Accounts Receivables - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesAdditionalInformation Revenue Recognition and Accounts Receivables - Additional Information (Detail) false false R34.htm 135 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureMedicareAndMedicaidElectronicHealthRecordsIncentivesDeferredGainMedicareElectronicHealthRecordsIncentivesAdditionalInformation Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) false false R35.htm 136 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsGoodwill Goodwill and Intangible Assets - Goodwill (Detail) false false R36.htm 137 - Disclosure - Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetOfAmortizationIntangibleAssets Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) false false R37.htm 138 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation Goodwill and Intangible Assets - Additional Information (Detail) false false R38.htm 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebt Long-Term Debt - Summary of Long-Term Debt (Detail) false false R39.htm 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtTraceRDALoanAndTraceWorkingCapitalLoanAdditionalInformation Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) false false R40.htm 141 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSHPPRDALoanAdditionalInformation Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) false false R41.htm 142 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) Notes http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtCarmichaelNotesAdditionalInformation Long-Term Debt (Carmichael Notes) - Additional Information (Detail) false false R42.htm 143 - Disclosure - Insurance settlement - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureInsuranceSettlementAdditionalInformation Insurance settlement - Additional Information (Detail) false false R43.htm 144 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R44.htm 145 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R45.htm 146 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfContractualObligationsCommitmentsAndContigencies Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) false false R46.htm 147 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) false false R47.htm 148 - Disclosure - Financial Information by Segment - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentAdditionalInformation Financial Information by Segment - Additional Information (Detail) false false R48.htm 149 - Disclosure - Financial Information by Segment - Segment Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentSegmentInformation Financial Information by Segment - Segment Information (Detail) false false All Reports Book All Reports Element us-gaap_DebtInstrumentInterestRateEffectivePercentage had a mix of decimals attribute values: 0 3. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Process Flow-Through: Removing column '0 Months Ended Jan. 31, 2015' Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) ssy-20150331.xml ssy-20150331.xsd ssy-20150331_cal.xml ssy-20150331_def.xml ssy-20150331_lab.xml ssy-20150331_pre.xml true true XML 64 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt - Summary of Long-Term Debt (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2015

Jun. 30, 2014

Debt Disclosure [Line Items]

Other $ 170us-gaap_OtherLongTermDebt

Total 12,314us-gaap_LongTermDebt 12,509us-gaap_LongTermDebt

Total 12,314us-gaap_LongTermDebt 12,509us-gaap_LongTermDebt

Less current maturities (840)us-gaap_LongTermDebtCurrent (561)us-gaap_LongTermDebtCurrent

Total Long-term debt, excluding current maturities, total 11,474us-gaap_LongTermDebtNoncurrent 11,948us-gaap_LongTermDebtNoncurrent

Trace RDA Loan [Member]

Debt Disclosure [Line Items]

RDA Loan 8,290 8,624

SHPP RDA Loan [Member]

Debt Disclosure [Line Items]

RDA Loan 2,002 2,033

Carmichael Notes [Member]

Debt Disclosure [Line Items]

Carmichael Notes $ 1,852 $ 1,852

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including both current and noncurrent portions, carrying amount as of the balance sheet date of other forms of debt not elsewhere specified in the taxonomy with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_OtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_CarmichaelCashwayPharmacyNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables (Tables)
9 Months Ended

Mar. 31, 2015

Receivables [Abstract]

Summary of Revenues Before Provision for Doubtful Accounts

Revenues before provision for doubtful accounts by payor were as follows for the three and nine months ended March 31, 2015 and 2014:

 Three Months Ended
March 31, Nine Months Ended
March 31,

 2015 2014 2015 2014

Healthcare Facilities Segment:


Medicare
 $ 6,573 $ 6,784 $ 20,536 $ 20,407

Medicaid
 3,591 3,287 10,562 10,131

Self-pay
 1,565 1,978 5,555 6,683

Managed Care & Other Insurance
 3,911 3,855 12,425 12,427

Other
 55 50 151 148









Revenues before provision for doubtful accounts
15,695 15,954 49,229 49,796

Provision for doubtful accounts
(1,845 ) (1,837 ) (6,060 ) (6,125 )









Healthcare Facilities Segment Net Revenues
13,850 14,117 43,169 43,671

Specialty Pharmacy Segment Net Revenues
9,307 10,217 25,191 26,385

Other Revenues
194 132 493 319









Total Net Revenues
$ 23,351 $ 24,466 $ 68,853 $ 70,375









Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:

 March 31,
2015 June 30,
2014

Accounts receivable (net of contractual allowances)
 $ 15,650 $ 16,753

Less allowance for doubtful accounts
 (5,632 ) (6,903 )





Patient accounts receivable - net
$ 10,018 $ 9,850





Summary of Allowance for Doubtful Accounts

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and nine months ended March 31, 2015:

Three Months Ended March 31, 2015: Healthcare
Facilities Specialty
Pharmacy Total

Balance at January 1, 2015
 $ 7,055 $ 224 $ 7,279

Additions recognized as a reduction to earnings
 1,554 65 1,619

Accounts written off, net of recoveries
 (3,165 ) (101 ) (3,266 )







Balance at March 31, 2015
$ 5,444 $ 188 $ 5,632







Nine Months Ended March 31, 2015: Healthcare
Facilities Specialty
Pharmacy Total

Balance at July 1, 2014
 $ 6,649 $ 254 $ 6,903

Additions recognized as a reduction to earnings
 7,805 145 7,950

Accounts written off, net of recoveries
 (9,010 ) (211 ) (9,221 )







Balance at March 31, 2015
$ 5,444 $ 188 $ 5,632







Three Months Ended March 31, 2014: Healthcare
Facilities Specialty
Pharmacy Total

Balance at January 1, 2014
 $ 6,760 $ 479 $ 7,239

Additions recognized as a reduction to revenues
 2,521 75 2,596

Accounts written off, net of recoveries
 (2,552 ) (39 ) (2,591 )







Balance at March 31, 2014
$ 6,729 $ 515 $ 7,244







Nine Months Ended March 31, 2014: Healthcare
Facilities Specialty
Pharmacy Total

Balance at July 1, 2013
 $ 7,286 $ 475 $ 7,761

Additions recognized as a reduction to revenues
 8,138 170 8,308

Accounts written off, net of recoveries
 (8,695 ) (130 ) (8,825 )







Balance at March 31, 2014
$ 6,729 $ 515 $ 7,244







X

- Definition

Allowance for doubtful accounts.

+ References

No definition available.

+ Details

Name: ssy_AllowanceForDoubtfulAccountsTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35755915&loc=SL9156464-115641

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 55

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755955&loc=SL9156489-173031

+ Details

Name: us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Commitments and Contingencies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2015 acre	Mar. 31, 2014	Mar. 31, 2015 Physician Hospital acre	Mar. 31, 2014
Commitment And Contingencies [Line Items]
Real property	24.74us-gaap_AreaOfRealEstateProperty		24.74us-gaap_AreaOfRealEstateProperty
Number of hospital facilities			3ssy_NumberOfHospitalFacilities
Number of physicians under guarantee agreements			1
Number of years required for maintaining practice within a hospital geographic area			3 years
Expenditure on physician guarantees and recruitment	$ 15	$ 16	$ 46	$ 83
Castlemark Properties, LLC [Member]
Commitment And Contingencies [Line Items]
Promissory note Principal amount	600		600
Promissory note term			5 years
Estimated fair value of the real property			$ 500

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 15,650us-gaap_AccountsReceivableGrossCurrent		$ 16,753us-gaap_AccountsReceivableGrossCurrent
Less allowance for doubtful accounts	(5,632)	(7,279)	(6,903)	(7,244)	(7,239)	(7,761)
Patient accounts receivable - net	$ 10,018us-gaap_ReceivablesNetCurrent		$ 9,850us-gaap_ReceivablesNetCurrent

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) (SHPP RDA Loan [Member], USD $) In Thousands, unless otherwise specified	9 Months Ended
	Mar. 31, 2015	Oct. 31, 2012
Debt Disclosure [Line Items]
Debt instrument maturity period	25 years
Floating rate of interest, spread	2.00%
Floating rate of interest, lesser	5.00%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	5.25%
Loan proceeds used for acquisition	1,800ssy_LoanProceedsUsedForAcquisition
Debt instrument description	The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%
Subsidiaries [Member]
Debt Disclosure [Line Items]
Loan agreement amount		$ 2,100
Date of loan agreement	Oct. 31, 2012

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Current Assets:
Cash and cash equivalents	$ 4,885	$ 3,587
Receivables - net	10,018us-gaap_ReceivablesNetCurrent	9,850us-gaap_ReceivablesNetCurrent
Inventory	3,936us-gaap_InventoryNet	3,757us-gaap_InventoryNet
Deferred income tax asset	1,861us-gaap_DeferredTaxAssetsNetCurrent	2,978us-gaap_DeferredTaxAssetsNetCurrent
Due from third party payors	1,525us-gaap_AccountsReceivableNetCurrent	2,786us-gaap_AccountsReceivableNetCurrent
Current assets held for sale	0	270
Prepaid expense and other assets	2,705	2,547
Total current assets	24,930us-gaap_AssetsCurrent	25,775us-gaap_AssetsCurrent
Property, plant and equipment, at cost	54,567us-gaap_PropertyPlantAndEquipmentGross	53,466us-gaap_PropertyPlantAndEquipmentGross
Less accumulated depreciation	32,030	30,389
Property, plant and equipment - net	22,537us-gaap_PropertyPlantAndEquipmentNet	23,077us-gaap_PropertyPlantAndEquipmentNet
Noncurrent Assets:
Intangible assets - net	2,873	2,979
Goodwill	461us-gaap_Goodwill	461us-gaap_Goodwill
Deferred income tax asset	5,100us-gaap_DeferredTaxAssetsNetNoncurrent	4,432us-gaap_DeferredTaxAssetsNetNoncurrent
Noncurrent assets held for sale	0	6,111
Other noncurrent assets	1,522us-gaap_OtherAssetsNoncurrent	1,012us-gaap_OtherAssetsNoncurrent
Total noncurrent assets	9,956	14,995
TOTAL ASSETS	57,423us-gaap_Assets	63,847us-gaap_Assets
Current liabilities:
Accounts payable	4,429us-gaap_AccountsPayableCurrent	4,530us-gaap_AccountsPayableCurrent
Current maturities of long-term debt	840us-gaap_LongTermDebtCurrent	561us-gaap_LongTermDebtCurrent
Accrued payroll and related taxes	3,415	4,186
Income tax payable	32us-gaap_AccruedIncomeTaxesCurrent	73us-gaap_AccruedIncomeTaxesCurrent
Current liabilities held for sale	0	4,842
Other accrued expenses	1,981us-gaap_OtherLiabilitiesCurrent	2,314us-gaap_OtherLiabilitiesCurrent
Total current liabilities	10,697us-gaap_LiabilitiesCurrent	16,506us-gaap_LiabilitiesCurrent
Long-Term Liabilities
Long-term debt	11,474us-gaap_LongTermDebtNoncurrent	11,948us-gaap_LongTermDebtNoncurrent
Noncurrent liability for professional liability risks	992	1,268
Other noncurrent liabilities	755us-gaap_OtherLiabilitiesNoncurrent	807us-gaap_OtherLiabilitiesNoncurrent
Total long-term liabilities	13,221us-gaap_LiabilitiesNoncurrent	14,023us-gaap_LiabilitiesNoncurrent
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0us-gaap_PreferredStockValue	0us-gaap_PreferredStockValue
Common Shares, without par value: Issued and outstanding, 9,444 shares at March 31, 2015 and at June 30, 2014	4,722us-gaap_CommonStockValue	4,722us-gaap_CommonStockValue
Additional paid-in capital	13,478	13,444
Retained earnings	15,639	15,486
Accumulated other comprehensive loss	(334)	(334)
Total Shareholders' Equity	33,505	33,318
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 57,423	$ 63,847

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 840
Payments due in 2 years	798
Payments due in 3 years	1,971
Payments due in 4 years	610
Payments due in 5+ years	8,095
Contractual obligations, commitments and contingencies	12,314
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	795
Payments due in 2 years	351
Payments due in 3 years	221
Payments due in 4 years	95
Payments due in 5+ years	75
Contractual obligations, commitments and contingencies	1,537
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	709
Payments due in 2 years	697
Payments due in 3 years	642
Payments due in 4 years	498
Payments due in 5+ years	2,649
Contractual obligations, commitments and contingencies	$ 5,195

Basis of Presentation	9 Months Ended
Basis of Presentation	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Note 1. – Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of March 31, 2015 and for the three and nine month periods ended March 31, 2015 and 2014 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and nine month periods ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Goodwill and Intangible Assets - Goodwill (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Goodwill [Line Items]
Goodwill	$ 461us-gaap_Goodwill	$ 461us-gaap_Goodwill
Specialty Pharmacy Segment [Member]
Goodwill [Line Items]
Goodwill	$ 461	$ 461

Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Total	$ 2,873	$ 2,979
Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	3,858	3,858
Accumulated Amortization	(985)	(879)
Total	2,873	2,979
Trade Name [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Indefinite-Lived Intangible Assets	2,000	2,000
Customer Relationships [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite-Lived Intangible Assets, Gross	$ 769	$ 769

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Jun. 30, 2014
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000us-gaap_PreferredStockSharesAuthorized	2,000,000us-gaap_PreferredStockSharesAuthorized
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	9,444,000us-gaap_CommonStockSharesIssued	9,444,000us-gaap_CommonStockSharesIssued
Common shares, outstanding	9,444,000us-gaap_CommonStockSharesOutstanding	9,444,000us-gaap_CommonStockSharesOutstanding

Related Party Transactions	9 Months Ended
Related Party Transactions	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. – Related Party Transactions A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $42 and $258 for legal services to these law firms in the three months ended March 31, 2015 and 2014, respectively. The Company has expensed an aggregate of $232 and $577 for legal services to these law firms in the nine months ended March 31, 2015 and 2014, respectively. Included in the Company’s condensed consolidated balance sheets at March 31, 2015 and June 30, 2014 is $43 and $116, respectively, of amounts payable to these law firms.

Document and Entity Information	9 Months Ended
Document and Entity Information	Mar. 31, 2015	May 13, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,443,408dei_EntityCommonStockSharesOutstanding

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives	9 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives	Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services. For the three and nine months ended March 31, 2015, the Company reported $64 Medicaid incentive payments. For the three and nine months ended March 31, 2014, the Company reported net gains of $43 and $1,258, respectively, for Medicare and Medicaid EHR incentive payments.

Income Taxes	9 Months Ended
Income Taxes	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. – Income Taxes Income tax benefit of $169 ($272 federal tax benefit and $103 state tax expense) and income tax benefit of $105 ($112 federal tax benefit and $7 state tax expense) was recorded for the three months ended March 31, 2015 and 2014, respectively. Income tax expense of $816 ($591 federal tax expense and $225 state tax expense) and income tax benefit of $200 ($190 federal tax benefit and $10 state tax benefit) was recorded for the nine months ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company had $5,084 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At March 31, 2015, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,961. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

Insurance Settlement	9 Months Ended
Insurance Settlement	Mar. 31, 2015
Text Block [Abstract]
Insurance Settlement	Note 9. – Insurance settlement In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the nine months ended March 31, 2015.

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) (Carmichael Notes [Member], USD $) In Thousands, unless otherwise specified	9 Months Ended	0 Months Ended
	Mar. 31, 2015 Installment	Oct. 22, 2012	Apr. 22, 2012	Jun. 30, 2014	Apr. 22, 2008
Debt Disclosure [Line Items]
Loan agreement amount					$ 3,000us-gaap_DebtInstrumentFaceAmount
Interest rate percentage	8.00%				8.00%
Date of loan agreement	Apr. 22, 2008
Principal and interest payment	185us-gaap_DebtInstrumentPeriodicPayment
Carmichael Notes	1,852us-gaap_NotesPayable			1,852us-gaap_NotesPayable
Note due date	Oct. 22, 2017
Number of semi-annual installment of interest payment	5
Scenario, Forecast [Member]
Debt Disclosure [Line Items]
Carmichael Notes	1,255
Payment in Kind (PIK) Note [Member]
Debt Disclosure [Line Items]
Principal and interest payment		$ 252	$ 247

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
Net Cash Provided by Operating Activities	$ 1,292	$ 3,319
Cash Flows from Investing Activities:
Proceeds from sale of hospital	6,090
Net change in cash in escrow		(160)
Expenditures for property, plant and equipment - continuing operations	(995)	(1,130)
Expenditures for property, plant and equipment - discontinued operations	(11)	(83)
Net Cash Provided by (Used in) Investing Activities	5,084	(1,373)
Cash Flows from Financing Activities:
Proceeds from long-term debt	175	0
Payments on long-term debt - continuing operation	(411)us-gaap_RepaymentsOfLongTermDebt	(529)us-gaap_RepaymentsOfLongTermDebt
Payments on long-term debt - discontinued operations	(4,842)	(91)
Net Cash Used in Financing Activities	(5,078)	(620)
Net increase in Cash and Cash Equivalents	1,298	1,326
Cash and Cash Equivalents Beginning of Period	3,587	2,497
Cash and Cash Equivalents End of Period	4,885	3,823
Cash Paid (Received) for:
Interest	614us-gaap_InterestPaid	854us-gaap_InterestPaid
Income taxes	203us-gaap_IncomeTaxesPaidNet	(1,625)us-gaap_IncomeTaxesPaidNet
Assets acquired under capital least obligation - continuing operations	$ 41	$ 0

Discontinued Operations - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended	0 Months Ended	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Jul. 02, 2012	Dec. 31, 2014	Mar. 16, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		$ 6,090
Contribution to pension plan	84us-gaap_PensionContributions	84us-gaap_PensionContributions
Memorial Hospital of Adel [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale			8,350
Fulton Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale				6,090
Loss on sale of assets	6	197		197
Fulton RDA Loan [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loan agreement amount					5,000
Date of loan agreement				Mar. 16, 2012
Fulton RDA Loan [Member] \| Fulton Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of outstanding loan		4,745		4,745
Early repayment penalty		$ 237		$ 237

Long-Term Debt - Summary of Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Debt Disclosure [Line Items]
Other	$ 170us-gaap_OtherLongTermDebt
Total	12,314us-gaap_LongTermDebt	12,509us-gaap_LongTermDebt
Total	12,314us-gaap_LongTermDebt	12,509us-gaap_LongTermDebt
Less current maturities	(840)us-gaap_LongTermDebtCurrent	(561)us-gaap_LongTermDebtCurrent
Total Long-term debt, excluding current maturities, total	11,474us-gaap_LongTermDebtNoncurrent	11,948us-gaap_LongTermDebtNoncurrent
Trace RDA Loan [Member]
Debt Disclosure [Line Items]
RDA Loan	8,290	8,624
SHPP RDA Loan [Member]
Debt Disclosure [Line Items]
RDA Loan	2,002	2,033
Carmichael Notes [Member]
Debt Disclosure [Line Items]
Carmichael Notes	$ 1,852	$ 1,852